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Abstract
The aim o f this thesis was to develop novel antimalarial drug candidates. This was achieved 
through drug design, targeting established parasite survival mechanisms. The project focused 
on the biomineralisation of hematin to hemozoin, a process critical for parasite survival 
(Figure A). In order to impart selectivity over host cells, functionalities shown to accumulate 
via parasite induced permeation pathways were exploited.
Figure A. Hematin crystallisation to non-toxic hemozoin 
Chapter I provides a brief overview o f vector borne infectious disease, discussing malaria 
epidemiology and chemotherapy. The thesis covers two drug forms consisting of mono- 
cationic and dicationic drug templates hence Chapter II is divided into two parts. Part I 
reviews dications and their consignment within antiplasmodial drug design. Part II covers the 
polyaromatic hydrocarbon fluorene; its chemistry and medicinal properties are introduced 
since fluorene forms the basis o f the mono-cationic drug template.
A novel series o f dicationic diamidines and diguanidines were synthesised. A novel 
diphenylthiazole compound was found to be the most active analogue, with an IC50 of 6.2 nM 
against chloroquine resistant parasites, making this compound more active than DB75 (75 
nM). Chapter III describes the synthetic preparation o f diamidines and diguanidines, along 
with the challenges encountered through the project. The design of these compounds was 
based on structure activity relationships obtained for the anti-protozoal agent pentamidine. 
The latter part o f this chapter focuses on fluorene as a heme binding unit for mono-cationic 
antimalarials. This template was designed based on the antimalarials chloroquine, 
lumefantrine and amodiaquine. Referred to as Fluorene-Mannich Hybrids, these compounds 
are potent antimalarials and strong inhibitors o f hemozoin formation with the lead compound 
having an IC50 o f 12.7 nM, approximately three times more active than lumefantrine.
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CHAPTER I
Vector Borne Infectious Disease
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1.0 An Introduction to Vector Borne Infectious Disease
Cardiovascular disease is the foremost cause of fatality as shown in Figure 1, with infectious and 
parasitic disease being a close second.1 However, this balance is dependent on location. The 
Western world is mainly affected by degenerative diseases where the structure or function of the 
affected tissue deteriorates, mainly due to age and/or lifestyle. In stark contrast, the developing 
world is held hostage to a multitude of vector-borne infectious diseases that are rampant in 
certain areas. Of these diseases African trypanosomiasis, leishmaniasis, malaria, dengue and 
dengue haemorrhagic fever are among the most prevalent, affecting the Western world with 
travel and tourism. Many of these diseases are the oldest in the world for instance malaria, a 
disease that prehistoric man is believed to have suffered. The level of malaria infection is now 
endemic in Sub Saharan Africa and South East Asia restricting economic growth and 
development.2
Cardiovascular diseases
Infectious and 
parasitic diseases
Malignant neoplasms
Violence/lnluries/ 
accidents/suicides 
Chronic lung 
diseases
Pregnancy-related deaths 
Other
Digestive diseases 
Neuropsychiatic disorders 
Diabetes mellilus
16.733.000 (29%)
14,867,000 (26%)
7,121.000 (12%) 
5,168,000 (9%) 
3.702,000 (6%)
[2 ,972,000 (5%) 
2,398,000 (4%)
11,968,000 (3%)
|1;,1^000 (2%)
[980,000 (2%)
Total deaths 
57,029,000
Figure 1. Leading causes of death worldwide 2002. Adapted from the National Institute of Allergy and Infectious
Diseases.1
Assessing malaria specifically, prevention and control programmes have had some success. In 
1930, a malaria epidemic in Brazil was eradicated due to the fast action of the Brazilian 
government and the Rockefeller Foundation. In addition to this, in 1943 Anopheles gambiae 
spread from Central Africa to Egypt, the Egyptian Government together with the Rockefeller 
Foundation again eradicated the disease in the affected Egyptian terratorries.3
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During the Vietnam War and World War II, many resources were ploughed into the development 
of novel antimalarials leading to the development of mefloquine (America), halofantrine 
(America) and proguanil (Britain).4 However, the collapse of the Empire and a reliance on 
chloroquine (CQ) led to the cessation of clinical research, drug development, and prevention and 
control measures. Even today only moderate resources from the pharmaceutical industry are 
placed into the development of novel, cheap therapies for the treatment of these diseases. The 
treatment of infectious parasitic disease is a neglected and underdeveloped area, for example 
Pentamidine (PMD) is still in clinical use today for the treatment of trypanosomiasis some 70 
years after its introduction despite associated toxicity, and CQ for malaria, even though in most 
parts of the world CQ resistant P. falciparum malaria is now widespread.
Our interests lie within the development of novel chemotherapeutics for the treatment of malaria, 
thus accordingly the parasite lifecycle will be introduced to gain a better understanding of the 
processes we aim to target chemotherapeutically.
1.1 Malaria Epidemiology
1.1.1 Introduction
Originating in Africa, malaria accompanied human migration to India, South East Asia and the 
Mediterranean shores, due to the trade of slaves and goods. Once occurring widely in temperate 
areas, including Western Europe and the United States, malaria receded with economic 
development and public health measures.5,6 Malaria is a major public health issue affecting more 
than a third of the world’s population (approx 40%).2 Every year, more than 500 million people 
become severely ill with malaria, with one billion people estimated to carry parasites at any one 
time. Pregnant women and children are the most vulnerable with the parasite killing one child
2 7every 30 seconds in Africa alone. ’
In spite of global economic development, more people die from malaria today than 40 years 
ago,6 causing much devastation and a staggering amount of chronic ill health that not only 
impedes the economic development of these countries already stricken by poverty, but also 
affecting fertility, population growth, worker productivity, and premature mortality. The burden
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of malaria can be observed clearly by certain genetic polymorphisms, such as sickle cell trait, 
selected due to the protective effect against malaria when inherited from one parent, though the 
same allele inherited from both parents is fatal.9
Malaria was reduced considerably in the 1950s due to the effectiveness of the World Health 
Organisation (WHO) prevention and control programme using drugs such as CQ together with 
‘residual’ insecticides. However, drug resistance in the parasite and insecticide resistance in the 
vector exacerbated the situation, resulting in an explosion of treatment failures leading to the 
breakdown of the programme and the endemic situation present today. In addition, some of the 
newer antimalarials developed as alternative therapies have severe side effects and in most cases 
are more expensive than older treatments such as CQ, thus despite parasite resistance and 
treatment failures CQ is still the most widely used drug due to cost and availability.10
1.1.2 Plasmodium  Life Cycle
The life cycle of malaria is complex and multifaceted since there is an asexual phase within the 
intermediate host and a sexual cycle in the mosquito." Malaria is a vector-borne infectious 
disease of protozoan parasites of the genus Plasmodium transmitted by the female Anopheles 
mosquito. There are four species of Plasmodium which cause malaria in humans, P.malariae, 
P.ovale, P. vivax and P. falciparum, the latter two forms being the most prevalent. Due to the 
rapid rate of parasitic reproduction and an ability to sequester within vital organs such as the 
brain, P. falciparum  causes the most severe clinical form.
Malaria transmission begins with the requirement for a mosquito to mature her eggs via a blood 
meal attained by a bite. Within her saliva she holds primitive malarial parasites named 
sporozoites that are injected via the salivary glands before feeding, thereby resulting in their 
release into the bloodstream where the parasite lives luxuriously, extracting nutrients and waiting 
to invade the CNS and other organs of their mammalian host, as outlined in Figure 2.
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THE UFE CYCLE OF MALARIA
MaSQUITO HUMAN
Sporozoites migrate to 
salivary gland
Mature oocyst bursts 
and replaces 
sporozoites
Sporozoites migrate 
to the liver
Oocyst grows
Ookinete 
attaches to 
gut and 
becomes 
oocyst
Fertilized 
female 
gamete forms 
a zygote 
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becomes an 
ookinete
rierozoites leave the 
liver and infect red 
cells
‘Trophozoites mature 
in red cells to 
' become either 
schizonts or 
gametocytes
chizonts release 
more me rozo it es
0 ametocytes wait for 
mosquito
Figure 2. The parasite life cycle12
Once within the intermediate host bloodstream, sporozoites circulate for a short time, settling in 
the liver where pre-erythrocytic schizogony occurs when the parasites enter the parenchymal 
cells and multiply. After incubation periods of up to twelve days there can be merozoites (young 
parasites) in the order of thousands within one liver cell. The parasites exist within a cell in two 
forms consequential of sexual and asexual cycles. The sexual cycle creates male and female 
gametocytes which circulate in the blood and are taken by the mosquito when obtaining a blood 
meal. These gametocytes fuse forming oocysts in the stomach lining of the mosquito which 
develop over a few days. Within them are large colonies of sporozoites which move to the 
salivary gland ready to be injected into man. In the asexual cycle the budding parasites form 
schizonts which contain many merozoites. The cell undergoes lysis causing the release o f more 
than 10,000 free merozoites armed to parasitize red blood cells thus completing the cycle. In the 
case o f P. malariae, P. vivax, and P. ovale all stages of development prior to the liver cycle can 
be observed in the blood. For these strains the liver cycle continues though parasites are 
eliminated with a course of primaquine.13 However, P. falciparum  does not have a continuing 
liver cycle and only ring forms and gametocytes are present in peripheral blood. The developing
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forms adhere to the blood vessels of large organs such as the brain, restricting blood flow leading 
to cerebral malaria.2’5,12,14
1.2 Antimalarial Chemotherapy
1.2.1 Introduction
Approaches to the control of malaria must be multifaceted in order to attain success; with 
vaccine development, health education, primary health care, chemotherapy and vector control 
working together alongside socio-economic improvements. Where malaria elimination programs 
have been successful, such as those implemented in the US and Europe, vector control was an 
essential program component5 and is the course of action taken by various bodies funding 
projects for the development of novel, safe insecticides. Our interests are within the development 
of novel antimalarial chemotherapies and thus the history of antimalarial drugs will be briefly 
discussed.
There are many avenues of pharmacological intervention within the malarial parasite and the 
development of a therapeutic arsenal commenced with study of the parasite cell structure as 
illustrated in Figure 3. Furthermore, the recent elucidation of the malaria parasite genome 
sequence has provided a foundation for future studies of this organism and is being exploited in 
the search for new drugs and vaccines to fight the parasite.15'20
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Figure 3. Structure of a parasitised red blood cell.
Ptastid Pigment vacuole
Food vacuoles
Cytostomes
Free ribosomes
Within the parasitised host cell, haemoglobin is degraded for the attainment of amino acids, used 
for parasite growth and development. The parasite cannot survive without digestion of 
haemoglobin since it is unable to achieve the biosynthesis of many essential amino acids. This 
process occurs in the food vacuole where haemoglobin is degraded to heme and globin, the latter 
being used for amino acid synthesis. Heme is however toxic to the parasite and is detoxified by 
oxidation to hematin with subsequent crystallisation within the pigment vacuole. Aside from this 
process of haemoglobin degradation, it is clear from Figure 3 that there are many potential 
targets of bio-chemical intervention. Furthermore, since protozoa are unicellular eukaryotes, 
knowledge of structures such as the nucleus, rough endoplasmic reticulum and mitochondrion 
are well established.
The main groups of antimalarial drug therapies will now be discussed in addition to their 
mechanism of action.
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1.2.2 Endoperoxides
The development of the endoperoxide antimalarial subclassclass is owed to the isolation of 
artemisinin 1, a sesqueterpene lactone and the active ingredient within the Chinese herb 
‘qinghao’ {Artemisia annua) used traditionally for treating fever.
1 2 R=H Dihydroartemisinin
3 R=Me Artemether
4 R=Et Arteether
5 R=C0(CH2)2C 02H Artesunate 
Figure 4. Artemisinin and its semi-synthetic derivatives
The development of semi-synthetic derivatives of artemisinin generated a water soluble 
derivative, artesunate 5, and the analogues, artemether 3 and arteether 4, all having superior 
activity and absorption to artemisinin. All derivatives are metabolised to the active agent 
dihydroartemisinin in vivo acting against gametocytes, the sexual stages of the parasite that infect 
mosquitoes, thereby preventing transmission of parasites in subsequent blood meals.
Artemisinin although poorly soluble is fast acting, effective for both the treatment of acute vivax 
and falciparum  malaria. The artemisinins do not have any effect on liver hypnozoites and are not 
useful for chemoprophylaxis. Artemesinin can be administered orally, intramuscularly or by 
suppository; artemether orally or intramuscularly; and artesunate intramuscularly or 
intravenously. Artemisinin derivatives are extensively used against malaria; however cost, 
supply, short half-life and high recrudescence remain issues with this class of drug.21’22 Thus they 
are mainly used in combinations with lumefantrine or mefloquine in order to avoid the 
coexistence of multiple parasite stages and increase treatment compliance, an approach adopted 
in most affected regions based upon the recommendation of the WHO.23’24
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1.2.2.1 Mechanism of Action
Many studies have been undertaken to elucidate the mechanism of action of artemisinin. ' The 
mechanism by which these compounds act is poorly understood but is believed to involve iron- 
catalysed decomposition to form free radicals able to modify key biological targets4,31-33 
Endoperoxides are known chemically to breakdown in the presence of iron to generate free 
radicals,26’28’34’35 a factor that can explain the selective toxicity of artemisinin to parasites, since 
the malaria parasite is rich in heme-iron due to the breakdown of haemoglobin. Furthermore 
artemisinin and derivatives are inactive against parasite forms that lack hemozoin such as certain 
strains of P. berghei36 and the related parasite Babesia microti,4’37
The endoperoxide bridge has been shown to be essential for activity.30,38 For instance Brossi and 
co-workers synthesised and evaluated deoxy and peroxy derivatives of artemisinin. The deoxy 
analogues showed poor activity when compared to their peroxy counterparts, clearly 
demonstrating the requirement of the endoperoxide bridge for antimalarial activity.39
The reactivity of 1,2,4-trioxane molecules structurally related to artemisinin assessed with the 
heme model manganese(II) tetraphenylporphyrin, led to the observation that pharmacologically 
active drugs form covalent adducts by the addition of a drug-derived radical onto the porphyrin 
macrocycle, whereas no reaction is obtained with compounds lacking activity, suggesting that 
alkylation is likely to be one of the key factors of the pharmacological activity of endoperoxide- 
based antimalarial drugs.40 It has also been reported that in vitro dihydroartemisinin and 
artemisinin react covalently with several malaria specific proteins for instance, the 
translationally controlled tumour protein (TCTP) in the presence of hematin.41 Furthermore, it 
has been shown that artemisinins, but not quinine or CQ, inhibit the plasmodial protein sarco 
endoplasmic reticulcum Ca2+-ATPase (SERCA) orthologue (PfATP6) of P . falciparum.42
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1.2.2.2 Synthetic Endoperoxides
Several novel peroxide antimalarials have been synthesised based on the knowledge that the 
endoperoxide-bridge is crucial for activity leading to the development of among others, synthetic 
tetraoxanes and trioxalanes.32,43'47 Araewu and co-workers assessed a range of orally active 
dispiro 1,2,4,5-tetraoxane 6 with activity superior to artemisinin.48,49
N
r4 R], R2 = cyclic ketones
R3, R4 = amines, amino acids
6
Figure 5. Novel tetraoxanes
In addition, trioxolane 7 was selected for Phase I clinical trials in humans since it has been 
shown to possess potent antimalarial activity against both P. falciparum  and P. berghei in 
addition to comprising a good toxicology profile 44 Hybrids such as 8 that attempt to combine 
two pharmacophores have been developed by Meunier and co-workers.50 Although potent many 
of these “trioxaquines” have been prepared as mixtures of enantiomers and diasteriomers.
7 8
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1.2.3 Quinoline Containing Antimalarials
1.2.3.1 Aminoquinolines
Natural products quinine 9 and isomers quinidine 10, cinchonidine 11 and cinchonine 12 are
centuries for the treatment of malaria (quinine is the most active ingredient). In 1908, the 
structure of quinine was theorised and later confirmed in 1944. Subsequent structure activity 
relationships confirmed that the quinoline nucleus is essential for activity, an understanding that 
led to the development and assessment of various synthetic derivatives creating the 4- 
aminoquinoline (4AMQ) antimalarials.
alkaloids found in the bark of the cinchona tree that were used by native South Americans for
.OH
9 10
.OH
11 12
13
Figure 6. Structures of quinine 9, quinidine 10, cinchonidine 11 cinchonine 12 and chloroquine 13
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The most significant example of Ehrlich’s ‘magic bullet’51 within the field of antimalarial drug 
design is undoubtedly CQ 13. CQ is one of the most important synthetic antimalarial 
chemotherapeutic agents in history since it is well tolerated, cheap and potent against all forms of 
plasmodium. CQ is a potent schizonticide that does not inhibit the liver cycle but has been used 
for both treatment and prophylaxis of malaria. Without doubt the demise of CQ through parasite 
resistance produced the biggest blow to the control and eradication of malaria. The molecular 
basis for the development of CQ resistance has been under much debate, with studies conducted 
by Bray and co-workers suggesting that modifications in the food vacuole lead to the decreased 
uptake o f CQ by CQ resistant parasites, rather than enhanced cellular exit of preaccumulated 
drug. In addition, they found that the initial rate of CQ accumulation by resistant parasites is 
increased by the calcium channel blocker Verapamil,53 although this cannot be used for the 
clinical treatment of malaria.
I.2.3.2 Mechanism of Action
CQ causes many biomolecular alterations, including the rapid degeneration of ribosomes, 
inhibition of protein synthesis and dissimilation of ribosomal RNA, when used against Bacillus 
megaterium,54 As yet a precise mechanism of parasite death by CQ is not completely understood. 
It is, however, generally accepted that inhibition of hemozoin formation and FPIX-CQ 
interactions are a crucial part of their antimalarial efficacy. In the presence of free hematin, CQ 
and quinidine associate with the hematin monomer.55 Furthermore, inhibitors of haemoglobin 
digestion antagonise CQ activity.56 It is believed that the association of the quinoline nucleus 
with hematin restricts the growing hemozoin crystal preventing further sequestration of 
additional heme that then accumulates to levels that kill the parasite.55 In addition, a correlation 
was observed between the hematin binding constant of these compounds and their ability to 
inhibit hematin crystallisation, suggesting that these compounds mediate their activity through 
binding to hematin.57
CQ is a dibasic drug which diffuses down the pH gradient to accumulate about 10,000-fold in the 
acidic food vacuole of the parasite (pH 5.4-5.558). It has been shown that CQ uptake is due to 
binding of CQ to hematin rather than active uptake,52 or by exchange for protons, by the
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plasmodial Na+/H+ exchanger, and is therefore independent of NHE (Na+/H+ exchanger) 
activity.59 Furthermore, 4AMQs related to CQ have been shown by SAR to require electron 
withdrawing groups at the 7-position of the quinoline ring for activity against hematin 
polymerisation and parasite growth, with chlorine giving the most potent activity.60
There are a vast range of 4-aminoquinoline and quinoline containing antimalarials developed as 
analogues of CQ, possibly the most significant of which are amodiaquine (4-aminoquinoline) 14 
and mefloquine (quinoline methanol) 15.
14 15
Amodiaquine has been part of the chemotherapeutic armoury against malaria, as an alternative to 
CQ since the 1940s. Generated through mass screening programmes in the U.S. at the end of 
World War II it was used for prophylaxis in 1963 due to problems in Vietnam with CQ resistant 
malaria. However, adverse side effects linked to metabolic activation in vivo have limited its 
clinical use. Furthermore, cross-resistance between amodiaquine and CQ has been reported.4,61’62
1.2.3.3 New Strategies
Isoquine 16a is a 4-aminoquinoline antimalarial developed by O’Neill and co-workers as an 
alternative to amodiaquine. By interchanging the 3’ hydroxyl and the 4 ’ Mannich side-chain 
function of amodiaquine they produced a compound with potent in vivo and in vitro activity. 
Furthermore, isoquine does not undergo bioactivation in vivo thus having potential as a safer 
alternative to amodiaquine.63 A drawback with 16a was extensive first pass metabolism of the 
diethylamino side-chain. This was solved by replacement of this moiety with an N-tert-buty\ 
functional group giving analogue 16b. N-tert-butyl isoquine (16b) has just entered Phase 1 
clinical trials in humans in a project sponsored by GSK and MMV.
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1.2.4 Quinolinemethanols
The quinoline methanol subclassclass are synthetic derivatives of quinine developed alongside 
the aminoquinoline antimalarials. Mefloquine (Lariam®) 15 is a quinolinemethanol that exhibits 
potent antimalarial activity for both the treatment and prophylaxis of malaria, though resistance 
was reported shortly after introduction.64 The quinolinemethanols are understood to share their 
mechanism of action with CQ since it has been shown that CQ competitively antagonises 
mefloquine accumulation and mefloquine competitively antagonises CQ accumulation.65 
Furthermore blocking heme release with a protease inhibitor such as RO40-4388, an inhibitor of 
plasmepsin I, reduced the incorporation of radiolabelled CQ and quinine into malarial pigment 
by 95%, while causing a 70% reduction in the incorporation of radiolabelled mefloquine.56 In 
addition, the cysteine protease inhibitor E64 reduced the incorporation of CQ and quinine into 
malarial pigment by 60 and 40% respectively, confirmed later by Sullivan and co-workers 
finding that inhibition was antagonistic to mefloquine action as it is to CQ action. This suggests a 
common mechanism for quinoline antimalarial action dependent on drug interaction with both 
hematin and hematin polymer.55 Although mefloquine interacts weakly with free FPIX it has 
been shown to inhibit FPIX polymerization in vitro with an efficiency similar to or somewhat 
less than that of CQ.4’57
Since Mefloquine exhibits potent activity versus CQ resistant parasites it has been widely used 
for prophylaxis and treatment of patients with CQ resistant malaria and is usually well tolerated 
though severe adverse effects have been reported, some of which have been reported as 
permanent.66,67
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1.2.5 Quinoline Related Compounds
1.2.5.1 Phenanthrene Methanols
The phenanthrene methanol antimalarial drugs were developed as analogues of quinine as part of 
the Walter Reed Army Institute of research screening programme,68 where the two fused rings of 
quinoline were replaced by other aromatic systems resulting in the use of a three ring 
phenanthrene system. The 9-phenanthrenemethanol halofantrine 17 (HF, Halfan®) showed the 
most potent activity69 and has been used clinically with some success.70,71 However, severe and 
potentially fatal side effects are associated with its use. ’ Furthermore, HF pharmacokinetics 
are variable due to poor bioavailability. Though absorption is enhanced by administration with 
fatty foods, this leads to unpredictable and often unacceptably high serum levels.4 Resistance to 
HF is linked to a mutation in the pfmdr-1 (plasmodium falciparum multi-drug resistant) gene as 
observed for related compounds quinine and mefloquine.74
1.2.5.2 Lumefantrine
Lumefantrine 18 is a racemic fluorene methanol synthesised and assessed for antimalarial 
activity in Beijing.75 It shares many properties with HF, including structural similarities in 
addition to poor and variable bioavailability resulting in a requirement for co-administration with 
fat.76,77 A joint development between Novartis Pharma and the Academy of Military Medical 
Sciences (Beijing, China)75 led to its successful use in combination therapy with artemether 
(Coartem®).78,79
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I. 2.6 Protease Inhibitors
Protease inhibitors are used routinely as part of HIV-1 (human immuno deficiency virus) 
combination treatment regimens80,81 and have displayed significant activity against malaria 
parasite growth.82 Therefore protease inhibitors have applications within malaria treatment and 
prophylaxis in addition to the treatment of HIV/ malaria co-infection.
The intraerythrocytic degradation of haemoglobin is required for amino acids used for parasitic
oi o4
growth and development, believed to be an ordered process mediated by protease enzymes. ’ 
Plasmodium aspartic protease enzymes, termed plasmepsins, degrade host cell haemoglobin 
releasing amino acids and toxic monomeric heme and it is believed that plasmepsins I, II and IV
Of
are responsible for the initial cleavage. The process is specific with Plasmepsin I being 
responsible for the initial cleavage of the haemoglobin tetramer at the hinge position, making a 
single cleavage between a-33Phe and 34Leu and since this takes place at the hinge position, the 
molecule unravels exposing other sites for proteolysis.86 A second aspartic protease, Plasmepsin
II, has also been identified and may have a role in the cleavage of denatured haemoglobin.84 
Falcipain, a cysteine protease of the papain family, is also implicated in the cleavage of peptides 
from the denatured haemoglobin. There are four known falcipains (FP) labelled FP-1, FP-2, 
FP2’ and FP3 with FP2 and FP3 being responsible for haemoglobin hydrolysis. Furthermore, it 
has been shown that alterations in the FP2 gene cause the accumulation of undegraded 
hemoglobin in trophozoites. ' The globin fragments resulting from this process are presumably 
transported to the parasite cytosol where they are degraded further to release amino acids that are 
used by the parasite. As previously discussed, it is generally agreed that the remaining hematin
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residue, which is potentially toxic, is removed via a polymerization process, degradation, or 
export.
Several protease inhibitors have been developed with chalcone 1990 and phenothiazine 2091 
showing in vitro antimalarial activity, therefore becoming a promising class of antimalarials 
particularly applicable for combination therapies.
1.2.7 Others
Antifolates -  Knowledge of cell biology led to the development of the antifolates examples of 
which are pyrimethamine, proguanil, chloroproguanil, sulfadoxine and dapsone all acting on the 
folate pathway thereby preventing DNA synthesis as shown in Figure 7. Antimalarial antifolates 
have been central for prophylaxis and treatment of malaria. This drug family was discovered 
during World War II, since this time no novel antimalarial antifolates have been developed that 
have reached Phase I/II stages since little research has been done in this area.92
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Figure 7. Folate biosynthetic pathway
The most clinically significant antifolate is the combination of pyrimethamine 21, an inhibitor of 
dihydrofolate reductase, and sulpfadoxine 22, a sulfonamide that interferes with the action of 
dihydropteroate synthetase. Both drugs act on the folate pathway thereby inhibiting the 
production and maintenance of new cells by impeding nuclear division at the time of schizont 
formation in erythrocytes and the liver.
Fansidar® (pyrimethamine-sulfadoxine) acts synergistically, an advantage since this can be a 
method of negating parasite resistance mechanisms, although parasite resistance to this
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combination is reported.92,94 More recently, chloroproguanil has been developed in combination 
with dapsone as LapDap® by work supported by the WHO at the University o f  Liverpool with 
the cost of synthesis covered by GSK, WHO and the UK Department for International 
Development. The mechanism of action is synergystic by inhibition of the folate pathway at two 
points, in a similar manner to Fansidar®, since chloroproguanil targets dihydrofolate reductase 
and dapsone targets dihydropteroate synthetase similar to pyrimethamine and sulfadoxine 
respectively. Unforunately LapDap has been withdrawn from the market due to adverse reactions 
observed in a Phase III trial of LapDap and artesunate.
Tetracyclines -  are a slow acting class of antimalarials whose mechanism of action is unclear95 
but believed to involve inhibition of protein synthesis, blocking expression of the apicoplast 
genome, resulting in the distribution of nonfunctional apicoplasts into daughter merozoites.96,97 
The most notable members of this class are the semi-synthetic tetracycline antibiotics 
doxycycline 23 and tetracycline 24 which are effective for the prophylaxis of malaria.98,99
Napthoquinones have a broad spectrum of activity100' 102 and are believed to work by inhibition 
of parasite electron transport systems.103,104 Atovaquone 25a is a napthoquinione used in 
combination with proguanil as Malarone® for treatment and prophylaxis of malaria.98,105 
Recently GSK in collaboration with the MMV developed a novel class of pyridones with activity 
against atovaquone resistant parasites such as 25b.
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1.2.8 Drugs Used Against Other Diseases
As the biological knowledge of the malarial parasite grows there are various novel targets being 
exploited for the design of innovative chemotherapeutic strategies. Type 2 fatty acid 
biosynthesis,106' 108 plastid DNA replication and transcription,95’109 glucose transport,110 nutrient 
uptake,111’112 and nucleotide biosynthesis93’108’113 being examples of novel antimalarial targets. 
Furthermore the elucidation of the malarial genome and the discovery of its high AT (adenine 
and thymine nucleotides) content15 termed super-AT islands,114 have rendered compounds with 
an ability to bind to DNA potential drug templates.114’115 A common approach to the design of 
novel agents for chemotherapy begins with the screening of drugs for other diseases thus there 
are many reports of this form of drug development within the literature such as folate 
antagonists,116' 119 natural products,120' 125 antibiotics,126' 128 antiretrovirals,129’130 and iron 
chelators.131' 134 The most exciting of which is the study of HIV antiretroviral therapies since 
these protease inhibitors could have an added benefit in patients suffering from HIV and malaria. 
Although findings suggest that the effectiveness and tolerability of antiretrovirals in patients with 
malaria and HIV-1 co-infection may contribute to altered malaria disease outcomes.135’136 
However, a synergistic relationship between CQ and various HIV protease inhibitors is 
recognised82’137' 140 within both CQ resistant and -sensitive parasites with saquinavir 26, ritonavir 
27, and lopinavir 28 being the most potent137’139 both in vivo and in vitro although to date they 
have not been employed clinically.
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Of significance to us is the aromatic diamidine pentamidine 29 (PMD) used clinically for the 
treatment of the parasitic infections leishmaniasis and African trypanosomiasis (sleeping 
sickness) in addition to the fungal infection Pneumocystis carinii pneumonia (PCP) caused by 
Pneumocystis jirovecii,]A1 an opportunistic infection in immunocompromised patients such as 
those receiving immunosuppressants but more frequently in HIV/AIDS patients. The 
antimalarial activity, possible mechanism of action and properties of PMD are discussed in detail 
within Chapter II since this is the seed of the research completed within this thesis.
NH NH
29
Figure 8. Other antimalarials
CHAPTER II 
PARTI
Dicationic Antimalarial Chemotherapy
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A review of the medicinal properties of dicationic compounds is important due to the nature of 
the work described in this thesis. The research undertaken is divided into two sections that 
discuss dicationic and mono-cationic antimalarial drug templates their development and 
antimalarial activity.
A separate numbering system will be used in this chapter for all Figures, Schemes and 
Compounds.
2.0 An Introduction to Dicationic Antimalarials
2.0.1 Ammonium Derivatives
Post plasmodial invasion, the parasitised erythrocyte becomes highly modified. Among these 
alterations, the phospholipid content of the infected erythrocyte increases approximately 500 
fold, of which phosphatidylcholine (PC) becomes the major component at 40-45% of the total 
phospholipid content.142,143 PC is required for membrane biogenesis, a process necessary for 
parasite growth and development. PC biogenesis does not occur in mature erythrocytes,142 and it 
is synthesised de novo via the Kennedy pathway as shown in Figure l 144 or by the 
decarboxylation of phosphatidylserine.145,146 The Kennedy pathway is responsible for the 
majority o f the phospholipid formed and is the most important pathway.146
H O
Choline
ATP ADP 
1ÜK1
______Kennedy pathway
CTP PPi
Phosphocholine------------- ^ — j » C D P-Choline Ic p H7 T
DAG CMP
> -  PC
Figure 1. Kennedy pathway for PC biosynthesis and the structures of choline. Abbreviations; CK, choline kinase; 
CCT, choline phosphate cytidylyltransferase; CDP-Choline, cytidine diphosphate choline; CPT, choline 
phosphotransferase; DAG, diacylglycérol; PC, phosphatidylcholine.144
The first step of the de novo pathway involves incorporation of choline, followed by enzymatic 
steps with choline kinase (CK), choline phosphate cytidylyltransferase (CCT) and choline
An Introduction to Dicationic Antimalarials 22
phosphotransferase (CPT) respectively to generate PC. CK is the first enzyme in the Kennedy 
pathway, the precise role of which with respect to parasite growth and survival is not fully 
understood, although it is believed to play a pivotal role in trapping the essential choline polar 
head group inside the malaria parasite.144
The incorporation of choline is essential for this pathway to occur, inhibition of choline uptake 
proving lethal to the parasite. Ammonium derivatives have been employed as analogues of 
choline, some of which exhibit potent antiprotozoal activity against P. falciparum  inhibiting CQ 
sensitive and -resistant parasite forms.144,147' 150 Hexadecyltrimethylammonium bromide 1 is a 
potent inhibitor of P. falciparum growth in vitro and P. yoelii in vivo with trophozoite and 
schizont stage parasites being particularly sensitive to its effects.144
B r
The mechanism of action of these ammonium salts is believed to involve inhibition of CK 
leading to a decrease in PC and parasite death.144 Interestingly, the stage specificity o f these 
molecules corresponds to the expression pattern of P. falciparum-CK correlating to a decrease in 
phosphocholine generation. Furthermore ammonium salts 2 and 3 are believed to inhibit CCK 
and CPT action respectively.144
N \
Br‘
3
The evaluation of mono-cationic quaternary ammonium salts, led to the elucidation that 
antimalarial activity is related to the ability of quaternary ammoniums to mimic choline. 
Development of these compounds was essentially centred on the variation of carbon chain 
length.144,147,150 Naturally, the next stage of development involved the evaluation of bis- 
quatemary ammoniums150,151 allowing variation of the parent structure. The structural
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requirements of ¿us-quatemary ammonium salts are similar to those of mono-quaternary 
ammonium salts i.e. polar head, steric hindrance and lipophilicity around the nitrogen function 
such as methyl, hydroxy ethyl, ethyl and pyrrolidinium.151
G25 (4), is a product of this concept possessing potent antimalarial activity, inhibiting 50% 
parasite growth (IC50) at a concentration of 0.65 nM .152 In addition, G25 concentrates within 
infected erythrocytes to several hundred fold higher than the surrounding medium being 1000- 
fold less toxic to mammalian cell lines, curing monkeys infected with P. Falciparum and P. 
Cyanomolgi.l53
N - ( C H 2) 16— n
Naturally, additional analogues were generated in a bid to develop more potent compounds. 
Unfortunately, the poor oral bioavailability and toxicity associated with G25 became evident 
halting its development.154 Using a similar strategy, ¿w-2-aminopyridinium salts such as 5 and 6 
were generated displaying potent antimalarial activity with I C 5 0 S  of 0.5 nM although their oral 
activity is not reported.152
(CH2)12 2Br"
N NH2 
(CH2)12 2Br"
NH2
5 6
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5/s-quatemary iodide salt 7 (T16) is a direct analogue of G25 showing potent antiplasmodial 
activity. Choline transport is the suggested mode of action for these compounds; however their 
precise mechanism of parasite inhibition as yet cannot be stated definitively. G25 and T16 inhibit 
choline uptake into P. falciparum and Saccharomyces cerevisiae infected cells, inhibiting their 
growth.155,156 Furthermore, G25 inhibits both the de novo PC metabolic pathway (Kennedy 
pathway) and the synthesis of phosphatidylethanolamine from phosphatidylserine (alternative 
route) indicating that G25 specifically targets the pathways for synthesis of the two major 
phospholipids, PC and phosphatidylethanolamine to exert its antimalarial activity.155
Interestingly, it appears that inhibition of phospholipid synthesis is not the sole mode of action 
by which these compounds work. T16 shows potent antimalarial activity and an ability to bind 
significantly to heme, an attribute which also correlates to the observed activity of this 
compound since accumulation assays reveal that this compound is readily concentrated several 
hundredfold into parasitised erythrocytes while approximately 80% of the drug was distributed 
within the parasite itself, 50% of which was located in the parasite food vacuoles. Furthermore, 
decreasing ferriprotoporphyrin IX (FPIX) concentration caused a marked decrease in the 
antimalarial activity of T16. In addition to these factors, it appears that this dication is a substrate 
of the induced permeability pathways present within malaria infected erythrocytes, 157 a process 
that will be discussed in more detail within section 2.5.3.
Further developments within this series led to the generation of the 6/s-thiazolium salt T3 10 and 
its prodrug TE3 8. The non-ionic pro-moiety was developed in the hope that it would improve 
the bioavailability of the drug. Although in-depth metabolism studies on this prodrug do not 
appear to have been undertaken, an intermediate metabolite with a molecular weight of 577 is 
noted which corresponds to compound 9. TE3 is rapidly converted in vivo to the active
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compound, both prodrug and active moiety possessing potent oral activity with ED50S of 5 and
15813 mg/kg respectively versus P. vinckei.
o o
Motoshima and co-workers pyridinium series 12 is derived from antiplasmodial structure activity 
relationships developed previously for analogue 11, From these studies they developed a range 
of dicationic analogues inexpensively from low cost materials in two synthetic steps.159
R= CmH2m+,NH n = 6,8,10,12 
m = 4,6,8
13 ED5o = 8.2 mg/kg
PhNH
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Compounds bearing alkyl or phenyl groups were found to have enhanced antimalarial activity in 
vitro in comparison to other analogues tested. In addition, compound 13 (R= C4H9NH n=12) is a 
molecule with potent antiplasmodial activity in vivo (P. berghei-infected mice) with an ED50 of
8.2 mg kg '1. Furthermore, the relative position of the amide bond and pyridinium ion had little 
effect on activity. In terms of in vitro activity, the lead compound 13 had enhanced activity 
compared to CQ however the in vivo activity of this analogue was reduced. The authors attribute 
this relationship to the high level of excretion resulting from the hydrophilicity imparted from 
their cationic character although some analogues showed enhanced activity in vivo compared to 
their in vitro activities and visa versa.159 Studies into the mechanism of action of these analogues 
remain unpublished at present but based on those published for similar compounds presumably 
involve the inhibition of PC biogenesis and binding to FPIX.
2.0.2 Xanthones
Hydroxyxanthones have been identified as novel antimalarial agents, believed to exert their 
activity within the parasite food vacuole targeting heme detoxification. 4,5-Dihydroxyxanthone 
14 has been shown to subvert the detoxification of free heme by forming a hydrogen bonding 
interaction between the hydroxyl groups and propionate side chains of heme, in addition to n-n  
stacking between both aromatic systems forming a complex with the heme dimer. Furthermore 
the xanthone carbonyl moiety coordinates to the heme iron.160
O
Xanthones 15 and 16 are potent compounds designed as analogues of 14 with protonable side 
chains in an attempt to enhance the interaction of these compounds with the propionate functions 
of heme, while enhancing their accumulation into the acidic parasite food vacuole. The potency 
of the analogues increases with carbon chain length until carbon 6 after which activity begins to
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diminish. Interestingly, the correlation between heme binding affinity and antimalarial potency is 
almost linear, suggesting that a high binding affinity to heme is a critical factor to their 
antimalarial potency.161
IC50 = 0.07 |iM versus all strains IC50 = 0.10 mM vs. D6
0.11 pM vs. W2
D6; CQ sensitve, W2; multidrug resistant, 8.26 (iM vs. F86
F86; CQ resistant
Compound 16, was employed for confocal fluorescence microscopy studies to elucidate the 
subcellular location of this compound and was observed to be in the digestive vacuole, where it 
accumulates from 5 to approximately 33,000 pM within 1 hour o f exposure to parasitised red 
cells through the mechanism of uptake described in Figure 2.162
Figure 2. Proposed mechanism of uptake and accumulation in the acidic vacuole of P. falciparum -infected red
blood cells.162
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2.0.3 Summary
It is generally accepted that 6/s-ammonium compounds enter infected erythrocyte by new 
permeability pathways (NPP) after which they accumulate to high concentrations, a process 
required in order for them to exert their antimalarial effect.163 They are not transported by the 
host erythrocyte choline carrier and penetration of the host cell compartment is solely through 
the NPP. They are however, carried by the parasite choline carrier therefore adding a level of 
selectivity over interactions with intracellular targets.164 The precise anti-malarial mechanism of 
action of ¿»«-ammonium compounds is not fully understood however and it has been shown that 
they inhibit the synthesis of phosphatidylcholine de novo, their precise point of inhibition 
varying between inhibition of choline uptake and/or the enzymes required in the pathway.155 
They have also been shown to be able to bind to FPIX, a process usually inferred within the 
accumulation of drugs within the parasite and antimalarial action.157,163 Potent against multi drug 
resistant P. falciparum  malaria these molecules are an exciting class of drug with TE3 scheduled 
to commence clinical trials, having the advantage that its mechanism of action is unexploited 
within present chemotherapeutic regimens.165 It is quite likely that these compounds are dual 
molecules, exerting their antimalarial activity via two simultaneous toxic effects on intracellular 
intraerythrocytic parasites.163
Other functional groups with the ability to ionise readily at physiological pH are discussed 
below.
2.1 Diamidines
NH
Figure 3. The amidine functional group
The amidine moiety consists of two nitrogen atoms bonded to a carbon centre as the N=C-N 
functional group shown in Figure 3. The pKa of the group is large (12.4166) due to the ability of
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the nitrogen atoms to stabilise the positive charge by resonance forms 17 and 18, the electronic 
distribution over the functional group represented by structure 19.
The existence of resonance form 18 gives rise to the possibility of restricted rotation about the C- 
N bond. Rotational barriers are expected to lie between those of single and double bonds being 
few tens of KJ mol’ 1 for single and few hundred kJ mol' 1 for double bonds.167
The application of amidines has been demonstrated within synthetic chemistry as organocatalysts 
and nucleophiles168’ 174 in addition to ligand based coordination chemistry.175’ 177 Medicinally, 
diamidines find applications within the areas of cardiovascular, 178’ 181 antiviral,182’183 
antibacterial184,185 and antitumor186,187 drug templates in addition to being present within the 
DNA and RNA component, cytosine 20.
Since the medicinal properties of diamidines form the basis of the research undertaken, they will 
be discussed separately under section 2.5.
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2.2 Diguanidines
Figure 4. The Guanidine Moiety and Resonance Forms
The guanidine moiety consists of three nitrogen atoms bonded to a carbon centre as the N=C-N2 
functional group shown in Figure 4. Guanidines are more basic than amidines, the pKa of this 
group being 13.6.188 The increased ability of the molecule to stabilise positive charge is derived 
from the formation of guanidinium ion 2 1 , the increase in electron density delocalised over three 
nitrogens, each having a third of a positive charge. The resonance stabilization imparted by the 
guanidine functionality and to a lesser extent the amidine, may be characterised in terms of 
properties commonly associated with “conventional” aromatic systems. Such properties include 
enhanced thermodynamic stability, delocalization of 7i-electrons through p-orbital overlap and 
energetic barriers to rotation of 71-energy.189 As a consequence, aqueous guanidine solutions are 
close in basicity to solutions of sodium hydroxide and are therefore readily protonated at 
physiological pH .166
Synthetically, guanidines are employed as catalysts, chiral auxiliaries and chiral bases within 
asymmetric synthesis.190' 197 Examples include the nitroaldol reaction, 198 Strecker reaction199’200 
and conjugate addition.201,202 Interestingly, guanidines have found a role within the development 
of greener fuel systems aimed at replacing the chemical additives currently classified as 
dangerous by European legislation.203 Juyal and Anand have developed guanidines, functioning 
as highly effective fuel stabilisers and dispersants that are non-toxic, non-polluting fuels. 
Aside from their synthetic applications, interest surrounding the guanidine moiety centres around 
its biological importance. There are many guanidine and guanidinium-bearing natural 
products204'209 such as those within marine systems,210'214 the DNA nucleobases arginine 24 and
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guanine 26 in addition to the skeletal muscle component creatine 25, and endogenous 
compounds agmatine 27, guanabenz 28 and amiloride 29.
24 25
Within medicinal chemistry the guanidine moiety is frequently used as a DNA binding agent due 
to a high specificity for AT-rich DNA sequences. This property of the guanidine functionality 
can be further observed in the case of the Zus-amine ethidium 30a.
30a 30b
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A monocationic intercalator of DNA and RNA, ethidium bromide intercalates into nucleic acid 
base pairs with little sequence specificity.215'217 Interestingly, replacement of the amines for 
guanidines gives a ligand (30b) with selectivity for binding at AT-rich sequences in a non- 
intercalative manner, with a weak intercalatory interaction at GC sites. Furthermore, the binding 
strength of the 625-guanidine is much greater than that of ethidium.217
Guanidines and diguanidines boast many therapeutic properties which include; anticoagulant,207 
antifungal,211'213’218’219 antiprotozoal,212’220'224 cytotoxic,211’213’225'228 antiviral,226'230 inhibition of 
insulin release,231 peptide mimetic,232'235 neuroprotective,236'240 protease inhibition206 and have 
applications as drug delivery systems.241 The antiplasmodial and antiprotozoal activity of 
guanidines have not been studied as extensively as diamidines, however several guanidine 
analogues have shown significant antitrypanosomal,221’223’224 leishmanial222 and antimalarial 
activity.220’224
Guanidines of furamidine 31 (DB75), a highly efficacious antiprotozoal compound currently in 
Phase II clinical trials, have been synthesised displaying potent activity versus P. Falciparum 
and T. brucei. rhodesiense. Lead compound 32 displays enhanced activity in vitro versus 
plasmodial rather than trypanosomal protozoa. Furthermore, the activity of this compound is 
enhanced with respect to those of PMD and DB75 itself.
HN
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The antiprotozoal mechanism of action of diguanidines is unknown though they exhibit a high 
selectivity for the parasite and are believed to be subject to transport mediated uptake. ’ 
Interestingly, diguanidines have been shown to possess potent antiplasmodial activity as shown 
in Figure 5, though this analogue is a poor inhibitor of hemozoin formation in vitro inferring a 
different mechanism of action.244
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In terms of their antitrypanosomal activity, it is believed that binding to DNA at AT-rich sites is 
part of their mechanism of action, as guanidines with this form of activity have been shown to 
bind specifically at this region,223’244 an interesting point when considering the AT richness of the 
malarial parasite genome.15,115 However, it is unclear what role this binding interaction plays 
within the cessation of trypanosomal survival mechanisms since there is evidence that binding to 
DNA does not directly kill the parasite,220 but rather leads to the inhibition of DNA dependent 
enzymes or inhibition of transcription by inducing alterations within the base pair structure.245,246 
Interestingly, the ability of guanidine 31 to bind to DNA was of a lower affinity than that of 
PMD and DB75, being 20-40% lower than the latter.220
Other guanidines with antimalarial activity include the tricyclic guanidine alkaloids 33 and 34, 
identified from the marine sponge Monanchora Unguífera. A mixture of which was found to be 
active against P. falciparum with an IC50 value of 3.81 pg/mL.212
NH NH
33 34
Diguanidines and Aralkyl diguanidines have been synthesised using the fluorene template 
showing potent in vitro activity against both T. brucei rhodesiense and P. falciparum ,224 The 
antimalarial activity of the most potent compounds versus P. falciparum is shown in Figure 6 
alongside their associated IC50 values.
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Figure 6. Fluorene Diguanidines
Clearly, addition of the A-alkyl group causes a reduction in antiplasmodial activity as observed 
for compounds 36 and 37 showing a decline in activity with increasing alkyl size; an isopropyl 
analogue gave an IC5o of 35.7 nM. Interestingly however, the /V-methyl analogue showed high 
activity in vivo although this was only assessed in the African trypanosomiasis animal model. 
The antimalarial mode of action of these compounds was not studied though the ability of these 
compounds to bind to DNA at the minor groove was confirmed.
Finally, within our assessment of dications as antiplasmodial agents, the finding that ¿«-tertiary 
amines such as G25 experience enhancement in activity due to the nature of the dication was of 
importance. It has been shown that when the dication is a ¿«-amidine or ¿«-guanidine the 
activity o f the compound is improved by approximately 2-fold against P. falciparum  as shown 
schematically in Figure 7.152
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Figure 7. Effect of dication replacement on antiplasmodial activity
2.3 Reversed Diamidines
Reversed Amidine
Figure 8. Structures of reversed amidine, amidine, and guanidine
The ‘reversed amidine’ moiety essentially comprises of an amidine functionality ‘reversed’ due 
to the bonding position to the desired drug template as shown in Figure 8. The concept of a 
‘reversed amidine’ is derived from the requirement for structure based relationship studies into 
the ability of this moiety to interact with DNA.
The antiprotozoal activity of reversed-amidines have been studied, although less than 
diamidines, particularly for antiplasmodial investigations. The antitrypanosomal and 
antileishmanial activity of reversed diamidines have been assessed against their diguanidine 
counterparts finding that a reversed amidine series was most effective against T. cruzi and L. 
donovani. ’ ’ In addition, Stephens and colleagues synthesised reversed amidine analogues
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of 2,5-diarylfurans for studies into their antimicrobial activity finding that compound'38 was 
fungicidal.219
The mechanism of action of the reversed amidines is unknown, although DNA binding is 
believed to play a role. Reversed amidines have been shown to induce cellular effects such as 
altered morphology of nuclei, swelling of endoplasmic reticulum and Golgi structures in addition 
to damage of mitochondrial and kinetoplast structures249 thus additional targets are believed to 
play a role.
Unfortunately, enhanced toxicity in vivo and poor oral bioavailability has limited the exploration 
of reversed amidine ligands. To date, a successful reversed amidine prodrug has not been 
generated.
Following the principles of drug design, our objective is the development of an agent toxic to the 
target whilst being non-toxic to host cells and host biological systems. Our interest in dicationic 
molecular systems will become evident, based on structural differences between plasmodium 
infected and non-infected cells. The 6/s-ionic systems chosen for development are the diamidine 
and diguanidine moieties based on their antiplasmodial properties. Naturally, our work 
commenced with the development of a structure activity relationship profile to gain information 
on the requirements of a drug template. We decided to use the aromatic diamidine PMD since its 
antimalarial activity is known versus P . falciparum, the most virulent malarial strain.250
PMD
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PMD is used clinically for the treatment of African trypanosomiasis, leishmaniasis and 
Pneumocystis carinii pneumonia. Although knowledge of the antimalarial activity of PMD is 
known, PMD has never been employed clinically for the treatment of malaria. Thus part of this 
chapter will discuss properties associated to trypanosomiasis, leishmaniasis and P. carinii 
pneumonia activity as knowledge of these systems are important to gain an insight into the 
properties of the compounds we are working with.
2.4 An Introduction to Diamidines and Their Development
In 1902, Thomas (Liverpool School o f  Tropical Medicine) demonstrated the trypanocidal activity 
of the synthetic compound p-aminophenylarsenic acid or atoxyl 39 in mice and rats infected with 
trypanosoiasis.3 Bertheim, Hata and Ehrlich broadened the target organisms to include the 
causative agents of syphilis, the spirochaete bacterium Treponema pallidum. After the 
elucidation of the structure of atoxyl, the two chemists and microbiologist Hata commenced 
medicinal chemistry drug design as we know it today, by varying the atoxyl structure leading to 
the discovery of salvarsan in 1910.251 The structure of salvarsan itself has caused much debate, 
the structure has however recently been confirmed as a mixture of compounds 40 and 41.252
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With the subsequent development of tryparsamide 42 at the Rockefeller institute for the 
treatment of trypanosomiasis and neurosyphilis, it seems the scientific community at this time 
were keen on the development of arsenides. In addition, tryparsamide had the advantage that it 
could penetrate the blood brain barrier (BBB) and thus was active during late stage sleeping 
sickness, a state that is hard to blockade.
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The first purely organic compound for the treatment of trypanosomiasis was Germanin 43 (or 
Suramin), highly effective for early stage disease but not late stage as it cannot penetrate the 
BBB.
The toxicity of arsenides and the effectiveness of Germanin led to the use of diamidine and 
diguanidine moieties as analogues, studied for the treatment of trypanosomiasis, presumably 
commencing with the replacement of the carbonyl oxygen function of Germanin for a nitrogen 
moiety.
Lourie and Yorke first demonstrated the activity of dicationic compounds versus 
trypanosomes253 by noting the curative properties of decamethylenediguanidine dihydrochloride 
44 later finding that diamidinoalkanes were more active than diguanidines,254 the most active 
being 11-diamidinoundecane dihydrochloride 45.255
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The work of Lourie and Yorke began the investigation of dicationic structures and analogues 
were synthesised by various groups,3’255 such as Kirk et al. 4,4’-diamidinostilbene 46 and Adams 
et al. 4,4’-diamidinodiphenoxypentane 47 employed for the treatment of Mediterranean and 
Indian kala azar.255 In 1942, Ashley studied the relationship between the chemical constitution 
and trypanocidal activity of a number of aromatic amidines255 finding that the greatest activity 
was obtained by bis- rather than mono-amidines of the type 48 where X is an alkyl chain; the 
most active being when one or more of the CH2 groups is replaced by O. Reviewing the 
literature, this is the earliest sighting of PMD, used extensively by the Belgians, British and 
French for the treatment of trypanosomiasis during the colonial period.3
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2.5 The Medicinal Chemistry of Diamidines
2.5.1 Introduction
The amidine moiety is often used for staining or molecular tagging applications due to its strong 
fluorescence256'258 and is a pharmacophore frequently employed within medicinal chemistry for 
its antiparasitic,259'261 anticoagulant,180’262’263 amoebicidal,264'267 insecticidal/pesticidal,268,269 
antiviral,270'274 antifungal,275'278 antibacterial,276’279'281 antihypertensive,282 antitumor,283'288 
antiinflammatory289,290 and analgesic properties.290 The attributes of the amidine moiety are not 
restricted to biological systems since it is also used within organic synthesis for instance as a 
chelating ligand, ' however it is their medicinal properties that will be discussed in detail 
commencing with the key compound pentamidine.
2.5.2 An Introduction to Pentamidine (PMD)
Pentamidine is an odourless, white, hygroscopic aromatic diamidine supplied as the isothionate, 
methanesulfonate (Lomidine®) or hydrochloride salt. Prior to the increased clinical use of PMD 
in North America for the treatment of AIDS associated P. carinii pneumonia,294 little was known 
about this compound. As with most amidines and diamidines, PMD and its analogues have a 
broad spectrum of activity, inhibiting a plethora of processes within tumor cells,295'299 MRSA,300 
A. Keratitis,264 trypanosomes,255’301'303 plasmodia,304,305 leishmania,304’306'310 Crithidia
fasiculata,3" S. aureus,311,312 C. neoformans,3'3 C. albicans,314'2'1 Escherichia coli K12,318 
Leptomonas sp, Fusarium, Babesia microti, Aspergillus, T. vaginalis, Scedosporium 
prolificans324 and Pneumocystis carinii pneumonia.297’325'328 In addition, PMD and PMD 
analogues have been shown to be NMDA receptor antagonists, neuroprotective in vitro from 
NMDA toxicity.329’330 An ability to interact with DNA is widely reported in the literature for 
diamidines245’284’331'337 with PMD in particular found to be 60 times more potent than cisplatin, 
inducing a higher frequency of programmed cell deaths associated to the inhibition of DNA 
synthesis by binding to DNA causing conformational changes.338 Furthermore, PMD was found 
to interact with the regulatory protein ubiquitin causing alterations to its conformation and a 6 % 
increase in P-sheet content.338
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2.5.2.1 Trypanosomiasis
Since the work of Ashley, PMD has been used for the treatment and prophylaxis of human 
African trypanosomiasis effective versus T. brucei. gambiense infection only.255,301 PMD is 
rapidly absorbed by trypanosomes and is lethal both in vitro and in vivo being specific for the 
parasite rather than the host cell.311 It has been shown that prolonged exposure to PMD in vivo 
may be of importance since the exposure time affects the sensitivity of the parasite. PMD is 
parasiticidal against trypanosomes, effective in the early stages of the disease prior to CNS 
infection due to an inability to permeate the blood brain barrier effectively.301’302 Although 
studies in patients with T. brucei. gambiense excluding involvement of the CNS have shown that 
after the last dose the cerebral spinal fluid contains small amounts of PMD.302 Therefore PMD 
could be used in the early-late stages of the disease, a hypothesis that has been confirmed 
clinically.340
2.5.2.2 Pneumocystis carinii pneumonia
Pneumocystis carinii pneumonia (PCP) is a disease mostly observed within the 
immunosupressed host, particularly those suffering from Acquired Immune Deficiency 
Syndrome (AIDS) were PCP is one of the most common AIDS-defining diagnoses.325 In 1958, 
the efficacy of PMD versus PCP was revealed.341 Since then, PMD has found routine use in the 
treatment of PCP.325 Furthermore, many diamidine analogues have been developed and screened 
as anti-PCP agents in the hope that they may circumvent the adverse reactions associated with 
the clinical use of PMD in PCP treatment that can cause severe morbidity and sometimes 
mortality.342 However, little development had been made within the area of PCP treatment with 
more than 50% of patients under PMD treatment suffering from adverse effects343 until the 
recent development of DB75 49 and the orally bioavailable prodrug DB289 50.
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To date, human trials suggest that DB289 is well tolerated and clinically efficacious against PCP 
and Pneumocystis jiroveci pneumonia.344
2.5.2.3 Malaria
PMD has never been used for the treatment of malaria although its activity is reported345,346 
therefore the antiplasmodial properties of PMD will be reviewed later within section 2.6.
2.5.2.4 PMD Toxicity
Due to poor oral bioavailability,347 PMD was administered through slow intravenous (i.v) 
injection, however when administered this way, hypotensive reactions and subsequent collapse 
due in part to the liberation of histamine have been observed, thus i.v administration is no longer 
recommended.348 To avoid the possibility of immediate toxic reactions associated with iv 
administration, the drug is now given intramuscularly to humans.349 PMD administered 
intravenously is reported to be painful, can cause sterile abscesses, sciatic nerve damage or 
gangrene.301
Other adverse effects reported with PMD use include fainting, hypotension,350 rash351 and 
cardiac toxicity. In addition, nephrotoxicity to PMD is reported, ' understood to be due to 
the ability of PMD to accumulate and localize significantly in the kidneys357 furthermore, PMD- 
induced acute pancreatitis is also observed clinically. That being said, insulin dependent 
diabetes is most commonly reported within the literature following PMD use.358'360 PMD- 
induced hypoglycaemia associated with high plasma insulin concentrations due to inappropriate 
insulin release and B cell destruction are reported.359,361 This process generates insulin dependent
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diabetes mellitus,362,363 the effects of which are irreversible, dose and time dependent.363 In
358certain cases, an increased insulin requirement even when PMD treatment ceased was noted.
Toxicity to PMD has been linked to the metabolic oxidative cleavage of the ether oxygens.364 A 
means o f circumventing PMD associated toxicity seems to be within the route of administration. 
Aerosolised PMD is now recommended for PCP treatment with studies confirming enhanced 
tolerance in HIV infected patients.365 Although this route does not appear to be applicable to 
trypanosomiasis and leishmaniasis presumably due to an inability of this route to target blood 
stage protozoa whereas PCP is localised within the lungs.
2.5.3 PMD Uptake in Malaria Parasites
2.5.3.1 Introduction
PMD and other diamidines accumulate significantly within the infected erythrocyte242,366 which 
begs the question, how does this dicationic drug molecule traverse the cell membrane? Specific 
pathways are understood to mediate the accumulation of PMD within leishmaniasis, 
trypanosomiasis and the new permeability pathways within the malaria parasite.242,36 '371
Pathways that mediate the uptake of nutrients into infected red cells are known processes we aim 
to target and therefore their properties will be discussed with respect to PMD and plasmodium 
induced permeability pathways. Out of interest, PMD uptake within trypanosome and leishmania 
infected cells will be briefly discussed.
2.5.3.2 Trypanosomiasis and Antimony Resistant Leishmaniasis
The specificity' of diamidines for infected cells is important when considering the amidine 
moiety as our choice of cation. Although we are not using the trypanosomal system, it is 
important to be aware of their properties within this system also. It is known that cationic drugs 
can accumulate into cells and concentrate in the mitochondria to concentrations up to 10,000
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fold.366 This level of accumulation cannot be due to simple penetration through a pore. Many 
mechanisms have been proposed for this accumulation,372 the most reasonable being that the 
differences induced within the cell membrane by the parasite play a role within the specificity of 
the drug for these cells, since it is known that diamidines are bound strongly by specific 
phospholipids.373,374
It has been shown that the PMD transport system in T. brucei and Leishmania parasites is carrier 
mediated311,370 showing substrate specificity and high affinity for the amidine moiety of PMD .311 
Specifically, PMD and other diamidines have been shown to be transport substrates for the P2 
aminopurine transporter.368 In addition, the diamidines PMD and berenil 51 have a high affinity 
for the P2 transporter with little affinity for the PI or H2 purine transporters even though it 
has been shown that P2 transports only adenine and adenosine whereas PI has a broader 
specificity.376,377 It has been shown that in addition to the P2 transporter, PMD uptake is 
mediated by other transporters termed the high affinity PMD transporter (HAPT1) and the low 
affinity PMD transporter (LAPT1) in addition to the adenosine-sensitive PMD transporter 
(ASPT1).371,378
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2.5.3.3 Malaria; New Permeation Pathways
The transporters of the malarial parasite and parasitised cells are of potential use as drug targets 
by inhibiting the uptake of essential molecules or as routes for the delivery of drug molecules, 
giving selectivity to parasitised rather than host cells. Upon parasitisation of the erythrocyte, 
various changes are induced within the cell, the most notable of which are new permeation 
pathways (NPP) occurring 10-20 hours post invasion.379 In order to proliferate and develop, the 
intraerythrocytic period of the parasite life cycle' produces 16-32 offspring asexually over 48
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hrs.380 To facilitate this, the parasite by its very nature is dependent on the acquisition of the 
necessary essential materials from the host cell and host environment, since the parasite is devoid 
of the metabolic equipment required for their synthesis.
Evidence for the presence of NPPs comes from the fact that in order to maintain parasite growth, 
haemoglobin is digested to obtain amino acids,381 choline used for phospholipid synthesis,143 and 
purine bases for the synthesis of nucleic acids382 using glucose for energy.383,384 Aside from 
haemoglobin which is abundant within the cell, these materials must be acquired from their host 
environment into the erythrocyte and indeed the parasite itself. Interestingly, other nutrients have 
also been identified,112’385 particularly for use in culture.386,387 Furthermore, the infected 
erythrocyte has been noted to have a high rate of lactate production, ’ particularly at the 
schizont stage of reproduction.388 This large rate of lactate production observed by the acidic pH 
within the food vacuole (pH 5.5)390 is important since additional pathways must be in place to 
prevent acidification of the parasite and host cell.
These processes impart a necessity for the parasite to acquire these essential molecules from its 
host whilst securing the removal of waste from the cell. This is achieved by modification of the 
red cell membrane enabling the increased transport of solutes in and out of both the parasite and 
host cell. The result of which is a modified erythrocyte cell membrane with an increased 
permeability to a diverse range of low molecular weight solutes, ’ phosphorylation of which 
is believed to trap these compounds within the cell.112
Knowledge of this increased permeability to solutes increased speculation within the scientific 
community that these processes could be targeted as a means of enhancing drug delivery into 
infected host cells while avoiding drug accumulation into healthy cells. Thus knowledge of the 
features of the NPP is important to our choice of dicationic moiety within the drug template and 
therefore will be discussed.
An Introduction to Dicationic Antimalarials 46
2.5.3.4 Properties of the NPP
Malaria infected human erythrocytes have been shown to have a broad specificity and 
increased permeability to organic cations391 and low molecular weight solutes via transporters 
different to those of healthy erythrocytes and more similar to chloride channels (Cf) in other cell 
types. ’ Therefore, akin to Cl' channels, there is an expectation for them to be permeable to 
cations, the magnitude of which would be a function of the counter-anion present. However, it 
has been noted that they are anion selective with significant cation permeability394 resulting in an 
increased permeability to a range of inorganic and organic monovalent ions (both cations and 
anions), zwitterions, and nonelectrolytes.379 The increased access of a variety of low molecular 
weight solutes via NPPs gives substantial permeability to a range of monovalent organic 
(quaternary ammonium) cations, the largest having an estimated minimum cross-sectional 
diameter of 1 1 - 1 2  A .391 Cations both small379 and large379,391 have been shown to pass through 
the NPP.
Staines et al. found that the rate of cation permeation was dependent on the nature of the anion 
present with no clear relationship between the permeation rate and size or hydrophobicity of 
these solutes showing a preference for small hydrophobic ions over larger or less hydrophobic 
solutes.391 Indications that the NPP is a channel come from the fact that it has broad specificity 
absent of discrimination of isomers393 and it does not saturate with increasing substrate 
concentration.392 Other attributes of the NPP include; flux blockade by a variety of reagents, it is 
nonsaturable, the activation energy for the transport of solutes is lower than that typical of carrier 
mediated transport but typical of that for a diffusive process, there is no discrimination between 
the enantiomeric forms of permeating solutes (though they do show differential sensitivity to the 
R- and 5-enantiomers of several optically active arylaminobenzoates), they have a general 
preference for anions and electro-neutral solutes over cations, are able to discriminate between 
alkali metal cations, and the rate of cation permeation is dependent on the nature of the anion
->7Q
present in the suspending medium.
PMD has been shown to accumulate into malaria infected red cells only.367 Interestingly, the 
accumulation of PMD into parasitised red cells can be blocked by inhibitors of haemoglobin
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digestion36' suggesting that PMD is a hematin binder. Indeed, a range of diamidine compounds 
have been shown to bind to FPIX and inhibit hemozoin formation in vitro. PMD uptake has 
been shown to be selective, sharing characteristics with the NPP due to two transport factors; an 
initial rapid non-saturable phase is observed for PMD uptake and the nature of the counterion has 
an effect on PMD transport (Cf < Br' < N 0 2' < SCIST ).367 Furthermore, ¿«-quaternary 
ammoniums have also been shown to bind to FPIX in the digestive vacuole being critical for 
both the accumulation and activity of these drugs.157
Choline is an essential nutrient required by infected cells, the transport of which is increased 
upon parasitisation of the red cell. Choline entry occurs by a facilitated-diffusion system 
involving an endogenous carrier, or through the NPP, this high increase in choline transport 
activity related to modifications in choline carriers and/or in their environment after plasmodium 
infection.379,395 The mechanism by which choline penetrates the intracellular parasite is not fully 
understood however, it has been shown that a parasite choline transporter is responsible for the 
uptake of choline into the intracellular parasite and not the host cell choline carrier. Furthermore, 
antimalarial choline analogues are transported by the parasite choline carrier and not the host cell 
carrier. In addition, ¿«-amidines and ¿«-quaternary ammoniums are acquired by a cooperative 
transport system between the induced permeability pathways in the host erythrocyte membrane 
and the parasite choline transporter as shown in Figure 9 .164 A factor that is very important 
within structured drug design since presumably in addition to the IPP, there is the possibility of 
additional routes of drug uptake by the parasite. However, it is not clear through which route 
choline inhibition by amidines occurs,156 through the endogenous carrier, the parasite choline 
carrier or the NPP.164
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Figure 9. Schematic representation shows the transport of drug and binding to FPIX. Definitions: (1) NPP; New 
Permeation Pathway, (2) Choline Carrier, (3) ß/crt; Plasmodium falciparum chloroquine resistant transporter.
It should however be noted that the antimalarial activity of amidines may not be related solely to 
uptake since if activity is dependent on uptake through the NPP, this does not explain why
 ^A i ^Aj^
amidines shielded by aliphatic groups are less active than unsubstituted amidines ’ (as shown 
in Figure 10) due to the preference of the NPP for compounds with an increased 
hydrophobicity.391
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Figure 10. Activity of shielded diimidazolines versus diamidines against CQ resistant parasites
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2.5.4 PMD- Pharmacokinetics and Metabolism
Pentamidine pharmacokinetics exhibit inter-individual differences in maximum plasma 
concentrations as well as pronounced drug accumulation302 with a long elimination half-life > 4 
days,397 an issue when considering the toxicity issues associated with PMD use. The metabolism 
of PMD (Figure 11) is important for the rational design of compounds in the hope of 
circumventing PMD associated toxicity. It has been shown that PMD is rapidly metabolised in 
vivo by P450 dependent mixed-function oxidase mediated mechanisms398'400 to at least seven 
primary metabolites with /V-hydroxylation resulting in a loss of activity.398,401 Therefore with 
respect to activity, it appears metabolism is deactivating.
343Figure 11. Metabolism of PMD (brackets and asterisks indicate compounds that have not been isolated)
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2.5.5 Resistance
Searching the literature, it is clear that little work has been done regarding resistance 
mechanisms for PMD or diamidines for that matter, and malaria. There are however many 
citations regarding resistance in the trypanosome which will be covered briefly.
Since trypanosomes are unable to metabolise PMD,400 metabolism based mutations can be ruled 
out as a resistance mechanism in the parasite. Diamidine-arsenical cross-resistance has been 
observed experimentally and appears to arise from alterations in the P2 transporter402'404 since 
the P2 transporter has been shown to accumulate melaminophenylarsenicals also.377 Additional 
evidence for the shared transport system between melaminophenyl arsenicals and diamidines 
comes from the varying degrees of cross-resistance to diamidines in the order stilbamidine > 
berenil > propamidine > PMD405 further suggesting that these compounds are recognised by the 
same transport system. Trypanosomal resistance to diamidines may therefore be due to 
alterations in the P2 transporter causing decreased accumulation of drug368 although it is noted 
that resistance to arsenicals and PMD is not as pronounced as to diminazene (berenil) indicating 
the presence of other transporters for the residual uptake of melaminophenyl arsenicals.369 The 
presence of more than one transporter could explain why some parasites without P2 activity have 
been shown to be sensitive to PMD.406
It is probable that high-level resistance is due to loss of more than one transporter and in the case 
of mutations at one or more of the transporters, the uptake of PMD may be unaffected since there 
is the possibility of switching over to one of the other transporters. It is therefore likely that 
transport/uptake mediated resistance for PMD will take longer to develop than for those drugs 
whose uptake has been shown to involve one transporter such as the melaminophenyl arsenicals. 
Despite its widespread use as a prophylactic, resistance to PMD has not been a significant 
problem in the field.242 This is illustrated by the fact that T. brucei rhodesiense strains from west 
and central Africa isolated in the periods 1960-1996 and 1999-2004 showed little difference in 
IC50 values to PMD.407
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2.5.6 Mechanism of Action
The mechanism of action of diamidines is unclear and heavily debated since they are active 
against many targets, therefore the elucidation of their major mode of action is difficult. It is 
however generally accepted that more than one mechanism may be taking place. PMD itself has
• 310been shown to interact with systems such as the respiratory chain within mitochondria, 
uncoupling of oxidative phosphorylation in rat liver mitochondrion,366 nucleolar dispersion, 
aggregation and loss of ribosomes,374 in vivo and in vitro inhibition of dihydrofolate reductase,349 
irreversible inhibition of monoamine oxidase enzymes in vivo,408 disruption of amino acid 
accumulation and oxygen consumption,311 inhibition of DNA, RNA, and protein 
synthesis,295’311’312 and the inhibition of group I intron splicing.315’316 In addition, diamidines have 
been shown to disrupt mitochondrial function409 inducing damage to the mitochondrial 
membrane with lesions apparent 5-6hrs after treatment,374 loss of cytoplasmic ribosomes373’374’410 
disintegration of the kinetoplast DNA core374 and the inhibition of cytosolic oligopeptidase 
action.411
The biochemical changes induced as a consequence of these effects with respect to cell death do 
however remain indefinable as are the interactions between diamidines and DNA. It is the 
interactions of diamidines with DNA that are widely reported within the literature.245’284’335’412’413 
The role that binding to DNA plays within the antimalarial activity of diamidines is unclear and 
largely un-linked by reports within the literature since mostly, DNA binding affinity is calculated 
with respect to antitrypanosomal activity. Though few papers report DNA binding affinity 
alongside both antimalarial and antitrypanosomal activity,414’415 the link between DNA binding 
and antimalarial activity remains unresolved.
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Unfused aromatics
Figure 12. DNA-binding properties
Studying the aryl diamidine structure shown in Figure 12, it is clear that the structure contains 
properties of a typical DNA binder, the binding mode is however a matter of debate. It is 
generally accepted that the binding of ¿A-amidines to DNA occurs at the AT-rich (adenine and 
thymine base pairs) region of the minor groove, an area where the interactions are governed by 
shape, distribution and dimension properties manifested in the isohelicity to DNA through the 
nature of the linker between the two amidine moieties, amidine H-bonding and the lipophilicity 
of the alkyl linker.416 It is largely accepted that the binding of aryl diamidines to DNA is of a 
non-intercalatory manner at AT-rich sites with intercalation at GC-sites,417 the major interaction 
being at the AT-rich region of the DNA minor groove.
With respect to PMD, this interaction is understood to be intercalatory at the AATT motif in a 
noncovalent manner418 through the formation of H-bonding and Van de Waals interactions 
between the amidines and base edges.336 However, extensive studies have also shown that PMD 
has the ability to bind at the minor groove of DNA with a strong preference for AT-rich 
sequences, in a non-intercalative manner.419 Van Dross and Sanders observed that PMD does not 
target topoisomerase I or inhibit the catalytic activity of topoisomerase I nor does it stimulate 
topoisomerase I mediated DNA cleavage.420 PMD does however promote the linearization of 
minicircle DNA at therapeutic levels.421 Furthermore it has been demonstrated that PMD binds to
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tRNA through non-specific hydrophobic interactions inhibiting aminoacylation and translation,
422challenged by replacing the oxygen moiety with sulphur which is less able to hydrogen bond.
The ability of PMD and its analogues to recognise and selectively bind to AT-rich sequences 
within DNA is dependent on the length of the alkyl linker. Studies with analogues of PMD found 
that butamidine, hexamidine, octamidine and nonamidine were poorly sequence selective334 
whereas propamidine, PMD and hexamidine have been found to bind selectively at AT-sites with 
propamidine binding more strongly than PMD which binds more strongly than hexamidine.423 
Understandably, geometry is also a function of binding with cis isomers binding more strongly 
than their trans counterparts. ’
Cationic diamidines are known to enter the kinetoplast within minutes of treatment,425’426 
possibly due to its increased content of A and T compared to nuclear DNA.374 The binding 
interaction involves the formation of a ‘close-fit’ with the convex floor of the minor groove 
through bending of the molecule to optimise contacts between drug and AT base pairs 423,427
DAPI 52 is known to inhibit protein synthesis,428 the relaxation of DNA429 and interact 
preferentially with A and T bases of double stranded nucleic acids, though this interaction is non- 
intercalative and reversible.4'8 Two modes of binding are evident, at the A and T bases and also 
external stacking absent of base specificity of an electrostatic nature.430 Although the precise 
mode is not fully understood it is believed to consist of a strong, specific H-bonding interaction 
between the amidino and base pairs. DAPI should therefore be viewed as an intercalator that has 
unusual and very favourable interactions in the minor groove at AT sequences.431
NH
52
DB75 and other furans appear to bind to DNA by two modes; strong minor groove binding 
interactions at AT sites432 due to favourable AT specific DNA binding and intercalation at GC
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containing sequences.433 Furthermore, DB75 makes direct hydrogen bond interactions with the 
d(CGCGAATTCGCG)2 DNA sequence through both amidinium groups to oxygen atoms of 
thymine bases.434
The role of DNA binding on the absolute mechanism of parasite death is unclear nevertheless, it 
is largely accepted that DNA binding results in the cessation of a number of DNA dependent 
enzymes accompanied with inhibition of transcription processes.224 The specificity of the 
cationic amidine moiety for A and T sequences is presumably due to their stronger negative 
zones o f electrostatic potential.435 There is also a belief that these compounds are able to bind in 
a way that causes the DNA-drug complex to be unstable and eventually destroyed. Therefore the 
additional cellular effects noted earlier, are suggested to be secondary to DNA binding.
The role of DNA binding within the antimalarial mode of action remains unclear. Since the 
elucidation of the genome and discovery of AT-rich super-islands, there is a cause to explore 
these properties in more detail within the malarial parasite, since it is clear that these compounds 
have an affinity to AT-rich biological sites.15
2.6 Diamidines as Potential Novel Dicationic Antimalarial Chemotherapeutics
The possibility of transferring malaria parasites to canaries, achieved in 1926,3 led to the 
assessment of antitrypanosomal drugs versus malaria. In 1938, Christophers assessed the activity 
of undecane diamidine 53 showing that a daily dose of the diamidine could treat an infection of 
P. know lesi™  The development of the guanidine containing compound paludrine (proguanil 
hydrochloride) 54, in 1944, a result of war-time research led to a brief investigation into 
diamidines and diguanidines as antimalarials since paludrine displayed excellent antimalarial 
activity, having the advantage that it was less toxic than other compounds and could be used for 
both treatment and prophylaxis.3
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However, the low cost and efficaciousness of CQ resulted in a preference and reliance on its use 
by clinicians and patients, thus diamidines such as 53 were not investigated for antiplasmodial 
use. However, the recent emergence of widespread resistance to CQ (among other antimalarials) 
has caused treatment failures leading to a requirement for novel agents able to circumvent 
resistance pathways due to their originality.
PMD was naturally the starting point of investigations into diamidines as antimalarials since 
PMD is widely used for the treatment of protozoal infections with a long history in this area. 
Furthermore, it has long been known that patients treated for kala azar with PMD or stilbamidine 
rarely suffer from malaria even when in endemic areas.242 Consequently, experiments have been 
performed using both CQ resistant and susceptible plasmodia finding that PMD is concentrated 
500 fold by erythrocytes infected with P.Falciparum.367
The antimalarial mechanism of action of PMD and other diamidines is not fully understood. 
Conceivable mechanisms include the inhibition of hemozoin formation. Mayence et al. used 
infrared spectroscopy and colorimetry to examine the interaction between ferriprotoporphyrin 
(IX) (FPIX) and diamidines in cell-free systems finding that te-benzamidine-heme complexes 
are formed.437 They found that amidines form adducts with FPIX, and that removal of the 
amidine function resulted in analogues that do not inhibit hemozoin formation. Furthermore, 
Stead and Bray studied the interaction between PMD and propamidine with heme, finding that 
PMD accumulation can be blocked by inhibitors of haemoglobin digestion, suggesting that PMD 
binds to FPIX. Both compounds were found to bind to FPIX, inhibiting the formation of 
hemozoin.367 Of particular importance however, is the finding that binding to FPIX may be the 
main mechanism by which diamidines exert their antiplasmodial effect since inhibitors of 
haemoglobin digestion diminish their activity.367 Furthermore the Bray group have shown that
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diamidines inhibit hemozoin formation in vitro with a concentration-dependent potency similar 
to CQ as shown in Figure 13 (unpublished data).
O Pentamidine •  Berenil □ Propamidine ■  Stilbamidine -A- Chloroquine
Figure 13. Inhibition of hemozoin crystal formation by diamidines.
When discussing the antimalarial mode of action for diamidines, hematin binding is a common 
talking point though there are suggestions that the bcl complex could also be a potential target 
for diamidine antimalarials.328 The basis for this argument is plausible when combining the 
evidence; the mitochondrion is commonly linked to the biological effects of diamidines thus it is 
reasonable to suggest that they are effective in the malarial parasite and more pertinently, the bcl 
complex contains heme. Interactions between antimalarials and the bcl complex are known438'440 
it seems however that study within this area concerning diamidines is slight therefore these 
claims as yet cannot be substantiated.
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2.6.1 Amidine Containing Molecules with Antiplasmodial Activity
Although this compound is mono-cationic at physiological pH, the diphenylurea amidine 
derivative WR268961 55 has been included out of interest.
H H 
55
Malarial parasites use the aspartic proteases, plasmepsins I and II to digest haemoglobin.85,441 
From a range of compounds screened from the Waiter-Reed database, WR268961 was found to 
inhibit P. falciparum  growth in vitro at concentrations between 0.03 and 0.16 pg/ml. 
Interestingly, WR268961 is selective for P. falciparum plasmepsin II and P. vivax plasmepsin 
while being a poor inhibitor of human aspartic protease, thus making the molecule selective for 
malaria parasites rather than mammalian cells with parasites unable to accumulate intact 
haemoglobin upon treatment with WR268961.
Similar compounds absent of the amidine moiety were also assessed. Although they showed 
specificity for plasmepsins rather than human proteases, they were poor inhibitors of plasmodial 
growth (IC50 typically 100 times greater) and lacked specificity over host cells. These results 
suggest that the amidine moiety may play a part in the binding of the compounds to plasmepsins 
however, docking experiments show that it is the urea core that interacts with the plasmepsin 
active site as shown in Figure 14.442
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Figure 14. Model of WR268961 bound to plasmepsin. The main chain of the plasmepsin enzyme is represented by 
a semitransparent yellow ribbon. The side chains of four plasmepsin residues involved in hydrogen bonds (purple 
dashed lines) are coloured by atom type.442 Red = Oxygen, White = carbon, Blue = Nitrogen.
This suggests that additional mechanisms are in play since the basic amidine containing 
compound WR268961 is the only diphenylurea derivative of the series that not only prevents 
parasite growth but also plasmepsin activity. Furthermore, Bhattacharaya and co-workers have 
synthesised amidine-containing derivatives of WR268961 against erythrocyte-stage P. 
falciparum  again finding that amidine containing diphenylureas gave the most active 
compounds.443 Presumably hematin binding is the additional mode operating here, although 
studies regarding the ability of these compounds to inhibit hemozoin formation have not been 
performed.
The tripyrrole amidine distamycin A 56 is a natural antibiotic isolated from Streptomyces 
distallicus cultures444 that possesses antibacterial and antiviral properties.445 It is a known minor 
groove binder (non-intercalative) with high sequence specificity to AT-rich sequences in 
DNA446’447 via electrostatic interactions, hydrogen bonds (drug-DNA) and Van der Waals 
contacts as drug-drug and drug-DNA stacking interactions with base pairs, disrupting replication 
and transcription.448 It is not cytotoxic against tumour cells and thus has been used as a carrier 
for targeting cytotoxic alkylating moieties in the minor groove of DNA.449
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Distamycin has shown antimalarial activity in vitro against CQ sensitive and resistant strains of 
P. falciparum  however there are toxicity issues with its use. Lombardi et al. synthesised 
analogues of distamycin, the most active compound being compound 57 giving 100 % inhibition 
of parasites after 4 hrs incubation in vitro. Cytotoxic testing showing the analogue to have a low 
toxicity shown in Figure 15 as the dose required to reduce a given biological effect by 50% 
(ID5o).260
57
ID50 = 0.25 pM
Figure 15.
58
ID50 = 0.3 pM
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Analogues of PMD were synthesised by Bell and co-workers exhibiting antimalarial activity 
versus P.falciparum?06 The position of the amidine functionality clearly plays a role within the 
activity of these compounds with the p-amidine functionality (PMD) giving the most potent 
compound versus CQ sensitive parasites though the m-amidine appears to avoid any pfcrt based 
efflux resistance mechanisms as demonstrated by the IC50S shown in Figure 16.
n h 2 h 2n
p-Am «-Ain
IC50 = 0.129 pM CQ resistant IC50 = 0.085 pM
0.051 pM CQ sensitive 0.082 pM
Figure 16. Effects of ring substitution
As shown in Figure 17, heteroatom substitution was also found to exert an effect on the activity 
of these compounds though not to a large extent with chlorine substitution producing the most 
marked effect on CQ sensitive parasites.
X  x
X IC50 CQ resistant IC50 CQ sensitive
N 0 2 0.114 pM 0.124 pM
OCH3 0.101 pM 0.108 pM
Cl 0.129 pM 0.080 pM
Br 0.146 pM 0.181 pM
Figure 17. Effects of heteroatom substitution
The effect of exchange of the oxygen moiety for nitrogen is shown in Figure 18 demonstrating 
an enhancement in activity for both resistant and sensitive parasites. Clearly, the nature o f ring 
substitution has an effect on the activity of these molecules with the larger NO2 groups causing a 
marked decrease in activity.
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X IC50 CQ resistant IC50 CQ sensi
H 0.045 pM 0.030 pM
N 0 2 0.248 pM 0.109 pM
n h 2 0.183 pM 0.084 pM
Figure 18. PMD structure activity relationships
Figure 19 shows the effect the nature of the dication imparts on antiplasmodial activity. PMD 
gave an IC50 of 0.129 pM versus CQ resistant parasites and 0.051 pM versus the CQ sensitive 
strain however, the imidazole containing analogue causes a decrease in the potency of this 
compound. Furthermore, substitution on the aromatic ring for (9-methyl groups results in an 
increase in activity for CQ resistant strains whilst giving a decrease in potency for CQ sensitive 
ones.
V X X Y
X = Y = H
1C50 = 0.548 mM 
0.072 mM
CQ resistant 
CQ sensitive
X = OCH3; Y = H
IC50 = 0.066 mM 
0.236 mM
Figure 19. PMD structure activity relationships
The flexible pentyldioxy linker in PMD was replaced with various restricted linkers by Huang et 
al. and tested for activity against CQ sensitive and -resistant P. falciparum  strains in vitro. The 
most active compounds were to-benzamidines linked with a 1,4-piperazinediyl 59 or 1, 4- 
homopiperazinediyl 60 moiety with IC50 values as low as 7 nM.304
59 60
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Constraints have been imparted on the biphenyl PMD structure by introduction of a non-flexible 
core. Mayence et al. synthesised a range of ¿us-benzamidines and related congeners with activity 
versus CQ resistant and sensitive strains of P. falciparum the most active analogues are shown in 
Figure 20.
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IC50 = 5 nM versus both strains yested
IC50 CQ sens IC50 CQ rest
3 nM 4 nM Diamidine 61
3 nM 4 nM
3 nM 4 nM
4 nM 8 nM
;J 6 nM 18 nM
3 nM 4 nM
Figure 20. Conformationally restricted diamidines
The ability of these analogues to bind to DNA was also assessed. The parent compound 
diamidine 61, has a strong binding affinity for DNA at AT-rich sequences, though when 
comparing the binding affinities of potent compounds with inactive ones, it is apparent that DNA 
binding does not correlate with activity, thus suggesting that DNA binding is unlikely to play a 
major role in the antimalarial activity of these compounds. Analogues were therefore assessed 
for an ability to act within the haemoglobin degradation stage of parasite maturity by interacting 
with FPIX finding that all benzamidines formed complexes with FPIX and inhibited the 
formation of hemozoin. However, analogues devoid of the amidine moiety did not inhibit
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hemozoin formation in agreement with their IC50S all of which were greater than 500 nM. 
Interestingly, some analogues had IC50S within the same range versus both CQ resistant and 
sensitive parasites indicating that these compounds are unaffected by the pfcrt based efflux 
mechanisms deemed responsible for CQ resistance in P. falciparum. The fact that replacement 
of the amidine moieties leads to a loss in activity infers a requirement for basic, nonsterically 
hindered amidine moieties. The toxic potential of these analogues were also assessed finding that 
each of the active compounds had a low cytotoxicity.305
A series of near-linear biphenyl benzimidazole diamidines have shown potent antimalarial 
activity versus P. falciparum, exhibiting IC50 values ranging from 0.5 to 23 nM, the most potent 
of which are shown in Figure 21.415 The mode of antimalarial activity is not discussed nor 
investigated however it is clear that these analogues display increased activity versus P. 
falciparum than their protozoan counterpart T. brucei rhodesiense, the most potent compound 
giving an IC50 of 3 nM in this genus.
NH
IC50 vs CQ rest K1
R] = H; R2 = H; R3 = H 0.5 nM
R, = F; R2= H; R3 = H 1.0 nM 
R , = H ; R 2= H ; R 3 = F 1.0 nM
Figure 2 1 . Dicationic near-linear biphenyl benzimidazole derivatives
As shown in Figure 22, several linear diamidines have been synthesised exhibiting potent
-IT 7
activity versus P. falciparum the most potent giving an IC50 of 0.5nM.
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Figure 22. Antiplasmodial activity of the most potent terphenyl diamidine analogues versus K1 CQ resistant strain
Investigations into the mode of antiplasmodial activity were not undertaken, presumably fixing 
the structure results in an increased binding strength to the carboxylate residues of heme 
although the role of the nitrogen atoms within the central linker is unclear.
Diaza-analogues of the antiprotozoal agent DB75 have been synthesised with compounds 62, 63 
and 64 showing greater in vitro activity than the parent compound (DB75).4j0
NH
62 IC50 = 6.5 nM 63 IC50 =8.8 nM
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Imidazo-phenyl based diamidines 65 and 66 have been synthesised showing activity versus P. 
falciparum in vitro the lead compounds inhibiting 50 % parasitic growth at a concentration of 14 
nM.451
2.7 Summary
Essentially, the finding that diamidines can bind to DNA without associated antimalarial activity 
suggests that the mechanism of diamidine activity against P. falciparum  may be different from 
those noted for trypanosomal and leishmanial parasite systems.
Clearly, diamidines possess antimalarial activity, some boast potent activity, and as such a 
portfolio of their antimalarial activity and properties is being generated. This has led to the 
emergence of diamidines as an antimalarial subclass in their own right. It seems evident, that the 
diamidine moiety would be a good choice of substituent for the development of antiplasmodial 
agents and therefore was the functionality chosen for our drug template. The DNA binding 
properties of these molecules are of concern in terms of their ability to exert this effect on 
healthy cells; however their specificity for infected cells over host cells leaves us positive that 
although this form of toxicity could indeed occur, it would be unlikely. Furthermore, the rate of 
DNA synthesis in parasitic cells is known to be much higher than mammalian cells.142 It is 
probable therefore, that a compound whose mechanism of action involves targeting DNA would 
be much more damaging to the parasite than its mammalian host.
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2.8 Other PMD Analogues with Antiprotozoal Activity
The ability for a compound to inhibit the processes of one protozoan form does not mean that it 
will be able to inhibit another form, observed clearly in the case of malaria and trypanosomiasis. 
However, out of interest other diamidines possessing antiprotozoal activity are reviewed from 
the perspective of evaluating active antiprotozoal diamidine structures.
Das synthesised cyclic amidines and diguanyls of furan, thiophene, and pyrrole giving activity 
versus T. rhodesiense in mice.452’453 Within the same biological system, Das used oxazole and 
1,3,4-thiadiazole heterocycles finding that the activity of the diamidines was greater than their 
cyclic guanyl analogues, the activity of compounds 67 and 68 being comparable to PMD.454
Jones exchanged amidine groups for imidazolines giving lead compounds DIMP 69 and DIPP 70 
both of which are more effective and less toxic than PMD versus PCP. PCP infected rats treated 
with DIMP for 2wks at 1 mg/kg/day gave results equivalent to 10 mg/kg/day PMD.341
NH NH
67 68
OMe OMe
DIMP, 69 DIPP, 70
NH NH
OMe OMe
DAMP
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DAMP and DIMP have also demonstrated activity versus Giardia lamblia335 with DAMP being 
most active with an IC50 superior to two of the compounds used to treat giardiasis; metronazole 
and tinidazole.
Extended aromatics systems also exhibit anti-PCP activity. DB75 and extended derivatives 71 
and 72 have been shown to exhibit activity against PCP with a lead compound approximately 
100 times more effective than PMD itself. Substitution of an alkyl group onto the nitrogen of the 
amidino group gives a compound with an increased affinity for DNA attributed to the increased 
stability imparted on the DNA complex by the enhanced Van der Waals interactions. It is also 
interesting to note that a strong correlation between top II inhibition and anti-PCP activity is not 
observed for extended systems.455'458
Diamidine analogues were assessed by Calonge et al. in order to assess their effect on polyamine 
metabolism and cell proliferation in Crithidia fasciculate. A structural requirement for two arylic 
groups rather than one was observed giving adducts 73 and 74 which were ten times more active 
against cell growth 459
73 EC50= 10.3 mM 74 EC50 = 8.7 mM
Organometallic compounds containing platinum have been shown to have trypanocidal 
activity.187,460 Iridium and rhodium containing organometallic derivatives of PMD have been 
synthesised showing antileishmanial activity against L. donovani with some analogues giving
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IC50S better than PMD such as the Iridium (Ir) analogue 75.461 Furthermore, cz's-Pt PMD iodide is 
active in a single dose both in mouse and sheep trypanosomiasis models.462
2+
Ring-based analogues of PMD with benzene, pyrimidine or pyridine at the centre have also been 
shown to be active against PCP in culture with benzene and pyridine generating analogues with 
anti-PCP activity, the pyrimidine analogue 76 being much less active.463
NH NH2 NH
76
DB293 77 is a benzimidazole analogue of DB75 which unlike previous analogues discussed, 
binds to both GC and AT base pairs in the binding site.464’465
n h 2
Donkor and colleagues synthesised a range of dicationic compounds related to PMD with 
trypanocidal activity. They found that diamidines are more potent than diimidazolines shown by 
diamidine 78 and diimidazoline 79 with antitrypanosomal activity decreasing when polar groups 
were introduced into the carba linker.466
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When it comes to binding at the DNA minor groove it seems that sometimes there are no rules. 
The aromatic diamidine CGP 40215A 80 has a shape that does not match the curve of the 
groove, although it has been shown to bind strongly monomerically with a binding strength 
approximately six times higher than for berenil with the AATT hairpin.467 These results are in 
accordance with the potent antitrypanosomal activity of CGP 40215A. This compound was 
active against multidrug-resistant trypanosomes with an IC5o of 0.0045 pM in addition, it was 
significantly less toxic than other compounds tested.468
A series of fixed long chain derivatives of PMD have been developed with activity against T. 
cruzi in vitro.469 The lead compound DB709 81 inhibits the intracellular stages of the parasite, a 
target that is hard to attack. In addition to the potency of this compound, toxicity to host cells 
was not observed.
81
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2.9 Enhancement of Bioavailability
2.9.1 Introduction
Advances in drug design have increased the number of ‘hits’ obtained in a shorter amount of 
time in comparison to conventional medicinal chemistry using methods such as combinatorial 
chemistry and high-throughput screening. Despite these advances, many drug candidates fail to 
negotiate the development process due to inadequate absorption, distribution, metabolism and 
excretion (ADME) properties. A drug can fail the process via one of these qualities or a 
combination. It has been estimated that approximately 40% of drug candidates fail the clinical 
trial stage due to poor ADME properties, problematic since late-stage failures contribute 
significantly to the ever-increasing cost of investigational drug development.470 The efficacy and 
kinetics of therapeutically active compounds are a function of their ADME properties, all of 
which influence the pharmacological effects of the drug by determining the drug concentration 
within the target and surrounding tissues. Poor ADME properties are the most common reasons 
for the termination of a drug during development, hence the increasing emphasis on the rigorous 
pre-assessment of these properties.
When designing a drug molecule, oral activity is the objective all medicinal chemists hope to 
attain as this is the most beneficial route for both the patient and health worker. However, oral 
absorption is a multifaceted process surpassing a gauntlet of enzymes with little absorption 
occurring until the drug enters the small intestine. The efficiency with which the molecule does 
this is dependent on the molecular constitution of the drug, the physiology of the gastrointestinal 
tract (gastrointestinal motility, splanchnic blood flow) and the method by which the drug has 
been formulated.471 Therefore absorption of drugs from the GI tract is dependent on the ability of 
the molecule to traverse the intestinal cell membrane. As expected, strong bases of pKa 10 or 
greater are poorly absorbed, as are strong acids of pKa 3 or less since they are fully ionised. 
There are several clinically important drugs that are strong bases and consequently administered 
intravenously since they are poorly absorbed from the GI tract,471’472 PMD being the most 
relevant illustration of this.
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Overall, the mechanism of drug absorption involves passive transfer through cell membranes of 
the intestines at a rate determined by the ionisation and lipid solubility of the molecules. In 
addition, active transport carrier mediated across the GI mucosa may be the method by which 
drugs traverse the membrane.471 All drugs must undergo this process if they are to arrive at their 
site of action.
The poor oral bioavailability of PMD is clearly understood by applying these principles, the 
amidine moiety being protonated readily within the acid milieu of the stomach thus generating an 
inability to enter the blood stream for uptake by parasitised erythrocytes. We therefore must 
establish a method to overcome this barrier associated with the oral activity of diamidine and 
diguanidine based compounds.
2.9.2 A Prodrug Approach
As discussed, the clinical use of diamidine and diguanidine containing drugs is compounded by 
their poor oral bioavailability furthermore, this property leads to inter-individual differences and 
pronounced drug accumulation.302 This issue arises from the highly basic nature of the amidine 
functionalities through a pKa > 10 (12-13) rendering the functionality cationic at physiological 
pH causing an inability to traverse the endothelial cell membrane from the acidic environment of 
the stomach. Furthermore the antimalarial activity of many compounds appears to be related to 
the basicity of the cationic group with the optimal pKa being > 12.5.152 In order for a molecule to 
traverse the intestinal epithelium, the basicity of the cationic group must therefore be reduced 
prior to uptake by target cells. Masking these cationic moieties by depressing their ability to 
protonate at physiological pH would therefore provide a feasible route to the enhancement of 
their oral potency. Clearly, the attachment of a pro-moiety to the amidine nitrogen 82 would 
lower its ability ionise, similarly addition to the amidine amino group 83 would lessen the 
availability of the lone pair for stabilisation of the positive charge (dependent on the 
functionality) thereby decreasing the ionisation potential of the amidine nitrogen as shown in 
Figure 23. Effectively, this concept entails a prodrug approach.
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Studying the literature, the first instance of the term prodrug was in Albert’s discussion of the 
chemical aspects of selective toxicity,473 defined later as a bioreversible chemical derivative of 
an active parent drug, besides salts and complexes which may also be regarded as water soluble 
prodrugs for oral drug delivery.474 A prodrug approach is delicate to perfect since the prodrug 
itself must be therapeutically benign yet chemically reactive in order to undergo chemical 
conversion at a sufficient rate to release the reactive chemical entity such that the molecule can 
pass the endothelium prior to metabolic cleavage.471
Prodrugs are now established as a way of optimising ADME requirements thereby overcoming 
limitations commonly encountered in oral drug delivery and there are various examples on the 
market as shown in Figure 24. They have been shown to substantially improve the 
bioavailability, efficacy, toxicity and formulation of drugs.270,475
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Figure 24.
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There are alternative approaches to the improvement of drug delivery aside from the attachment 
of a pro-moiety for instance, encapsulation in sugar grafted liposomes has been used enhancing 
the bioavailability and potency of PMD476 however, most frequently chemical derivitisation is 
used. Af-hydroxymethylation and A^-aminomethylation of amides, imides and urea derivatives as 
well as jV-Mannich bases for compounds containing a primary or secondary amino group are 
possible ways of attaining prodrugs, with 7V-amidomethylation decreasing amine pKa by 3-4 pKa 
units.4'’5,477 For the amidine functionality in particular, TV-alkoxy337,478-480 or TV-carbamate478,481 
pro-moieties are frequently used.
Several approaches to the development of amidine prodrugs have failed due primarily to poor 
conversion to the active compound or increased clearance.337 It has been shown that PMD is 
rapidly metabolised in vivo to at least seven primary metabolites with hydroxylation resulting in 
a loss of activity.401 It is this discovery that led to the consideration of amidoximes as prodrugs 
with ¿us-amidoximes of DB75 being orally active and less toxic than PMD.482 It has been 
suggested that diamidoxime prodrugs are effective against extracellular parasites because they 
enter host cells where they are reduced to the active amidine form, released extracellularly and 
then taken up by the infecting organism.480
It has been suggested that amidoximes are suitable pro-moieties for any pharmacologically active 
amidine however; through the work of Boykin and Tidwell it is evident that this is not the case 
for all compounds.337,347,414,480,482 For instance, linear dications boasting in vivo activity superior 
to DB75 hold significantly reduced oral activity when converted to their methamidoxime 
prodrugs.337 The point is further stressed by the fact that aromatic amidoximes 84, 85, and 86 
tested for anti-pneumocystis activity lacked significant oral and intravenous activity despite their 
parent drugs possessing potent activity by i.v. injection.347
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This is not an isolated case for this form of fused aromatic system. The poor activity of the 
diamidoxime carbazoles 87 was presumed to be due to the presence of the carbazole nitrogen 
therefore dibenzofuran derivatives 88 were synthesised in the hope that the amidoxime 
dibenzofuran prodrug would be more active. Unfortunately, although the dibenzofuran 
derivatives displayed potent anti-PCP activity, their amidoximes were less active than the 
amidoxime of PMD.482
NOH NOH
This lack of activity for particular amidoxime prodrugs has been attributed to inadequate 
bioconversion to the active moiety and reduced cellular uptake consequently rendering these 
prodrugs inactive.337,480 That being said, amidoximes have been observed to possess enhanced 
oral activity compared to the parent drug347,480’483'485 though methylamidoximes have shown 
significantly less toxicity on intravenous dosage than amidoximes.480 A further illustration of this 
can be derived from the case of DB820 89. DB820 is an aza-analogue of DB75 with potent
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activity in vitro but poor oral bioavailability. Its methoxy prodrug DB844 90 has potent activity 
for both early and late stage African trypanosomiasis, the O-methyl and O-ethyl analogues again 
being the most effective.450 Studies regarding the metabolism of DB844 in human liver 
microsomes found a dependence on NADPH (nicotinamide adenine dinucleotide phosphate) 
resulting in the production of over 8 metabolites in 90 minutes of incubation. The parent 
compound DB280 was the last metabolite formed.483
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2.9.3 DB289
DB75 and its prodrug DB289 were developed by the Boykin and Tidwell groups for the 
treatment o f African trypanosomiasis with prodrug routes initially centering on the development 
of the amidoxime. The finding that the amidoxime for this compound possessed poor oral 
activity led to the assessment of ¿»«-methyl and -ethyl amidoximes of DB75 with the O-methyl 
amidoxime being the most effective and least toxic of the compounds tested.480
DB289 metabolism is believed to undergo an ordered process of O-demethylations and 
dehydroxylations of the amidoxime as depicted in Figure 25, with cytochrome bs and bs 
reductase shown to play a direct role in the metabolic activation of DB289 to DB75.486’487 The 
prodrug undergoes first-pass metabolism mediated by CYP4F enzymes catalysing the initial 
oxidative O-demethylation of DB289.488
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R, = OH; R2 = OCH3; R3 = H -------- ► R, = R2 = OH; R3 = H
DB75 R , = R 2 = H; R3 = H
Figure 25.
As discussed, for oral activity there is a requirement for the drug molecule to traverse the 
epithelium in order for uptake into the intestinal tract. It has been suggested that the increased 
oral activity of DB289 compared to the parent drug could be due to their varying transport 
routes.480 This has been substantiated by studies regarding the transport of DB75 and its prodrug 
across caco-2 cell monolayers where DB75 transport occurs via a paracellular route, however 
DB289 has a transport rate 85-fold higher than that of DB75 and is transported transcellularly.485 
The implications of which are clear when considering that paracellular transport involving 
passive diffusion is less efficient than the transcellular route due to a lower surface area available 
to the molecules entering the intercellular space.485,489 Distribution studies within trypanosomal 
systems suggest that DB289 would have limited activity during the late stages of the disease 
since oral administration of DB289 showed distribution into the brain parenchyma, but 
concentrations of the active drug were low490 therefore also having possible implications for use 
against the cerebral malaria stage.
Within the malarial parasite, DB75 is active versus P. vivax 15 fold more than against P. 
falciparum attributed to the slow onset of activity for DB75 and hence a requirement for more 
than an incomplete blood stage cycle to display its full effect.491 DB75 and DB289 were assessed 
for the first time for the treatment of P. vivax and acute uncomplicated P. falciparum  infections 
in patients at the Hospital for Tropical Diseases, Bangkok for three months. A cure rate of 96 %
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was achieved by the oral dosing of DB289 at 100 mg twice a day with parasitemia cleared in 
most patients by day 7. Patients with P. vivax infections were also treated with primaquine on 
days 10-23. Excitingly, DB289 was well tolerated and any adverse effects observed were 
mild492
Aside from amidoximes, other prodrug approaches have been used for the masking of the 
amidine moiety for instance, the acetylation of the antiarrhythmic benzamidine 91 improving 
oral activity markedly.493
In addition, diacetyldiamidoximeesters of PMD 93 have been used as prodrugs enhancing the 
efficacy of PMD by improving its lipophilicity. The biotransformation to the active drug 
occurring via cleavage of the ester moiety and /V-reduction.484
Carbamates have been used as pro-moieties for the amidine unit within selective factor Vila and 
thrombin inhibitors 94 and 95 which possess low oral bioavailability. For these compounds, a 
carbamate prodrug approach yielded little improvement on activity due to poor conversion to the 
amidine postulated by Riggs et al. to be due to the biaryl scaffold not being recognised as a
A’7O AO  I
substrate for the enzymes necessary to effect the amidine prodrug conversion. ’
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2.9.4 Guanidine prodrugs
It seems the first example of a pro-moiety for the guanidine functionality originated from the 
work of Saulnier et al. regarding the improvement of the formulation and overall bioavailability 
of potential guanidine containing drug candidates. Using A/,/V’-/u.s(acyloxymethoxycarbonyl)-S- 
methylisothioureas and a primary amine they formed compounds 96 and 97, shown to function 
as enzyme labile prodrugs for the free “drug” 98.494 In addition to compounds 96 and 97 other 
guanidine prodrugs have been shown to be activated to their parent guanidine containing drugs
i 495-497by esterases.
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Approaches using A-alkoxy and -carbamate pro-moieties have been employed for use within the 
African trypanosomiasis animal model generating carbamates possessing in vivo activity with 
compound 99 giving a cure rate of 4/4. In contrast, the A-alkoxy analogues assessed in this 
model, 100 and 101, were ineffective as prodrugs.224
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The guanidine containing compound 102 is a potent antithrombotic agent in animals when given 
systemically however its oral activity is poor due to poor intestinal absorption. Prodrug 
methodology was implemented generating lead acyl prodrugs 103 and 104 with compound 103 
giving limited improvement in permeability across caco-2 monolayers while compound 104 
produced a marked improvement.497
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Searching the literature, investigations into the study of diguanidine prodrugs within the field of 
malaria is limited. However, WR182393 is a 2-guanidinoimidazolidinedione mixture with high 
prophylactic and radical curative antimalarial activity.498 The development of WR182393 was 
however compounded by its poor aqueous and organic solubility thus rendering purification of
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the mixture and structure identification problematic. Guan and co-workers developed carbamate 
prodrugs 105 and 106 from the title mixture finding that the solubility of the product was 
enhanced thereby enabling its separation and purification. After structural determination of the 
two components within WR182393, further alkyl carbamate analogues were prepared with lead 
compounds 107 and 108 possessing an increased intramuscular efficacy than WR182393 against 
Plasmodium cynomolgi in the Rhesus monkey.495
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2.10 Summary
In what can only be described as an escalating battle, malaria has proliferated to epidemic levels 
thus the development of novel drug templates is vital, particularly drugs that are parasite specific 
with moieties unrecognisable by the parasite. Evidently, amidine and guanidine containing drugs 
are a promising class of anti-infective agents. They have a broad spectrum of activity inhibiting a 
range of cellular processes in various organisms furthermore there are amidine and guanidine 
containing compounds possessing potent antimalarial activity.
The deployment of these drugs is however plagued by issues surrounding their poor oral 
bioavailability, though advances in prodrug design facilitate a route to their oral use. Host cell 
toxicity to these molecules is frequently reported in the field, a factor connected to their route of 
administration and poor absorption. That being said, the most notable diamidine pentamidine has 
been used clinically for the treatment of trypanosomiasis for over 50 years.
Further studies are required to ascertain their mode of action in the malaria parasite, especially 
regarding their DNA binding properties and possible interactions with the bcl complex since as 
yet, the role these properties play remain unknown.
As antimalarials, diamidines are fast becoming a subclass in their own right, their future as anti- 
infective agents firmly grounded in the applicability of prodrug approaches.
CHAPTER II 
PART II
Fluorene
LSTM» f U N I V E R S I T Y  O ELIVERPOOL
Fluorene 82
The aromatic hydrocarbon fluorene forms the template used for the generation of mono- and bis- 
cationic antimalarials and hence the structure, chemistry and medicinal chemistry of the fluorene 
unit and fluorene containing compounds is reviewed here. This chapter will contain a separate 
numbering system for all compounds, figures and schemes.
2.11 An Introduction to Polycyclic Aromatic Hydrocarbons and Fluorene
Polycyclic aromatic hydrocarbons (PAHs) are molecules consisting of two or more fused 
aromatic rings, the simplest of which is naphthalene. PAHs are not essential for the growth of 
living cells and are generated as a by-product of fossil fuel combustion, and in fact are the most 
widespread pollutants. The majority of PAHs are linked to ill heath effects, the most notable 
being genotoxicity.499,500 For many years the scientific community has recognised that exposure 
to coal tar induces tumours which do not correlate with the benzopyrene content and are due to 
PAH fractions. Bioactivation to reactive intermediates that bind to DNA is widely accepted to be 
the mechanism by which this happens since PAHs are enzyme inducers, substrates and 
inhibitors.501’502 The ability of fluorene (PAH, Figure 1) and fluorene containing compounds to 
form adducts with DNA has been demonstrated503,504 by Koganti et al. who observed that a 
hydrocarbon with a mass greater than 216 was responsible for the formation of a chemical-DNA 
adduct. Also noted is the fact that the toxicity of PAHs generally decreases with increasing 
molecular weight,505 presumably because absorption is less efficient.
2
Figure 1. Structure and numbering system of 9//-fluorene
Fluorene is a crystalline solid found in various natural products and petrol engine exhaust gas, 
the molecular structure and numbering system is shown in Figure 1. The name fluorene is 
attributed to the bright violet fluorescence discharged under UV light. The fluorene unit has 
found widespread use due to its properties including; conductivity,506’507 emittability,508-510 light 
and temperature sensitivity/ stability,509,511 heat resistance512-514 and resistance to corrosion.515 
Insoluble in water, fluorene is however soluble in most organic solvents; isopropanol (IPA),
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ethanol (EtOH), «-butanol, dimethylbenzene, methylbenzene, benzene, acetone and ether. 
Applications of fluorenes are highly varied for instance pharmaceutical and medicinal chemistry 
research,516'519 plastics, dyes,509 pigments (optical brightening agent),514 pesticides, synthetic 
resins, organic synthesis (protecting groups, ’ ligands in metallocene catalysis, 
organolanthanides524), LEDs,525’527 microscopy509 and as a building block for the generation of 
dendrimers,528-530 polymers531,532 and oligomers.533-535 They are used in the applications 
of thermo and light sensitizers, liquid crystal chemistry, luminescence chemistry,
spectrophotometric analysis, molecular chemistry, and organometallic complexes. More recently 
fluorenes are being assessed as a component for solar cells.536
2.12 The Structure of Fluorene -  Uniplanar vs. Folded
The structure of fluorene has caused much debate,537’538 with the main argument regarding 
whether this seemingly simple molecule is uniplanar or folded with the planes of the six 
membered rings at an angle to the plane of the central ring. In 1925, a structure for fluorene 
(Figure 2) was generated to explain the separation of two forms of 9-aminofluorene although 
attempts to repeat this separation have been unsuccessful or disproved.538’539
Figure 2. The two structures of fluorene proposed by Kuhn and Jacob.
Ten years later, Pinck and Hilbert commenced x-ray crystallographic studies and noted that the 
benzene rings adjacent to the central five membered ring must be distorted by 12° or 13° in order 
for the bond distances obtained to be correct as depicted in Figure 3. If this were indeed the case 
then the rigidity of the phenyl rings would indicate that the central ring would be under strain to 
distort to this degree. This proposal can be questioned since the calculations are based on a single 
fixed bond structure.537,538
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Figure 3. Pinck and Hilbert’s distortion of the valence angles from the benzene rings by 12-13° gives a
slightly bent structure.538
Pinck used the degree of strain argument to add to speculation that fluorene was indeed non- 
planar by means of the premise, that if the molecule was under a degree of strain then it would be 
readily open to ring expansion. Pinck and Hilbert applied the Stieglitz rearrangement for the 
synthesis of a phenanthridine derivative, the idea being that strain would be evident by the ease 
of ring expansion of the 9-substituted fluoryl nitrogen. They established that rather than forming 
imide 2 via migration of the R group, the six membered ring 1 was generated via ring expansion 
thus concluding that ease of strain of the five membered ring was an important molecular feature.
It seems however, that Pinck was himself mystified by the nature of fluorene noting that Stuart’s 
interpretation of Hengstengerg’s 1929 x-ray data favours a planar structure.540 It appears that 
most o f the debate surrounding the structure of fluorene arose from the method of analysis and 
quality of data obtained. X-ray crystallographic data of Cook and Iball supports Pinck’s folded 
molecule, although the angle at which this distortion occurs differs from Pinck (12-13 ) with 
Iball stating it to be 20 ,541 The x-ray analysis of fluorene was also undertaken by Brown in 1954, 
the results of which correlate with Iballs 1936 structure.542 The x-ray studies undertaken were of 
a qualitative mode and consequently did not give comprehensive data for interpretation.
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In 1954, Bums completed a detailed quantitative analysis of the fluorene crystal complete with 
bond lengths (mean bond length in benzene ring = 1.403 A) concluding that the structure must be 
planar.543 Further evidence for the elucidation of the fluorene structure, can be obtained from 
resonance energies and bond characters of the relevant carbon-carbon bonds since if the structure 
was indeed folded, resonance would occur through the benzene rings only, however this is not 
the case. In addition, the resonance energy of fluorene is larger than that of two benzene 
molecules alone (101 vs. 82 Kcal/mole).544
Non-planarity across the structure would have its consequences since the asymmetry induced 
would lead to the possibility of isomer formation via substitution at the 9 position cis or trans to 
each ring. Therefore if two isomers could be separated this would add weight to the non-planar 
argument. Examining the literature, it is clear that the resolution of fluorene isomers was 
problematic since there are few successful reports. Ray and Kreiser did successfully resolve 9- 
hydroxyfluorene-2-carboxylic acid and 9-aminofluorene-2-carboxylate into its dextro and levo 
forms using strychnine and ¿-tartaric acid respectively.545 Weisburger et al. were less successful, 
unable to resolve a rao«o-substituted spirobifluorene leading them to conclude that fluorene is 
planar.544
As illustrated by this discussion, the evidence for the structure of fluorene differs based on the 
data presented. Dipole measurements, x-ray studies and absorption data suggest a flat planar 
arrangement since the spectmm is similar to that of biphenyl544 whereas ring enlargement can be 
interpreted as alleviation of ring strain due to bent biphenyls.537 Post 1960, literature concerning 
fluorene refers to the fluorene structure as being planar.546'549 However, studies have shown that 
substitution at the 2 and 9 positions produces compounds with crystal structures that consist of 
planar molecules symmetrically placed with their planes inclined at 28°549 and 55°550 
respectively. In addition, carbanions of fluorene have been shown to have both fused phenyl 
rings planar with the 5-membered ring. The a-carbon is also sp2 hybridised and therefore the 
negative charge can resonate into both planar aromatic rings.551 Zerger et al. obtained the 
molecular and crystal structure of fluorenylpotassium and fluorenyllithium from single crystal X- 
ray data, which correlates with Gerkin’s findings that the fluorenyl carbanion deviates from 
uniplanarity. Both phenyl rings were found in the same plane with carbon 9 pulled out of the
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plane of one benzene ring towards the lithium cation by 0.042 A .552 Moreover the analysis 
previously obtained by Bums and Iball, which led them to conclude a planar structure, did not 
account for or report any disorder in the fluorene crystal. Gerkin et al found that the entire 
fluorene unit is not planar. The asymmetric unit bisecting C (1) to C (7) is planar and this gives 
the molecule the ‘V ’ shape depicted in Figure 4 .553
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Figure 4. Deviation of the C-atom positions from the mean 
molecular plane of the fluorene molecule gives a fluorene a ‘V’ shape.
The disparity concerning whether fluorene is uniplanar or not is still unresolved, with Belsky554 
and Gerkin553 in disagreement some 40 years after the work of Pinck and Hilbert.537 There is a 
0.019 A  difference in bond lengths obtained, which may be due to an alternate conformation of 
the molecule at different temperatures. However, Gerkin et al. performed their calculations at 
both 295 and 159 K finding that fluorene is planar at the asymmetric unit only, whereas Belsky 
et al. establish uniplanarity in the molecule at 295 K only. The symmetry of fluorene is on the 
other hand in agreement as being C2V553’555 as is the nature of the intermolecular bonding being 
entirely Van der Waals based.549,550,554 The discrepancy regarding the structure of fluorene is 
difficult to access since the literature is absent of a definitive answer. Nevertheless, we have used 
density functional theory in order to access the data in-house leading to the structure depicted in 
Figure 5. Based on our calculations (using density functional theory B3LYP/6-31G) we 
established a uniplanar fluorene structure.
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Figure 5. In-house representation of the structure of fluorene.
2.13 Fluorene Preparation
Most PAHs are not synthesised chemically but are isolated from natural sources such as oils and 
hydrocarbons usually by pyrolysis followed by subsequent purification through repeated 
distillation and crystallization.556 Fluorene itself is a major component of anthracene oil557 and 
coal tar where it can be isolated from the middle oil fraction or distillation of
C CO
fluorenedicarboxylic acid with lime.
The fluorene unit can also be constructed via synthetic methods in order to generate fluorene 
analogues. Stokker used aluminium chloride to induce an intramolecular Friedel-Crafits 
alkylation of the 2-cyanoacrilic acid precursor (Scheme 1) forming the product, 2-cyano-2-(l,3- 
dichloro-7-fluoro-9H-fluoren-9-yl)acetic acid 4 in moderate yield (60 %).559
Scheme 1. Friedel-Crafts alkylation of 2-cyano-3-(3,5-dichloro-4’-fluorobiphenyl-2-yl)acrylic acid
They again performed ring closure in order to prepare several symmetrical fluorenone 
derivatives from aniline and the nitrile precursor. Pschorr ring closure of benzophenone 8 was
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achieved by generating nitrous acid in situ by mixing aminobenzophenone and hot concentrated 
sulphuric acid; quenching with sodium nitrite provides fluorenone 9 in a 43 % yield (Scheme 2).
Scheme 2. Synthesis of l,3,6,8-tetramethyl-9//-fluoren-9-one by Stokker et a/.559
Acid chlorides can also facilitate ring closure to give the fluorene unit. Ladd et al. used a two- 
step procedure through sulfonyl chloride and stannic chloride to form the fluorenone shown in 
Scheme 3. This reaction can also be achieved in one step using thionyl chloride though the yield 
of the reaction is compromised (94 vs. 30 %).560
Scheme 3. Synthesis of substituted fluoren-9-ones by Ladd et al.560
It has also been shown that cyclodehydration of p-fluoro and p-chloro substituted alcohols 
mediated by H2SO4 and water or MeOH forms the corresponding fluorenes represented in 
Scheme 4 .561-563
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X = F, Cl
1. H2S04
2. H20  (or MeOH)
OH (or OMe)
Scheme 4. Cyclodehydration of p-fluoro and p-chloro substituted alcohols
The mechanism of reaction involves the formation of an unstable cation via protonation of the 
hydroxyl group under acidic conditions. Subsequent loss o f water followed by ring closure, 
protonation and hydrogen migration restores aromaticity.
F-iC H
Scheme 5. Mechanism of reaction of cyclodehydration of p-fluoro and p-chloro substituted alcohols
Since the methylene carbon of the diphenyl starting material can be functionalised, this permits 
the construction of other analogues such as the acid, ester, and amide.
COR
1. H2S04 or CF3SO3H 
---------------------------- ►
ROC H
Scheme 6. Cyclodehydration of diphenyl analogues
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2.14 Brief Review of the Reactivity of Fluorene
2.14.1 Introduction
PAHs are known to react with molecular oxygen over 200°C to form oxi and peroxi radicals by 
molecular condensation yielding polymeric molecules with a non-planar structure. These 
compounds do not incorporate oxygen into their structure removing most of it as water, a process 
exploited in the isolation of PAHs.557’564 Most studies concerning the reactivity of fluorene have 
employed a comparison to biphenyl.547,548 It is noted that fluorene is more reactive than biphenyl, 
due to the fact that the biphenyl system deviates from planarity.565
Fluorene is a weak acid with five different positions that are susceptible to nucleophilic attack; 
the phenyl rings and the C-9 position. The protons at C-9 are particularly labile due to their 
increased ionisability566 with a pKa of 2 5 567 which changes to approximately 9 in the singlet 
excited state568 thus enabling rapid ionization. Deprotonation of fluorene is therefore facile and 
can be achieved easily using mixtures such as, dimethyl sulphoxide-methanol-sodium methoxide 
or alcohols-sodium alkoxides569 and alky lithiums in the appropriate solvent.570 The chemistry of 
the methylene hydrogens is analogous to cyclopentadiene (Cp). The driving force for anion 
formation at C-9 is the increase in aromatic character attained, since anionic fluorene has a 671 
internal cyclic array thereby imparting greater stability of the anion by satisfying Huckel’s rule 
requiring (4n+2) n electrons, where n is an integer. Photochemically the reactivity of fluorene is 
somewhat different. Fluorene does not undergo deprotonation upon photochemical excitation571 
even though this would generate a 4«+2 ground-state anion.
2.14.2 Ring Expansion
As depicted in Scheme 7, substitution of fluorene at the C-9 position enables the formation of 
phenanthridine derivatives as the sole product through ring expansion, group migration to form 
the imide does not occur.537 The nature of the R groups which can undergo this transformation is 
non-specific ranging from aryl, alkyl and fluorylamines.
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Scheme 7. The synthesis of Phenanthridine derivatives.537 Route a; ring expansion to give the 
Phenanthridine. Route b; R group migration to form the imide product.
2.14.3 Oxidation
Fluorenone can be obtained naturally as a constituent of coal tar or synthesised by the oxidation 
of fluorene with reagents such as chromic acid,572 sodium dichromate573"576 peracetic acid,577 
nickel peroxide,578 hot potassium permanganate,579 silver acetate in pyridine566 and molecular 
oxygen in the presence of Triton B and pyridine.575 Examples of the use of fluoreneone en route 
to products of chemotherapeutic interest are vast_573>574’577’579-582 Agrawal used fluoreneone 
derivatives as part of his route to the development of compounds with antitumor activity. He 
synthesised 2,7-dihydroxyfluorenone by the dehydration of 4,4’-dihydroxybiphenyl-2-carboxylic 
acid mediated by zinc chloride580 as shown in Scheme 8.
Scheme 8. Dehydration of 4,4’-dihydroxybiphenyl-2-carboxylic acid mediated by zinc chloride
c o  i C O T  c q q
Fluorenone is widely used as part of the synthetic chemist’s arsenal ’ ‘ since it enables the 
generation of a diverse range of compounds such as phenanthridines, conjugated oligomers,
584  587monomers for the synthesis of highly functionalised polymers and copolymers, ’ 
benzimidazoles and spiro-thiazolidinone derivatives585 and accordingly its reactions will be
examined.
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Fluoreneone undergoes the Wittig reaction to give a substituted methylenetriphenylphosphine 
which when reacted with a second molecule of the phosphorous compound gives spirobicyclics 
such as 10 (Figure 6). When benzyldiphenyl- phosphinoxide is used with potassium tert- 
butoxide a benzylidiene fluorene is formed.591
Figure 6. Spirans generated from the Wittig reaction.
Reduction of fluorenone with reagents such as aluminium «o-propoxide,588 hydrazine hydrate574 
and sodium borohydride592 confers a point of diversity, one which was exploited by Arcus in his 
studies of organic azides and their reactions.593 Reduction of fluorenones with sodium 
borohydride was found by Parry to be inhibited by electron releasing groups and accelerated by 
electron withdrawing groups when in the 2 position.592 Fluorenone can also undergo alkylation 
with alkyl, allyl, and phenyl magnesium bromides to yield the 9 substituted fluorylidene 
product.544’591 The ionic autoxidation of fluorene in an oxygen atmosphere is achieved by stirring 
fluorene in pyridine at room temperature with a small quantity of Triton B™. Heat and water are 
generated as by products with the reaction proceeding through an ionic mechanism.566
0 2
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Diphenic acid can also be used for the synthesis of fluorenone. The acid can be synthesised from 
2-(chlorodiazenyl)benzoic acid594,595 and heated to evolve carbon dioxide and form quantitative 
yields of fluoreneone (Scheme 9).596 The reaction is robust and does not require the use of pure 
dipenic acid or indeed diphenic acid alone since fluorenone-4-carboxylic acid and diphenic 
anhydride have been used to the same effect producing only trace amounts of the diphenyl 
product.596
Fluorene 93
Scheme 9. The preparation of fluorenone from diphenic acid.596
Fluorenone carboxylic acid can also be formed from the oxidation of fluoranthene (component of 
carbon black and coal tars) with potassium dichromate in sulphuric acid. The carboxylic acid 
can then be converted to fluorenone by distillation.597
2.14.4 Reactions at the 9-Position
The hydrogen atoms at the 9 position are labile and susceptible to electrophiles. The anion of 
fluorene can be prepared at room temperature in a variety of solvents by bringing a solution of 
the hydrocarbon into contact with an alkali metal,598 although it is noted that 9-fluorenyl-sodium 
can be difficult to work with.599 Due to the nature of its absorption spectrum, the fluorenyl anion 
has received much attention.598,600,601 The counterion, solvent and temperature used all exert an 
effect on the anion which has been understood by Hogenesc to be due to an equilibrium between 
contact and solvent-separated ion pairs.600 Acrylonitrile reacts in a Michael fashion with fluorene 
to give the dicyanoethylated product in the presence of a base.602 Examples of bases employed 
for this reaction include sodium or potassium methylate, potassium or sodium hydroxide and 
Triton B™. The mono cyanoethylated product can also be formed by using crotononitrile as the
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Michael acceptor. In the presence of potassium hydroxide, indene and fluorene undergo a 
Michael reaction with salicylideneacetophenone to give a mixture of products 11 and 12.591
The hydrogens at the 9 position can be made more reactive by esterification of one hydrogen to 
form the carboxylate (Scheme 10). This enhances the activity of the remaining hydrogen thereby 
facilitating the addition of the chosen allyl cyanide.603
Scheme 10. Michael addition of crotononitrile to fluorene-9-carboxylate.603
The base catalysed alkylation of fluorene with alcohols or hydroxy acid salts gives 9- 
alkylfluorenes and 9-fluorenylalkanoic acids respectively in good yields.567 9-Fluorenylalkanoic 
acids can be generated by the addition of a strong base (for example potassium hydroxide) to a 
lactone at 200-220°C generating the hydroxy acid salt in situ. Fritz found that when hydroxy acid 
salts of lactones including butyrolactone, valerolactone and caprolactone are used, the reaction 
proceeds to give the mono substituted product (Scheme 12). However, when the contributing 
lactone is propiolactone a ¿«-substituted product is formed (Scheme 11). Fritz postulates that 
since acrylate esters are known to condense with activated methylene groups, the formation of 
the ¿«-substituted product could be explained by ring opening of propiolactone in the usual 
fashion to give a hydroxy acid salt which dehydrates to form an acrylate. This can react again via 
Michael addition to give the ¿«-substituted product 13.
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Scheme 11. The proposed mechanism for the reaction of fluorene and propiolactone to form a to-substituted
product.
9-Substituted fluorenes cannot undergo reactions of this type since the reaction requires both 
hydrogen’s in the 9 position to form an alkylidene intermediate. The mechanism of reaction for 
most lactones involves oxidation of the alcohol function of the hydroxyl acid salt, to form a 
carbonyl moiety which condenses with the fluorenyl anion to form an alkylidene intermediate 
which is reduced, either by hydrogen present from the dehydrogenation of alcohol or by an 
alkoxide to yield the 9-fluorenyl pentanoic acid product (Scheme 12).
Scheme 12. The proposed mechanism for the reaction of fluorene and lactones. Various lactones have been
used567, 8-valerolactone is used here.
The popularity of the protecting group Fmoc (9-fluorenylmethyloxycarbonyl) for structures 
containing an amino functionality led to the requirement for a convenient large scale synthetic 
route to the key precursor of all Fmoc derivatives ((9-fluorenyl)methanol) (15) (Scheme 13).604
Scheme 13. The key precursor (9-fluorenyl)methanol (15) is synthesised from aldehyde (14).
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The aldehyde precursor is obtained by condensing fluorene and ethyl formate in ether using 
sodium ethoxide as the condensing agent.560,605 When potassium ethoxide was used the quantity 
of aldehyde formed was increased due to the improved stability of the aldehyde upon storage. (9- 
Fluorenyl)methanol was then generated using aqueous formaldehyde in 10 % sodium hydroxide 
solution. The mechanism of reaction was shown, by radiolabelled l4C, to involve methylation of 
the hydroxyl group followed by deformylation catalysed by the base (Scheme 14). Unreacted 
formaldehyde was not radioactive thus ruling out exchange between formylfluorene and 
formaldehyde, or between formate and formaldehyde.606
H
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Scheme 14. Mechanism of reaction of 9-Formylfluorene-C14 with formaldehyde606
Carpino attempted the preceding method for the production of (9-fluorenyl)methanol finding the 
procedure tedious since a significant number of polymeric bi-products were produced which 
were difficult to separate from the desired material, therefore impacting the yield of 
reaction.604,607’608 Ten years after trying this method, Carpino solved these difficulties by using 
sodium borohydride in place of formaldehyde for the conversion o f 14 to 15.604 In addition to 
increasing the yield of the reaction from 50-60 to 80 %, the purity of the product increased 
markedly, so much so that it can be used directly from the reaction mixture. More recently, 
Chong et al. synthesised 9-fluorenylmethanol from fluorene using butyl lithium and 
paraformaldehyde609 generating the required product in a yield of 73 % avoiding the formation of 
9-fluorene carboxaldehyde which is both unstable and a lachrymator. A small amount of the diol 
was formed, eliminated by recrystallisation from a mixture of hexane and ethanol. The choice of 
solvent, base and stoichiometry used is critical since when performed in conditions other than 1 
equivalent of BuLi and paraformaldehyde in THF only trace amounts of fluorenylmethanol or 
increased amounts of the diol were isolated.
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2.15 Metallation
Conversion of the parent hydrocarbon to metallo-hydrocarbon adducts is widely used to 
functionalise the parent structure.610'616 When fluorene is reacted with alkali metals such as 
lithium at room temperature in aprotic solvents for instance THF, a yellow solution of the 
fluorene anion is produced.598,601 If  the temperature is lowered to -70°C, a stable blue solution of 
the fluorene radical anion 17 (Scheme 15) is formed which decays to the previous yellow colour 
when the temperature is increased. The rate of which depends on the nature of the counter ion, 
solvent and temperature.
Scheme 15. Formation of a fluorene radical anion at -70°C where M represents the alkali metal
The rate is not the only factor that is dependent on these factors. By studying the electronic 
absorption spectra of the fluorenyl anion, Casson598,601 recorded three types of ion pair in 
equilibrium (Scheme 16), contact 18, solvent separated 19 and dissociated 20. The equilibrium 
transfers from contact to solvent separated with increasing solvent polarity, decreasing 
temperature and size of the cation.617
Scheme 16. The nature of the fluorene radical ion pairings present in solution601
Most ion pairs of the fluorenyl-lithium salt are solvent separated at room temperature.600 The 
decay of the radical anion is believed to be dependent on the concentration of neutral
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hydrocarbon,618 being stable if no unreacted hydrocarbon is present in solution.619 Stability is 
also dependent on the nature of the cation. In the case of sodium, the kinetics for radical-anion 
decay are the most complex and difficult to analyse.620 Lithium is the most stable counterion of 
the alkali metals in the order Li > Na > K .619’621 For substituted fluorenes the nature of the 
substituent markedly affects the rate of decay in the order -OMe> -CN> -Me > -H > -NO2 when 
substituted at the 2 position.621 Waack found dianions of the antiaromatic compounds 
biphenylene and anthracene, leading to the credence that fluorene may also form dianions 
although there is little evidence of this.622
Cp and indene react with alkali metals to form an organometallic compound and hydrogen 
evolution. Consequently the lithiation of fluorene was assumed to proceed in a manner akin to its 
more acidic counterparts as shown in Scheme 17. Quantitative monitoring of lithium 
consumption found that lithium hydride was not produced, nor was the evolution of hydrogen
H H H Li
Scheme 17. Proposed mechanism of metallation of fluorene with lithium in THF623
When lithium metal reacts with fluorene, a dark green precipitate is observed on the metal 
surface. Hence, the mechanism is believed to involve initial formation of an ionic fluorene- 
lithium species 21 (responsible for the precipitate), which deprotonates a fluorenyl phenyl ring 
after which the radical anion 23 is generated. Subsequent quenching of the anion is realised by 
accommodation of an electron from another unreacted fluorene molecule (Scheme 18). The 
mechanism of fluorene lithiation is analogous to biphenyl aided by the fact that fluorene is able 
to form kinetically stable radical anion bases. Hence the reason a small amount of tetrahydro- 
and hexahydrofluorene forms.623
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Scheme 18. Mechanism of lithiation of fluorene with lithium metal in THF623
The observed rate of reaction regarding fluorene with alkali metals is in the order K>Li>Na.618 
Greenhow et al. condensed 9-fluorenylsodium with various alkylating agents including methyl 
iodide or sulphate, ethyl bromide or sulphate, allyl chloride, benzyl chloride and ethylene 
dichloride forming the appropriate 9-substituted fluorene.599 As previously mentioned, the 
chemistry at C9 is analogous to Cp (25) and as such the reactivity of fluorenyl anions with 
carbonyl compounds can be compared to that of the anions of Cp.
U
25
Cp reacts with carbonyl compounds to form anion 26 which stabilises itself by fulvene formation 
(27).
26 27
Fulvene formation becomes increasingly difficult with annulation, a factor that is apparent when 
evaluating the ease of condensation of Cp with aldehydes and ketones, formed via a myriad of 
bases including; alcoholic alkaline hydroxides or alkoxides, aqueous or alcoholic ammonia, 
primary or secondary amines, ethylmagnesium bromide and alkyl or aryllithiums. Indene 28 will 
react with ketones but requires harsh conditions. Fluorene will also react with ketones though 
only in the form of their bromomagnesium or lithium derivatives and not under the influence of 
alkoxides.591
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28
Alkylation using the 9-lithium fluorene derivative via treatment of a slight excess of 2,7- 
dichlorofluorene with butyl lithium, has revealed an alternative synthetic route to Fmoc 
derivatives.570 Once the anion is generated, addition of less than 1 equivalent of ethylene oxide 
gives the desired product as illustrated in Scheme 19. The reaction is however sensitive to 
stoichiometry. If ethylene oxide is not used as the limiting reagent at -10°C, the èù-alkylated 
derivative 31 is formed as the major product since the alkoxide anion intermediate formed in the 
reaction can abstract another fluorenyl proton. It is likely that this proton is rendered more 
reactive by the addition of the alkyl group since the anion generated can be better stabilised.
Cl
H H
Scheme 19. Alkylation of 2,7-dichlorofluorene with ethylene oxide.
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2.15.1 Metallation of Dichloro Adducts
Mono alkylation of fluorene is relatively simple. 2,7-Dichloro fluorene derivatives are however 
more stubborn since the èz's-alkylated adduct 35 is more often formed as the major product due to 
the increased reactivity of the remaining hydrogen. Protection is viable as a way of overcoming 
this problem and was tried by Perumattam using TMS and carboxylation (Scheme 20 and 21).570 
However use of TMS furnished the ¿»/^-alkylated product due to a 1,4-shift exchanging lithium 
for hydrogen thereby enabling the second phase of alkylation. The carboxylic acid derivative 36 
forms an unstable intermediate 37 enabling decarboxylation to give the desired compound 38.
Scheme 20. Alkylation of 2,7-dichlorofluorene
Scheme 21. Formation of (9-fluorenyl)methanol from 2,7-dichloro-9-//-fluorene-9-carboxylic acid
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2.16 Wittig Reaction
Generation o f the ylide can be achieved through reaction o f fluorene 9-alcohol with 
triphenylphosphine hydrogen bromide624 or, via bromination at the 9 position to generate 9- 
bromofluorene (39) which upon treatment with trimethylphosphine furnishes trimethylfluorenyl- 
phosphonium bromide (40). Addition of phenyllithium and subsequent heating under reflux for 
6hrs generates the trimethylphosphonium ylide shown in Scheme 22.625
Scheme 22. The formation of a trimethylphosphoniumylide from 9-bromofluorene.
The ylide reacts with a range of carbonyl containing compounds under standard Wittig 
conditions. Johnson and LaCount performed the reaction to give benzylidene fluorenes (42).
Other ylides that can be formed with fluorene include dimethylsulfonium, triphenylarsenide, 
tributyl (reacts with a range of carbonyls and is more reactive than triphenylphosphonium) and 
triphenylphosphonium (reacts best with ^-substituted benzaldehydes).626 The outcome of the 
reaction depends heavily on the choice of ylide as illustrated by triphenylphosphoniumfluoren- 
ylide whose selectivity is dependent on the choice of benzaldehyde and dimethylsulfonium-
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fluorenylide which when condensed with p-nitrobenzaldehyde forms fluorene oxide 43 as the 
major product.625
Fletcher et al prepared a number of ylidene fluorenes with extended conjugation from the 9 
position.627 Initially they used sodium ethoxide for the condensation reaction between fluorene 
and o-chlorobenzaldehyde. However, the crude mixture was very hard to purify due to the 
presence of a side product later identified as o-chloro-benzylfluorene. They then looked for an 
alternative route and found that the formation of 9-o-chlorobenylidenefluorene (45) could be 
achieved in high purity by the reaction of o-chlorobenzaldehyde (a) and 9-triphenylphosphine 
fluorenylide (44).
Scheme 23. Formation of 9-o-chlorobenylidenefluorene from condensation of 9-triphenylphosphine fluorenylide
and o-chlorobenzaldehyde.
A modified Wittig reaction was used by Ulmschneider et al. during the synthesis of inhibitors of 
aldosterone synthase. Potassium carbonate and 18-crown-6 were used for the coupling of 
fluorenyl triphenylphosphine bromide salts and various heterocycles.624
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2.17 Reactions at the Phenyl Rings
2.17.1 Introduction
The 2 and 7 positions of fluorene are greatly activated towards electrophilic substitution due to 
the inductive effect and co-planarity the methylene bridge imparts.547,548,573,628 Electrophilic 
substitution reactions of fluorene give predominantly 2 substituted and 2,7-disubstituted 
products. Direction into the 3-position can be realised by reaction at carbon-2. 2-Acetamido 
fluorene was successfully chlorinated to give 3,7-dichlorofluorene.573 Nitration of fluorene in 
acetic acid with an excess of fuming nitric acid gives 2, 5 and 2, 7-dinitrofluorene with a small 
amount of the 3-isomer,629 suggesting that the 2- and 4-positions have comparable reactivities. 
However to ensure substitution at the 4-position 2,7-disubstitution can be used. Substitution at 
the 1-and 8-positions is electronically disfavoured but can be achieved by protection of the 3- 
and 6-positions. Teri-butyl groups have been employed in combination with mercury (II) as a 
sterically demanding electrophile for the generation of 1 ,8-diiodofluorenes for ligand 
synthesis.630
2.17.2 Bromination
As formerly referred to, blockade of the 2 position can enable versatility on the site of 
electrophilic substitution. 2-Aminofluorene has been shown to undergo bromination in the 1-, 3-, 
and 7-positions, the position of bromination dependent on whether chloroform or pyridine is 
used as a solvent.631 Bromination of fluorene is more facile than chlorination which corresponds 
to the yield of product obtained with NCS and NBS at 25 and 55 % respectively. At the 2- and 7- 
positions of (9-fluorenyl)methanol bromination has been achieved using NBS in acetic acid and 
HBr in an attempt to generate Fmoc analogues for use with highly base sensitive molecules.604 
Bromine, ferric chloride (99 % yield) and copper bromide on alumina in CC14 (98 %) have also 
been used.632 Bromination of fluorene enables access to a range of products and are useful 
intermediates in the field of polymer synthesis.506,533'535,572 Common methods include coupling of 
the bromo adduct directly with aryl zinc chlorides under palladium catalysis535 or conversion into 
organometallic derivatives which are then coupled with aryl dihalides.
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2.17.3 Chlorination
Chlorination of fluorene can be achieved through dropwise addition of 3 equivalents of chlorine 
in acetic acid to furnish 2,7-dichlorofluorene as the main product offset by a small quantity of 
2,3,7-trichlorofluorene. Selectivity of the reaction can be enhanced by bubbling chlorine gas 
through the reaction mixture in the presence of anhydrous ferric chloride.573 NCS in acetic acid 
with concentrated HC1 can also affect this reaction; however selectivity is compromised 
generating only 25 % of the 2,7 derivative.604 More recently, chlorination of fluorene has been 
achieved in good yields using NCS and cone. HC1 in MeCN at room temperature. This method 
tolerates a range of functionalities at the 9-position as represented in Table l .570
Table 1. Tolerance of functionalities at the 9-position for the chlorination of fluorene
R Yield (%)
H 90
Et 55
Br 73
Br 58
SiMe3 65
CH2 CO2 H 77
(CH2)2C 0 2H 52
CH2 CH2 OH 65
R
Fluorene iodination methodology is limited. A popular route to iodo fluorene utilizes fluorenone. 
In spite of the carbonyl group, fluorenone can be easily mono- and ¿>zs-iodinated (tri-iodination 
gives a product that is difficult to purify) with NIS in sulphuric acid to give 2-iodo and 2,7- 
diiodofluoreneone.633 Reduction of which can give the fluorene adduct if required.
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2.17.4 Nitration, Sulfonation
Nitration of fluorene does not appear to be a recurrent and exploited reaction. Again, protection 
of the 2-position enables a level of control over the position of substitution. 2-Acetamino- 
fluorene can undergo mono-nitration at positions 3 and 7 however the selectivity of the reaction 
is poor, forming the products in a ratio o f 2.5:1 respectively. Control can be attained however by 
substitution at the 4-position via use of an acetamidodiphenyl group to give the 3 nitrated 
product exclusively.631
Sulfonation of fluorene was used in Andrews’ preparation of tilorone and related fe-alkamine 
ethers from 2,7-dihydroxy-9//-fluoren-9-one (46). Fluorene was sulfonated using hot 
concentrated sulphuric acid at 100°C for 5 minutes. After which the product was neutralised as a 
dipotassium salt and oxidised to the oxo derivative 47.579
2.17.5 Reduction
Aromatic rings can be reduced using the Birch reduction reaction,634’635 accomplished by a 
metal-ammonia solution to form 1,4-cyclohexadiene from benzene. Appropriate metals include 
sodium, lithium and potassium in alcoholic solvents such as ethanol or tert-butanol although the 
use of TFIF is becoming increasingly popular.636,637 Donohoe reduced a series of hetero- and 
carbocyclic aromatic compounds under ammonia free conditions using lithium ¿¿s-tert- 
butylbiphenyl (LiDBB) as the electron source and ¿N-methoxyethylamine (BMEA) as the 
protonating agent.636 Birch reduction is not limited to benzene and can be employed for the 
reduction o f aromatic and poly nuclear aromatic compounds alike. The reduction of fluorene 
produces a mixture of isomers 48 and 49 as indicated in Figure 7 in 39 and 37 % respectively, 
together with 8 % unidentified material and 1 1  % starting material.637
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Figure 7. Metal-ammonia Birch reduction products
These products were difficult to isolate and purify therefore Smith applied Rabideau’s findings638 
to perform the reduction using trimethylsilated fluorene in order to alter the regiochemistry of the 
reduced product, successfully producing one isomer dependent on the solvent and quantity of 
lithium used as depicted in Scheme 24.637 The silyl groups are removed using TBAF in THF for 
30 min. The regiochemical control observed could be due to the steric influence of the large 
TMS groups leading to the formation of one isomer 52 or 54 depending on the conditions used.
TBAF
fi
54
Scheme 24. Birch reduction of trimethylsilated fluorene637
2.17.6 Acetylation
Acetylation of fluorene occurs readily under standard conditions with aluminium chloride and 
acetic anhydride to give the C2 acetylated product in 83%.639 The reaction is heavily dependent 
on reagents and condition as illustrated by using acetyl chloride plus aluminium chloride in 
carbon disulfide giving compound 56 in 8% yield.640
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55 56
Friedel-Crafts diacylation of fluorene with chloroalanoyl chlorides was used by Albrecht et al for 
the formation of ¿«-basic-substituted polycyclic aromatic compounds of fluorene.575 They used 
fluorene and the appropriate chloroalkanoyl chlorides to form ¿«-chloroalkanoyl fluorenes 
which could be aminated in the presence of excess amine to a number of aminoacyl analogues 
for antiviral testing (Scheme 25).
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Scheme 25. The formation of 2,7-6/5-(chloroacetyl)fluorene. This was then converted to a range of
aminoacyl derivatives.
Jones also used a Friedel-Crafts reaction to affect the ¿«-electrophilic substitution of fluorene in 
the 2- and 7-positions as part of his synthesis of the key intermediates 57, 58 and 59 for the 
synthesis o f antiviral agents since this facilitated divergence from the parent structure for 
structure activity relationships.641
58 59
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2.17.7 Carboxylation
Fluorene carboxylic acids can be generated by reaction at the 1-, 2- and 4-positions.639’640 Ray 
and Rieveschl formed a range of fluorene carboxylic acids by heating diphenic acid 60 in 
sulphuric acid to form fluorenone-4-carboxylic acid 61, oxidation of fluoranthene 62 to give the 
1 substituted product 63, and oxidation of 2-acetylfluorene to give fluorenone-2-carboxylic acid 
64.640
h 2s o 4
2.17.8 Organometallic Derivatives
Several mixed ligand metallocarboranes have encompassed the fluorene hydrocarbon642,643 to 
form a sandwich complex. These complexes are synthesised through fluorene mediated thermal 
displacement of alky ligands generating structures of the nature in Figure 8. This validates the 
ease of which fluorene sandwich complexes can be generated. In addition, manipulation of the 
fluorene unit facilitates the generation of a diverse array of complexes.
Fluorene 110
Figure 8. Metallocarborane containing fluorene
2.18 Use of Fluorenes in Synthesis (Fmoc)
An increased interest in amino acids and their synthesis led to the development of the base- 
sensitive compound 9-fluorenylmethyloxycarbonyl or Fmoc 65 for use in the protection of amino 
groups.
Carpino proposed the use of the fluorenyl system during a conversation with Professor A. 
Ceccon644 regarding the ease of /? elimination from 9-fluorenyl thiocyanates and analogous 
systems relative to the corresponding benzhydryl derivatives.607 The significance of this 
conversation was the development of Fmoc, a 9-fluoreneylmethyl system used for the protection 
of sensitive moieties. Since its development, Fmoc has been used extensively for amongst other 
things, the rapid assembly of peptide segments645 and the synthesis of pentapeptides.646 
Introduction of Fmoc into the substrate is achieved by treatment of the appropriate amine with 
either the chloro or azido formate of 9-fluorenylmethyl with sodium carbonate in dioxane. 
Cleavage occurs under extremely mild conditions (Scheme 26), either by standing the reaction 
mixture in liquid ammonia for several hours or subsequent aqueous work-up via an elimination 
process believed to be ElcB .608 Other convenient cleavage methods include dissolution in 4-
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(aminomethyl)piperidine,646 ethanolamine, morpholine or a similar amine.607 Carpino has also 
modified Fmoc in order to augment accommodation of more sensitive substrates.604
Scheme 26. Removal of the Fmoc protecting group
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There are numerous chemotherapeutic agents that encompass the fluorene unit. Applications 
range from free radical scavengers647,648 and treatment of brain edema,649 to marketed drugs such 
as Lumefantrine (Lu).650-652 Fluorenes of the type 9-R-9-aminofluorene640 (where R is naphthyl, 
methyl or phenyl) and fluorenone-2-carboxylic acid, are known to possess a numbing effect 
when applied topically and therefore have applications within anaesthesia. Fluorenone-2- 
carboxylic acid boasts antispasmodic action640,653 while the oximinofluorene 66 is a selective 
antagonist for the p2 adreno receptor for which there is no chiral preference since both the R and 
S enantiomers possess equal activity.654,655
2.19 Medicinal Properties of Substituted Fluorenes
In addition to this there are many fluorene based compounds that inhibit tumour 
growth.573,580,582,627,656-658 Benzyl and benzylidene fluorenes boast the ability to inhibit the 
aggregation of platelets,659 6z'.s-alkamine esters of fluorenone581 and &zs-(aminoacyl)fluorenes and 
fluorenones575 induce interferon in mice and have broad spectrum antiviral properties an example 
of this being the orally active interferon inducer tilorone. Derivatives of fluorene have also been 
revealed to possess antiviral activity,579,641 with fluorenol and fluorene based compounds being 
significantly less active than fluorenone based compounds.579 However fluorene analogue 67; 
l,r-(9H-Fluorene-2,7-diyl)6/s[2-(diethylamino)ethanone]dihydrochloride was synthesised as an 
antiviral agent possessing activity both orally and parenterally.575
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N-2-Fluorenyl mustards exhibit their greatest activity against tumour systems and low toxicity 
when an activating group is in the 7 position.657
Halogenofluorenes have been found to have antitumor properties being particularly active in the 
treatment of adenocarcinoma.573,582 Furthermore, 9-o-chlorocinnamylidene- fluorene 68 was 
initially thought to have activity against animal tumour cells after showing slight antitumor 
activity in the mouse sarcoma S I80 tumour system.627,660 Fletcher et al made a range of 
analogues based on 9-o-chlorocinnamylidenefluorene but found that they did not show any 
antitumor activity and the activity of the title compound was never confirmed.627
2,7-Disubstituted fluorenone oximes rearrange in polyphosphoric acid (PPA) as shown in 
Scheme 27 to produce the structurally related 3,8-disubstituted phenanthridinones. Both 
derivatives of fluorene were designed to enhance their efficacy by increasing the hydrophilicity 
of the parent halogenated fluorene, and have been shown to exhibit potent antitumor activités in 
a range of test systems including W256 (rat Walker carcinoma), L1210 (mouse lymphocytic 
leukemia cells) and S I80 (mouse sarcoma).661 The generation of mono halogenated 
phenathradinones was attempted in order to compare their activities however the oxofluorene 69 
was the sole product.
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X = N 0 2, Y = H or X = Y = F, Cl, Br, N 02 
Scheme 27. PPA mediated rearrangement of 2,7-disubstituted fluorenone oximes.
The development of Ibufenac (1960s) and Ibuprofen (available by prescription 1969) led anti­
inflammatory research in the 1970s to focus on arylacetic acids. They were the most actively 
investigated class of compounds in the nonsteroidal anti-inflammatory area leading to the 
development of non-steroidal anti-inflammatory drugs.662'665 The arylacetic acids became a sub 
group in their own right, of which the commonly used anti-inflammatory agent Naproxen is a 
member. The anti-inflammatory activity of certain fluorenes is also documented.662,666,667 
Sprague and Heikes developed compounds based on fluorene-2-acetic acid as agents exhibiting 
activity in this area. They developed an analogue of their lead compound 70, to test the effect of 
partial saturation of the fluorene ring system 71 on biological activity and found that anti­
inflammatory activity was retained despite saturation of one of the aromatic rings with an 
activity comparable to Ibuprofen.662
H 02C h o 2c
70 71
Various fluorenyl analogues were created as calcium (II) antagonists for SAR and mechanism of 
action studies into the effect of substitution around the quaternary carbon. Most analogues were 
inactive but three did show activity. Compound 72 boasted cardiovascular activity superior to 
Verapamil (Calan™, Isoptin™, Verelan™).668
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2.20 Toxicity
Fluorene derivatives are themselves known carcinogens particularly when containing amido and 
amino functional groups.503,574’577’669,670 Namkung et al prepared difluoro-2-acetamidofluorene 
analogues for mechanistic studies regarding carcinogenicity. They established that when fluorine 
is in the 7-position hepatic carcinogenicity is enhanced, possibly due to blockade of a 
detoxification site or modification of the potency of an TV-hydroxy metabolite which is more 
carcinogenic than the parent compound.503 The metabolite A-hydroxy-2-acetylaminofluorene is a 
known carcinogen shown to bind to hepatic proteins at high levels after administration of 2- 
acetylaminofluorene and its derivatives.669,671 2-Acetyl-aminofluorene is itself a known 
carcinogen metabolically activated to highly electrophilic adducts that interact with DNA, RNA 
and proteins.672'674 When administered, A-hydroxylation of acetylaminofluorene to A-hydroxy-2- 
acetylaminofluorene is the essential first step in its metabolic activation.673 As one would 
anticipate the reactivity of various A substituted fluorenes differ. A-hydroxyfluoren-2-amine 73 
has been found to react with guanine in nucleic acids at acidic pH while A-acetoxy-A-2- 
fluorenylacetamide 74 reacts with guanine at pH 7 and is involved with binding to hepatic
. 574proteins.
HO.
73 74
A-Hydroxy-A-2-ftuorenylacetamide is also a known carcinogen, esters of which react in vitro 
with methionine under physiological conditions to give A-2-(3-methylthiofluorenyl)acetamide
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which has also been isolated from liver proteins of rats administered with the parent 
compound.577
Scheme 28. In vitro reaction of esters of N-hydroxy-N-2-fluorenylacetamide with methionine.
2-Aminofluorene and 2-acetamido fluorene are the most extensively used models for the study of 
metabolic pathways and bioactivation of fluorenes since it has long been understood that 
bioactivation and covalent binding to cellular macromolecules can lead to adverse effects for 
compounds, including teratospermia, mutagenicity and carcinogenicity.502’504,672,675’676 Aryl 
amides and amines are activated to a more electrophilic species by A-hydroxylation. This species 
is then able to react with residues on cellular material. 2-(A-hydroxyacetamido)fluorenes (Figure 
9) are bioactivated by A-arylhydroxamic acid A,0-acyItransferase.675
PH 
N
COCH3
R = H, F, Br, I, CN, COCH3, OCH3, 0(CH2)3CH3
Figure 9. 2-(7V-Hydroxyacetamido)fluorene. 7-Substituted analogues were generated to probe substituent effects on
bioactivation675
Elfarra used analogues substituted in the 7-position to probe the effect of substituents on 
bioactivation, concluding that electronegative substituents increased the amount of key reactive 
species, such as the aryl nitrenium ion, and thereby formed an increased number of adducts. This 
is achieved by the transfer of an acyl group from N to O by the hamster hepatic enzyme AHAT 
and is depicted in Scheme 29.
Scheme 29. The mechanism by which AHAT catalyses the formation of electrophilic substituents.
Fluorene 117
Inhibitors o f HMG-CoA reductase have been studied in the hope of developing more efficient 
agents. In this search the inhibitory activities of fluorenylidene lactones 75 and biphenyl lactones 
76 were analysed finding that the presence of the fluorene unit enhances reductase inhibitory 
activity.559
A = H, Cl, CH3 
B = H, Cl, CH3 
X = H, CH3 
Y = H, F 
Z = H,CH3
Aminomethyl fluorenes are also documented to be dopaminergic binders.560 9- 
(Aminomethyl)fluorenes bind weakly to D2 dopamine receptors. 2,5,6-Trihydroxy-9H-fluorene- 
9-methanamine 77 binds to D1 receptors in a manner comparable to apomorphine.
OH
77
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This chapter will contain a separate numbering system for all compounds figures and schemes.
3.0 Pentamidine Analogues: Structure Activity Relationships
3.0. 1 Introduction
Structure activity relationships (SAR) are frequently studied as a parameter in the development 
of novel drugs and have become an important primary phase in the design of novel 
chemotherapeutic agents. This is because they are usually based on known drugs to obtain the 
optimal physicochemical properties and combination of chemical moieties for biological action.
PMD is used extensively for the treatment of protozoal infections and although antimalarial 
activity has been observed, PMD has received minimal clinical interest for malaria. Moreover 
the antimalarial mode of action and accumulation of this weak membrane permeable molecule 
(6/s-cationic) within the parasitised red blood cell is poorly understood.
3.0. 2 Aims and Rationale
Malaria parasites use host cell haemoglobin for the acquisition of amino acids essential for 
parasitic growth and development. During this process monomeric heme is released and 
autoxidised to ferriprotoporphyrin IX (FPIX). However, FPIX is toxic to the parasite inducing 
lipid peroxidation677 and destabilisation of membranes through a colloid osmotic mechanism678 
resulting in cell death.679 However, the parasite has developed a method of detoxification by 
formation of malarial pigment hemozoin, formed by the crystallisation of FPIX to the non-toxic 
“polymer” hemozoin by hematin crystallisation. This process of heme detoxification is an 
established point of pharmacological intervention believed to be the site of action of the 4- 
aminoquinolines. For instance CQ, which by complex formation with FPIX rapidly induces lipid 
peroxidation more so than FPIX alone.680 The kinetics by which this occurs is not fully 
understood but is believed to involve incorporation of CQ into the growing crystal thereby 
inhibiting crystal growth.681
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The Bray group have previously shown that PMD is concentrated 500 fold in erythrocytes 
infected with P. falciparum  and that accumulation can be blocked by inhibitors of haemoglobin 
digestion,367 suggesting that the haemoglobin degradation pathway is important for PMD 
accumulation, implicating this process in the antiparasitic mode of action for PMD. In addition, 
electron microscopy studies have shown that PMD binds to hemozoin in parasitised red cells as 
shown in Figure 1.
PMD
bound
Hz
Figure 1. PMD bound to Hemozoin
PMD accumulation in P. falciparum has been shown to proceed through penetration of the 
infected erythrocyte cell membrane via a parasite specific process attributed to the new 
permeability pathway, induced upon parasitisation of the red cell leading to modifications in the 
cell membrane after which intracellular accumulation is achieved by transport through the 
choline carrier.164 Since PMD not only exhibits antimalarial activity but also possesses a parasite 
specific mode of uptake, aryl diamidines demonstrate a potential new class of antimalarial 
chemotherapeutics and as such their development requires focused drug design. In addition, 
these compounds have never been synthesised by the O’Neill group before, therefore there is an 
additional requirement to become accustomed to their complex physical nature and chemical 
properties governed by their polarity.
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We instigated our development of novel antimalarial aryl dications with the assessment of SAR 
related to PMD. Studying the PMD carbon skeleton, it is clear that there are 4 points of 
divergence that can be adapted for the investigation; the presence of the aryl group, linker length, 
alkoxy groups and mono- substitution versus bis- as shown in Figure 2.
Figure 2. Points of chemical divergence of the PMD structure
Determination of the effect of these modifications on the inhibition of parasitic growth and 
development, in addition to their individual ability to inhibit the formation of hemozoin in vitro 
will enable focused drug design for future aryl dications. Furthermore SAR can provide 
increased knowledge regarding their mode of action alongside molecular modelling.
3.1 The Preparation of PMD Analogues
3.1.1 Alkylation
In order to determine the optimum inter-amidine separation of ¿¿.s'-benzamidines, alkyl chain 
length was varied using in situ generated sodium ethoxide as a base for the deprotonation of 4- 
cyanophenol as shown by Scheme 1. Subsequent nucleophilic substitution with the appropriate 
dibromoalkane gave ¿«-substituted nitriles 2-5 in good yields.682’683
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CN A , 2days CN CN
79-89%
n
1 2 2
3 3
4 4
5 5
n
6 2
7 3
8 4
9 5
Scheme 1. Synthetic route to aromatic amidine analogues
The formation of mono amidines 12 and 13 is shown in Scheme 2. The reaction proceeds in 
much the same way as for the Zus-nitriles, with addition of phenol after formation of the mono- 
substituted alkyl intermediate to form mono-nitriles 10 and 11 in 72-82 % yield.
phenol 
1 72-82%
n
10 2 
11 4
NHj.EtOH
82-85%
n
12 2
13 4
Scheme 2. Synthetic route to mono amidine analogues
As depicted in Scheme 3, methyl substituted nitrile 14 is generated in a similar manner to mono­
nitriles 10 and 11 using ¿»-cresol as the secondary coupling agent to give the product in a 
reasonable yield (72 %).
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1. Na, EtOH 
CN A ,0/N
/ ( C H 2) 5\0  2 5 o
1. HC1, EtOH
_  rS rj  v dry benzene, T  T1 1 
CN Me 3 days, 0°C
i
MeH,N NH
2. Na, EtOH, 
p-cresol 14
2. EtOH, NHj.EtOH 
72% 85%
Scheme 3. Synthetic route to methyl substituted amidine analogue 15
15
Initially, exclusive formation of mono-substituted nitriles 10, 11 and 14 proved to be 
problematic, with a significant quantity of the ¿n's-nitrile observed as a by-product. This problem 
was overcome by carefully controlled addition ofphenol/p-cresol.
3.1.2 Pinner Reaction
Whilst looking for alternate strategies for the formation of PMD analogues, we found several 
examples in the literature were Pinner methodology had been employed in the preparation of 
amidines.309,432,682,683 Thus Pinner methodology was used for the conversion of nitrile precursors 
2-5, 10, 11 and 14 to their respective amidines. Alkyl amidines 16-18 were generated from their 
commercially available nitriles as shown in Scheme 4.
NC
1. HC1, EtOH, dry benzene, 
3-4 days, 0°C
2. EtOH, NH3.EtOH 
78-82 %
NH
NH2 n h 2
n
Scheme 4. Synthetic route to alkyl diamidine analogues
16 4
17 5
18 6
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The Pinner reaction involves the condensation of nitrile and alcohol moieties under anhydrous 
conditions using acid catalysis with gaseous hydrogen chloride or hydrogen bromide.684 The 
reaction mechanism as outlined in Scheme 5 involves the formation of imidate 21 generated by 
nucleophilic attack from the nitrogen lone pair of nitrile 19 to the acidic hydrogen giving cation 
20 which itself becomes subject to attack from the oxygen lone pair of the chosen alcohol to 
yield imidate 21. The imidate must be isolated under an anhydrous atmosphere after which it is 
reacted with ethanolic ammonia to give the cationic species 22 quenched by elimination of EtOH 
to give the target amidine 23. The imidate can be reacted with an excess of alcohol to form an 
orthoester, with ammonia (or choice of amine) to form amidine 25 or with water to form an ester.
R
\o
\o
R
\O
V /
V /
\  /
23
Scheme 5. Pinner reaction mechanism
EtOH
- H+
The Pinner reaction proved highly successful in the preparation of the desired amidines. One 
drawback to the procedure was the use of gaseous hydrogen chloride which is highly corrosive 
and toxic in addition to the requirement for extremely careful handling of the imidate under a
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nitrogen atmosphere. Furthermore the synthetic route is linear lacking points of divergence with 
long reaction times; 2 days for the alkylation reaction and 3-4 days for the Pinner step.
Table 1 shows the yields of amidines 6-8, 12,16-18 obtained from the Pinner route. Purification 
of Pinner reaction products 2-5, 10, 11 and 14 was most effective when formulated as the 
hydrochloride salt since column chromatography was unsuitable due to the polarity of these 
compounds.
Table 1. Synthesis of pentamidine analogues (with Lipinski’s parameters)
Comp Structure 
No.
Yield Formula H bond H
(%) weight acceptors bond
donors
NH
NH,
H2N NH HN NH2
o ^ (CH*N )
H2N NHh 2N NH
70 C,6H18N40 2
298.34
78
86
86
c I7h 20n 4o 2
312.37
c ,8h 22n 4o 2
326.39
C)9H24N40 2
340.42
HN NH2 HN NH2
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12
13
15
16
NH2
82 C,5H,6N20 2
256.30
85 C,7H2oN202
284.35
85 C i9H24N20 2
312.41
78 C6HI4N4 
142.20
4 2
4 2
4 2
4 4
17
18
82 C7H16N4
156.23
82 Q H ,8N4
170.26
4 4
4 4
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3.2 PMD Analogues: Antiplasmodial Activity
3.2.1 In-Vitro Parasitic Sensitivity
SAR of analogues 6-18 and hexamidine (HEX), heptamidine (HEPT) and octamidine (OCT) 
were obtained in infected erythrocytes using the concentration of drug required to inhibit 
parasitic growth by 50 % (IC5o) as a measure of parasitic sensitivity reported in nM. In order to 
further probe the activity of these compounds their ability to inhibit hemozoin formation in vitro 
was assessed. We used P.falciparum from two strains of varying CQ sensitivity, TM6 (resistant) 
and HB3 (sensitive) as shown in Table 2 with CQ and ART as controls. As expected all 
analogues including PMD itself, have varying degrees of activity towards each strain of 
plasmodium being less potent than CQ and ART against CQ sensitive strains. The importance of 
amidine substitution i.e. mono- versus bis- is discussed in addition to the effect of the phenyl 
groups and carbon linker length. Additionally, HEX, HEPT and OCT (Figure 3) were 
previously used for similar studies by the Bray group and hence were not synthesised here, 
though their antiplasmodial activity profile was assessed.
N H
N H N H N H .
Octamidine
Figure 3. Structures of HEX, HEPT and OCT.
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Table 2. Origin and CQ sensitivity of lab strains of P. falciparum used in this section
Isolate CQ Sensitivity Origin
TM6 Resistant Thailand
HB3 Sensitive Honduras
3D7 Sensitive Unknown
DD2 Resistant Genetically modified
Table 3. In vitro antimalarial activity of PMD derivatives
Compound *ICS0 (nM) TM6 *IC50 (nM) HB3
6 45 131
7 33 29
8 317 127
9 106 87
HEX 431 235
HEPT 702 334
OCT >1000 391
12 776 625
13 >1000 >1000
15 >1000 >1000
16 >1000 >1000
17 >1000 694
18 626 815
Art 1.0 1.6
CQ 52.6 11.0
*SD within 10%; IC50 from an average of triplicate determinations
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3.2.2 The Importance of Aryl and Oxygen Functionalities
n h 2 n h  n h  n h
16 17 18
Figure 4. Alky] analogues 16-18
Three compounds 16-18 were synthesised to assess the importance of the oxygen and aromatic 
moieties for antiplasmodial activity of ¿»«-benzamidines such as PMD. These analogues are 
deficient of the phenyl and oxygen moieties within PMD molecular structure, the effect of which 
is a marked reduction in activity against both strains of plasmodium. Analogue 16 was the most 
inactive o f the alky series with IC50S > 1000 nM for both isolates. Compounds 17 and 18 are 
however more active than analogue 16 with IC50S versus CQ sensitive parasites of 694 nM and 
815 nM respectively. Interestingly these two analogues have varying degrees of susceptibility to 
CQ sensitive and CQ resistant parasites with compound 18 having an activity greater than 17 to 
both isolates. However, compound 17 is the most active analogue of this series versus CQ 
sensitive parasites and looses activity when tested against CQ resistant parasites represented by 
an IC50 of 694 nM in the CQ sensitive test system and >1000 nM in the resistant assay. 
Compound 18 exhibits activity converse to this with its greatest activity against CQ resistant 
isolates with a reduction in activity when tested with CQ sensitive parasites (626 nM to 815 nM 
respectively).
The lack of activity of this series demonstrates a requirement for the phenyl group which if heme 
binding is involved in their mechanism of action, can be explained by the ability of planar phenyl 
groups to form an additional n-n stacking interaction with the planar portion of heme. An 
explanation for the varying susceptibility of these analogues to CQ sensitive and CQ resistant 
parasites cannot be clarified from this data, although clearly inter-amidine separation plays a role 
in the affinity of these compounds for the P. falciparum CQ resistant transporter (Pfcrt) of the P. 
falciparum multidrug resistance 1 (^/mdrl) polymorphism.
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3.2.3 The Effect of Inter-Amidine Separation
Six compounds 6-8, HEX, HEPT and OCT were assessed for the effect of the carbon linker 
length on parasite growth using the same system as previously described. The optimum number 
of carbons is shown by compound 7 as being 3 for both CQ resistant and sensitive parasites with 
IC50S of 33 and 29 nM respectively. This is followed by compound 6 whose activity is also 
greater than PMD with an IC50 of 45 nM against CQ resistant parasites. Conversely the weakest 
analogue o f the series is OCT against both isolates tested with IC50S > 1000 nM for resistant 
parasites and 391 nM for the sensitive strain. A strict relationship between linker length and 
activity is not evident however, with a linker length greater than 5 carbons we observe 
decreasing activity as linker length increases. Furthermore this series of compounds are more 
active against CQ sensitive rather than CQ resistant parasites, the most prevalent example of this 
selectivity being OCT with IC50S of 391 nM and >1000 nM respectively. Below a carbon length 
of 5 carbons the least active analogue is 8 (n=4), the most active being 7 (n=3) against both 
strains tested. In addition, compounds 6 and 7 (n = 2 and 3 respectively) were found to be more 
effective than CQ against the CQ resistant strain though none of the analogues including PMD 
were more active than CQ or ART against the CQ sensitive isolate.
Interestingly, these compounds also show susceptibility for Pfcri and Pfmdrl mutations with the 
susceptibility of compound 6 to CQ resistant parasites being much greater than to CQ sensitive 
ones. Activity for this compound is decreased by over 3 fold when tested against CQ sensitive 
isolates represented by IC50S of 45 nM and 131 nM versus resistant and sensitive parasites 
respectively. This specificity for parasite mutant forms actually causes compound 6 to become 
the least active analogue versus CQ sensitive isolates pre n = 5 linker length, whereas for CQ 
resistant forms it is the second most active compound after analogue 7. This pattern of activity 
versus CQ sensitive and resistant isolates can also be seen with compound 8 which exhibits its 
most potent activity in sensitive parasites (317 nM compared to 127 nM in resistant and sensitive 
strains respectively). Evidently, a fixed trend between alkyl chain length and activity is not 
apparent pre n=5 however, inter-amidine separation clearly has an effect on anti-parasitic 
activity. Presumably the most active compounds are those where the chain length may allow 
optimum binding between the amidine and propionate groups.
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3.2.4 The Effect of Amidine Substitution for Hydrogen and Methyl Functionalities
6, 7, 8, 9
o o
vs. NH
NH
O O
15 12,13
Figure 5. Analogues used to determine the effect of amidine substitution on anti-parasitic activity
Possibly the most significant structure activity effect is the exchange of one of the amidine 
functions for hydrogen giving a mo/zo-amidine, the result of which is a significant reduction in 
activity. Analogues 13/8 and 12/6 are direct mono- and Zus-amidine analogues of each other. 
Diamidine 8 has an activity of 317 nM in resistant mutants with its mono-amidine analogue 13 
having an activity >1000 nM. This pattern is also observed for bis-amidine 6 with an IC5o of 45 
nM in resistant isolates falling to 776 nM on removal of an amidine moiety (compound 12), a 
trend also observed in sensitive isolates. Furthermore, for compounds 6 and 12 there is a switch 
in activity with compound 6 giving its most potent IC50 against CQ resistant parasites (45 nM 
versus CQ resistant, 131 nM versus CQ sensitive). In contrast, compound 12, the mono-amidine 
analogue of compound 6, is more potent against CQ sensitive parasites (776 nM versus CQ 
resistant parasites, 625 nM versus CQ sensitive). For compounds 8 and 13 a switch in activity 
upon mo/zo-substitution is not observed since the mo/zo-amidine 13 is inactive against both 
strains with IC50S >1000 nM.
Substitution of an amidine moiety for a methyl group also results in a decrease in activity in fact, 
a complete loss of anti-malarial activity is observed. Compound 15, has a methyl moiety in place 
of an amidine function which results in a change in activity from 106 nM to >1000 nM in 
resistant isolates and 87 nM to >1000 nM in sensitive ones. This series exemplifies the 
requirement for two cationic functions, presumably to enhance binding of these terminal groups 
to the terminal dianionic carboxylate residues of heme thereby locking this flexible molecule in 
place as shown by subsequent molecular modelling studies.
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3.3 Inhibition of Hemozoin Formation
3.3.1 Methodology
In 2000, Pagola et al. determined the crystal structure of P-hematin using simulated annealing 
techniques to analyse powder x-ray diffraction data obtained from P-hematin crystals.685 They 
demonstrated that P-hematin is formed by a bonding interaction between the iron and 
carboxylate groups in each porphyrin molecular side chain. In addition hydrogen bonding linked 
chains form as shown in Figure 6.
013(7" Cl 5
Figure 6. P-hematin and P-hematin dimer formed through iron-carboxylate bonds
Synthetic P-hematin is chemically and crystalographically identical to the malaria pigment 
hemozoin,685'687 a property that was exploited during the course of our development o f novel 
dications. By calculating the degree of inhibition of P-hematin formation in vitro for analogues 
6-18, we used P-hematin as a seed for the crystallisation of hemin, in a manner similar to the 
crystallisation of heme to hemozoin in parasitised red cells, thus allowing the determination of 
the effect o f structural variations on the formation of p-hematin enabling focused antimalarial 
drug design.
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3.3.2 Preparation of p-Hematin
We wanted to develop a high-throughput method using P-hematin as the crystal seed since it has 
been shown that P-hematin can support heme polymerisation at 37 °C.688 Furthermore, this 
technique avoids the use of radioactive chemicals and laborious centrifugation steps that are used 
as standard test systems within our group. P-Hematin was prepared in one step from the iron 
containing hydrochloride of hematin, hemin as shown in Scheme 6.
Hemin
NaOAC, H20
NaOH, HC1 
2Hrs, 60 °C
P-Hematin
Scheme 6. Preparation of B-hematin
The synthesis was straightforward and gives p-hematin in a quantitative yield. Infrared 
spectroscopy confirmed the formation of P-hematin with bands at 1660.3 and 1209.6 cm'1 
corresponding to the C=0 and C-0 stretch of the carboxylate group coordinated to the Fe (III) 
centre (these peaks are absent in hemin).690’691 Furthermore, powder X-ray diffraction showed the 
product to be of good purity with negligible residual hemin.
3.3.3 High-Throughput Assay
The high-throughput protocol initially involved the addition of solutions of analogues 6-18 in 
triplicate over a concentration range to a 48-well plate,692 although the solubility of the alkyl 
analogues in the suspending medium (in ammonium acetate) was poor. To this hemin dissolved 
in DMSO, and p-hematin as a hemozoin seed suspended in ammonium acetate, were introduced 
and the plates incubated at 37°C for 48 hours after which NaHCCVSDS solution was introduced
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to dissolve the dimer and the absorbance calculated as a measure of P-hematin inhibition (similar 
to IC50). We aimed to develop this system as the preferred P-hematin assay within the Bray and 
O’Neill groups. The method did however prove to be problematic. We repeated the above 
method numerous times after which we varied the reaction parameters in order to obtain an 
acceptable inhibition curve that was consistent and reproducible, but the results obtained were 
inconsistent, presumably due to the insoluble nature of P-hematin in sodium or ammonium 
acetate (the media required to maintain physiological pH) giving inaccurate and inconsistent P- 
hematin concentrations. We could no longer adapt this method within our time frame in order to 
move to the design of novel compounds and therefore halted the investigation into high- 
throughput methodology. The methods and results of these adaptations are discussed within the 
Appendix, Section 1. In addition, the method used to obtain hemozoin inhibition data is 
discussed within the experimental section.
Due to the issues encountered with the high throughput assay, we were keen to ascertain that the 
material synthesised was indeed P-hematin to ensure that this was not the cause of the problems. 
Powder X-ray diffraction was carried out by Dr J. Bacsa, University o f  Liverpool, the result of 
which confirms that the material used was indeed P-hematin of a high purity with cell parameters 
corresponding to those found by Pagola et al. as depicted in Figure 7.685
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Figure 7. X-ray crystal structures of synthetic p -hematin
Results and Discussion 135
3.3.4 T h e A b ility  o f  PM D  A n alogues to Inh ib it the In -V itro  F orm ation  o f  H em ozoin
Table 4. Inhibition of Hemozoin formation in vitro
Compound *F-P crystal growth Inhibition
/p M
6 36
7 28
8 41
9 8
12 77
13 120
15 98
16 386
17 369
18 315
CQ 35
*SD within 10 % of reported figure calculated from an average of triplicate determinations
Alkyl analogues 16-18 were the weakest at preventing the in vitro formation of hemozoin with 
compound 16 being the least active corresponding to the lack of antiplasmodial activity observed 
for these analogues. The most active amidine aside from PMD (8 pM) is compound 7 (bis 
amidine n=3) with an IC50 of 28 pM, corresponding to its antimalarial activity though the 
antimalarial potency of this compound is greater than PMD. Compound 15 the methyl analogue, 
inhibits the formation of F-P crystal growth at 98 pM thereby having moderate activity within 
this range o f analogues.
As observed for the biological activity of these agents versus plasmodium , hemozoin crystal 
growth activity decreases upon mono-amidine substitution as apposed to their diamidine 
counterparts illustrated by compounds 6 and 12 giving inhibition concentrations of 36 pM and 77 
pM respectively. This pattern of activity was most markedly observed for mowo-amidine 13 and 
its ¿«-analogue 8 which has a 3 fold loss in activity upon substitution of an amidine moiety for
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hydrogen (120 and 41 |iM respectively). These results indicate that the ability o f diamidines to 
inhibit the formation of hemozoin is dependent on the same factors highlighted as being 
important for the inhibition of plasmodial growth and development, particularly ¿«-substitution 
and aromatic nature. This factor is shown by the most potent analogue 7 inhibiting FP crystal 
growth in a similar manner to CQ as depicted in Figures 8 and 9.
Figure 8. % Hemozoin Inhibition Curve for fits-amidine 7
Results and Discussion 137
Clearly, a correlation between inhibition of hemozoin formation and antiplasmodial activity is 
evident as shown in Figure 10, inferring that inhibition of hematin biomineralisation is part of the 
antimalarial mode of action for 6/s-phenyl diamidines.
Correlation of Inhibition of Parasite Growth and Linker
Length
Correlation of FP Crystal Growth Inhibiton and Linker
Length
Figure 10. Relationship between inhibition of hemozoin formation and inhibition of parasite growth.
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3.4 Molecular Modelling of PMD Analogues
A conformational search using a Monte-Carlo method with the MMFF94 forcefield was 
performed on the diprotonated molecules by Dr Neil Berry, University o f  Liverpool (for details 
refer to section 5.1.6). The Boltzmann weighted average of the inter amidine separation (as 
measured from the carbon bonded to the two nitrogens) was calculated for each molecule. These 
values were then plotted against logio(-activity) using the TM6 and HB3 data outlined in Table 3, 
shown graphically by Figures 11 and 12.
5 -I------------- 1------------- 1------------- .------------- .------------- .------------- 1------------- .------------- .------------- 1
5.00 7.00 9.00 11.00 13.00 15.00 17.00 19.00 21.00 23.00
Boltzmann Weighted Inter-Amidine Distance (Angs)
Figure 11. Plot of log10(-TM6 Activity) against Boltzmann weighted inter-amidine separation as a function of alkyl 
chain length (numbers indicate number of CH2 groups in chain).
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Figure 12. Plot of logio(-HB3 Activity) against Boltzmann weighted inter-amidine separation as a function of alkyl 
chain length (numbers indicate number of CH2 groups in chain).
The results show an optimum inter-amidine separation of approximately 14 A against both 
strains o f plasmodium tested and similarities between the two strains with regards to a decline in 
activity for longer alkyl chains being clearly observed in Figures 8 and 9 particularly past a 
carbon value of n=5. Presumably a longer separation between the dicationic moieties leads to a 
large loss in entropy upon binding of the longer analogues to the anionic carboxylate residues of 
the heme template. For the in vitro antimalarial activity determinations we observed a loss in 
activity for the alkyl analogues 16, 17 and 18, explained by the ability of their amidine groups to 
bind to heme carboxylates but not its planar portion. This can also explain why morco-amidines 
have reduced activity since their aromatic rings have the ability to form a n- n stacking 
interaction with heme but cannot since they can bind only to one portion of the carboxylates 
leaving the rest of the molecule in a non-fixed orientation. There must be a requirement for both 
amidines in order to form a stable, ordered, heme-drug complex involving an energetically 
favourable interaction between the cationic amidines and anionic carboxylates of heme. Thus the 
binding modes of aromatic amidines and heme most likely involve a 7i- 7t stacking interaction
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between the planar phenyl components and heme, a feature that corresponds to the biological 
activity obtained for alkyl vs. aromatic analogues.
PMD can adopt three different conformations, two bending and one linear, the formation of each 
presumably affected by which will form the favoured energy conformation. These factors were 
validated by a conformational search on the most active ¿¿y-benzamidine compound 7 (n=3) 
interacting with a molecule of heme as shown by Figure 13. The interaction between the 
protonated amidines and the carboxylates is in the form of hydrogen bonding to form a sandwich 
complex around monomeric heme. In addition the benzene rings do not appear to form an 
interaction with the entire heme template but rather a n-n interaction with the edge of heme 
possibly stabilising the structure. Clearly heme appears to be distorting somewhat to 
accommodate the binding amidines forming a complex that would have the ability to prevent the 
formation of reciprocal bonds for conversion of toxic heme to its non-toxic polymer hemozoin, 
while presumably maintaining the toxic properties of monomeric heme since its chemical 
constitution with respect to the central iron molecule is unchanged
Figure 13. Lowest energy conformation of compound 7 (n=3) and heme. Hydrogen bonds are indicated with dashed 
black lines with the heme in red and benzamidine coloured by element; H -  white, C -  cyan, O -  red, N -  blue
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The effective dose required to inhibit trypanosomal development in half the test population 
(ED50) was calculated by Dr H. De Koning University o f  Glasgow and is reported in pM using 
diminazene as a control. All analogues were not equally potent having varying degrees of 
activity. The importance of the nature of amidine substitution in addition to the effect of the 
linker length and phenyl groups on WT (wild type), KO (knock out) and the resistance factor are 
discussed.
3.5 PMD Analogues: Antitrypanosomal Sensitivity
Table 5. In vitro trypanosomal activity
Compound *EDSo / pM 
Average WT
*EDS0 / pM 
Average KO
Resistance Factor3
6 0.55 1.39 2.54
7 0.07 0.16 2.32
8 0.02 0.04 2.17
9 0.01 0.01 1.04
12 18.13 15.85 0.87
13 2.84 1.71 0.60
15 1.34 1.27 0.95
16 ISb ISb ISb
17 ISb ISb ISb
18 60.30 92.50 1.53
diminazene 0.21 1.60 7.61
* SD within 10% calculated from a triplicate of determinations; Resistance Factor -  Confers degree of drug 
resistance, larger number = greater degree of resistance; bIS = Insoluble
3.5.1 The Im portance of the Aryl and Oxygen Moieties
The activity of compounds 16 and 17 could not be assessed due to their insolubility in the testing 
media therefore compound 18 is the only alkyl analogue that was assessed. Nonetheless, the 
activity observed for this analogue shows a pattern similar to that observed in plasmodia, with
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the absence of phenyl and oxygen functionalities resulting in a loss of activity. Analogue 18 is 
the least active of all compounds tested against WT mutants and KO giving ED5o’s of 60 pM and 
92 pM respectively, furthermore the resistance factor of this analogue is slightly more than PMD 
(1.53 w. 1.04 for PMD) but lower than some of the other analogues.
3.5.2 Further SAR
PMD (n=5) is the most potent anti-trypanosomal agent of the series followed closely by n=4 and 
n=3 represented by compounds 8 and 7 respectively, all of which are more active than 
diminazene in terms of WT and KO for the 6A-amidines. Compound 6 (n=2) is the least active of 
the aromatic Zns-amidine series with a WT ED50 of 0.55 pM and a KO of 1.39 pM.
The effect of mono- and fe-amidine substitution is shown by compounds 6/12 and 8/13 with a 
marked decrease in activity upon mono-substitution from 0.55 pM to 18.13 pM for 6/12 and 0.02 
pM to 2.84 pM for 8/13 a trend also observed in terms of KO. Substitution of an amidine moiety 
of PMD for a methyl group (compound 15) resulted in a marked decrease in activity in both test 
systems. The methyl substituted compound 15 was amongst the least potent antimalarial 
compounds, however for trypanosomes this was not the case with mono-amidine 12  being the 
least active of the benzamidine series, compound 15 being poorly active is ~18 times more 
potent than compound 12. For the mono-amidines 12 and 13 the KO is slightly less than the WT 
whereas for the 6A-amidines 6, 7 and 8 the KO is approximately double the WT value aside from 
compound PMD whose values remain constant. In addition, the methyl analogue 15 also has a 
reduced KO when compared to its ¿/.s-amidine counterpart 9.
The resistance factors obtained for the series are interesting with mono-amidines giving the 
lowest resistance factors of the series and diminazene possessing the greatest. A trend is present 
for RFs (resistance factor) among the diamidine analogues since as the linker length increases the 
RE decreases as illustrated by compounds 6, 7, 8 and 15, the latter compound being the lowest. A 
similar trend is observed for the mono-amidines although substitution of H for CH3 results in a 
slight increase in the RF.
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3.6 Summary
We have designed and synthesised a range of (di)amidines in good yields and purity while 
gaining an insight into the structural requirements of aromatic (di)amidines for the inhibition of 
malarial parasitic growth and development, knowledge that is required for the creation of novel 
agents of this nature. In addition we have compared the effect of these modifications on 
antiplasmodial and anti-trypanosomal growth finding that the chemical functional requirements 
are similar for both. Furthermore, we have demonstrated the ability of these compounds to 
inhibit the formation of hemozoin, a possible target in the biological action of dications of this 
nature. Further studies to assess the requirement of the oxygen moiety directly could have been 
assessed, in addition to enhanced increases in alkyl chain length and variation of the oxygen 
moiety for other heteroatoms such as sulfur in order to obtain a more robust structure activity 
profile, however we felt that we gained the data necessary to move forward in our design of 
novel dications and therefore complete our investigation.
Figure 14. Structure activity profile of aromatic diamidines
The structure activity profile established is outlined in Figure 14 as requiring an aromatic moiety, 
in addition to bis amidine substitution being essential for antiplasmodial activity with an 
optimum inter-amidine separation of 14 A. These analogues also display an interesting activity 
profile versus CQ sensitive and resistant parasites with some exhibiting more potent activity in 
the later isolates, a prospect very exciting to us as we anticipate the possibility that we may be 
able to access novel compounds with an ability to act preferentially on CQ resistant parasites.
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3.7 Heterocyclic Diamidines
3.7.1 Introduction
Structure-activity investigations based on PMD established propamidine as a lead compound for 
antimalarial drug development. Specifically, aryl moieties with bis- rather than rao«o-amidine 
substitution are requirements for antimalarial activity. Furthermore, a linker length of 14A (3 
carbons) is optimal for antiplasmodial potency. It is the nature of this linkage that we wish to 
establish as illustrated by Figure 15.
HN
LINKER
/
H2N
14 A
Xn h 2
Figure 15. Diamidine Drug Template 1
3.7.2 Rationale
Through in silico molecular modelling, we established that the flexible carbon linker of 
propamidine aids the formation of the drug-heme ‘complex’. In addition to this, the amidine 
moiety interacts with the heme propionate groups. With this in mind, our aim was to enhance the 
affinity of these molecules for heme. In order to achieve this, molecular spatial arrangement is an 
important factor, fi/s-benazmidines such as PMD are flexible due to the possibility of rotation 
around the central carbon linker. It has been revealed that analogues of PMD with a double bond 
present show an enhancement in anti-protozoal activity,693,694 presumably the rigidity imparted 
by the double bond aids binding to the bio-molecular target.
The locking of flexible molecules is well established within chemotherapeutic drug design, as an 
approach to enhancing the specificity of a drug molecule for its site of action, a feature 
commonly used for lead optimisation. In addition to double bonds, heterocycles have also been 
used to form conformationally restricted diamidines.304,305,309
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3.7.3 Proof of Concept
A furan heterocycle was employed by Das and Boykin as a linker between the two phenyl 
amidine groups giving DB75 (26), a molecule with potent anti-trypanosomal activity.452 In 
addition, this compound has potent antimalarial activity in vitro versus P. falciparum  CQ 
resistant isolates (15.5 nM, K l)695 with weak toxicity to mammalian cells. Furthermore DB289, 
the dimethoxy prodrug of DB75 has been tested for the treatment of P. vivax and acute, 
uncomplicated P. falciparum infections with success.492
Figure 16. Structure of Furamidine (DB75)
As mentioned, structure activity relationships denote an inter-amidine separation of 
approximately 14A (given by a carbon linker of 3) for optimum activity. A requirement that can 
be achieved by use of a five membered heterocycle furthermore, doubly atom containing 
heterocycles can act as isosteres for the two oxygen atoms linking the benzamidines of PMD as 
shown in Figure 17.
Figure 17. Lead Compound Propamidine and Isosteres
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Clearly heterocycles 28-33 have similar molecular shapes and distributions of electrons, more so 
than 32 and 33. In addition to locking of the central linker, variation of the amidine position on 
the ring may exert an effect on antimalarial activity therefore isomers will also be assessed.
3.8 3,5-Diphenylisoxazole
3.8.1 Chemistry
Scheme 7. Intended synthetic route for the formation of isoxazole diamidines
The synthetic route utilised is outlined in Scheme 7. The first step of the sequence involved the 
condensation of the appropriate commercially available bromobenzoate 34 and bromophenyl- 
ketone 35, using sodium hydride in the presence of a small amount of methanol.696 1,3-Diketones 
36 were formed in moderate yields. However, the generation of these compounds was not 
straightforward. The work-up of the reaction mixture was problematic due to the formation of an 
emulsion during the extraction process which rendered separation of products difficult. We 
found that benzene was the only suitable solvent for product extraction from the reaction media, 
since solvents such as Et20, DCM and chloroform failed to adequately separate aqueous and 
organic fractions thereby minimising emulsion formation. In addition to these factors, 
purification of the product was compounded by its insoluble nature in most organic solvents.
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Purification was however achieved by multiple recrystallisations from benzene and suspension 
of the product in hot EtOH.
Studying the literature, common methodologies for isoxazole formation involve the attack of 
hydroxylamine on a molecule containing three-carbon atoms for instance a 1,3-diketone, a a,p- 
dibromoketone or intramolecular cyclisations of amino acids.695,697 Diketone 36 was converted to 
isoxazole 37 upon treatment of a suspension of 36 in dioxane with aqueous sodium hydroxide 
and hydroxylamine heating to reflux over 2 days after which the product was purified by column 
chromatography.698
The conversion of dibromoisoxazoles to their dinitrile counterparts was a key step in the 
synthesis o f target molecules. However the reaction was hampered by the generation of copper 
halide salts and this made product isolation difficult. We commenced our conversion of 
dibromoisoxazoles to their dinitriles using the method of Das and colleagues.452 Das used one 
equivalent of Cu2(CN)2 in refluxing quinoline to form a ¿«-nitrile derivative. This methodology 
was attractive since this was used for the cyanation of a closely related aryl furan compound. 
However Cu2(CN)2 could not be purchased thus we replaced one equivalent of Cu2(CN)2 for 
two equivalents of Cu(II)CN (Table 6, entry 1). However, starting material and the mowo-nitrile 
were recovered, which we assumed to be due to insufficient CuCN thus we repeated the reaction 
with 4 equivalents of CuCN again in quinoline however after laborious column chromatography 
steps the mono substituted product was again isolated. Following the failure to achieve the 
desired transformation we then considered the Rosenmund Von Braun (RVB) reaction. The RVB 
reaction involves cyanation of aryl halides using an excess of copper (II) cyanide in a polar high- 
boiling solvent, most frequently DMF since the reaction requires high temperatures (150-280°C).
Table 6 shows the reaction conditions used in an attempt to improve the formation of the bis- 
substituted product. Modifications include the number of CuCN equivalents, reaction duration 
and temperature. We were cautious not to elevate the temperature too much over concerns over 
the stability of the weak N -0 bond. In addition to these parameters, the work-up procedure was 
varied in some cases to include pouring the cooled reaction mixture into solutions from 10% 
NH4OH to cone. NH4OH and pouring the hot reaction mixture into a solution of hot KCN (10%)
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after which the mixture was stirred at room temperature overnight. The TLC showed the reaction 
mixture to be mowo-nitrile and starting material. We also tried various methods of combining the 
mixture from sequential addition, to combination of the isoxazole and CuCN in a pestle and 
mortar, to pre heating in DMF all of which resulted in recovery of the starting material and 
mono-nitrile. Unfortunately, in all cases degradation occurred.
Ta b le  6. Variations of reaction conditions used for the conversion of dibromoisoxazoles to nitrile 
Entry Reaction CuCN / Temp / Yield of 
Number Time / Equivalents °C Mono
hrs Product (%)
1 17 2 150 15
2 5 4 190 ND*
3 17 4 190 24
4 21 4 150 19
5 4 13 150 ND*
ND* Not Determined
Having met with failure with the CuCN approach we decided to investigate an alternate strategy 
where the nitrile function is in place at the start of the synthesis.
N C
N - 0
C N
43
Scheme 8. Alternative strategy to the formation of dinitriles
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Claisen condensation was achieved by combining methyl 4-cyanobenzoate 41 and 4- 
acetylbenzonitrile 40 in THF in the presence of NaH. Although 42 was produced in good yield 
(76%), access to the isoxazole via subsequent ring closure was not accomplished by TLC. This 
was also confirmed by the presence of the dicarbonyl proton singlet in the 'H NMR spectrum.
We considered that the oxazole structure would have enhanced stability and therefore its 
analogues could have superior in vivo activity. The synthesis of oxazole 46 had an additional 
advantage that access to the heterocycle was in one step. The procedure involved heating 
ethanone 44 and bromobenzamide 45 at 150°C for 4hrs.699
O
44
Scheme 9. Oxazole strategy
Oxazole 39 was shown by ]H NMR to be the synthetic product however its isolation was so 
problematic that we assessed alternative heterocyclic linkers.
The thiazole unit has been employed leading to the generation of ¿«-thiazolium salts, some of 
which show potent antiplasmodial activity, their suggested mode of action being inhibition of 
choline transport.155,156 T16 is a potent heme binding antimalarial that accumulates several 
hundredfold into parasitised erythrocytes.157 In addition, the hydroxy analogue of T16, T3, has 
been developed as the prodrug TE3 possessing potent oral activity with an ED5o of 5 mg/kg as 
shown in Figure 18.158
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Figure 18. Structures of T16, T3 and prodrug TE3
3.9 2,4-Diphenylthiazoles
3.9.1 Chemistry
The synthetic route designed for the generation of 2,4-diphenylthiazoles is outlined in Scheme 
10.
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Scheme 10. Synthetic route to Thiazole analogues. TFA salts generated by reverse phase HPLC
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Using the Hantzsch synthesis for the construction of the thiazole unit, thioamide 41 was 
condensed with a-haloketone 42, the thioamide being prepared from the reaction of nitrile 
derivative 40 and gaseous hydrogen sulphide (H2S) in triethylamine and pyridine.700 Subsequent 
condensation of a-halo ketone 42 with thioamide 41 afforded the precipitation of 
dibromothiazoles 43-46 in excellent yield after warming to45°C for 1 hr.700
Generation of ¿us-nitrile derivatives 54-57 once again proved to be difficult. The desired bis- 
cyano thiazoles were prepared after refluxing the appropriate dibromothiazole overnight in a 
mixture of CuCN and DMF450 in yields ranging from 23-60% dependent on the isomer. The 
reaction was again subject to the sensitivity of the reactant and product under the reaction 
conditions, degradation products and isolation of the mono-nitrile were commonly observed. The 
6/s-nitrile however was formed for all analogues in one cyanation step and the crude material 
purified by column chromatography. In our hands the success of the reaction was dependent on 
the reaction temperature and the removal of DMF and copper halide salts generated during the 
reaction process. Specifically, the temperature must be maintained at 150 °C; lower temperatures 
give an increased recovery of the starting material and mono-nitrile, at temperatures above 150 
°C degradation occurs. The generation of copper halide salts during the reaction process 
complicated the purification of the crude material therefore their separation from the nitrile 
products by stringent washing and filtering processes were imperative due to the low solubility 
of the nitrile crude mixture for column chromatography. In addition the insolubility of the nitrile 
in the Pinner reaction media means that any residual inorganics cannot be removed. Furthermore 
the use of polar, high-boiling DMF as solvent complicates extraction/washing processes and 
purification of the nitrile and therefore its removal from the crude reaction mixture by 
evaporation to dryness overnight (high vac) prior to column chromatography was crucial for 
good separation.
Due to the difficulties encountered with the cyanation reaction, whilst screening the final 
analogues alternate methodology for the generation of the nitrile was briefly assessed. Weissman 
et al. report methodology for the ligand-free conversion of a bromo moiety to a nitrile function in 
a mild manner.701 They apply palladium catalysis using palladium acetate in dimethylacetamide 
with potassium hexacyanoferrate as the nitrile source as shown in Scheme 11.
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Scheme 11. Alternative route to the cyanation of dibromothiazoles
The course of the reaction was monitored by TLC, product formation was initially observed, 
ceasing after a few minutes; presumably the thiazole moiety was poisoning the catalyst thus 
rendering this methodology unsuitable. Nonetheless the reaction was applied to the formation of 
dicyanoisoxazoles and again monitored by TLC. After 5-10 minutes formation of the bis- nitrile 
was observed. At this point however, we did not move forward with this methodology due to our 
focus on the thiazole heterocycle.
Pinner methodology was again employed for the transformation of nitriles 54-57 to their 
appropriate diamidines 58-62 however this was troublesome due to the partial solubility of the 
dinitriles in the appropriate solvent media. Over the period of the reaction we also observed the 
formation of the mono substituted product precipitating of solution. As opposed to the PMD 
analogues previously synthesised, the conversion of thiazole nitriles to diamidines required a 
minimum of 1 week for the formation of the imidate. The extended reaction times, careful 
handling of intermediates under an inert atmosphere, low yields and difficulty with purification 
of the diamidine product led us to briefly assess alternative methodology. Routes to the 
formation of diamidines by methods other than the Pinner reaction are limited; however 
Garigipati found that alkylchloroaluminium amides can affect the transformation of amidines 
from a nitrile precursor in one high yielding step by the direct nucleophilic addition of an amine 
to a nitrile.702,703 Accordingly we applied the Garigipati reaction for the conversion of nitriles 49 
and 50 to their corresponding diamidines 53 and 54 as shown in Scheme 12.
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NHj . HCI + (CH3)3AI
h2o
S i0 2
Scheme 12. The Garigipati reaction of nitriles 56 and 57
The alkylchloroaluminium amide reagent is generated from trimethyl aluminium ((CH3)3A1) and 
ammonium chloride (NH3.HCI).704 Addition of the aluminium amide to the nitrile forms an 
intermediate aluminium complex which is hydrolysed by water adsorbed on silica gel. When 
used in this case we found that although the low reaction time was an advantage and fewer side 
products were formed, the low solubility of the nitrile in toluene led to lower yields (22 %) than 
those obtained using Pinner methodology. Another route to the formation of amidines involves 
amidoxime reduction, a method used by Anbazhagan and co-workers for a range of amidoxime 
containing molecules.705 Amidoximes were generated from the nitrile precursor using potassium 
/er/-butoxide and hydroxylamine hydrochloride in dimethylsulfoxide450 as shown in Scheme 13.
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N O H
Scheme 13. Alternative route to the amidine via reduction of amidoxime 56
We attempted the direct reduction of amidoxime 56 using catalytic transfer hydrogenation with 
palladium on carbon in ammonium formate and acetic acid. Although this reaction has been 
reported previously for biphenyl heterocyles,415,705 thiazole amidoxime 56 was not affected. Due 
to the low reaction yield obtained for the Garigipati reaction and the failure of the amidoxime 
reduction, the Pinner reaction was used for the generation of all other 2,4-diphenylthiazole 
diamidines 51, 52 and 55 as reported in Table 7.
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Table 7. Structures of Targets
Comp Structure 
No.
Yield Formula 
(%) weight
H bond H bond Log P 
acceptors donors
58 22 C 1 7 H 1 5 N 5 S
321.40
3.21
59
60
61
62
. 2TFA . H20
H,N
31
22
33
52
c ,7h ,5n 5s
321.40
C 1 7 H 1 5 N 5 S
321.40
c 17h ,5n 5s
321.40
C i7HI5N5S
321.40
3.21
3.21
3.21
3.21
. 2HC1.2  H20
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3.10 In -V itro  Antiplasmodial Activity and Inhibition of Hemozoin Formation 
of Thiazole 5/s-Aryl Diamidines
3.10.1 In-Vitro  Parasitic Sensitivity
Diphenylthiazoles 51-54 were assessed for antimalarial activity in vitro against CQ sensitive 
P.falciparum. The compounds were evaluated for their ability to inhibit parasitic growth by 50 % 
(IC50) the results of which are shown in Table 8.
Ta ble  8. Activity of thiazoles versus 3D7 and DD2 strains.
Compound *ICS0 (nM) 3D7 *IC50 (nM) DD2
58 257 ± 28 107 ± 15
59 279 ±41 127 ±25
60 225 ± 32 ND
61 273 ± 19 ND
CQ1 7 ± 4 96 ± 17
PMD2 162 ±41 81 ± 11
= Chloroquine;2 = Pentamidine * Calculated from an average of triplicate determinations
Thiazoles 58-61 were formulated as trifluoroacetate (TFA) salts due to their purification method 
(preparative HPLC).706 These analogues exhibit moderate antiplasmodial activity from 225 to 
279 nM versus CQ sensitive parasites. Clearly the position of the amidine functionality on the 
phenyl ring has an effect on the activity of these analogues although not to a great extent, the 
meta-meta analogue being the most potent against CQ sensitive parasites; the meta-para 
diamidine is the most active against the resistant strain. Interestingly, these analogues are 
unaffected by the CQ resistant mutation thereby exhibiting their greatest potency against CQ 
resistant parasites with an enhancement of activity over 2-fold for most analogues tested. That 
being said, we were disappointed with their moderate activity especially when considering the 
activity of the closely related molecule DB75 (15.5 nM versus CQ resistant K l695 75 nM versus 
DD2).
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At this point we were concerned about the project, especially due to our previous disappointment 
with isoxazole and oxazole heterocycles. Our resolve was further tested by a publication from 
the Tidwell group regarding the antimalarial efficacy of 3,5-bis(4-amidinophenyl) isoxazoles. 
Tidwell and co-workers synthesised isoxazole compounds with enhanced potency against P. 
falciparum in comparison to DB75 however, the majority of these compounds had cytotoxic 
indices ranging between 10 and 120 times higher than DB75.695
HC1 salts contribute over 50% of all basic pharmaceutical salts approved in the last twelve years 
by the FDA (US Food and Drugs Administration).707 Furthermore the isoxazoles assessed by the 
Tidwell group were formulated as HC1 salts. We therefore considered that the salt form could 
play a crucial role in the potency of these compounds and hence reformulated compound 62 as a 
HC1 salt.
T a b le  9 . A c t iv ity  o f  th ia z o le s  versus 3 D 7  and D D 2  stra in s.
Compound *ICS0 (nM) 3D7 *IC5o (nM) DD2
59 225 ± 56 156 ±25
62 11.3 ±2.1 6.2 ± 1.3
CQ1 7 ± 4 96 ± 17
DB752 153 ±26 75 ±7.7
PMD3 162 ±41 81 ± 1 1
'= C h lo r o q u in e ; 2=  F u ram id in e; 3= P e n ta m id in e  * O b ta in ed  fro m  an a v e r a g e  o f  tr ip lic a te  d e te rm in a tio n s
To our excitement, reformulation dramatically enhanced the antimalarial potency o f the para- 
meta HC1 analogue 62 giving IC50S of 11.3 and 6.2 nM versus CQ sensitive and resistant 
parasites respectively thereby displaying enhanced activity against CQ resistant parasites. We 
have not looked into the reasoning for the counterion effect in detail. Presumably TFA associates 
to the amidine nitrogen with a higher affinity than HC1 affecting the amidine-propionate 
interaction or the solubilisation of the compound.
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3.10.2 Inhibition of Hemozoin Formation
Earlier studies within this thesis have shown that PMD and propamidine inhibit the in vitro 
formation o f hemozoin in line with their respective antiplasmodial activity. In addition, the Bray 
group have shown that PMD binds to FPIX in the test tube giving a pronounced quenching of the 
FPIX Soret peak on addition of 1 molar equivalent of PMD as shown in Figure 19.
- - - FPIX + Pentam idine —  FPIX 
F ig u r e  19. P M D  q u e n c h in g  o f  F P IX  S o r e t p e a k
We therefore assessed the ability of diamidine 62 to inhibit the formation of hemozoin using the 
inhibition assay of hemozoin formation from monomeric FPIX with ghost membranes via the 
same procedure employed for the PMD analogues assessed previously. Thiazole 62 was shown 
to be inhibit the formation of hemozoin in vitro when incubated with erythrocyte ghost 
membranes in a mode similar to CQ and PMD as shown in Figure 20.
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Figure 2 0 . In Vitro in h ib it io n  o f  h e m o z o in  fo rm a tio n  fro m  m o n o m e r ic  F errip rotop orp h yrin  IX . (G en er a ted  fro m  an 
a v e r a g e  o f  tr ip lica te  d e te rm in a tio n s ) . C o m p o u n d s  are P M D  (o ) ,  6 2  ( • ) ,  C Q  ( 1=1)
However, the affinity of this binding interaction (230 pM) appears to be lower than PMD (152 
pM) and CQ (121 pM) respectively. Clearly, this observation does not correlate with the in vitro 
potency of this compound. This suggests that this diamidine molecule may have additional 
specific uptake mechanisms compared with PMD. Alternatively, the key interaction may take 
place in the cytosolic/non-membrane component such that the ghost membrane assay is not a 
representative model for mechanism of action.
3.11 Molecular Modelling and Cytotoxicity
3.11.1 Molecular Modelling
To further investigate the heme binding properties of thiazole diamidine 62 in silico molecular 
modelling with heme was undertaken by Dr N. Berry (University o f  Liverpool) as depicted by 
the lowest energy conformation shown in Figure 21. Structurally the compound has heme 
binding properties, confirmed by the electronic interaction between the cationic amidines and 
anionic propionate groups.
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Figure 21. L o w  e n e r g y  c o n fo r m a tio n  o f  d ia m id in e  th ia z o le  61 b in d in g  to  h e m e  rep resen ted  by; w h ite  =  H, 
b lu e  =  N , y e l lo w  =  S , g r ey  =  ca rb o n . F or m eth o d  s e e  s e c tio n  5.1.6.
It is apparent from the conformation that the interaction is largely dependent on the diamidine- 
carboxylate contacts as oppose to propamidine where in addition to diamidine-carboxylate 
binding, the aromatic rings form a stacking interaction with the planar portion of the heme 
molecule, possibly explaining the reduced hemozoin inhibition activity profile produced by this 
molecule in comparison to PMD and CQ.
3.11.2 Cytotoxicity
Diamidine cytoxicity is widely reported,310 frequently resulting in the termination o f the 
development of compounds with potent antiplasmodial properties. In order to assess the toxic 
effects of biaryl thiazole 62 on the host cell, toxicity assays using hepatic Huh7 and Caco-2
'lf\Q '7AQ
intestinal cell lines were performed by A. Owen, University o f  Liverpool. ’ As shown 
graphically by Figures 22 and 23, the cytotoxicity of diamidine 62 was established to be less than 
DB75 against hepatic and intestinal cell lines with a promising therapeutic index of 
approximately 10,000.
Results and Discussion 161
F ig u r e  2 2 . C y to to x ic ity  o f  th ia z o le  6 2  a g a in st  h e p a tic  c e l l  l in e s  (H u h 7 ). C o m p o u n d s  are D B 7 5  (o ) ,  6 2  ( • )
F ig u r e  2 3 . C y to to x ic ity  o f  th ia z o le  6 2  a g a in st  in testin a l c e l l  l in e s  (C a c o -2 ) .  C o m p o u n d s  are D B 7 5  (o ) ,  6 2  ( •  )
Encouraged by the high potency and low cytotoxic potential of analogue 62, we discussed a 
prodrug approach using this compound. We considered the re-synthesis of all analogues to assess 
their viability as HC1 salts, particularly compounds 58 and 60 since they possessed enhanced 
activity against CQ resistant parasites and/or sensitive parasites compared to 52. Accounting for 
the time it would take for their re-synthesis and re-assessment of antiplasmodial efficacy, we 
moved forward with analogue 55 as we were keen to explore the in vivo efficacy of appropriate 
prodrugs.
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3.12 Thiazole Prodrugs
3.12.1 Rationale and Prior Art
Diamidine compounds have a long history in the treatment of infectious disease particularly 
protozoan infections. However, their clinical deployment has been restricted due to problems 
associated with poor bioavailability, toxicity and the route of administration of the charged drug. 
Diamidines have long been known to possess the ability to suppress the growth of the 
plasmodium malaria parasite; however drugs with better physicochemical profiles, such as CQ 
and amodiaquine, became the principal compounds for prophylaxis. The efficacy and kinetics of 
pharmacologically active compounds are a function of their ADME properties. Due to a high 
pKa, the amidine moiety ionises readily within the acid milieu of the stomach and thus drugs 
such as PMD become inactive on oral administration and are therefore administered 
intravenously. A prodrug approach depressing the ability of the amidine functionality to 
protonate at physiological pH would therefore provide a route to the enhancement of oral 
potency. Such a strategy led to the development of the orally active DB75 prodrug DB289 64.
We therefore commenced the synthesis and assessment of antimalarial activity of novel 
diamidine prodrugs possessing a thiazole linker.
NH2 64
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3.12.2 The Synthesis of 2,4-DiphenyIthiazole Prodrugs
NOH
DMSO, 5°C
55 98 % 63
Prodrugs 63 and 65-72 were formed from the key intermediate dinitrile 55. Amidoxime prodrug 
63 was formed in excellent yield by the nucleophilic substitution reaction between dinitrile and 
hydroxylamine hydrochloride mediated by potassium ie/7-butoxide. Compounds 65 and 66 were 
formed from amidoxime 63 using alkylation methodology employing the appropriate alky 
sulphate in dioxane to give the alkylated product in typically 42-45% yield after purification by 
column chromatography.450 This reaction was attempted several times before success was 
attained due to issues with the extraction of the product from the aqueous media. Pyridine was 
employed as an alternate base in an attempt to improve the yield of the reaction and ease of
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product isolation however, use of pyridine led to a large decrease in the yield of reaction and thus 
NaOH was re-employed. Finally, acetate prodrug 67 and trifluoroacetate 68 were synthesised 
from a mixture of glacial acetic acid and acetic anhydride furnishing the title compound in an 
89% and 79 % yields respectively. Table 10 shows the yield of formation and properties relating 
to each prodrug. Melting points are included since depression of melting point is a property used 
to ascertain prodrug qualities.
T a b le  1 0 . P ro p er tie s  o f  th ia z o le  p rod ru gs and p aren t c o m p o u n d
Compound
Number
Pro-moiety Yield / % pKa Log P Melting 
Point / °C
63 NOH 98 8-9 3.55 218-220
65 NOMe 42 - 4.07 175-176
66 NOEt 45 - 4.75 145
67 NO Ac 89 - - 193
68 NOCOCFj 79 - - 197
Parent Drug - 52 12-13 3.21 370
The synthesis of sulfonyl pro-analogues 69 and 70 was also attempted however, despite variation 
of the reaction conditions via variation of the base, the amidoxime was unaffected.710
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Alternative chemical derivitisation approaches were attempted via the amidine free base using 
potassium carbonate in a mixture of DCM and water however this resulted in recovery of the 
starting material.711 This reaction was also attempted via the amidine hydrochloride salt again 
using potassium carbonate and the appropriate sulfonyl chloride. Although this reaction has been 
reported previously for amidines, in this instance the reaction was unaffected.
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Scheme 16. S y n th e tic  R o u te  to  S u lfo n y l P ro d ru g s
The reaction was therefore attempted using the amidine free base in the presence of 
triethylamine,712 although consumption of the starting material was observed, the product formed 
was impure with a poor solubility profile thereby making its purification difficult.
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Scheme 17. S y n th e tic  ro u tes to  su lfo n y l p rod ru gs fro m  th e  d ia m id in e  fr ee  b a se  62
Bis phenylcarbonates have been used as prodrugs to form protected amidines in good yields, thus 
we applied their methodology to the thiazole analogue.496 Firstly the diamidine hydrochloride 
salt was converted to its free base, after which diamidine 62 was reacted with bis(4- 
fluorophenyl)carbonate 76 generated by reaction of 4-fluorophenyl chloroformate 74 and 4- 
fluorophenol 75 in DCM and pyridine, purification of 76 by column chromatography furnishing
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the product in a yield of 83%. Carbonate 76 was then reacted with the amidine free base in DMF 
to give prodrug 77. However due to issues with the purification of compound 77 related to its 
poor solubility profile in organic solvents this chemistry is ongoing.
Scheme 18. Alternative prodrug strategy
We assessed th'e in vitro antiplasmodial activity of these compounds and can confirm that they 
are indeed inactive with IC50S > 1000 nM as expected.
3.13 Conclusion and Future Work
In conclusion, we have developed a series of novel diamidines that show moderate to excellent 
activity against P. falciparum strains in vitro dependent on the salt counterion. The activity of 
2,4-diphenylthiazole diamidines is enhanced by mutant alleles of Pjfndrl and P/crt thereby 
surpassing the CQ resistance pathway. Furthermore, thiazole 62 is approximately 10-fold more 
active than DB75 against P.falciparum in vitro as shown by IC50S of 6.2 and 75 nM respectively 
against the DD2 CQ resistant strain. This is important since it should allow for their novel 
application in combination chemotherapy where the diamidine moiety becomes more effective as 
resistance develops. With respect to mechanism of action, it is believed that diamidine 
compounds can bind to heme in a similar manner to the 4-aminoquinolines and maintain toxic 
monomeric heme within the parasite. Inhibition of hemozoin detoxification within the parasite as 
a mode of action for diamidines is further suggested by the observation that diamidines inhibit 
hemozoin formation in vitro with similar efficacy to CQ. In addition, compound 62 is effective
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against CQ resistant P. falciparum with potency greater than the diamidine counterpart DB75 
whose prodrug DB289 is currently in phase III clinical trials as a new orally active candidate 
drug to treat first-stage human African trypanosomiasis.713 Furthermore, toxicity data established 
a favourable therapeutic index for thiazole 62 of 10 ,000.
An explanation for the failure to form the dinitrile isoxazole analogues in our hands is difficult to 
comprehend. Tidwell and co-workers synthesised isoxazole derivatives using CuCN in refluxing 
DMF to form the diycano product in yields from 21 -  69% from the dibromo precursor. For 
completion we repeated their methodology, again finding that the mono nitrile was formed 
alongside degradation products. Nonetheless, this is essentially the beginning of our 
investigations into the thiazole template. The chemistry prior to the cyanation step is facile 
forming the dibromo template in good yields without purification issues. Furthermore, thiazole 
chemistry circumvents the hurdles placed at every step of the synthetic route associated with 
isoxazole chemistry.
Future work and indeed work in-progress primarily involves a full assessment of in vivo oral 
bioavailability, antimalarial potency and pharmacokinetics of thiazole prodrugs using the P. 
vinckei rat model. Further investigations into the importance of hematin binding for activity by 
assessing the effect of inhibitors of haemoglobin digestion will also be undertaken. In addition, 
interactions with parasite lines of known drug resistance will be assessed in order to generate a 
profile o f the probable resistance and/or cross resistance pattern of thiazole diamidines. 
Preclinical cell toxicity, genotoxicity and mutagenesis studies will also be performed.
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3.14 Alternative Dications
3.14.1 Project Aims
As well as preparing a small library of diamidine based heterocycles, we wished to expand upon 
this area through the study of alternative dications and heme binding templates. Our aims were to 
observe the effect of pKa on antiplasmodial activity by increasing the pKa of the dication. In 
addition to this, we further deviated from our previous studies by employing a fused ring system 
as oppose to one linked through a heterocycle.
3.14.2 Rationale and Prior Art
The antiprotozoal properties of diguanidines are known.I52,220'224’244’714,715 Calas and co-workers 
developed alkyl diguanidine 78, a potent antimalarial with subnanomolar activity against a 
Nigerian strain of P. falciparum, found to exert an early effect on phosphatidylcholine (PC) 
biosynthesis.152
NH NH
X  X
h 2n  n - ( c h 2) , - n  n h 2
H H
78
IC50 = 0.35 nM
In addition to this, using the fused fluorene ring system, Arafa et al. developed diguanidine 79 
showing potent in vitro antiplasmodial activity against the CQ resistant K1 P. falciparum
. 2 24strain.
Our objective was to expand upon the studies of Arafa et al. by investigating the tolerance of a 
lumefantrine type template and a prodrug approach with respect to antimalarial activity.
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3.14.3 M olecular Design
Molecules acting against the hematin crystallisation process have a long history within 
antimalarial drug design. It is believed that these molecules interact with hematin preventing its 
conversion to non-toxic hemozoin. Typical heme binding molecules contain a flat planar ring 
structure in order to form a 71-71 stacking interaction with the planar portion of heme; the fluorene 
unit possess such a ring structure. As previously discussed, the uniplanarity of fluorene has been 
debated. However, incorporation of the benzylidene unit at the fluorene methyl bridge can 
further enforce uniplanarity across the structure via sp2 hybridisation. Furthermore, substitution 
at the phenyl ring allows variation of the lipophillic character of the molecule as shown in Figure 
24.
Finally, incorporation of the è/s-guanidine functions at the 2- and 7- positions enables binding to 
the anionic propionate groups, accumulation at vacuolar pH and the possibility of specificity for 
host cells via the new permeability pathway. However, the oral bioavailability of these molecules 
is subject to the highly basic nature of the guanidine moiety. Depression of the basicity of the 
guanidine moiety can be achieved by the attachment of a pro-moiety as represented by template 
2, Figure 25.
R esu lts  a n d  D iscu ss io n 170
Figure 25. Boc-Diguanidine Template 2
3.14 Preparation of Fluorene Diguanidines
Due to the applications for extended tr-electron systems, methods for the generation of 9- 
substituted fluorenes are widespread in the literature, particularly regarding benzylidene 
formation.716'719 Substituted diguanidines 87-92 were synthesised from commercially available 
2,7-dinitrofluorene as depicted in Scheme 19.
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Scheme 19. Synthetic Route to Benzylidene Diguanidines
The first step of the synthesis involved the condensation of the appropriate benzaldehyde and 
dinitrofluorene 80. In the presence of alumina supported potassium fluoride (KF-AI2O3) 
compound 80 was stirred at room temperature overnight to give compounds 81-86 in moderate 
yields.720 It should however be noted that formation of the desired material was achieved after 
optimisation of the procedure. Lu et al. condensed fluorene with aromatic aldehydes using KF- 
AI2O3 in DMF at 150 °C to give fluorene benzylidenes in yields of 44-90%.720 Flowever, when 
attempting this reaction with 2,7-dinitrofluorene for the formation of benzylidenes 81 and 82 
decomposition products were obtained, presumably due to the increased activity of this molecule 
upon nitro-substitution. We achieved the conditions shown in Scheme 19 by firstly performing 
the reaction at room temperature in order to monitor its course by TLC. We found that after 17
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hours, a single product was formed however upon removal of excess DMF under vacuum at 65 
°C we observed decomposition of the material. Therefore the product was isolated by filtering 
the solid product/ KF-AI2O3 reaction mixture and washing the solid with chloroform. Though the 
yield of reaction is adequate (71-83%), due to the poor solubility of the benzylidene product, 
separation from solid KF-AI2O3 was difficult. We did however further optimise the yield of 
benzylidene formation by drying the KF-alumina reagent at 130 °C under vacuum for 7 hrs prior 
to use.721
We also screened alternative procedures for the generation of benzylidenes. By heating 
dinitrofluorene 80 and benzaldehyde at 150°C in DMF we attempted the formation of 
fluorenebenzylidene 81. However, in our hands, degradation occurred. We therefore assessed a 
base strategy facilitating the use of milder conditions. Using the methodology of Mysyk et al. 
and Plater et al. we employed pyridine and potassium hydroxide respectively as shown in 
Scheme 20.
Scheme 20. Benzylidene Formation
In addition to these bases sodium ethoxide was also used however, degradation products were 
observed with all three bases respectively.
Following benzylidene formation, the nitro groups were reduced using zinc dust and calcium 
chloride as shown in Scheme 19.724 Reduction of the nitro moieties was not without its problems,
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compounded by the low solubility of the benzylidene starting material. We found that use o f zinc 
dust, calcium chloride and EtOH markedly elevated the yield of reaction by enhancing the 
solubility of the starting material giving diaminobenzylidenes 87-92 in yields ranging from 70- 
82% after purification by column chromatography. This procedure was also applied to the 
formation of diaminofluorene 106 as shown in Scheme 21.
n h 2
N B o c
M eS
A
N H B o c
T E A , H g C l2, D M F , R T , O /N  
6 0 %
B o cN
v\ ^NHBoc
H
H C Ife), D C M  
E tO H , R T , 3 d a y s  
41 %
N H
H ,N A
N
H
H N
A
N
N H 2
107 108
Scheme 21. Synthetic Route to Fluorene Diguanidine 108
Initially we attempted the reduction using tin and hydrochloric acid, the intense effervescence of 
the reaction mixture upon heating however made this method unsuitable.725 Ammonium formate 
and zinc in refluxing methanol was also used for the reduction, however the yield of product was 
low (20%) and the product proved difficult to purify.726
The conversion of ¿»«-amines 106, 87-92 to their Boc-protected guanidines as shown in Scheme 
19, proceeded with fewer issues. Using triethylamine, mercury (II) chloride and the methyl 
thiopseudourea derivative in DMF, Boc protected guanidines 107, 93-98 were formed in 60-67% 
yield as shown in Table 11 after purification by column chromatography.727
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Table 11. Formation of Boc-protected diguanidine prodrugs
Comp Structure Yield FW H bond
No.
~~93
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C42H52N 60 8 14
768.99
94
BocHN
NBoc BocN
NHBoc
62 C43H 54N6O 8
782.92
14
95
BocHN
NBoc BocN
NHBoc
65 C43H5,F3N(i0 8
836.90
14
C42H3,FN608
786.89
C42H51C1N60 8
803.34
14
14
98
BocHN
NBoc 67 C42H5oCl2N(;08
837.79
14
107 N B o c__ .
BocHN ' l L /'U '
NHBoc
60 C35H48N(;08
680.79
14
H bond 
donors
4
4
4
4
4
4
4
Boc-protected analogues were converted to diguanidines 108, 99-104 by bubbling HC1 gas 
through a DCM/EtOH mixture to saturation and sealing the vessel at room temperature over 3 
days, to form the product in yields from 17-72% as shown in Table 12.224,727
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Table 12. Formation of Diguanidines
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Due to the moderate yields for these reactions and a requirement for gaseous HC1, we assessed 
alternative synthetic routes. The Rathke reaction involves nucleophilic attack by the amine 
moiety on the amidine derivative 2-methyl-2-thiopseudourea to yield a guanidine and has been 
used successfully for the generation of phenylguanidines.728 Unfortunately, when attempted in 
this case product formation was not observed.
R =  H ; 106 
R =  B e n z y l id e n e  87
Scheme 22. The Rathke reaction
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3.16 In -V itro  Antiplasmodial Activity of Fluorene Diguanidines
3.16.1 In-Vitro  Parasitic Sensitivity
Seven diguanidines 108 and 99-104 were assessed for antimalarial activity in vitro against CQ 
sensitive and CQ resistant P.falciparum strains 3D7 and DD2 respectively, the results o f which 
are shown in Table 13.
Table 13. Activity of diguanidines 108 and 99-104
Compound *IC50 / nM 
DD2
*IC50 / nM 
3D7
99 703 207
100 >1000 291
10 1 829 275
102 768 204
103 842 219
104 802 231
108 >1000 201
CQ 64 8
PMD 105 106
*SD within 10% taken from an average of triplicate determinations
Against CQ resistant parasites, fluorene and fluorenebenzylidene diguanidines show high nM 
activity. The most potent analogue is benzylidene 99 with an IC50 of 703 nM, the least potent 
being diguanidines 108 and 100 with IC50S >1000 nM. These analogues were found to be more 
potent against CQ sensitive analogues as their activity improved markedly against the 3D7 
isolate. This can be observed most notably for diguanidines 100 and 108 with activity ranging 
from 1000 nM to 291 and 201 nM respectively against the 3D7 strain. Moreover fluorene 
diguanidine 108 is the most potent of the 3D7 series followed closely by compound 102 (204 
nM), the /?-fluoro analogue.
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It appears that benzylidene formation does not affect activity to a great extent as shown by the 
non-substituted fluorene 108 and benzylidene 99 with IC50S of 201 and 207 nM respectively 
against CQ sensitive isolates. This is not however the case for CQ resistant isolates as shown by 
IC50S of >1000 and 703 nM for the same analogues respectively. Furthermore, heteroatom 
substitution at the phenyl ring did not appear to have a positive affect on compound activity. 
However, while fluorine substitution gave the more potent analogue 102, trifluoromethyl 
substitution gave an analogue with reduced activity from 204 to 275 nM for compounds 102 and 
101 respectively. Boc prodrugs 107 and 93-98 were also tested for antimalarial activity against 
P. falciparum  as shown in Table 14.
Table 14. Activity of Boc prodrugs
Compound *IC50 / nM  3D7
93 156
94 aIS
95 183
96 119
97 142
98 87
107 aIS
CQ 6
PMD 109
aIS = Insoluble; * SD within 10% taken from an average of triplicate determinations
Interestingly, the Boc prodrugs were more active than their diguanidine counterparts against CQ 
sensitive isolates. The most potent analogue 98, the 2,6-dichlorobenzylidene analogue, gave an 
IC50 of 87 nM compared to 231 nM for the parent drug. The least active compound of the series 
was 95, the trifluoromethyl analogue gave an IC50 of 183 nM although this was still greater than 
its parent drug whose IC50 was 275 nM. The least potent analogue of the diguanidine series was 
methyl substituted fluorenebenzylidene 100 (291 nM) however, an ICsowas not generated for the 
Boc prodrug as this compound was only partially soluble in both DMSO and a mixture of EtOH
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and water. Considering the activity of the previously assessed fluorene diguanidine 79, we are 
surprised at this result.
224
NH HN
H2N y - n h 2
79
IC50 = 2.3 nM
It should however be noted that molecule 79 was assessed against the K1 CQ resistant strain of 
plasmodium while our compounds were assessed against DD2 since we have found cross 
contamination with the K1 strain to be a problem. Furthermore, differing strains can give rise to 
varying activity profiles. In addition, the diguanidine analogues proved difficult to solubilise 
since this form of aromatic system can aggregate readily thereby affecting solubility, a factor 
likely to contribute to the poor in vitro activity of the parent drugs. The increased pKa o f the 
guanidine functionality compared to the amidine group may also affect its uptake into parasitised 
cells, possibly explaining why Boc prodrugs are more active than the parent drug since their 
uptake into infected erythrocytes is enhanced.
3.17 Conclusions and Future Work
We have synthesised a range of phenyl substituted fluorene diguanidines in moderate yields from 
commercially available 2,7-dinitrofluorene with a route to the Boc prodrug. When assessed for 
antimalarial activity, the parent compounds were poorly active versus CQ resistant parasites and 
moderately active against a CQ sensitive strain. However, when assessing the antimalarial 
activity of the parent diguanidine compounds, there were issues with the solubility o f these 
compounds which may have played a role in their poor activity. Furthermore these compounds 
were not tested against the CQ resistant K1 strain, which may account for their low activity in 
comparison to compound 79. The in vitro activity of Boc prodrugs was promising, thus a future 
assessment of their in vivo activity will give superior information regarding the chemotherapeutic 
potential of these compounds.
CHAPTER III 
PART II
Results and Discussion -  Mono-Cationic
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3.18 Medicinal Chemistry of Amino-Alcohol Antimalarials
3.18.1 An Introduction to Lumefantrine ((E)-2-(dibutylamino)-l-(2,7-dichloro-9-(4-chloro- 
benzylidene)-9H-fluoren-4-yl)ethanol))
Lumefantrine (Lu, formerly Benflumetol, Figure 26) is a racemic fluorene methanol of the 
amino-alcohol antimalarial subclass that was synthesised and assessed for antimalarial activity 
by the Academy of Military Medical Science, Beijing, and registered in China in 1992. It is well 
tolerated in both adults and children when combined with Artemether (COARTEM ), having a 
very low acute and subacute toxicity, ’ which has been confirmed by extensive cardiological 
investigations652 with both enantiomers exhibiting the same blood schizontocidal activity. The 
mechanism by which the amino-alcohol class works is unclear although blood stage parasites 
and heme detoxification are inferred to be the target but since mefloquine, halofantrine (Figure 
26), quinine and Lu have been shown to be poor inhibitors of p-hematin formation in vitro,73' 
additional targets to the haemoglobin degradation pathway may possibly be involved.
Cl Cl OMe
Halofantrine (HF) Lumefantrine (Lu) Artemether
Figure 26. Structure of Halofantrine, Lumefantrine and Artemether
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However, it has recently been shown that HF (halofantrine, Halfan®) co-ordinates to heme via 
three modes consisting of co-ordination to the central Fe(III) porphyrin centre through the HF 
aryl alcohol group, 7t-stacking between the phenanthrine ring and planar porphyrin system and 
intermolecular hydrogen bonding between the protonated nitrogen atom of HF and heme 
propionate residues. In addition, this propionate forms a second hydrogen bond with an adjacent 
Fe(III)PPIX propionate group as shown in Figure 27 a and b.732 This provides a new model for 
the mechanism of action of HF, having implications for the possible mechanism of action for the 
amino-alcohol antimalarial subclass and the F-M hybrids discussed herein.
Figure 27. a) HF-Fe(III)PPIX crystal structure b) n-stacking and hydrogen bonding in the crystal732
There are several disadvantages associated with the use of Lu, including cost (related to the 
synthetic route)733 and bioavailability which is dependent on co-administration with fat,76,77’734’735 
increasing approximately 16-fold736 meaning that administration must be accompanied by food; 
thus absorption is variable, improving with recovery from malaria. This is a setback since most 
patients suffering from malaria suffer from anorexia, are unable to eat and experience emesis due 
to the nature of the infection.
Artemisinins were originally available as monotherapy; however if used as a single dose, 
treatment must be adhered to for no less than five, and typically seven days.737 Since the 
treatment period is long, in practice compliance to these treatment regimens is low.738 
Additionally, short course monotherapy of artemisinin, artemether (Artme, Figure 26) and 
artesunate result in recrudescence.739,740 Lu/Artme combinations display substantial synergism,741 
particularly in the IC90 and IC99 regions of laboratory models. This has been confirmed clinically
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in the form of COARTEM® and RIAMET® (Novartis) for the treatment of falciparum  malaria, 
within which it is the dominant component (20 mg Art, 120 mg Lu).78,652,742 Since drug 
combinations have the potential to delay drug resistance the world health organization (WHO) 
recommends the use of fixed-dose combinations of antimalarial drugs,743 most notably 
Artemesinin based combination therapies (ACTs) as they have been shown to aid treatment 
compliance thereby optimising clinical efficacy, avoiding recrudescence and developing 
resistance. Several countries (see Figure 28) including Kenya,744 Burkina Faso745 and 
Bangladesh746 have changed their policy to encourage the use of ACTs with Uganda changing its 
policy in 2005 to incorporate Artme-Lu as the first-line antimalarial therapy and artesunate-ADQ 
as an alternative.747 Artme-Lu is now more effective than sulfadoxime-pyrimethamine (S-P) for 
uncomplicated malaria in Nepal.748
Figure 28. Countries that have adopted ACTs as National policy for the first-line treatment of 
uncomplicated falciparum malaria. Reproduced by kind permission of the Global Malaria Program, World
Health Organisation749
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At present, ACTs are the first-line favoured treatment for uncomplicated falciparum  malaria. 
Resistance is emerging to combinations of artesunate/mefloquine thus becoming ineffective in 
some areas of the Thai-Cambodian border.735 Therefore the development of alternative 
combinations is required. Artme has a schizontocidal effect superior to Lu and hence clears the 
bulk parasite mass thereby rapidly reducing parasitaemia. Due to its extended elimination half 
life, Lu (Artme ~ lhr, Lu 4-6 days) is used within the combination to eradicate residual parasites 
with best cure rates at 99 % with a six-dose regimen given over five days.652 Lu is structurally 
related to HF which has associated toxicity issues due to QTc (heart rate interval) prolongation. 
This protraction of ventricular repolarisation is significant, positively correlates to HF treatment 
and is therefore exposure dependent. Use of Lu-Artme combination therapy has been studied 
extensively showing that the QT interval is unchanged and no significant cardiovascular toxic 
effect of this type is observed in vivo.72’13,750
3.19 Medicinal Chemistry of Aminoquinoline Antimalarials
Erythrocytes are the cellular target for malarial protozoa. Host cell haemoglobin is used for the 
acquisition o f cellular material essential for parasitic growth and development. The elucidation 
of the molecular structure of quinine (1854)751 facilitated the exploitation of this process through 
the cessation of parasitic growth. Investigations into the total synthesis of quinine led to the 
development of the 4-aminoquinoline subclass of antimalarials of which CQ and ADQ 
(amodiaquine) are members with quinine and mefloquine representing the quinoline-methanol 
subclass.
3.19.1 Mechanism of Aminoquinoline Antimalarial Activity: Chloroquine.
Haemoglobin degradation occurs within the parasitic food vacuole creating heme and globin 
protein, the later being utilised for amino acids (Figure 29). Redox active monomeric free heme - 
FPIX (also referred to as hemin) is toxic to the parasite. The parasite is unequipped to manage 
and degrade this toxic by-product resulting in a disposal problem, solved through a detoxification
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pathway converting heme to a nontoxic polymer hemozoin the 4 aminoquinoline antimalarials 
(CQ and ADQ) work through inhibition of hemozoin formation by means of an interaction with
hematin).56’57’691’753
Figure 29. Degradation of haemoglobin and hematin polymerisation.'
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Free heme and heme-CQ complexes kill parasites by inducing oxidative stress from the 
formation of reactive oxygen species (ROS) and the inhibition of heme binding proteins 
(glutathione, GSH), which may lead to peroxidation of parasite membrane lipids, damage of 
DNA, oxidation of proteins and finally parasite death as depicted in Figure 30.754,755
■ Chloroquine
Heme
Heme -chloroquine 
complex
Inhibition of 
hemozoin formation
Inhibition of GSH Increase free heme
mediated heme concentration
degradation
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Oxidative stress
Membrane lipid DNA Protein-carbonyl 
peroxidation damaue formation
Death of the parasite
Figure30. Mechanism of antimalarial activity of chloroquine755
In the presence of free heme, CQ and quinidine associate with polymeric heme. It has been 
revealed that within parasite culture, blocking heme release with protease inhibitors is 
antagonistic to MQ (mefloquine) and CQ action.55 The 4-aminoquinolines; CQ and ADQ (ADQ 
used for chemoprophylaxis rather than treatment), quinoline methanols; MQ and quinine are 
understood to be proficient in prevention of the formation of hemozoin due to their flat planar 
ring systems which permit interaction electronically with hematin through ti- ti stacking between 
monomeric hemin sheets. In addition the terminal nitrogen provides efficient accumulation into
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the acidic parasite food vacuole. CQ, AQ, QN, MQ and HF all exert an effect at the erythrocytic 
stage of development. Haemoglobin degradation is believed to be part of their mechanism of 
action although the interactions between the various drug classes and hematin are fundamentally 
different as the more lipophillic quinoline methanols MQ and QN are not concentrated so 
extensively in the food vacuole and therefore it is likely they have additional/alternative modes 
of action.56’756’757
CQ can traverse the erythrocyte unprotonated as a diprotic weak base progressing down the pH 
gradient (Figure 31) to enter the food vacuole. Protonation within the acidic environment causes 
an accumulation of CQ 10,000-fold when compared to uninfected cells.758 Furthermore, CQ 
resistant parasites accumulate less CQ than CQ sensitive ones.52 CQ has such a wide range of 
pharmacological effects in addition to antimalarial activity759'761 that the elucidation of the 
mechanism of action has been difficult and under debate.762'765 Most theories could not explain 
the non-toxicity of CQ toward mammalian cells. However, CQ is active only against the 
erythrocytic stages of malaria parasites. Specifically, CQ acts during the stages of the 
intraerythrocytic cycle exclusively where the parasite is actively degrading haemoglobin.766
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Figure 3 1 . A c c u m u la t io n  o f  C h lo r o q u in e  w ith in  a  p a ra sitised  red  b lo o d  c e ll .
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3.20 Fluorene-Mannich Hybrids: Drug Design
3.20.1 Rationale
CQ is arguably one of the most important agents in the history of drug design however 
widespread resistance has limited its use, resulting in an urgent requirement for alternative 
chemotherapeutic agents. The haemoglobin degradation pathway is a well established target of 
antiplasmodial pharmacological intervention and novel chemical entities that are capable of 
complexing hematin provide an accessible route to circumvent the 4-aminoquinoline resistance 
mechanism. Knowledge of the critical features of CQ that facilitate its antimalarial efficacy and 
ability to achieve a high concentration in the food vacuole highlight ion-trapping and high 
affinity binding to hematin as key to the mechanism of action. Based on this knowledge it seems 
logical that a new class of antimalarials should be accessible by use of the fluorene unit as a 
hematin binding group in addition to a basic protonable side chain. Moreover fluorene is a 
known hematin binder present in the antimalarial compound Lu. Lu has issues associated with its 
clinical use due to inadequate bioavailability leading to a variation in treatment success 
dependent on the fitness of the individual.77 Another setback to the use of Lu is the cost linked to 
its expensive synthesis733 in addition to the fact that Lu is chiral, a property we wish to avoid.
The chemistry, medicinal chemistry and structural properties o f fluorene were previously 
reviewed in order to introduce the fluorene unit. The structure of fluorene is of importance since 
there is a requirement for a flat planar structure in order to form a n-% stacking interaction with 
planar heme. Although some evidence points towards a flat fluorene molecule we have enhanced 
the planarity across the template by the introduction of a double bond at carbon-9. In addition to 
this, the rationale behind the design of Fluorene-Mannich (F-M) hybrids includes a protonable 
amino side chain for accumulation and a hydrogen bond donating group for possible interaction 
with the carboxylate residues of heme as described in Figure 32. Furthermore we have 
accomplished their synthesis using a three step modular process to an achiral template. When 
designing the compounds we were keen to avoid the use of diprotic analogues in an attempt to 
avoid the toxicity issues associated with non-specific cellular accumulation of antimalarials such 
as ADQ 63
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Figure 32. Fluorene-Mannich Hybrid Drug Design
X  = C l;  Y  = C l ;  A  = O H ;  B  = A m in e
Chart 1. Structure of Fluorene-Mannich Hybrids
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3.21 The Preparation of Fluorene-Mannich Hybrids
3.21.1 Chlorination of Fluorene
An examination of the reactivity of fluorene, in particular electrophilic substitution at the phenyl 
rings and carbon-9 led to the development of the synthetic route outlined in Schemes 23 and 24. 
When designing the process it was imperative to us that the synthetic route adhered to the 
challenges met within the pharmaceutical industry and medicinal chemistry, paying particular 
attention to process design: assessing both the volume and nature of waste produced, number of 
synthetic steps, chirality and cost of materials in a divergent route if possible.
Scheme 23. Formation of 4-hydroxy analogues
Initially 2,7-dichlorofluorene was purchased from Aldrich. However we were keen to find an 
effective method for the conversion of fluorene to its dichloro adduct avoiding the use of 
methods that would lead to laborious separation and purification of the products, which are 
commonly mono, di and tri chlorinated, as experienced during the current method used for the 
synthesis of Lu. Beutler et al. (Novartis Pharma) use chlorine in acetic acid at 40°C generating 
mono, tri, 2,5 and 2,7 dichlorinated fluorene.733
An examination of the literature made it apparent that methods for the chlorination of fluorene in 
good yields were sparse and mainly involved gaseous chlorine and acetic acid. However, further
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investigations revealed Perumattam’s 1994 paper in relation to the alkylation and chlorination of 
fluorene which was applied here to affect the chlorination of fluorene using NCS in MeCN at 
room temperature.570 Subsequent recrystallisation from MeOH furnished the 2,7-dichloro 
analogue in 90 % yield.
NCS, MeCN,
cone. HC1, 
RT, 24 hr
86%
3-hydroxybenzaldehyde,
KF-A120 3, DMF, 
150°C, O/N 
60%
Scheme 24. Formation of 3-hydroxy analogues
3.21.2 Aldol Condensation
Substitution at position-9 was a key step in the formation of Fluorene-Mannich hybrids and was 
more facile for para-hydroxy aldehydes than meta. KF/AI2O3 in DMF at 150°C has been shown 
to be effective for the aldol condensation of fluorene with aromatic aldehydes.720 We tried Lu’s 
method720 for the preparation of substituted guanidines (covered previously) finding that the 
reaction works best at room temperature. Consequently we tried to perform the reaction at room 
temperature however this resulted in a large presence of starting material. We then elevated the 
temperature to 150°C establishing that although the reaction generated the desired material, the 
yields were moderate. In an attempt to increase the yield of reaction, we deprotonated the 
starting material using sodium ethoxide generated in situ with ethanol. However, this resulted in 
a small quantity of the desired material and a large presence of side products which were difficult 
to separate hence use of Lu’s method at 150°C was re-employed for the synthesis of key
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intermediates 3 and 7. As observed with substituted guanidines, the outcome o f the aldol 
condensation reaction was observed to be sensitive to the hygroscopic nature of the supported 
potassium fluoride. The yield of the reaction was improved by recrystallisation of the aldehyde 
starting material and critically, intensive drying of KF-Alumina, without which the robustness of 
the reaction was compromised forming an unknown substance and lower yield of the desired 
material. By means of these modifications the desired product was produced in good yields by 
the aldol condensation o f the appropriate hydroxybenzaldehyde and 2,7-dichlorofluorene with 
alumina supported potassium fluoride.
3.21.3 The Mannich Reaction
The Mannich reaction is recognised as being highly important for access to functionalised 
amines,767’768 the catalytic asymmetric Mannich reaction being one of the most powerful methods 
for the construction of chiral nitrogen containing molecules.769 Since the elucidation of the 
reaction mechanism in 1912 by Carl Mannich, the reaction has been modified to be controlled 
enantioselectively, stereoselectively and asymmetrically for the preparation of these organic 
building blocks.769'776 The reaction was previously employed in our group for studies into the 
chemical basis of ADQ induced toxicity777 by the introduction of a second dialkylamino group, 
and also for the development of less toxic analogues.63,778,779 Typically the reaction takes place in 
the presence of formaldehyde and a primary or secondary amine usually in protic solvents. 
Examples of processes that utilize the Mannich reaction are varied, since many classes of 
biologically active molecules contain functionalities of this type including Tramadol® 
(analgesic), Moban® (management of schizophrenia) and Falicain® (local anesthetic) to name a 
few.
Hydroxy ylidene intermediates 111 and 124 were converted to their Fluorene-Mannich 
analogues 112-123 and 125-128 with formaldehyde and the appropriate amines under standard 
Mannich conditions to form the mono aminated products in good yields isolated by column 
chromatography (Table 15). Conversely the meta and para t-butylamine Mannich products 116 
and 128 were found to ring close on standing confirmed by a characteristic peak in the 'H NMR 
at 5.1 ppm and therefore were isolated as hydrochloride salts after treatment of the crude material 
with 20 % hydrochloric acid in Ao-propyl alcohol. Other amines including 5-amino-2-
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(trifluoromethyl)benzimidazole, 4-morpholinopiperidine, l-(2-cyanophenyl)piperazine, N-(2- 
aminoethyl)morpholine, and 4-(l-pyrrolidinyl)piperidine were tried, however in the case of 4- 
morpholinopiperidine and 5-amino-2-(trifluoromethyl)benzimidazole, even with extended 
reaction times and addition of catalytic quantities of acetic acid and additional formaldehyde, the 
reaction was unsuccessful producing mainly starting material and an unidentified bi-product.
Table  15. Synthesis of Fluorene-Mannich Flybrids (with Lipinski’s parameters)
Comp
No.
Structure Yield
( % )
Formula
weight
H bond 
acceptors
H
bond
donors
*Log
P
112
O
O 41 C25H23CI2NO
424.36
2 1 6.59
113
o
I
 
\
__
__
c
^
O
o
i
62 C25H2IC12N 0
422.35
2 1 6.23
114
o
I
 
^
 
^ o 67 C26H23C12N0
435.12
2 1 6.65
115
j C c P "
C I^ J
N 1.
64 C26H24CI2N2O
451.39
3 1 5.67
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W 3
121 48 C3oH25C12N30  4 1 6.01
514.45
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122 46 C38H3oC12F2N20
639.56
3 1 6.33
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2 2 6.41
*Log P calculated using ChemBioOffice 2008 predictive software
3.22 Fluorene Mannich Hybrids: Antiplasmodial Activity and Molecular 
Modelling
3.22.1 In-Vitro  Parasitic Sensitivity
The Fluorene-Mannich (F-M) hybrids described here are designed based on the structural 
backbone of Lu. Explicitly the dichlorofluorene unit with substitution at C9, in addition, the 
nature o f the Mannich side chain was chosen using Lipinski’s rule of five as a reference for H- 
bonding and donating properties. Additionally the key pharmacophore features of CQ that are 
essential for activity were integrated. Molecular features were adapted in order to probe SAR. 
The concentration of drug required to inhibit parasitic growth by 50% (IC50) as described 
previously was obtained using P.falciparum from various isolates is listed in Table 16. All 
hybrids were not equally potent but most did show activity in the nM range, some of which were 
greater than Lu (Table 17). The importance of the position and nature of the side chain is 
discussed and for completion, the SAR that the benzyl hydroxy group and carbon at position 9 
impart. The latter two variants were synthesised by Dr Eleanor Row (University o f  Liverpool) 
and are included for the purpose of comparison.
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Table 16. Origin and CQ sensitivity of lab strains of P. falciparum used in this chapter
Isolate CQ Sensitivity Origin
T994 Partial Thailand
BC11 Resistant Thai-Myanmar border in 
2000
PCM6 Partial Thai-Myanmar border in 
2000
3D7 Sensitive Unknown
Ta b le  17. In vitro antimalarial activity of fluorene-ylidene derivatives
Comp *ICso (nM) T994 *ic50 *IC5o (nM)
number (nM )B C ll PCM6
112 406.6 ± 151.9 303.0 ±66.1 992.5 ± 151.1
113 172.5 ±52.2 179.5 ±50.2 660.1 ± 141.2
114 491.7 ± 115.9 273.8 ±32.1 >1000
115 >1000 >1000 >2000
125 169.6 ±48.6 198.6 ±60.3 637.7 ± 151.4
126 36.7 ± 13.6 41.2 ± 11.2 150.9 ±23.0
127 98.9 ± 18.9 70.3 ±27.2 22.3 ±41.8
Lu1 120.4 ±37.3 89.0 ±21.6 236.8 ±74.6
CQ2 15.6 ±4.8 123.7 ±28.2 22.0 ±8.0
MQ3 12.1 ±2.2 10.1 ±4.5 13.6 ±5.0
Quin4 148.0 ±36.2 278.3 ±37.5 165.1 ±24.2
'Lumefantrine' 2Chloroquine; 3Mefloquine; 4Quinine *IC50 from an average of duplicate determinations
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Table 18. In vitro antimalarial activity of fluorene-ylidene derivatives
Compound number *IC50 (nM) 3D7
113 71.9 ± 16.7
114 194.4 ± 19.1
115 281.9 ±44.0
116 165.5 ± 104.7
117 >1000
118 >1000
119 >1000
120 >1000
121 >1000
122 >1000
123 >1000
126 22.3 ±5.7
127 12.7 ±5.3
128 40.2 ±21.9
'Lu 40.3 ±3.3
2CQ 4.5 ±2.5
'Lumefantrine; 2Chloroquine *IC50 calculated from an average of duplicate determinations
3.22.2 Size of the amine side chain and H-bond accepting capability.
The size o f the side chain exerts an effect on the antiplasmodial activity as shown by Tables 17 
and 18. As the size and degree of conjugation of the side chain increase, antimalarial activity 
decreases as displayed by compounds 119, 121, 122, and 123. The evidence is however 
inconclusive since the smaller side chains of compounds 117, 118, and 120 are also poorly 
active. Also noted is the effect of replacing the terminal carbon of compound 114 for sulphur 
(compound 120) which resulted in a decrease from 194 nM to >1000 nM.
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Dehydroxy versions of 112,125, and 115 were synthesised in our laboratory by Dr Eleanor Row. 
For the methyl piperazine analogue 115, this resulted in a decrease in activity from >1000 to 
>4000 nM in Thai isolates and 149 to >1000 nM in 3D7. The diethyl amine compounds 112 and 
125 were tested versus their de-hydroxy analogue confirming the results obtained for the methyl 
piperazine analogue 115. In the absence of the OH group, there is a marked decrease in activity 
from between 160 and 640 nM to >4000 nM. If the F-M hybrids do indeed bind to FPIX then 
this decrease in activity would be expected since the hydroxyl group is ideal for binding to the 
carboxylate residues of heme.
3.22.3 T h e im p ortan ce o f  the h ydroxyl group for activ ity; p ossib le  dock in g  o f  O H  to hem e.
3.22.4 The effect of substitution at C9; TV-alkyl carbazole compounds
//-Alkyl carbazole derivatives of compounds 114 and 115 were synthesised by Dr Eleanor Row 
and are included here for a comprehensive picture of structure activity relationships as illustrated 
in Table 19. These compounds were tested using CQ sensitive parasites. The lead compound of 
this series is the A-alkyl carbazole piperazine analogue 129 which is active in the 89 nM region 
compared to 194 nM for its benzylidiene analogue 114. The activities of the carbazole series as a 
whole were poor. Nonetheless, when comparing these particular analogues 129 and 130 to the 
parent compounds 114 and 115, the activity of the carbazoles is enhanced in orders of the same 
magnitude.
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Table 19. Activity of A-alkyl carbazole analogues expressed as IC50
Compound
Number
Structure *ICs0(nM)3D7
114
H° X )
194.7 ±27.0
115
X r p '
H° V  ^tM \
281.9 ±33.7
129
0
89.2 ±22.7
130
H° \ - f y ~
170.8 ±29.1
■“Calculated from an average of triplicate determinations
3.22.5 Structure activity relationships; nature of the amine side chain.
Of the variables tested, the nature of the Mannich side chain had the greatest effect. Seven 
compounds, 117-123 displayed poor activity against all strains of P. falciparum tested. 
Compounds 114 and 115 are more active against the CQ sensitive strains than those isolated 
from the Thai border with activities in the 100 and 1000 nM region respectively. It is clear that
Results and Discussion 200
across the Thai isolates compound 115 is inactive, nonetheless against the CQ sensitive strain an 
improvement in activity is observed. Compounds 112, 125, 113 and 114 showed the most 
varying activity against the Thai isolates, with lowest activity observed against PCM6. 
Specifically, compounds 112 and 114 were most active against the BC11 strain whereas 
compounds 125 and 126 were most active against the T994 strain. Compound 115 was inactive 
versus the Thai isolates with IC50 between 1000 and 2000 nM decreasing to 281 nM when tested 
in the CQ sensitive system.
126 127
Figure 33. Compounds showing activity > Lu
128
Three compounds (126, 127 and 128) showed activity better than or comparable to Lu against all 
strains tested. The /-butyl amine derivative 128 showed activity in the range of Lu when tested 
against 3D7. Meta substituted analogues 126 and 127 showed the best activity. Lu had an IC50 of 
40.3 nM in 3D7; compounds 126 and 127 are active in the 22.3 and 12.7 nM range respectively. 
For the Thai isolates, 126 and 127 again exhibit activity superior to that of Lu. Lu has inhibition 
concentrations of 120.4, 89.0 and 236.8 nM against the Thai isolates in the order T994, BC11, 
and PCM6. The piperidine analogue 127 has IC50 values of 98.9, 70.3, and 22.3 nM compared to 
those of compound 126, 36.7, 41.2 and 150.9 nM. Compound 127 is more active than compound 
126 against most of the strains tested and both compounds 126 and 127 are more active than Lu 
across all strains. In the BC11 strain CQ gave an activity of 123.7 nM, compounds 126 and 127 
gave 41.2 and 70.3 nM respectively. When compared to the activity of quinine versus the Thai 
isolates, compounds 126 and 127 did better across the range the activity of compound 126 being 
unsurpassed.
The data set illustrates that for most analogues the optimal positions for antimalarial activity are 
for the Mannich side chain to be positioned para to the fluorene-benzylidene function and the
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hydroxyl group meta. This is clearly illustrated by compounds 112 and 125. When the hydroxyl 
group is meta the IC50 value is 169.6 nM, exchange of the hydroxyl and Mannich side chain 
positions leads to an inhibitory concentration of 406.6 nM. Comparison of compound 113 to its 
isomer 126 further supports this. In CQ sensitive isolates, if  the side chain is in the meta position 
an IC50 of 71.9 nM is obtained, increasing to 22.3 nM when in the para position. This trend is 
also displayed with lead compound 127 compared to 114 and the tert-butyl amine derivatives 
116 and 128.
3.23 Inhibition of Hemozoin formation
The drug concentration required to inhibit formation of P-hematin by 50% (IC50) was determined 
for each compound by Silvia Parapini (Università di Milano). The results are the mean IC50 of 
two different experiments performed in duplicate using the method of Parapini et al.692 As 
previously mentioned, one of the biomolecular targets of antimalarial drug design is the process 
by which P. falciparum detoxifies monomeric heme released during haemoglobin catabolism to 
hemozoin. P-hematin is synthetic hemozoin identical in structure to plasmodial hemozoin. P- 
hematin can therefore be used as a seed for the formation of hemozoin in vitro, inhibition of 
which can be measured in order to ascertain the ability of a compound to inhibit the heme 
detoxification process.
Table 20. Inhibition of hemozoin formation in vitro
Compound *F-P crystal growth Inhibition / pM
126 1.24
127 4.44
CQ 1.78
"■Obtained from an average of triplicate determinations
Table 20 illustrates the ability of lead compounds 126 and 127 to inhibit the formation of 
hemozoin in vitro using CQ as a control. In our studies we found that CQ inhibits 50 % 
hemozoin formation at a concentration of 1.78 pM. When comparing this to the values obtained 
for compounds 126 and 127 it appears that compound 126 has the ability to inhibit the formation
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of hemozoin at a concentration lower than that of CQ whereas compound 127 does inhibit but 
not within the range of CQ showing that Fluorene-Mannich hybrids have the capability of 
preventing hemozoin formation in vitro by probable binding to FPIX.
3.24 Molecular Modelling
In order to further investigate the potential interactions between the Fluorene-Mannich hybrid 
126 and heme, molecular modelling was performed by Dr Neil Berry (University o f  Liverpool) 
using the Monte-Carlo method by means of the MMFF94 force field as illustrated in Figure 34. 
The low energy conformation generated for compound 126 reveals an interface between heme 
and 126 in the form of a 71-71 stacking interaction such that compound 126 could lay in the mode 
proposed here. In addition the terminal amine and hydroxyl functionalities are able to form a 
hydrogen bonding contact with the carboxylate residues of heme enhanced by a repulsive 
interaction between the fluorene hydrogen molecules and the phenyl ring causing this portion of 
the structure to twist in the manner depicted.
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Figure 34. Molecular modelling image of the lowest energy conformation for the binding interaction of 
compound 126 with heme. Fluorene unit represented by; Cl = green, hydrogen = white, carbon = grey, blue =
nitrogen, red = oxygen.
3.25 Conclusion and Future Work
We have successfully synthesised an array of F-M hybrids based on our knowledge of both the 
structural and chemical features of the fluorene template and our biomolecular target of interest, 
FPIX. The success of the synthetic route is dependent on the use of anhydrous KF-alumina in the 
aldol condensation step of the sequence furthermore the approach has major advantages in that it 
does not use costly reagents or starting materials. We have used fewer synthetic steps to 
construct mono-protic analogues that are superior in many cases to Lu. The results from anti- 
parasitic and molecular modelling data have inferred us to believe that the ability of a binding 
interaction between the hydroxyl group and carboxylates of heme is paramount for antimalarial 
activity o f the F-M hybrids generated here as shown if Figure 35. We have demonstrated that 
these compounds are able to prevent the formation of p-hematin in vitro, adding weight to the
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belief that they may be inhibitors of hemozoin formation in vivo, a known site of 
chemotherapeutic intervention for the cessation of parasitic development.
This is a preliminary investigation therefore further examination into their mechanism of action 
is required and in vivo activity data is being compiled at present (manuscript and patent 
application in preparation). The F-M template can be explored further especially within the 
carbazole series and we are currently outsourcing the synthesis of a range of analogues using 
microwave assisted synthesis in order to develop a more in-depth SAR profile.
Fluorene unit 
enables stacking between 
monomeric heme sheets
Protonable 
group para 
to
benzylidene
group
H-bonding 
donor group 
in 3-position
Figure 35. F-M hybrid pharmacophore
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4.0 Conclusion
Beginning with the anti-trypanosomal drug pentamidine, we have successfully developed a novel 
antimalarial thiazole template for the treatment of uncomplicated malaria with potential use in 
combination chemotherapy. We have shown that this compound is able to act within the 
haemoglobin degradation pathway and therefore propose that this contributes to the mode of 
action. Further efforts will be directed towards establishing the significance of hemozoin 
inhibition in the mode of action, primarily by quantifying the effect inhibitors of haemoglobin 
digestion have on their activity. Here we show that thiazole diamidines are not recognised by the 
chloroquine resistance mechanism thus offering advantages over other hematin binding drugs. 
Furthermore since these drugs are impermeable to human erythrocytes they are selective for 
parasitised cells.
Compound 62 is a potent antimalarial with activity superior to DB75. Furthermore, cytotoxicity 
studies show that thiazole 62 is less toxic than DB75 and has a high therapeutic index. These 
factors indicate that this analogue may have excellent therapeutic potential and thus an 
evaluation of the oral activity of corresponding prodrugs is underway in the malaria animal 
model. In addition, the stability of the thiazole heterocycle may impart increased metabolic 
stability on this molecule.
The synthesis of thiazole 62 is however compounded by cyanation and the Pinner mediated 
diamidine incorporation. Development of alternative methods to the formation of the 6«-nitrile 
and 6/.s-amidine will be investigated within the drug optimisation stage. With respect to thiazole 
prodrugs, synthetic routes to the formation of sulfonyl derivatives will also be addressed.
Considerable effort has been made toward the cyanation of diphenylisoxazoles however, issues 
regarding the formation of the Zn's-nitrile led to failure with this template. In contrast, fluorene 
diguanidine compounds were successfully synthesised using a route enabling access to the 
prodrug. Unfortunately, the parent compounds are poorly active against CQ resistant parasites 
and moderately active against sensitive isolates. Nonetheless we feel that these compounds may 
have potential and therefore further work regarding their activity versus the K1 CQ resistant
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strain will be carried out. Furthermore, issues surrounding the solubility of these drugs in the 
assay system may account for their low activity, thus the in vivo activity of Boc prodrugs will be 
investigated within the group.
A novel series of inhibitors of malaria pigment hemozoin have been designed based on the 
structural properties of chloroquine, amodiaquine and lumefantrine. Important structural features 
for activity include a flat heme binding template and protonable side chain. Inhibition of 
hemozoin formation is a proven target for the most effective antimalarial drugs. From our series, 
lead compounds with low nanomolar activity were identified and subsequent molecular 
modelling studies were performed. From initial modelling studies we have identified that the 
fluorene unit is capable of 7t-7t stacking over the porphyrin heme ring system and that the 
amodiaquine like side chain can hydrogen bond with the propionate groups of hematin. 
Substitution of the aryl ring with a meta-hydroxyl function and a ^-substituted Mannich side- 
chain is optimal for binding. The modelling is supported by (3-hematin inhibition assays in the 
sense that these molecules have comparable IC50S to existing antimalarials such as CQ and 
amodiaquine.
These compounds are potent against CQ sensitive parasites loosing activity against CQ resistant 
ones, exemplified by lead compound 127 with IC50S of 12.7 and 70.3 nM respectively. However, 
with activity superior to lumefantrine, F-M hybrids have the potential to be utilised within 
combination therapy, therefore ongoing studies are focused on the in vivo activity of these 
compounds. Preliminarily studies suggest that lead compound 127 also possess potent activity in
vivo.
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5.0 Experimental Details
5.1 General Experimental Details
5.1.1 Purification of Reagents
All solvents and chemicals were purchased from Sigma-Aldrich Chemical Company and used 
without purification aside from: p-hydroxybenzaldehyde and w-hydroxybenzaldehyde which 
were purified from CHCI3 and dried under vacuum overnight, NCS which was recrystallisation 
from water and dried in the same manner.
5.1.2 Purification of Solvents
Diethyl ether and THF were freshly distilled under a constant flow of nitrogen, from the sodium / 
benzophenone ketyl radical, prior to use. Dichloromethane was stirred over calcium hydride for 
12 hours prior to distillation under dry nitrogen.
5.1.3 Preparation of Glassware
All syringes, flasks, needles, condensers and stirrer bars were dried in an oven overnight at 150- 
200°C prior to use. Flasks, condensers and stirrer bars were cooled under a positive nitrogen 
pressure prior to use. All anhydrous reaction were performed with a small, static pressure of 
nitrogen.
5.1.4 Chromatography
Thin-layer chromatography (TLC) was carried out on aluminium-backed Merck Kiesgel plates 
(Merck, Darmstadt, Germany) with detection by UV (254 nm) fluorescence. Flash column 
chromatography was carried out using Merck Silica gel 60 (<63 pm) or Fisher Matrex 35 to 70 
pm eluting with various solvent mixtures and using bellows to apply pressure.
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5.1.5 Spectroscopy
NMR spectra were recorded employing a Bruker AMX 400 ('H, 400 MHz; l3C, 100 MHz) 
spectrometer. Chemical shifts (8) are reported in parts per million downfield relative to TMS as 
internal standard. Coupling constants (J) are in Hertz (Hz). Chemical shifts were referenced to 
residual non deuterated solvent present in the deuterated sample, e.g., CHCI3 in CDCI3. The 
following symbols have been adopted for the description of NMR spectra:
s = singlet 
d = doublet
dd = doublet of doublets 
t = triplet 
q = quartet 
m = multiplet 
br = broad
Chemical ionization (Cl), electron impact (El) and electro spray (ESP) mass spectrometry were 
recorded on VG analytical 7070E and Fisons TRIO machines by the University o f  Liverpool 
Mass Spectrometry Department. In the description of mass spectra M+ corresponds to the 
molecular ion peak.
Elemental analysis was performed by the University o/Liverpool Microanalysis laboratory.
Infra-red spectra were recorded in the range 4000-600 cm"1 using a Perkin-Elmer 1320 where 
samples were run as nujol / liquid paraffin mulls on sodium chloride plates and a JASCO FT/IR- 
4100 spectrophotometer were samples were obtained neat.
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5.1.6 Other Data 
Molecular Modelling
For PMD analogues (Section 3.1) a conformational search using a Monte-Carlo method using the 
MMFF94 forcefield was performed on the diprotonated molecules.' The Boltzmann weighted 
average of the inter amidine separation (as measured from the carbon bonded to the two 
nitrogens) was calculated for each molecule. These values were plotted against logio(-Activity) 
using the TM6 and HB3 data.
In order to generate a model for the binding of molecules 7, 61 and 126 with heme a 
conformational search using a Monte-Carlo method with the MMFF94 forcefield was performed 
on the chosen compound with a molecule of heme.
'Spartan'04, Wavefunction, Inc., Irvine, CA. http://www.wavefun.com/
Melting points were determined on a Stuart SMP3 and Gallenkamp melting point apparatus 
quoted uncorrected in degrees Centigrade.
5.1.7 Analytical Reverse-Phase HPLC
Reverse-phase HPLC was performed on a 250 mm x 4.6 mm, Gemini 5u C18 110 A reverse- 
phase column supplied from Phenomonex® eluting with a two buffer system; Buffer A: 0.1 M 
aqueous TEAB solution; Buffer B: 0.1 M aqueous TEAB solution containing 40% acetonitrile.
5.1.8 Preparative HPLC
Preparative HPLC was also performed using a 250 x 20 mm I.D, 5 pM YMC-pack ODS-A 
column supplied from YMC Europe GmbH eluting with MeCN: Water 0.1% TFA (20-80 % 
gradient over 20 min). After removal of solvent the compounds were isolated as their respective 
TFA salts.706 Columns were stored in HPLC grade MeCN.
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5.1.9 Preparation of HPLC Reagents
1 M aqueous TEAB solution: prepared by bubbling carbon dioxide gas through a 1 M aqueous 
triethylamine solution until attaining p R  7.65. Buffer A (0.1 M aqueous TEAB solution) was 
prepared by diluting 100 mL of the 1 M aqueous TEAB solution with 900 mL of distilled water 
to make 1 L of buffer A. Buffer B (0.1 M aqueous TEAB solution containing 40 % acetonitrile) 
was prepared by diluting 100 mL of the 1 M aqueous TEAB solution with 400 mL of HPLC 
grade acetonitrile and 500 mL of distilled water to make 1 L of buffer B.
Water containing 0.1 % TFA was prepared by addition of 1 g TFA to 1 L of HPLC grade water.
5.1.10 Other Apparatus
HC1 gas was generated via a steel cylinder purchased from Boc gases. H2S gas was generated via 
a 227 g steel cylinder purchased from Sigma-Aldrich Chemical Company.
5.2 Individual Procedures
1,2-Bis (4-cyanophenoxy) ethane (2) Sodium (0.16 g, 6.96 mmol) was added portionwise to 
anhyd. EtOH (4.0 mL) under an atmosphere of nitrogen. After dissolution of Na, a solution of 4- 
cyanophenol (0.75 g, 6.38 mmol) dissolved in anhyd. EtOH (4.0 mL) was added followed by 
dropwise addition of 1,2-dibromoethane (0.28 mL, 3.19 mmol). The reaction mixture was stirred 
at reflux under a nitrogen atmosphere for 3 days after which the mixture was cooled, filtered, the 
solid washed with water and dried under vacuum. Purification by column chromatography 
eluting with DCM: hexane (8:2) gave the desired compound 2 as a white solid (1.42g, 84%). Mp
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211-212°C; 'H NMR (CDC13,400 MHz) 5 7.61 (d, 4H , J =  9.0 Hz, ArH), 7.01 (d, 4H, J  = 9.0 
Hz, ArH), 4.39 (s, 4H, CH2); 13C NMR (CDC13, 100MHz) 5 161.6, 134.1, 118.9, 115.3, 104.7, 
66.4; vmax (Nujol) /cm' 1 3326 (C-O-C), 3033 (ArH), 2898 (C-H), 2223 (O N ), 1602(Ar), 
1509(Ar), 1247 (C-O-C); m/z (Cl) 282 ([M+NH4]+), found 282.12433, Ci6H ,60 2N3 requires 
282.12424; anal. Found C 72.07, H 4.51, N 10.54, Ci6H,20 2N2 requires C 72.71, H 4.57, N 
10.60.
N H
4,4’-(ethane-l,2-diyl6is(oxy))dibenzimidamide dihydrochloride dihydrate (6) Compound 2 
(0.51 g, 1.92 mmol) was dissolved in a mixture of anhyd. benzene (54 mL) and EtOH (2.90 mL), 
cooled to 0 °C and saturated with HC1 gas. The mixture was sealed and stirred at room 
temperature for 3 days after which anhyd. Et20  (28 mL) was introduced and the mixture stirred 
for 10 minutes. The solids were filtered under nitrogen and dissolved in a mixture of anhydrous 
EtOH (36 mL) and EtOH.NH3 (36 mL). The mixture was heated overnight (50 °C), cooled to 
room temperature and reduced by half in vacuo. Ether was added to precipitate the solid which 
was filtered, washed and dried under vacuum. Purification by recrystallisation (2N HC1) gave the 
desired compound 6 as fine white needles (0.54 g, 70%). Mp 333°C; 'H NMR (MeOD, 400 
MHz) 5 7.85 (d, 4H, J =  9.0 Hz, ArH), 7.23 (d, 4H, J  = 9.0 Hz, ArH), 4.52 (s, 4H, CH2); 13C 
NMR (MeOD, 100MHz) 5 167.9, 165.3, 131.5, 121.7, 116.7, 68.5; vmax (Nujol) / cm' 1 3362 (N- 
H), 3037 (ArH), 2940 (C-H), 1658 (C=N-H), 1606 (Ar), 1505 (Ar), 1245(C-0-C); m/z (ESP) 
299 ([M-H]'); anal. Found C 47.54 H 5.62 N 14.30, Ci6H24Cl2N404 requires C 47.18, H 5.94, N 
13.76.
Experimental Details 212
4-(2-phenoxyethoxy)benzonitrile (10) Sodium (0.15 g, 6.52 mmol) was added portionwise to 
dry EtOH (4.0 mL) under an atmosphere of nitrogen. After dissolution of Na, a solution of 4- 
cyanophenol (0.50 g, 4.19 mmol) dissolved in dry ethanol (4.0 mL) was added followed by 
dropwise addition of 1,2 dibromoethane (0.36 mL, 4.19 mmol). The reaction mixture was stirred 
at reflux and monitored by TLC. After consumption of 4-cyanophenol the reaction mixture was 
cooled to room temperature. In a separate flask Na (0.15 g, 6.52 mmol) was added portionwise to 
dry EtOH (4.0 mL) and dissolved under a nitrogen atmosphere. A solution of phenol (0.39 g, 
4.19 mmol) in ethanol (4.0 mL) was added and stirred for 10 minutes. This was added dropwise 
to the cooled mixture and stirred at reflux for 3 days after which the mixture was cooled, filtered, 
the solid washed with water and dried under vacuum. Purification by column chromatography- 
eluting with DCM: hexane (8:2) gave the desired compound 10 as a white solid (0.72 g, 72%). 
Mp 134-135°C; !H NMR (CDC13,400 MHz) 8 7.60 (d, 2H, J =  9.0 Hz, ArH), 7.31 (m, 2H, ArH), 
6.97 (m, 5H, ArH), 4.35 (m, 4H, CH2); 13C NMR (CDC13, 100MHz) 8 162.3, 158.7, 139.2, 
134.4, 129.9, 121.7, 119.5, 115.7, 115.0, 67.2, 66.4; vmax (Nujol) / cm' 1 3297 (N-H), 2929 (C-H), 
2223(C=N), 1602 (Ar), 1504 (Ar), 1236 (C-O-C); m/z (Cl) 257 ([M+NH4]+), found 257.12881, 
C 15H17N2O2 requires 257.12900; anal. Found C 75.20, H 5.49, N 5.81, C i5H |3N02 requires C 
75.30, H 5.48, N 5.85.
4-(2-Phenoxyethoxy)benzamidine hydrochloride hydrate (12) Compound 10 (0.27 g, 1.06 
mmol) was dissolved in a mixture of anhyd. benzene (100 mL) and ethanol (1.56 mL), cooled to 
0 °C and saturated with HC1 gas. The mixture was sealed and stirred at room temperature for 3 
days after which anhyd. Et20  (16 mL) was introduced and the mixture stirred for 10 minutes.
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The solids were filtered under nitrogen and dissolved in a mixture of anhyd. EtOH (20 mL) and 
anhyd. EtOH.NH3 (20 mL). The mixture was heated overnight (50 °C), cooled to room 
temperature and reduced by half in vacuo. Ether (30 mL) was added to precipitate the solid 
which was filtered, washed and dried under vacuum. Purification by recrystallisation (2N HC1) 
gave the desired compound 12 as fine white needles (0.24 g, 73%). Mp 209°C; 'H NMR (MeOD, 
400 MHz) 6 7.81 (d, 2H, J =  9.0 Hz, ArH), 7.28 (m, 2H, ArH), 7.20 (d, 2H, J =  9.0 Hz, ArH), 
6.94 (d, 3H, J  = 8.0 Hz, ArH), 4.45 (m, 2H, CH2), 4.36 (m, 2H, CH2); 13C NMR (MeOD, 
100MHz) 8 167.9, 165.3, 164.8, 131.4, 130.9, 122.5, 116.8, 116.1,68.9, 68.0; vmax (Nujol) / cm' 1 
3311 (N-H), 3143 (Ar-H), 2929 (C-H), 1650 (C=N), 1602 (Ar), 1504 (Ar), 1240 (C-O); m/z 
(ESP) 257.1 ([M+H]+), found 257.1279, C ,5H l7N20 2 requires 257.1290; anal. Found C 58.50 H 
6.20 N 9.09, C,5H 19C1N20 3 requires C 57.97, H 6.16, N 9.01.
OH
CN
4, 4’-(propane-l,3-diylZ»w(oxy))dibenzonitrile (3) Sodium (0.16 g, 6.96 mmol) was added 
portionwise to anhyd. EtOH (4.0 mL) stirring under an atmosphere of nitrogen. After dissolution 
of Na, a solution of 4-cyanophenol (0.75 g, 6.38 mmol) dissolved in dry ethanol (4.0 mL) was 
added followed by dropwise addition of 1,3-dibromopropane (0.32 mL, 3.19 mmol). The 
reaction mixture was stirred at reflux under a nitrogen atmosphere for 3 days after which the 
mixture was cooled, filtered, the solid washed with water and dried under vacuum. Purification 
by column chromatography eluting with DCM: hexane (8:2) gave the desired compound 3 as a 
white solid (1.40 g, 79%). Mp 190-191°C; 'H NMR (CDC13,400 MHz) 5 7.59 (d, 4H, J=  8.5 Hz, 
ArH), 6.96 (d, 4H, J =  8.5 Hz, ArH), 4.20 (t, 4H, J=  6.0 Hz, CH2), 2.32 (m, 2H, CH2); l3C NMR 
(CDC13, 100MHz) 5 161.9, 134.0, 119.1, 115.1, 104.2, 64.4, 28.8; vmax (Nujol) / cm’ 1 3104 (Ar- 
H), 2823 (C-H), 2221 (C=N), 1604 (Ar), 1509 (Ar), 1253 (C-O); m/z (Cl) 296 ([M+NH4]+), 
found 296.14037, C i7H i8N30 2 requires 296.13992; anal. Found C 73.22, H 5.13, N 10.03, 
C i7H,4N 20 2 requires C 73.37, H 5.07, N 10.07.
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4,4,-(propane-l,3-diyl6/s(oxy))dibenzimidamide dihydrochloride dihydrate (7) Compound 
3 (0.50 g, 1.79 mmol) was dissolved in a mixture of anhyd. benzene (55 mL) and anhyd. ethanol 
(3.0 mL), cooled to 0 °C and saturated with HC1 gas. The mixture was sealed and stirred at room 
temperature for 3 days after which ether (30 mL) was introduced and the mixture stirred for 10 
minutes. The solids were filtered under nitrogen and dissolved in a mixture of anhyd. EtOH (36 
mL) and EtOH.NFf (36 mL). The mixture was heated overnight (50 °C), cooled to room 
temperature and reduced by half in vacuo. Et20  (15 mL) was added to precipitate the solid which 
was filtered, washed and dried under vacuum. Purification by recrystallisation (2N E1C1) gave the 
desired compound 7 as fine white needles (0.59 g, 78%). Mp 200°C 'H NMR (MeOD, 400 MHz) 
5), 7.82 (d, 4H, J =  9.0 Hz, ArH), 7.19 (d, 4H, J =  9.0 Hz, ArH), 4.34 (t, 4H, J =  6.0 Hz, CH2), 
2.46 (m, 2H, CH2); 13C NMR (MeOD, 100MHz) 5 167.9, 165.5, 131.5, 121.5, 121.4, 116.6, 66.4, 
30.3; vmax (Nujol) / cm' 1 3280 (N-H), 3038 (Ar-H), 2929 (C-H), 1504 (Ar), 1606 (Ar), 1240 (C- 
O-C); m/z (ESP) 313 ([M-H]'); anal. Found C 48.60 H 6.10 N 13.25, Ci7H26Cl2N404Cl2 requires 
C 48.46, H 6.22, N 13.30.
4,4’-(butane-l,4-diyl6/s(oxy))dibenzonitrile (4) Sodium (0.10 g, 4.35 mmol) was added 
portionwise to dry EtOH (4.0 mL) stirring under an atmosphere of nitrogen. After dissolution of 
Na, a solution of 4-cyanophenol (0.47 g, 3.95 mmol) dissolved in dry ethanol (4.0 mL) was 
added followed by dropwise addition of 1,4-dibromobutane (0.24 mL, 1.98 mmol). The reaction 
mixture was stirred at reflux under a nitrogen atmosphere for 3 days after which the mixture was
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cooled, filtered, the solid washed with water and dried under vacuum. Purification by column 
chromatography eluting with DCM: hexane (8:2) gave the desired compound 4 as a white solid 
(1.03 g, 89%). Mp 174°C; 'H NMR (CDC13,400 MHz) 5 7.59 (d, 4H, J  = 8.9 Hz, ArH), 6.93 (d, 
4H, J  = 8.9 Hz, ArH), 4.08 (m, 4H, CH2), 2.01 (m, 4H, CH2); 13C NMR (CDC13, 100MHz) 5
162.1, 134.0, 119.1, 115.1, 104.0, 67.7, 25.7; vmax (Nujol) / cm' 1 3332 (C-O-C), 3033 (Ar-H), 
2956 (C-H), 2219 (C=N), 1604 (Ar), 1506 (Ar), 1251 (C-O-C); m/z (Cl) 310 ([M+NH4]+), found 
310.15532, C i8H20N3O2 requires 310.15555; anal. Found C 74.03, H 5.55, N 9.55, C ,8Hi6N20 2 
requires C 73.95, H 5.52, N 9.58.
NH
4,4’-(butane-l,4"diyl6is(oxy))dibenzimidamide dihydrochloride dihydrate (8) Compound 4 
(0.42 g, 1.44 mmol) was dissolved in a mixture of anhyd. benzene (46 mL) and anyhd. ethanol 
(2.50 mL), cooled to 0 °C and saturated with HC1 gas. The mixture was sealed and stirred at 
room, temperature for 3 days after which anyhd. Et20  (40 mL) was introduced and the mixture 
stirred for 10 minutes. The solids were filtered under nitrogen and dissolved in a mixture of 
anhydrous EtOH (34 mL) and EtOH.NH3 (34 mL). The mixture was heated overnight (50 °C), 
cooled to room temperature and reduced by half in vacuo. Ether (15 mL) was added to 
precipitate the solid which was filtered, washed and dried under vacuum. Purification by 
recrystallisation (2N HC1) gave the desired compound 8 as fine white needles (0.46 g, 73%). Mp 
286-287°C; 'H NMR (MeOD,400 MHz) 5, 7.80 (d, 4H, J =  9.0 Hz, ArH), 7.14 (d, 4H, J =  9.0 
Hz, ArH), 4.19 (m, 4H, CH2), 2.02 (m, 4H, CH2); 13C NMR (MeOD, 100MHz) 5 165.7, 131.4,
121.2, 116.7, 69.7, 27.2; vmax (Nujol) / cm' 1 3370 (N-H), 3129 (Ar-H), 2884 (C-H), 1650 (C=N), 
1606 (Ar), 1508 (Ar), 1257 (C-O); m/z (ESP) 327 ([M+H]+); anal. Found C 49.87 H 6.46 N 
12.67, C |8H28C12N40 4 requires C 49.66, H 6.48, N 12.87.
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4-(4-Phenoxybutoxy)benzonitrile (11) Sodium (0.16 g, 6.96 mmol) was added portionwise to 
dry EtOH (5 mL) and dissolved under a nitrogen atmosphere. To this a solution of 4- 
cyanophenol (0.53 g, 4.47 mmol) dissolved in dry ethanol (5 mL) was added followed by 
dropwise addition of 1,4-dibromobutane (0.53 mL, 4.47 mmol). The reaction mixture was stirred 
at reflux and monitored by TLC. After consumption of 4-cyanophenol the reaction mixture was 
cooled to room temperature. In a separate flask Na (0.16 g, 6.96 mmol) was added portionwise to 
dry EtOH (5 mL) stirring under nitrogen. A solution of phenol (0.42 g, 4.47 mmol) in ethanol (5 
mL) was added and stirred for 10 minutes. This mixture was added dropwise to the cooled 
mixture and stirred under reflux for 3 days after which the mixture was cooled, filtered, the solid 
washed with water and dried under vacuum. Purification by column chromatography eluting 
with DCM: hexane (8:2) gave the desired compound 11 as a white solid (0.98 g, 82%). Mp 
130°C; 'H NMR (CDC13,400 MHz) 8 7.57 (d, 2H, J =  8.9 Hz, ArH), 7.28 (d, 1H, J  = 7.5 Hz, 
ArH), 7.26 (d, 1H, J  = 8.1 Hz, ArH), 6.92 (m, 5H, ArH), 4.08 (t, 2H, J =  5.9Hz, CH2), 4.03 (t, 
2H, J  = 5.9Hz, CH2), 1.99 (m, 4H, CH2); l3C NMR (CDC13, 100MHz) 8 162.6, 159.2, 134.3, 
129.8, 121.1, 115.5, 114.8, 104.3, 68.3, 67.5, 26.2; vmax (Nujol) / cm' 1 3043 (Ar-H), 2884 (C-H), 
2219 (O N ), 1602 (Ar), 1504 (Ar), 1247 (C-O); m/z (Cl) 285 ([M+NH4]+), found 285.16020, 
Ci7H2|N20 2 requires 285.16031; anal. Found C 76.40, H 6.46, N 5.44, Ci7H )7N0 2 requires C
4-(4-Phenoxybutoxy)benzimidamide hydrochloride hydrate (13) Compound 11 (0.27 g, 1.01 
mmol) was dissolved in a mixture of dry benzene (100 mL) and ethanol (1.60 mL), cooled to 0 
°C and saturated with HC1 gas. The mixture was sealed and stirred at room temperature for 3 
days after which anhyd. Et20  (16 mL) was introduced and the mixture stirred for 10 minutes. 
The solids were filtered under nitrogen and dissolved in a mixture of anhyd. EtOH (20 mL) and
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anhyd. EtOH.NH3 (20 mL). The mixture was heated overnight (50 °C), cooled to room 
temperature and reduced by half in vacuo. Ether (30 mL) was added to precipitate the solid 
which was filtered, washed and dried under vacuum. Purification by recrystallisation (2N HC1) 
gave the desired compound 13 as fine white needles (0.28 g, 82%). Mp 134-135°C; 'H NMR 
(DMSO, 400 MHz) 5 9.28 (s, 2H, NH2)> 9.08 (s, 2H, NH2), 7.86 (d, 2H, J  = 9.0 Hz, ArH), 7.29 
(d, 1H, J =  7.0 Hz, ArH), 7.27 (d, 1H, J =  12  Hz, ArH), 7.16 (d, 2H, J =  9.0 Hz, ArH), 6.93 (d, 
3H, J =  7.8 Hz, ArH), 4.16 (t, 2H, J=  5.9 Hz, CH2), 4.03 (t, 2H, J =  5.9 Hz, CH2), 1.89 (m, 4H, 
CH2); 13C NMR (DMSO, 100MHz) 5 165.0, 163.3, 158.9, 130.5, 129.8, 120.7, 119.6, 115.1, 
114.7, 68.1, 67.2, 25.6, 25.5; vmax (Nujol) / cm' 1 3288 (N-H), 1656 (C=N-H), 1604 (Ar), 1506 
(Ar), 1234 (C-O-C); m/z (ESP) 285 ([M+H]+), found 285.1603, C,7H24N20 2 requires 285.1599; 
anal. Found C 59.50 H 6.75 N 8.33, CI7H23C1N20 3 requires C 60.26, H 6.84, N 8.27.
O H
4,4,-(pentane-l,5-diylA/s(oxy))dibenzonitrile (5) Sodium (0.11 g, 4.78 mmol) was added 
portionwise to anhyd. EtOH (5 mL) and dissolved under nitrogen atmosphere. To this a solution 
of 4-cyanophenol (0.52 g, 4.38 mmol) in anhyd. ethanol (5 mL) was added followed by dropwise 
addition o f 1,5 dibromopentane (0.30 mL, 2.20 mmol). The reaction mixture was stirred at 
reflux under a nitrogen atmosphere for 3 days after which the mixture was cooled, filtered, the 
solid washed with water and dried under vacuum. Purification by column chromatography 
eluting with DCM: hexane (8:2) gave the desired compound 5 as a white solid (1.12 g, 83%). Mp 
116-118°C; 'H NMR (CDC13>400 MHz) 5 7.58 (d, 4H, J =  9.0 Hz, ArH), 6.93 (d, 4H, J =  9.0 
Hz, ArH), 4.03 (t, 4H, J =  6.4, CH2), 1.89 (m, 4H, CH2), 1.68 (m, 2H, CH2); ,3C NMR (CDC13, 
100MHz) 6 162.6, 134.3, 119.6, 115.5, 104.2, 68.4, 31.3, 29.1, 23.0; vmax (Nujol) / cm' 1 3095 
(Ar-H), 2873 (C-H), 2221 (C=N), 1604 (Ar), 1508 (Ar), 1259 (Ar); m/z (Cl) 324 ([M+NH4]+), 
found 324.17142, CisiH22N30 2 requires 324.17120; anal. Found C 73.99, H 5.98, N 8.94, 
C,9Hi8N20 2 requires C 74.49, H 5.92, N 9.14.
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4,4’-(pentane-l,5-diylZ>w(oxy))dibenzimidamide dihydrochloride dihydrate (9) Compound 5 
(0.28 g, 0.91 mmol) was dissolved in a mixture of anhyd. benzene (107 mL) and ethanol (5.71 
mL), cooled to 0 °C and saturated with HC1 gas. The mixture was sealed and stirred at room 
temperature for 3 days after which anhyd. Et20 (20 mL) was introduced and the mixture stirred 
for 10 minutes. The solids were filtered under nitrogen and dissolved in a mixture of anhydrous 
EtOH (74 mL) and EtOH.NHj (74 mL). The mixture was heated overnight (50 °C), cooled to 
room temperature and reduced by half in vacuo. Ether (30 mL) was added to precipitate the solid 
which was filtered, washed and dried under vacuum. Purification by recrystallisation (2N HC1) 
gave the desired compound 9 as fine white needles (0.33 g, 81%). Mp 243-245°C; 'H NMR 
(DMSO.400 MHz) 5, 9.31 (s, 4H, NH2), 9.09 (s, 4H, NH2), 7.88 (d, 4H, J =  8.9 Hz, ArH), 7.14 
(d, 4H, J  = 8.9 Hz, ArH), 4.12 (t, 4H, J  = 6.4 Hz, CH2), 2.51 (quin, 2H, J  = 1.7, 1.9, 3.7 Hz, 
CH2), 1.82 (m, 4H, CH2); l3C NMR (DMSO, 100MHz) 5 165.0, 163.3, 132.7, 130.5, 119.5,
115.0, 79.7, 79.3, 79.0, 68.3, 28.5; vmax (Nujol) / cm’ 1 3303 (N-H), 1660 (C=N-H), 1606 (Ar), 
1509 (Ar), 1265 (C-O-C); m/z (ESP) 341 ([M+H]+), found 341.1978, C,9H25N40 2 requires 
341.1975; anal. Found C 50.29 H 6.33 N 12.29, C |9H3oC12N404 requires C 50.78, H 6.73, N 
12.47.
4-(5-(p-tolyloxy)pentyloxy)benzonitrile (14) Sodium (0.12 g, 5.22 mmol) was added 
portionwise to anhyd. EtOH (4.0 mL) and dissolved under a nitrogen atmosphere. To this a 
solution of 4-cyanophenol (0.57 g, 4.79 mmol) dissolved in dry ethanol (4.0 mL) was added 
followed by dropwise addition of 1,5 dibromopentane (0.65 mL, 4.79 mmol). The reaction 
mixture was stirred at reflux and monitored by TLC. After consumption of 4-cyanophenol the
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reaction mixture was cooled to room temperature. In a separate flask, Na (0.57 g, 4.79 mmol) 
was added portionwise to dry EtOH (4.0 mL) stirring under nitrogen. To this a solution of p- 
cresol (0.5 mL, 4.79 mmol) in anhyd. EtOH (4.0 mL) was added and stirred for 10 minutes. This 
mixture was added dropwise to the cooled mixture and stirred under reflux for 3 days after which 
the mixture was cooled, filtered, the solid washed with water and dried under vacuum. 
Purification by column chromatography eluting with DCM: hexane (8:2) gave the desired 
compound 14 as a white solid (1.02 g, 72%). Mp 133°C; 'H NMR (CDC13j400 MHz) 5 7.57 (d, 
2H, J =  9.0 Hz, ArH), 7.07 (d, 2H, J=  8.6 Hz, ArH), 6.93 (d, 2H, J =  9.0 Hz, ArH), 6.79 (d, 2H, 
J=  8.6 Hz, ArH), 4.02 (t, 2H, J =  6.4 Hz, CH2), 3.96 (t, 2H, J =  6.4 Hz, CH2), 2.28 (s, 3H, CH3), 
1.86 (m, 4H, CH2), 1.64 (m, 2H, CH2); 13C NMR (CDC13, 100MHz) 5 162.7, 157.2, 134.3,
130.3, 130.2, 115.5, 114.7, 104.1,68.5,68.0, 29.4, 29.1,23.0, 20.8; vmax (Nujol) / cm' 1 3322 (C- 
O-C), 3031 (Ar-H), 2921 (C-H), 2223 (O N ), 1602 (Ar), 1506 (Ar), 1234 (C-O-C); m/z (Cl) 313 
([M+NH4]+), found 313.19092, C 19H25N20 2 requires 313.19162; anal. Found C 77.19, H 7.13, N 
5.02, C i9H2,N 02 requires C 77.26, H 7.17, N 4.74.
. H C l . H 20
4-(5-(p-tolyloxy)pentyloxy)benzimidamide hydrochloride hydrate (15) Compound 14 (0.27 
g, 0.91 mmol) was dissolved in a mixture of anhyd. benzene (100 mL) and anhyd. ethanol (1.60 
mL), cooled to 0 °C and saturated with HCl gas. The mixture was sealed and stirred at room 
temperature for 3 days after which anhyd. Et20  (20 mL) was introduced and the mixture stirred 
for 10 minutes. The solids were filtered under nitrogen and dissolved in a mixture of anhydrous 
EtOH (20 mL) and EtOH.NH3 (20 mL). The mixture was heated overnight (50 °C), cooled to 
room temperature and reduced by half in vacuo. Ether (30 mL) was added to precipitate the solid 
which was filtered, washed and dried under vacuum. Purification by recrystallisation (2N HCl) 
gave the desired compound 15 as fine white needles (0.25 g, 75%). Mp 132°C; 'H NMR 
(DMSO;400 MHz) 5 7.84 (d, 2H, J =  9.1 Hz, ArH), 7.15 (d, 2H, J = 9.1 Hz, ArH), 7.06 (d, 2H, J
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= 8.4 Hz, ArH), 6.80 (d, 2H, J=  8.4 Hz, ArH), 4.11 (t, 2H, J =  6.4 Hz, CH2), 3.93 (t, 2H, J =  6.4 
Hz, CH2), 2.22 (s, 3H, CH3), 1.78 (m, 4H, CH2), 1.56 (m, 2H, CH2); l3C NMR (DMSO,
100MHz) 5 165.0, 163.3, 158.9, 130.5, 130.1, 115.1, 114.5, 79.5, 79.3, 79.0, 20.4; vmax (Nujol) / 
cm' 1 3430 (NH), 3309 (C-O-C), 3093 (Ar-H), 1658 (C=N-H), 1606 (Ar), 1508 (Ar), 1245 (C-O- 
C); m/z (ESP) 313 ([M+H]+), found 313.1916, C |9H25N20 2 requires 313.1907; anal. Found C 
62.19 H 7.42 N 7.66, C i9H27C1N20 3 requires C 62.20, H 7.42, N 7.66.
NH
NH .2HCI
Adipimidamide dihydrochloride (16) 1,4 dicyanobutane (0.31 mL, 2.75 mmol) was suspended 
in a mixture of anhyd. benzene (25 mL) and ethanol (1.8 mL), cooled to 0 °C and saturated with 
HC1 gas. The mixture was sealed and stirred at room temperature for 3 days after which anhyd. 
Et20  (20 mL) was introduced and the mixture stirred for 10 minutes. The solids were filtered 
under nitrogen and dissolved in a mixture of anhyd. EtOH (21 mL) and anhyd. EtOH.NH3 (21 
mL). The mixture was heated overnight (50 °C), cooled to room temperature and reduced by half 
in vacuo. Ether (10 mL) was added to precipitate the solid which was filtered, washed and dried 
under vacuum. Purification by recrystallisation (2N HC1) gave the desired compound 16 as fine 
white needles (0.38 g, 64%). Mp 191°C; 'H NMR (D20, 400 MHz) 5 2.52 (m, 4H, CH2), 1.76 
(m, 4H, CH2); l3C NMR (D20, 100MHz) 5 165.0, 32.0, 25.5; vmax (Nujol) / cm' 1 3301 (N-H), 
3079 (N-H), 2938 (C-H), 1677 (C=N); m/z (ESP) 143.1 ([M+H]+); anal. Found C 33.54 H 7.50 
N 25.80, C6H,6C12N4 requires C 33.50, H 7.50, N 26.04.
.2HC1,2H20
Heptaneftw(imidamide) dihydrochloride dihydrate (17) 1,5 dicyanopentane (0.34 mL, 2.64 
mmol) was suspended in a mixture of anhyd. benzene (24 mL) and EtOH (1.7 mL), cooled to 0 
°C and saturated with HC1 gas. The mixture was sealed and stirred at room temperature for 3 
days after which anhyd Et20  (20 mL) was introduced and the mixture stirred for 10 minutes. The
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solids were filtered under nitrogen and dissolved in a mixture of anhyd. EtOH (21 mL) and 
anhyd. EtOH.NH3 (21 mL). The mixture was heated overnight (50 °C), cooled to room 
temperature and reduced by half in vacuo. Ether (30 mL) was added to precipitate the solid 
which was filtered, washed and dried under vacuum. Purification by recrystallisation (2N HC1) 
gave the desired compound 17 as fine white needles (0.44 g, 63%); Mp 208°C; 'H NMR (D20, 
400 MHz) 5 2.50 (t, 4H, J  = 7.8 Hz, CH2), 1.73 (quin, 4H, J  = 7.9, 15.4, 15.6 Hz, CH2), 1.46 
(quin, 2H, J =  6.7, 12.1, 15.2, CH2); 13C NMR (CDC13,100MHz) 5 171.7, 32.2, 30.8, 27.3, 26.0; 
vmax (Nujol) / cn f1 3330 (N-H), 3075 (N-H), 2940 (C-H), 1678 (C=N); m/z (ESP) 157.1. 
([M+H]+); anal. Found C 32.50, H 7.77, N 22.51, C7H22C12N4 requires C 31.70, H 8.36, N 21.13.
2^
NH
2 1 .2H20
Octane6/s(imidamide) dihydrochloride (18) 1,5 dicyanohexane (0.30 mL, 2.14 mmol) was 
suspended in a mixture of anhyd. benzene (20 mL) and ethanol (1.4 mL), cooled to 0 °C and 
saturated with HC1 gas. The mixture was sealed and stirred at room temperature for 3 days after 
which anhyd. Et20  (20 mL) was introduced and the mixture stirred for 10 minutes. The solids 
were filtered under nitrogen and dissolved in a mixture of anhyd. EtOH (17 mL) and anhyd. 
EtOH.NH3 (17 mL). The mixture was heated overnight (50 °C), cooled to room temperature and 
reduced by half in vacuo. Ether (30 mL) was added to precipitate the solid which was filtered, 
washed and dried under vacuum. Purification by recrystallisation (2N HC1) gave the desired 
compound 18 as fine white needles (0.33 g, 63%). Mp 201°C; 'H NMR (D20,400 MHz) 5 2.48 
(t, 4H, J  = 7.5 Hz, CH2), 1.69 (m, 4H, CH2), 1.40 (m, 4H, CH2); 13C NMR (CDC13, 100MHz) 8
165.1, 32.4, 27.8, 26.2; vmax (Nujol) / cm' 1 3299 (N-H), 3074 (N-H), 2940 (C-H), 1677 (C=N); 
m/z (ESP) 171.1 ([M+H]+); anal. Found C 38.43 H 8.28 N 22.77, C8H20C12N4 requires C 39.51, 
H 8.29, N 23.04.
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3-bromobenzothioamide (48a) Triethylamine (3.80 mL) was added to a solution of 3- 
bromobenzonitrile (5.02 g, 27.57 mmol) in pyridine (17 mL). The solution was cooled to 10°C 
and H2S gas bubbled through for 15 min. The resulting green solution was stirred overnight. 
Nitrogen was bubbled through for 1 hr to remove any excess H2S. Water (27 mL) was added and 
the mixture stirred for 10 min, a further portion of water (62 mL) was added and the pale yellow 
suspension left stirring overnight. The precipitate was filtered and rinsed with water to afford the 
title compound 48a as bright yellow crystals (5.26 g, 88%). Mp 115-116°C; 'H NMR (CDCI3, 
400 MHz) 5 8.00 (t, 1H, J  = 1.9 Hz, ArH), 7.80 (brs, 1H, NH), 7.77 (ddd, 1H, J =  1.8, 1.9, 7.9 
Hz, ArH), 7.64 (ddd, 1H, J =  1.8, 1.9, 7.9 Hz, ArH), 7.28 (t, 1H, J =  7.8 Hz, ArH), 7.21 (brs, 1H, 
NH); 13C NMR (CDCI3, 100MHz) 5  201.4, 141.4, 135.1, 130.4, 130.4, 125.7, 123.0; vmax (Neat) / 
cm' 1 3353 (N-H), 3158 (Ar-H), 1605 (Ar), 1502 (Ar), 1471 (C-N), 1247 (C=S), 892 (C=S); m/z 
(Cl) 218 ([M+H]+), found 215.94800, C7H7BrNS requires 215.94826; anal. Found C 38.63, H 
2.74, N 6.42, C7H6BrNS requires C 38.91, H 2.80, N 6.48.
2-(3-bromophenyl)-4-(4-bromophenyl)thiazole (51) 2,4'-dibromoacetophenone (1.01 g, 3.63 
mmol) was added to a solution of compound 48a (790 mg, 3.66 mmol) in anhyd. EtOH (15 mL) 
and warmed to 45°C for 1 hr. The mixture was cooled to room temperature and stirred for 30min 
before filtering. The precipitate was washed with an EtOH : water mix (3:1, 10 ml) and dried to 
afford the title compound 51 as an off-white solid (1.30 g, 90%). Mp 166-167°C; 'H NMR 
(CDCI3, 400 MHz) 8 8.20 (t, 1H, J =  1.9 Hz, ArH), 7.91 (ddd, 1H, J =  1.7, 1.7, 7.8 Hz, ArH), 
7.86 (d, 2H, J  = 8.8 Hz, ArH), 7.56 (m, 3H, ArH), 7.49 (s, 1H, CH), 7.32 (t, 1H, J  = 7.7 Hz, 
ArH); 13C NMR (CDC13, 100 MHz) 8 166.2, 155.4, 135.4, 133.2, 133.0, 131.9, 130.4, 129.4,
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128.0, 125.2, 123.1, 122.4, 113.5; vmax (Neat) / cm' 1 3070 (Ar-H), 2927 (C-H), 1587 (Ar), 1560 
(C=N), 1508 (Ar), 744 (C-Br), 684 (C-S-C); m/z (ESP) 394/396/398 ([M+H]+), found 393.8901, 
Ci5Hio79Br2NS requires 393.8917; anal. Found C 45.37, H 2.23, N 3.46, CisHgB^NS requires C 
45.59, H 2.29, N 3.54.
3,4'-(thiazole-2,4-diyl)dibenzonitrile (55) A suspension of compound 51 (1.02 g, 2.58 mmol) 
and CuCN (906 mg, 10.11 mmol) in anhyd. DMF (15 mL) were heated to reflux for 21 hrs. On 
cooling, the reaction mixture was poured into aqueous NH4OH (10%, 50 ml) and extracted with 
CHCI3 (100 mL). Both layers were filtered to remove the dark precipitate. The organic layer was 
washed with water (2 x 50 mL), brine (50 mL) and dried (MgSO^. Removal of solvent gave a 
dark oily solid. Purification by column chromatography eluting with CHCI3. afforded the title 
compound 55 as a pale solid (191 mg, 26%). Mp 199-200°C; 'H NMR (CDC13, 400 MHz) 8 8.36 
(s, 1H, ArH), 8.24 (dt, 1H, J =  1.3, 8.0 Hz, ArH), 8.11 (d, 2H, J =  8.6 Hz, ArH), 7.74 (m, 3H, 
ArH), 7.70 (s, 1H, CH), 7.60 (t, 1H, J =  7.8 Hz, ArH); l3C NMR (CDCI3, 100 MHz) 5 165.7,
154.7, 137.9, 134.3, 133.4, 132.7, 132.1, 130.5, 130.0, 129.9, 126.9, 126.6, 120.7, 118.7, 118.0,
116.2, 113.5, 111.8; vmax (Neat) / cm' 1 3094 (Ar-H), 2996 (C-H), 2227 (C=N), 1606 (Ar), 1509 
(Ar), 676 (C-S-C); m/z (Cl) 288 ([M+H]+), found 288.0592, C ,7H 10N3S requires 288.0595 anal. 
Found C 69.93, H 3.08, N 13.39, C17H9N3S requires C 71.06, H 3.16, N 14.62.
3,4'-(thiazole-2,4-diyl)dibenzimidamide (62) A suspension of compound 55 (0.35 g, 1.22 
mmol) in anhyd. benzene (26 mL) and anhyd. EtOH (3.86 mL) was saturated with HC1 gas and
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the solution left stirring at room temperature for 1 week. Anhydrous Et20 was introduced and the 
precipitate was filtered under nitrogen and washed with anhyd. Et20 . Anhydrous EtOH.NH3 (26 
mL) was added to a solution of the imidate in anhyd. EtOH (26 mL) and heated at reflux 
overnight. On cooling anhyd. Et20 was added and the resulting precipitate filtered and washed 
with ether. Purification by recrystallisation (2N HC1) gave the desired compound 62 as fine 
white needles (0.26 g, 52%). Mp 370°C; 'H NMR (DMSO, 400 MHz) 5 9.61 (s, 2H, NH2), 9.48 
(s, 2H, NH2), 9.32 (s, 2H, NH2), 9.20 (s, 2H, NH2), 8.60 (s, 1H, CH), 8.47 (s, 1H, ArH), 8.41 (d, 
1H, J  = 7.8 Hz, ArH), 8.33 (d, 2H, J  = 8.7 Hz, ArH), 7.98 (m, 3H, ArH), 7.80 (t, 1H, J  = 7.8 Hz, 
ArH); 13C NMR (DMSO, 100 MHz) 5 166.2, 165.5, 165.3, 154.0, 138.7, 133.6, 131.5, 130.4,
129.7, 129.2, 126.7, 126.2, 119.2; vmax (Neat) / cm’ 1 3035 (N-H), 1660 (C=N-H), 1595 (Ar), 1501 
(Ar), 1232 (N=C-S), 671 (C-S-C); m/z (ESP) 322 ([M+H]+), found 322.1126, C ,7H 16N5S 
requires 322.1116; anal. Found C 49.49, H 4.64, N 17.12, C 17H21N5SO2CI2 requires C 49.52, H 
4.64, N 16.98.
yV,-hydroxy-3-(4-(4-A,-hydroxycarbamimidoyl)phenyl)thiazole-2-yl)benzimidamide (63)
Potassium tert butoxide (0.78 g, 6.95 mmol) was added portionwise to a suspension of 
hydroxylamine hydrochloride (0.48 g, 6.90 mmol) in anhyd. DMSO (3.72 mL) at 5°C under an 
atmosphere of nitrogen. The mixture was stirred for 30min after which the mixture was added to 
compound 55 (0.20 g, 0.69 mmol) via cannula and the mixture stirred at room temperature 
overnight. The mixture was poured slowly onto ice water, filtered, washed with water, EtOH and 
dried yielding the title compound 63 as a white solid (0.24 g, 98%). Mp 203°C; 'H NMR 
(DMSO, 400 MHz) 6 9.82 (s, IH, NH), 9.72 (s, IH, NH), 8.34 (s, 1H, ArH), 8.26 (s, IH, CH),
8.06 (m, 3H, ArH), 7.81 (m, 3H, ArH), 7.55 (t, 1H, J =  7.8 Hz, ArH), 6.00 (s, 2H, NH2), 5.88 (s, 
2H, NH2); 13C NMR (DMSO, 100 MHz) 5 167.1, 155.1, 150.8, 150.6, 138.8, 134.7, 134.6,
133.3, 133.1, 129.5, 126.8, 123.4, 115.5; vmax (Neat) / cm' 1 3432 (N-H), 3336 (N-O-H), 3066 
(Ar-H), 1650 (C=N-0), 1602 (Ar), 1506 (Ar), 1240 (N=C-S), 671 (C-S-C); m/z (ESP) 354
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([M+H]+), found 354.1025, C i7H i6N502S requires 354.1032; anal. Found C 57.80, H 4.27, N 
19.94, C i7H ,5N502S requires C 57.78, H 4.28, N 19.82.
Af’-methoxy-3-(4-(4-Af,-methoxycarbamimidoyl)phenyl)thiazole-2yl)benzimidamide (65)
Dimethylsulphate (0.09 mL, 0.84 mmol) in dioxane (0.15 mL) was slowly added to a solution of 
compound 55 (0.10 g, 0.28 mmol) in dioxane (0.5 mL) and 2N NaOH (2.5 mL) at 0°C. The 
mixture was stirred for 2hrs from 0°C to room temperature after which the mixture was extracted 
with EtOAc (3x) and reduced in vacuo. The yellow residue was purified by column 
chromatography eluting with EtOAc : Petroleum ether (60:40) to afford the title compound 65 as 
a white solid (49 mg, 46%). Mp 175°C; 'H NMR (DMSO, 400 MHz) 5 8.28 (s, 2H, CH, ArH),
8.08 (d, 3H, J  = 8.5 Hz, ArH), 7.80 (m, 3H, ArH), 7.56 (t, 1H, J =  7.8 Hz, ArH), 6.26 (s, 2H, 
NH2), 6.12 (s, 2H, NH2), 3.79 (s, 3H, CH3), 3.77 (s, 3H, CH3); 13C NMR (DMSO, 100 MHz) 5
167.0, 155.0, 151.0, 150.9, 135.0, 133.9, 133.2, 132.5, 129.6, 128.0, 127.4, 126.5, 126.2, 123.8, 
115.9, 61.1, 61.0; vmax (Neat) / cm' 1 3448 (N-O-C), 3305 (N-H), 1629 (C=N-0), 1240 (N=C-S), 
682 (C-S-C); m/z (ESP) 382 ([M+H]+), found 382.1338, C 19H20N5O2S requires 382.1319 anal. 
Found C 58.15, H 5.17, N 18.93, C ^H ^N jOí S requires C 59.82, H 5.02, N 18.36.
A,-ethoxy-3-(4-(4-A’-ethoxycarbamimidoyl)phenyl)thiazole-2-yl)benzimidamide (66)
Diethylsulphate (0.11 mL, 0.84 mmol) in dioxane (0.14 mL) was slowly added to a solution of 
compound 55 (0.10 g, 0.28 mmol) in dioxane (0.42 mL) and 2N NaOH (2.26 mL) at 0°C. The 
mixture was stirred for 2hrs from 0°C to room temperature after which the mixture was extracted
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with EtOAc (3 x 20mL) and reduced in vacuo. The yellow residue was purified by column 
chromatography eluting with EtOAc: Petroleum ether (60:40) yielding the title compound 66 as 
a white solid (52 mg, 45%). Mp 145°C; 'H NMR (DMSO, 400 MHz S 8.28 (s, 2H, ArH, CH),
8.08 (d, 3H, J  = 8.5 Hz, ArH), 7.81 (m, 3H, ArH), 7.56 (t, 1H, J  = 7.8 Hz, ArH), 6.20 (s, 2H, 
NH2), 6.06 (s, 2H, NH2), 4.01 (m, 4H, CH2), 1.26 (m, 6H, CH3); 13C NMR (DMSO, 100 MHz) Ô
167.0, 155.0, 150.9, 150.8, 134.9, 134.1, 133.2, 132.7, 129.5, 128.0, 127.4, 126.5, 126.2, 123.8, 
115.9, 68.3, 68.2, 15.1; vmax (Neat) / cm' 1 3459 (N-O-C), 3133 (N-H), 1623 (C=N-0), 1236 
(N=C-S), 686 (C-S-C); m/z (ESP) 410 ([M+H]+), found 410.1651, C2iH24N50 2S requires 
410.1652; anal. Found C 62.00, H 5.80, N 17.00, C2iH23N50 2S requires C 61.59, H 5.66, N 
17.10.
7V’-acetoxy-3-(4-(4-A’-acetoxycarbamiinidoyl)phenyl)thiazole-2-yl)benzimidamide (67)
Acetic anhydride (0.15 mL) was slowly added to a solution of compound 55 (0.15 g, 0.43 mmol) 
in glacial acetic acid (4.33 mL) at room temperature. The mixture was stirred overnight and 
poured slowly onto ice water, filtered, washed with water and dried yielding the title compound 
67 as a white solid (0.17 g, 90%). Mp 193°C; 'H NMR (DMSO, 400 MHz) 6 8.36 (s, 1H, CH), 
8.34 (s, 1H, ArH), 8.16 (m, 3, ArH), 7.84 (m, 3H, ArH), 7.63 (t, 1H, / =  7.8 Hz, ArH), 7.02 (s, 
2H, NH2), 6.89 (s, 2H. NH2), 2.16 (s, 6H, CH3); 13C NMR (DMSO, 100 MHz) 5 168.9, 168.8,
166.8, 156.4, 154.8, 136.0, 133.3, 133.0, 131.6, 129.8, 129.0, 128.9, 128.6, 124.7, 116.6, 20.24, 
20.21; vmax (Neat) / cm' 1 3612 (N-O-C), 3334 (N-H), 3035 (Ar-H), 2938 (C-H), 1739 (C=0), 
1603 (Ar), 1226 (N=C-S), 678 (C-S-C); m/z (ESP) 460 ([M+Na]+), found 460.1055, 
C2iHi9N50  423NaS requires 460.1071; anal. Found C 57.70, H 4.39, N 15.99, C2|Hi9N504S 
requires C 57.66, H 4.38, N 16.01.
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N'-(2,2,2-trifluoroacetoxy)-3-(4-(4-(N'-(2,2,2-trifluoroacetoxy)carbamimidoyl)phenyl)thiaz- 
ol-2-yl)benzimidamide (68) Trifluoroacetic anhydride (0.14 mL, 1.0 mmol) was slowly added 
to a solution of compound 55 (0.10 g, 0.28 mmol) in glacial acetic acid (2.83 mL) at room 
temperature. The mixture was stirred overnight and poured slowly onto ice water, filtered, 
washed with water and dried yielding the title compound 68 as a white solid (0.10 g, 65%). Mp 
198°C; 'H NMR (DMSO, 400 MHz) 5 8.36 (s, 1H, CH), 8.34 (s, 1H, ArH), 8.17 (m, 3, ArH), 
7.84 (m, 3H, ArH), 7.64 (t, 1H, J  = 7.8 Hz, ArH), 7.02 (s, 2H, NH2), 6.89 (s, 2H, NH2), 13C 
NMR (DMSO, 100 MHz) 5 174.7, 174.3, 168.9, 168.8, 166.8, 156.4, 154.8, 136.0, 133.3, 133.0, 
131.6, 129.8, 129.0, 128.9, 128.6, 124.7, 116.6, 111.5, 111.2; m/z (ESP) 568 ([M+Na]+), found 
568.0490, C2!H ,3F6N50423NaS requires 568.0506; anal. Found C 46.04, H 2.51, N 12.92, 
C2]H|3F6N504S requires C 46.24, H 2.40, N 12.84.
4-bromobenzothioamide (48b) Triethylamine (3.80 mL) was added to a solution of 4- 
bromobenzonitrile (5.01 g, 27.57 mmol) in pyridine (17 mL). The solution was cooled to 10°C 
and H2S gas was bubbled through for 15 min. The resulting green solution was stirred overnight. 
Nitrogen was bubbled through for 1 hr to remove any excess H2S. Water (27 mL) was added and 
the mixture stirred for 10 min, a further portion of water (62 mL) was added and the pale yellow 
suspension left stirring overnight. The precipitate was filtered and rinsed with water to afford the 
title compound 48b as bright yellow crystals (5.52 g, 93%). Mp 115-116 °C; 'H NMR (de­
acetone, 400 MHz) 6 9.07 (bs, 1H, NH), 8.92 (s, 1H, NH), 7.94 (dd, 2H, J =  2.0, 6.5 Hz, ArH),
Experimental Details 228
7.62 (dd, 2H, J  = 2.0, 6.5 Hz, ArH); 13C NMR (d6-acetone, 100 MHz) 5 201.9, 140.2, 132.3,
130.4, 126.5; vmax (Neat) / cm'l3253 (N-H), 3149 (Ar-H), 1610 (Ar), 1509 (Ar), 1482 (C-N), 
1257 (C=S), 883 (C=S); m/z (Cl) 216 ([M]+).
4-(3-bromophenyl)-2-(4-bromophenyl)thiazole (50) 2,3'-dibromoacetophenone (1.00 g, 3.59 
mmol) was added to a solution of compound 48b (777 mg, 3.60 mmol) in EtOH (15 mL) and 
warmed to 45°C for 1 hr. The mixture was cooled to room temperature and left for 30 min before 
filtering. The precipitate was washed with EtOH: water (3:1, 10 mL) and dried to afford thiazole 
50 as an off white solid (1.03 g, 73%). Mp 168°C; 'H NMR (d6-acetone, 400 MHz) 5 8.30 (s, 
1H, ArH), 8.15 (s, 1H, CH), 8.10 (s, 1H, ArH), 8.06 (d, 2H, J  = 8.6 Hz, ArH), 7.74 (d, 2H, J  =
8.6 Hz, ArH), 7.57 (dd, 1H, J =  1.0, 8.0 Hz, ArH), 7.45 (t, 1H, J  = 7.6 Hz, ArH); l3C NMR (de­
acetone, 100 MHz) 6 166.1, 155.4, 135.2, 133.1, 131.9, 130.6, 129.5, 128.3, 125.0, 124.1, 123.1,
122.5, 113.5; vmax (Neat) / cm' 1 3072 (Ar-H), 2926 (C-H), 1597 (Ar), 1560 (C=N), 1506 (Ar), 
1232 (N=C-S), 744 (C-Br), 685 (C-S-C); m/z (Cl) 396 ([M+H]+).
3,4'-(thiazoIe-2,4-diyl)dibenzonitrile (54) A suspension of compound 50 (978 mg, 2.50 mmol) 
and CuCN (895 mg, 10.0 mmol) in anhyd. DMF (15 mL) were heated to reflux for 21 hr. On 
cooling, the reaction mixture was poured into aqueous NH4OH (10%, 50 mL) and extracted with 
CHCI3 (100 mL). Both layers were filtered to remove the dark precipitate. The organic layer was 
washed with water (2 x 50 mL), brine (50 mL) and dried over MgS04- Removal of solvent gave 
a dark oily solid. Purification by column chromatography eluting with CHCI3, afforded the title 
compound 54 as a pale solid (380 mg, 53%). Mp 200°C; ‘H NMR (d6-acetone, 400 MHz) 8 8.36
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(d, IH, J  = 1.4 Hz, ArH), 8.30 (dt, 1H, J =  1.4, 8.0 Hz, ArH), 8.20 (s, IH, CH), 8.19 (d, 2 H ,J  =
8.6 Hz, ArH), 7.82 (d, 2H, J=  8.7 Hz, ArH), 7.66 (dt, 1H, J=  1.3, 7.6 Hz, ArH), 7.59 (t, 1H, J  =
7.8 Hz, ArH); l3C NMR (d6-acetone, 100 MHz) 5 165.4, 154.7, 134.3, 132.9, 131.9, 131.3,
131.1, 128.4, 119.6, 119.3, 118.6, 114.3; vmax (Neat) / cm' 1 3089 (Ar-H), 2948 (C-H), 2225 
(O N ), 1602 (Ar), 1503 (Ar), 678 (C-S-C); m/z (Cl) 288 ([M+H]+).
3,4'-(thiazole-2,4-diyl)dibenzimidamide (58) A suspension of compound 54 (310 mg, 1.08 
mmol) in anhyd. benzene (23mL) and anhyd. EtOH (3.4 mL) was saturated with HC1 gas and the 
solution left stirring at room temperature for 1 week. Anhydrous ether was added to the 
precipitate which was filtered under N2 and washed with anhyd. Et20 . Anhydrous EtOH. NH3 
was added to a solution of the imidate in EtOH (23 mL) and heated to reflux overnight. On 
cooling, anhyd. Et20 was added and the resulting precipitate filtered and washed with Et20 . 
Crude yield (249 mg, 72%). The crude product (100 mg) was purified by reverse phase HPLC 
using a YMC-pack ODS-A column (250 x 20 mm I.D, 5 pM) eluting with CH3CN: Water 0.1% 
TFA (20-80 % gradient over 20 min). Removal of solvent afforded the TFA salt of the desired 
compound 58 as a colourless solid (33 mg, 17%). Mp 257-258°C; 'H NMR (DMSO, 400 MHz) 
5 9.48 (bs, 6H, NH, NH2), 8.52 (s, 1H, CH), 8.49 (s, 1H, ArH), 8.43 (d, 1H, J =  7.8 Hz, ArH), 
8.30 (d, 2H , J =  8.4 Hz, ArH), 8.01 (d, 2H, J = 8.4 Hz, ArH), 7.85 (d, 1H, J =  7.8 Hz, ArH), 7.76 
(t, 1H, J  -  7.8 Hz, ArH); 13C NMR (DMSO, 100 MHz) 5 166.1, 166.0, 165.4, 159.2, 158.9,
154.5, 137.4, 134.7, 131.4, 130.0, 129.9, 129.6, 129.4, 128.2, 126.9, 126.1, 118.4; vmax (Neat) / 
cm' 1 3050 (N-H), 1652 (C=N-H), 1602 (Ar), 1496 (Ar), 682 (C-S-C); m/z (ESP) 322 ([M+H]+), 
found 322.1132, C i7H i6N5S requires 322.1126; anal. Found C 46.17, H 3.04, N 12.81, 
C2,H,7N504F6S requires C 45.91, H 3.11, N 12.74.
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2,4-6is(3-bromophenyl)thiazole (52) 2,3'-dibromoacetophenone (1.01 g, 3.63 mmol) was added 
to a solution of compound 48b (777 mg, 3.60 mmol) in EtOH (15 mL) and warmed to 45°C for 
1 hr. The mixture was cooled to room temperature and left for 30 min before filtering. The 
precipitate was washed with EtOH: water (3:1, 10 mL) and dried to afford thiazole 52 as a 
colourless solid (1.23 g, 86%). Mp 174°C; 'H NMR (d6-acetone, 400 MHz) 8 8.30 (m, 2H, ArH), 
8.15 (s, 1H, CH), 8.10 (d, 1H, 7 =  7.8 Hz, ArH), 8.06 (d, 1H, 7 = 7 .8  Hz, ArH), 7.70 (dd, 1H ,7 =
1.0, 8.0 Hz, ArH), 7.57 (dd, 1H, 7  = 1.0, 8.0 Hz, ArH), 7.51 (t, 1H, J =  8.0 Hz, ArH), 7.45 (t, 1H, 
J =  7.8 Hz, ArH); l3C NMR (d6-acetone, 100 MHz) 5 167.2, 137.8, 134.4, 134.3, 132.4, 132.3,
132.0, 130.4, 130.2, 130.1, 126.7, 126.4, 124.0, 123.8, 113.6; vmax (Neat) / cm' 1 3074 (Ar-H), 
2926 (C-H), 1597 (Ar), 1560(C=N), 1506 (Ar), 744 (C-Br), 686 (C-S-C); m/z (Cl) 396 
([M+H]+).
3,3'-(thiazole-2,4-diyl)dibenzonitrile (56) A suspension of compound 52 (1.00 g, 2.53 mmol) 
and CuCN (906 mg, 10.12 mmol) in anhyd. DMF (15 mL) were heated to reflux for 21 hr. On 
cooling, the reaction mixture was poured into aqueous NH4OH (10%, 50 mL) and extracted with 
CHCI3 (100 mL). Both layers were filtered to remove the dark precipitate. The organic layer was 
washed with water (2 x 50 mL), brine (50 mL) and dried (M gS04). Removal of solvent gave a 
dark oily solid. Purification by column chromatography eluting with EtOAc: hexane (2:8) 
afforded the title compound 56 as a pale solid (394 mg, 54%). Mp 204-205°C; :H NMR (de­
acetone, 400 MHz) 5 8.58 (s, 1H, ArH), 8.49 (m, 2H, ArH), 8.37 (s, 1H, CH), 7.97 (dt, 1H, J  = 
1.10, 6.3 Hz ArH), 7.81 (m, 4H, ArH); vmax (Neat) / cm' 1 3097 (Ar-H), 2904 (C-H), 2231 (C=N), 
1609 (Ar), 1505 (Ar), 676 (C-S-C); m/z (Cl) 288 ([M+H]+).
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Preparation of 0.67M Alkylchloroaluminium amide Solutions. Trimethyl aluminium (10 mL, 
2M in toluene) was added dropwise to a suspension of ammonium hydrochloride (1.07 g, 0.02M) 
in anhyd. toluene (20 mL) under N2. The reaction was warmed to room temperature and stirred 
until gas (CH4) evolution had ceased. The solution can be stored at 4°C for up to 48 hr.
3,3'-(thiazole-2,4-diyl)dibenzimidamide (60) The freshly prepared alkyl chloroaluminium 
reagent (5.2 mL, 0.67M, 3.48 mmol) was added to compound 56 (100 mg, 0.35 mmol) in anhyd. 
toluene (1 mL) and heated to 80°C overnight under a nitrogen atmosphere. On cooling, the 
aluminium complex was decomposed by pouring into a slurry of silica gel (2.0 g) in CHCI3. The 
mixture was stirred for 5 min, filtered and the solid washed with MeOH (20 mL), after which the 
filtrate was reduced in vacuo giving the crude amidine as a pale solid in quantitative yield. The 
crude product (100 mg) was purified by reverse phase HPLC using a YMC-pack ODS-A column 
(250 x 20 mm I.D, 5 pM) eluting with CH3CN: Water 0.1% TFA (20-80 % gradient over 20 
min). Removal of solvent afforded the desired compound 60 as a colourless solid (38 mg, 22%). 
Mp 246°C; 'H NMR (DMSO, 400 MHz) 5 9.50 (m, 6H, NH, NH2), 8.51 (s, 1H, CH), 8.43 (m, 
4H, ArH), 7.96 (d, 1H, J  = 8.0 Hz, ArH), 7.80 (m, 3H, ArH); l3C NMR (DMSO, 100 MHz) 5
166.2, 166.1, 165.8, 158.9, 154.2, 134.8, 133.7, 131.4, 130.4, 130.2, 130.0, 129.9, 129.5, 128.2,
126.3, 126.1, 119.0, 117.8, 116.0; m/z (ESP) 322 ([M+H]+), found 322.1141, C i7H 16N5S requires 
322.1126; anal. Found C 46.13, H 3.25, N 12.13, C2!Hi7N504F6S requires C 45.91, H 3.12, N 
12.74.
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2,4-6/s(4-bromophenyl)thiazole (53) 2,4'-dibromoacetophenone (1.00 g, 3.60 mmol) was added 
to a solution of compound 48b (777 mg, 3.60 mmol) in EtOH (15 mL) and warmed to 45°C for 
1 hr. The mixture was cooled to room temperature and left for 30 min before filtering. The 
precipitate was washed with EtOH: water (3:1, 10 mL) and dried to afford thiazole 53 as a pale 
solid (1.33 g, 94%). Mp 175-176°C; 'H NMR (CDC13, 400 MHz) 8 7.89 (d, 2H, J  = 8.0 Hz, 
ArH), 7.85 (d, 2H, J  = 8.0 Hz, ArH), 7.59 (d, 2H, J  = 5.5 Hz, ArH), 7.56 (d, 2H, J  = 5.5 Hz, 
ArH), 7.47 (s, 1H, CH); 13C NMR (CDCI3, 100 MHz) 5 166.5, 156.0, 135.2, 133.1, 132.0, 129.6,
128.5, 125.2, 124.3, 123.2, 112.7; vmax (Neat) / cm' 1 3072 (Ar-H), 2926 (C-H), 1590 (Ar), 1560 
(C=N), 1509 (Ar), 747 (C-Br), 684 (C-S-C); m/z (Cl) 396 ([M+H]+).
4,4'-(thiazole-2,4-diyl)dibenzonitrile (57) A suspension of compound 53 (1.00 g, 2.53 mmol) 
and CuCN (906 mg, 10.12 mmol) in anhyd. DMF (15 ml) were heated to reflux for 21 hr. On 
cooling, the reaction mixture was poured into aqueous NH4OH (10%, 50 mL) and extracted with 
CHCI3 (100 mL). Both layers were filtered to remove the dark precipitate. The organic layer was 
washed with water (2 x 50 mL), brine (50 mL) and dried (MgS04). Removal of solvent gave a 
dark oily solid. Purification by column chromatography eluting with CHCl3i afforded the title 
compound 57 as a pale solid (361 mg, 50%). Mp 200°C; !H NMR (CDCI3, 400 MHz) 5 8.14 (d, 
2H, J  = 8.3 Hz, ArH), 8.10 (m, 2H, ArH), 7.75 (m, 4H, ArH), 7.26 (s, IH, CH); 13C NMR 
(CDCI3, 100 MHz) 8 166.5, 137.4, 133.2, 133.1, 130.1, 127.4, 127.3, 127.2, 119.1, 118.6, 117.1,
114.2, 112.4; vmax (Neat) / cm' 1 3093 (Ar-H), 2987 (C-H), 2225 (C=N), 1602 (Ar), 1501 (Ar), 
669 (C-S-C); m/z (Cl) 288 ([M+H]+).
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4,4'-(thiazole-2,4-diyl)dibenzimidamide (61) The freshly prepared alkylchloroaluminium 
reagents (4 mL, 0.67 M, 2.7 mmol) was added to compound 57 (78 mg, 0.27 mmol) in anhyd. 
toluene (1 mL) and heated to 80 °C overnight under nitrogen. On cooling, the aluminium 
complex was decomposed by pouring into a slurry of silica gel (2.00 g) in CHCI3. The mixture 
was stirred for 5 min before filtering and washing the solid with MeOH (20 mL). Removal of 
solvent in vacuo gave the crude amidine as a pale solid in quantitative yield. The crude product 
(100 mg) was purified by reverse phase HPLC using a YMC-pack ODS-A column (250 x 20 mm 
I.D, 5 pM) eluting with CH3CN: Water 0.1% TFA (20-80% gradient over 20 min). Removal of 
solvent afforded the desired compound as an off-white solid (38 mg, 22%). Mp 271-272°C; 'H 
NMR (DMSO, 400 MHz) 5 9.32 (bs, 6H, NH , NH2), 8.54 (s, 1H, CH), 8.25 (d, 2H, J =  8.5 Hz, 
ArH), 8.22 (d, 2H, J  = 8.5 Hz, ArH), 7.92 (d, 2H, J  = 8.5 Hz, ArH), 7.90 (d, 2H, J  = 8.5 Hz, 
ArH); 13C NMR (DMSO, 100 MHz) 6 165.5, 165.4, 154.4, 138.7, 137.4, 129.6, 129.2, 127.9,
126.9, 126.8, 119.6; m/z (ESP) 322 ([M+H]+), found 322.1121, C 17H.6N5S requires 322.1126; 
anal. Found C 46.05, H 3.10, N 12.44, S 5.77, C2iHi7N504F6S requires C 45.91, H 3.12, N 
12.74, S 5.83.
3,4'-(thiazole-2,4-diyl)dibenzimidamide (59) A suspension of compound 55 (300 mg, 1.04 
mmol) in anhyd. benzene (22 mL) and anhyd. EtOH (3.3 mL) was saturated with HC1 gas and 
the solution left stirring at room temperature for 1 week. Anhydrous Et20  was added to the 
precipitate which was filtered under N2 and washed with anhyd. Et20 . Anhydrous EtOH. NH3 
was added to a solution of the imidate in EtOH (22 mL) and heated to reflux overnight (17hr). 
On cooling, anhyd. Et20  was added and the resulting precipitate filtered and washed with Et20 .
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Crude yield (249 mg, 72%). The crude product (100 mg) was purified by reverse phase HPLC 
using a YMC-pack ODS-A column (250 x 20 mm I.D, 5 pM) eluting with CH3CN: Water 0.1% 
TFA (20-80 % gradient over 20 min). Removal of solvent in vacuo afforded the TFA salt of 
compound 59 as a colourless solid (61 mg, 31%). Mp 258°C; 'H NMR (DMSO, 400 MHz) 5 
9.48 (m, 6H, NH , NH2), 8.58 (s, 1H, CH), 8.46 (t, 1H, J =  1.5 Hz, ArH), 8.42 (dt, 1H, J =  1.0, 
8.0 Hz, ArH), 8.33 (d, 2H, J =  8.5 Hz, ArH), 7.98 (d, 2H, J =  8.5 Hz, ArH), 7.94 (s, 1H, ArH), 
7.81 (t, 1H, J =  8.0 Hz, ArH); l3C NMR (DMSO, 100 MHz) 8 165.7, 165.5, 164.2, 159.1, 158.8,
157.6, 154.0, 138.8, 133.7, 131.5, 130.5, 130.3, 129.9, 129.2, 127.8, 126.8, 126.3, 119.1; m/z 
(ESP) 322 ([M+H]+), found 322.1150, C,7H 16N5S requires 322.1126; anal. Found C 44.54, H 
3.44, N 12.12, C2iH,9N505F6S requires C 45.45, H 3.37, N 12.34.
F
OH
Oxcr o o
2?ts(4-fluorophenyl)carbonate (76) 4-fluorophenyl chloroformate (1.02 g, 5.84 mmol) in DCM 
(2.2 mL) was added to a solution of 4-fluorophenol (0.65 g, 5.84 mmol) in pyridine (0.47 mL). 
The mixture was stirred at 0°C for 15 min after which the mixture was stirred at room 
temperature overnight. DCM (20 mL) was added to the reaction mixture and washed with water 
followed by 0.5N NaOH, brine, water, dried (Na2S 04) and reduced in vacuo. Purification by 
column chromatography eluting with CHCI3, afforded the compound 76 as a white solid (1.20 g, 
82%), Mp 126°C; 'H NMR (DMSO, 400 MHz) 8 7.23 (m, 4H, ArH), 7.09 (m, 4H, ArH); l3C 
NMR (DMSO, 100 MHz) 8 162.1, 159.6, 152.6, 147.2, 147.1, 122.8, 122.7, 116.8, 116.5; m/z 
(Cl) 268 ([M+NH4]+), found 268.07910, Ci3H 12F20 3N requires 268.07852; anal. Found C 62.43, 
H 3.21, C i3H8F20 3 requires C 62.41, H 3.22.
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9//-fluorene-2,7-diamine (106) To a suspension of 2,7-dinitro-9//-fluorene (0.12 g, 0.46 mmol) 
and zinc (0.98 g, 15.08 mmol) in EtOH (4.0 mL) was added calcium chloride (33 mg, 0.29 
mmol) in water (50 pL). The mixture was stirred for 2 hrs at reflux, filtered hot under reduced 
pressure, washed with excess hot EtOH and the fíltrate reduced. Purification by column 
chromatography eluting with (DCM: MeOH 8:2) afforded the compound 106 as a red solid (69 
mg, 76%). 'H NMR (CDCh, 400 MHz) 5 7.40 (d, 2H, J =  8.2 Hz, ArH), 6.82 (s, 2H, ArH), 6.67 
(d, 1H, J =  2.1 Hz, ArH), 6.65 (d, 1H, J =  2.3 Hz, ArH), 3.71 (s, 2H, CH2), 3.64 (brs, 2H, NH2), 
1.54 (brs, 2H, NH2); 13C NMR (CDC13, 100 MHz) 5 144.7, 144.4, 134.0, 119.6, 114.2, 112.4, 
37.1; vmax (Neat) / cm' 1 3561 (N-H), 3039 (Ar-H), 2942 (C-H), 1614 (Ar), 1495 (Ar); m/z (Cl) 
197 ([M+H]+), found 197.10836, C i3H i2N2 requires 197.10788; anal. Found C 79.20, H 6.19, N 
13.99, C 13H 12N2 requires C 79.56, H 6.16, N 14.27.
NBoc BocN
BocHN' ^v ,JT \ — x ^  N H Boc 
FrV-===/  V /  N H H
teft-butyl-(9//-fluorene-2,7-diyl)6is(azanediyl)6/s((ti'rr-butoxycarbonylamino)methan-l-yl- 
l-ylidene)dicarbamate (107) Compound 106 (0.1 g, 0.51 mmol), triethylamine (0.43 mL, 3.06 
mmol), l,3-6rs(to7-butoxycarbonyl)-2-methyl-thiopseudourea (0.31 g, 1.07 mmol), and mercury 
(II) chloride. (0.32 g, 1.17 mmol) were suspended in anhyd. DMF (3 mL) and stirred overnight 
under a nitrogen atmosphere. After which the mixture was diluted with DCM (100 mL), washed 
with Na2S 0 3 and filtered through a pad of celite. The filtrate was washed with water, brine, dried 
over Na2SC>4, filtered and reduced in vacuo. The resultant solid was recrystallised from 
DCM/MeOH after which purification by column chromatography eluting with DCM afforded 
compound 107 as a white solid (0.21 g, 60%); Mp >330°C; ‘H NMR (CDC13, 400 MHz) 5 11.67 
(s, 2H, NH), 10.42 (s, 2H, NH), 7.89 (s, 2H, ArH), 7.64 (d, 2H, J =  8.2 Hz, ArH), 7,49 (d, 1H, J  
= 1.8 Hz, ArH), 7.47(d, 1H, J =  1.8 Hz, ArH), 3.90 (s, 2H, CH2), 1.52 (m, 36H, CH3); l3C NMR 
(CDCh, 100 MHz) 5 164.0, 153.8, 144.6, 138.5, 135.7, 121.3, 120.1, 119.3, 84.0, 80.0, 37.6,
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31.2, 28.6, 28.5; m/z (ESP) 681 ([M+H]+), found 681.3612, C35H49N6O8 requires 681.3636; anal. 
Found C 61.10, H 6.97, N 12.19, Css^N eO g requires C 61.75, H 7.11, N 12.34.
NBoc 
BocHN"^.
BocN
>_x/rSIH B ocN
NH HN
H H N==s\ H
. 2HCI. H20
1, r-(9//-fluorene-2,7-diyl)diguanidine (108) Compound 107 (0.13 g, 0.19 mmol) was 
suspended in a mixture of anhyd. DCM (1.83 mL) and anhyd. EtOH (1.22 mL), cooled to 0°C 
and saturated with gaseous hydrogen chloride. The mixture was sealed and stirred at room 
temperature for 4 days after which the mixture was reduced in vacuo and the residue crystallised 
with EtOH/Et20 yielding compound 108 as a grey solid (41 mg, 41%); Mp >320°C; !H NMR 
(CDCI3, 400 MHz) 8 10.16 (brs, 2H, NH), 7.97 (d, 2H, J =  8.1 Hz, ArH), 7.54 (brs, 8H, NH), 
7.47 (s, 2H, ArH), 7.26 (d, 2H, J  = 8.1 Hz, ArH), 3.97 (s, 2H, CH2); 13C NMR (CDC13, 100 
MHz) 5 156.5, 144.9, 139.0, 134.2, 123.8, 121.8, 121.3, 36.9; m/z (ESP) 281 ([M+H]+), found 
281.1515, C i5H 17N6 requires 281.1519; anal. Found C 48.28, H 4.93, N 21.21, C,5H2oC12N60  
requires C 48.53, H 5.43, N 22.64. Reverse-Phase HPLC;
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9-benzylidene-2,7-dinitro-9//-fluorene (81) To a suspension of 2,7-dinitro-9//-fluorene (1.00 g, 
3.90 mmol) and KFiA^Ch (0.65 g, 4.68 mmol) in anhydrous DMF (16 mL) was added 
benzaldehyde (0.44 mL, 4.29 mmol), after which the mixture was stirred overnight at room 
temperature. The resulting suspension was filtered under reduced pressure, washed with an 
excess of DCM and reduced in vacuo furnishing 81 as a flocculent yellow solid (0.95 g, 71%). 
Mp >240°C (decomp); 'H NMR (CDC13, 400 MHz) 8 8.75 (d, 1H, J = 2.1 Hz, ArH), 8.57 (d, 1H, 
J=  2.1 Hz, ArH), 8.37 (dd, 1 H ,J=  1 .9 ,8 .4  Hz, ArH), 8.30 (dd, 1H, 7 =  2.1, 8.5 Hz, ArH), 8.07 
(s, 1H, CH), 7.98 (d, 1H, J =  8.3 Hz, ArH), 7.96 (d, 1H, J =  8.5 Hz, ArH), 7.63 (m, 2H, ArH), 
7.56 (m, 3H, ArH); 13C NMR (CDC13, 100 MHz) 5 154.2, 148.4, 148.0, 143.9, 141.9, 141.5,
138.3, 134.6, 133.7, 133.4, 129.9, 129.2, 129.1, 124.2, 123.8, 121.3, 121.2, 119.9, 116.2; vmax 
(Neat) / cm '1 3003 (Ar-H), 2927 (C-H), 1601 (Ar), 1503 (Ar), 1324 (N=0), 1230 (C-N); anal. 
Found C 69.55, H 3.44, N 8.19, CzqH ^ C L  requires C 69.76, H 3.51, N 8.13.
9-benzylidene-9//-fluorene-2,7-diamine (87) To a suspension of compound 81 (0.15 g, 0.44 
mmol) and zinc (0.94 g, 14.41 mmol) in EtOH (4.0 mL) was added calcium chloride (31 mg, 
0.28 mmol) in water (50 pL). The mixture was stirred for 2 hrs at reflux and filtered hot under 
reduced pressure, washed with excess hot EtOH and the filtrate reduced. Purification by column 
chromatography eluting with DCM:MeOH (8:2) afforded compound 81 as a red solid (87 mg, 
69%). 'H NMR (CDC13, 400 MHz) 8 7.54 (d, 2H, J =  7.8 Hz, ArH), 7.49 (s, 1H, CH), 7.42 (t,
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2H, J =  7.8 Hz, ArH), 7.33 (m, 3H, ArH), 7.02 (d, 1H, .7=2.1 Hz, ArH), 6.80 (d, 1H, J =  2.1 Hz, 
ArH), 6.65 (dd, 1H, J  = 2.1, 8.0 Hz, ArH), 6.58 (dd, 1H, J  = 2.1, 8.0 Hz, ArH), 3.54 (brs, 3H, 
NH), 1.65 (brs, 1H, NH); l3C NMR (CDC13, 100 MHz) 5 145.0, 144.4, 141.0, 138.0, 137.5,
137.3, 134.0, 132.0, 129.9, 129.5, 128.8, 128.2, 126.6, 119.5, 116.0, 115.9, 115.1, 114.5, 112.4,
112.0, 107.6; m/z (ESP) 285 ([M+H]+), found 285.1392, C20H 17N2 requires 285.1406; anal. 
Found C 83.29, H 5.75, N 9.38, C20H,6N2 requires C 84.47, H 5.67, N 9.85.
'ert-butyl(9-benzylidene-9/f-fluorene-2,7-diyl)6/s(azanediyl)6/s((,<!”-butoxycarbonylamino)- 
methan-l-yl-lylidene) dicarbamate (93) Compound 87 (0.15 g, 0.52 mmol) triethylamine 
(0.43 mL, 3.12 mmol), l,3-Zus(teri-butoxycarbonyl)-2-methyl-thiopseudourea (0.31 g, 1.09 
mmol), and mercury (Il)chloride (0.32 g, 1.19 mmol) were suspended in anhyd. DMF (3.2 mL) 
and stirred overnight under an atmosphere of nitrogen. The mixture was diluted with DCM (120 
mL), washed with Na2S03 and filtered through a pad of celite. The filtrate was washed with 
water (3x), brine (2x), dried over Na2S0 4 filtered and reduced in vacuo. The solid was 
recrystallised from DCM/MeOH after which purification by column chromatography eluting 
with DCM afforded compound 93 as an orange solid (0.26 g, 65%). Mp >290°C; 'H NMR 
(CDCI3, 400 MHz) 5 11.63 (s, 2H, NH), 10.32 (m, 2H, NH), 8.12 (s, 1H, CH), 7.76 (s, 2H, ArH), 
7.57 (m, 7H, ArH), 7.44 (d, 1H, / =  8.2 Hz, ArH), 7.28 (d, 1H, J =  7.9 Hz, ArH), 1.51 (m, 36H, 
CH3); ,3C NMR (CDC13, 100 MHz) 6 153.9, 153.8, 147.1, 140.6, 140.5, 137.8, 135.6, 130.5,
130.2, 126.4, 125.9, 125.3, 124.2, 123.1, 122.1, 120.4, 120.2, 120.1, 119.7, 114.8, 84.1,48.8,
39.3, 28.6; m/z (ESP) 769 ([M+H]+), found 769.3925, C42H53N6O8 requires 769.3939; anal. 
Found C 64.80, H 6.74, N 10.44, C42H52N60 8 requires C 65.61, H 6.82, N 10.93.
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l , l ’-(9-benzylidene-9//-fluorene-2,7-diyl)diguanidine (99) Compound 93 (0.21 g, 0.27 mmol) 
was suspended in a mixture of dry DCM (3 mL) and EtOH (2 mL), cooled to 0°C and saturated 
with gaseous hydrogen chloride. The mixture was sealed and stirred at room temperature for 4 
days after which the mixture was reduced in vacuo and the residue crystallised with EtOH/Et20  
yielding the title compound 99 as a grey solid (95 mg, 72%). Mp >320°C; 'H NMR (CDCI3, 400 
MHz) 5 10.15 (s, 1H, NH), 10.04 (s, 1H, NH), 9.96 (s, 1H, NH), 8.05 (s, 1H, CH), 7.97 (d, 1H, J  
= 8.2 Hz, ArH), 7.95 (d, 1H, J =  8.2 Hz, ArH), 7.92 (d, 1H, J =  8.2 Hz, ArH), 7.88 (s, 1H, ArH), 
7.69 (d, 1H, J  = 1A Hz, ArH), 7.50 (m, 5H, NH), 7.25 (m, 5H, ArH), 7.13 (s, 1H, ArH); '3C 
NMR(CDC13, 100 MHz) 5 171.4, 156.7, 156.5, 156.4, 148.5, 136.4, 134.5, 134.2, 134.1, 129.7,
129.6, 129.1, 128.5, 124.3, 121.7, 121.3, 120.4, 118.1, 79.7; m/z (ESP) 369 ([M+H]+) , found 
369.1828, C22H21N6requires 369.1813.
9-(4-methylbenzylidene)-2,7-dinitro-9//-fluorene (82) To a suspension of 2,7-dinitro-9/7- 
fluorene (1.5 g, 5.85 mmol) and KFiA^CK (0.98 g, 7.00 mmol) in anhyd. DMF (16 mL) was 
added p-tolualdehyde (0.69 mL, 6.43 mmol) and the suspension was stirred overnight at room 
temperature. The resulting mixture was filtered under reduced pressure, washed with an excess 
of DCM and reduced in vacuo furnishing 82 as a flocculent yellow solid. (1.61 g, 77%). Mp 
>240°C (decomp); 'H NMR (CDC13, 400 MHz) 5 8.73 (d, 1H, J =  1.9 Hz, ArH), 8.70 (d, 1H, J  = 
2.1Hz, ArH), 8.35 (dd, 1H, J =  1.9, 8.4 Hz, ArH), 8.30 (dd, 1H, J  = 2.1, 8.4 Hz, ArH), 8.03 (s, 
1H, CH), 7.96 (dd, 2H, J =  2.8, 8.3 Hz, ArH), 7.55 (d, 2H, J =  8.0 Hz, ArH), 7.37 (d, 2H, J=  8.0
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Hz, ArH), 2.49 (s, 3H, CH3); l3C NMR (CDC13, 100 MHz) 5 145.5, 134.5, 130.2, 129.8, 129.7, 
129.5, 123.8, 121.2, 116.1, 21.8; anal. Found C 70.70, H 3.99, N 6.97, C21H 14N2O4 requires C 
70.38, H 3.93, N 7.82.
9-(4-methylbenzylidene)-9//-fluorene-2,7-diamine (88) To a suspension of compound 82 (0.20 
g, 0.55 mmol) and zinc (1.18 g, 18.01 mmol) in EtOH (5 mL) was added calcium chloride (39.28 
mg, 0.35 mmol) in water (60 pL). The mixture was stirred for 2 hrs at reflux and filtered hot 
under reduced pressure, washed with excess hot EtOH and the filtrate reduced. Purification by 
column chromatography eluting with DCM:MeOH (8:2) afforded compound 88 as a red solid. 
(0.12 g, 73%). 'H NMR (CDC13, 400 MHz) 5 7.46 (m, 3H, ArH, CH), 7.32 (dd, 2H, J =  3.0, 8.0 
Hz, ArH), 7.23 (m, 2H, ArH), 7.03 (d, 1H, J=  1.9 Hz, ArH), 6.93 (d, 1H, J =  2.1 Hz, ArH), 6.65 
(dd, 1H, J  = 2.1, 8.0 Hz, ArH), 6.59 (dd, 1H, J =  2.1, 8.0 Hz, ArH), 3.59 (brs, 4H, NH), 2.42 (s, 
3H, CH3); i3C NMR (CDC13, 100 MHz) 8 148.3, 144.8, 138.1, 134.0, 129.6, 126.8, 119.6, 119.5,
115.9, 115.7, 114.5, 114.2, 112.4, 111.9, 107.5, 21.7, 21.5; m/z (ESP) 299 ([M+H]+), found 
299.1548, C21H 19N2 requires 299.1563; anal. Found C 84.65, H 6.26, N 8.72, C2iH,8N2 requires 
C 84.53, H 6.08, N 9.39.
tert-butyl(9-(4-methylbenzylidene)-9/y-fluorene-2,7-diyl)Z>¿s(azanediyl)¿>¿s((ÍÍT/butoxycarbon- 
ylamino)methan-l-yl-l-ylidene)dicarbamate (94) Compound 88 61mg (0.20 mmol), 
triethylamine (0.17 mL, 1.22 mmol), l,3-6A(ter/-butoxycarbonyl)-2-methyl-thiopseudourea
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(0.12 g, 0.42 mmol), and mercury (II) chloride (0.13 g, 0.46 mmol) were suspended in anhyd. 
DMF (1.22 mL) and stirred overnight under a nitrogen atmosphere. The mixture was diluted with 
DCM (100 mL), washed with Na2SC>3 and filtered through a pad of celite. The filtrate was 
washed with water, brine, dried over Na2SC>4 filtered and reduced in vacuo. After which the solid 
was recrystallised from DCM/MeOH, subsequent purification by column chromatography 
eluting with DCM afforded title compound 94 as an orange solid (97 mg, 62%). Mp >300°C; 'H 
NMR (CDC13, 400 MHz) 5 11.67 (brs, 2H, NH), 10.41 (s, 2H, NH), 7.89 (s, 1H, CH), 7.64 (d, 
2H, J  = 8.3 Hz, ArH), 7.56 (m, 5H, ArH), 7.48 (d, 2H, J  = 8.4 Hz, ArH), 7.30 (d, 1H, J =  8.0 Hz, 
ArH), 1.53 (m, 36H, CH3); 13C NMR (CDC13, 100 MHz) 5 154.7, 153.9, 147.6, 146.0, 141.2,
140.6, 137.6, 135.2, 130.2, 129.9, 128.3, 126.6, 125.9, 124.8, 123.8, 122.2, 121.4, 121.1, 119.4,
82.3, 39.6 28.6, 28.5; m/z (ESP) 805 ([M+Na]+), found 805.3887, C43H54N60 823Na requires 
805.3901; anal. Found C 65.97, H 6.95, N 10.73, C43H54N6O8 requires C 65.10, H 7.16, N 10.30.
l , l ’-(9-(4-methylbenzylidene)-9//-fluorene-2,7-diyl)diguanidine (100) Compound 94 (97 mg,
0.12 mmol) was suspended in a mixture of dry DCM (1.15 mL) and EtOH (0.76 mL), cooled to 
0°C and saturated with gaseous hydrogen chloride. The mixture was sealed and stirred at room 
temperature for 4 days after which the mixture was reduced in vacuo and the residue crystallised 
with EtOH/Et20 yielding compound 100 as an orange solid (10 mg, 16%). Mp >320°C; *H NMR 
(DMSO, 400 MHz) 8 7.97 (d, 2H J =  8.2 Hz, ArH), 7.51 (m, 14H, ArH, NH, CH), 7.26 (dd, 2H, 
J =  1.9, 8.2 Hz, ArH), 7.12 (m, 1H, ArH), 2.50 (s, 3H, CH3); l3C NMR (CDC13, 100 MHz) 5 
156.5, 148.6, 144.9, 139.1, 134.2, 129.6, 129.1, 123.8, 121.9, 121.3, 36.9, 34.7, 21.0; m/z (ESP) 
385 ([M+H]+), found 385.2141 C23H2.5N6 requires 385.2130.
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9-(4-trifluoromethylbenzylidene)-2,7-dinitro-9//-fluorene (83) To a suspension of 2,7- 
dinitro-P/7-fluorene (1.00 g, 3.90 mmol) and KF:Al2C>3 (0.65 g, 4.68 mmol) in anhyd. DMF (16 
mL) was added p-trifluorotolualdehyde (0.52 mL, 4.29 mmol), and the mixture was stirred 
overnight at room temperature. The resulting suspension was filtered under reduced pressure, 
washed with an excess of DCM and reduced in vacuo furnishing 83 as a flocculent yellow solid. 
(1.16 g, 72%). Mp >245°C (decomp); ]H NMR (CDC13, 400 MHz) 5 8.74 (d, 1H, J  = 1.9 Hz, 
ArH), 8.40 (d, 1H, J =  1.7 Hz, ArH), 8.38 (d, 1H, J =  1.9 Hz, ArH), 8.32 (dd, 1H, J =  1.9, 8.5 
Hz, ArH), 8.01 (s, 1H, CH), 7.98 (dd, 2H, J =  3.6, 8.4 Hz, ArH), 7.84 (d, 2H, J  = 8.4 Hz, ArH), 
7.75 (d, 2H, J =  8.0 Hz, ArH); 13C NMR (CDC13, 100 MHz) 5 145.1, 134.5, 130.1, 129.9, 125.1,
123.8, 121.8, 120.2, 118.0, 116.7; vmax (Neat) / cm' 1 3097 (Ar-H), 2944 (C-H), 1608 (Ar), 1505 
(Ar), 1339 (N=0), 1162 (C-F), 1120 (C-F); anal. Found C 61.03, H 2.68, N 6.74, C2iH i ,N204F3 
requires C 61.17, H 2.69, N 6.79.
9-(4-trifluoromethylbenzylidene)-9//-fluorene-2,7-diamine (89) To a suspension of 
compound 83 (0.12 g, 0.29 mmol) and zinc (0.62 g, 9.50 mmol) in EtOH (4 mL) was added 
calcium chloride (21 mg, 0.19 mmol) in water (30 pL). The mixture was stirred for 2 hrs at 
reflux and filtered hot under reduced pressure, washed with excess hot EtOH and the filtrate 
reduced. Purification by column chromatography eluting with DCM:MeOH (8:2) afforded title 
compound 89 as a red solid (82 mg, 80%). !H NMR (CDC13, 400 MHz) 5 7.53 (d, 2H, J  = 8.0 
Hz, ArH), 7.43 (s, 1H, CH), 7.36 (d, 1H, J =  8.0 Hz, ArH), 7.32 (dd, 2H, J =  2.3, 8.0 Hz, ArH),
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7.02 (d, 1H, J =  2.1 Hz, ArH), 6.64 (m, 3H, ArH), 6.45 (d, 1H, J =  1.9 Hz, ArH), 3.62 (brs, 4H, 
NH2); 13C NMR (CDC13, 100 MHz) 5 147.4, 146.4, 144.7, 141.5, 134.9, 134.3, 130.2, 129.7, 
124.4, 124.3, 119.8, 119.7, 114.7, 114.2; m/z (ESP) 353 ([M+H]+), found 353.1258, C2,H,6N2F3 
requires 353.1266; anal. Found C 71.62, H 4.65, N 7.43, C2iH i5N2F3 requires C 71.58, H 4.29, N 
7.95.
,m-butyl(9-(4-trifluoromethylbenzylidene)-9//-fluorene-2,7 diyl)Zn's(azanediyl) bis ((,ir,-but- 
oxycarbonylamino)methan-l-yl-l-ylidene)dicarbamate (95) Compound 89 (0.18 g, 0.53 
mmol), triethylamine (0.44 mL, 3.16 mmol), l,3-6A(Zeri-butoxycarbonyl)-2-methyl- 
thiopseudourea (0.32 g, 1.11 mmol), and mercury (II) chloride (0.33 g, 1.22 mmol) were 
suspended in anhyd. DMF (3.30 mL) and stirred overnight under a nitrogen atmosphere. The 
mixture was diluted with DCM (110 mL), washed with Na2S 0 3 and filtered through a pad of 
celite. The filtrate was washed with water, brine, dried over Na2S 0 4, filtered and reduced in 
vacuo. The solid was recrystallised from DCM/MeOH after which purification by column 
chromatography eluting with DCM afforded the title compound 95 as a yellow solid (0.29 g, 
65%). Mp >339°C; 'H NMR (CDC13, 400 MHz) 5 11.65 (s, 2H, NH), 10.41 (s, 2H, NH), 8.09 (s, 
1H, CH), 7.77 (d, 2H, J =  1.8 Hz, ArH), 7.58 (m, 6H, ArH), 7.49 (d, 2H, J =  8.2 Hz, ArH), 1.52 
(m, 36H, CH3); l3C NMR (CDC13, 100 MHz) 5 154.3, 153.9, 147.3, 142.1, 140.6, 137.7, 135.5,
130.2, 126.4, 125.6, 124.3, 123.4, 122.2, 122.1, 119.3, 82.2, 39.5, 28.6. m/z (ESP) 859 
([M+Na]+), found 859.3611, C43H5|F3N60 823Na requires 859.3627.
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l , l ,-(9-(4-trifluoromethylbenzylidene)-9.fir-fluorene-2,7-diyl)diguanidine (101) Compound 
95 (0.15 g, 0.18 mmol) was suspended in a mixture of dry DCM (1.66 mL) and EtOH (1.10 mL), 
cooled to 0°C and saturated with gaseous hydrogen chloride. The mixture was sealed and stirred 
at room temperature for 4 days after which the mixture was reduced in vacuo and the residue 
crystallised with Et0 H/Et20 yielding title compound 101 as a pale yellow solid (57 mg, 58%). 
Mp >320°C; 'H NMR (CDC13, 400 MHz) 6 10.17 (brs, 2H, NH), 8.10 (s, 1H, CH), 7.90 (m, 3H, 
ArH), 7.61 (d, 1H, J  = 8.2 Hz, ArH), 7.54 (brs, 8H, NH, ArH), 7.45 (d, 1H, J  = 8.2 Hz, ArH), 
7.35 (s, 1H, ArH), 7.27 (m, 2H, ArH); 13C NMR (CDC13, 100 MHz) 8 156.7, 156.5, 148.1, 140.6,
138.3, 135.9, 134.8, 134.5, 134.2, 130.6, 130.4, 129.1, 126.0, 125.2, 124.4, 121.7, 121.6, 121.4; 
m/z (ESP) 437 ([M+H]+), found 437.1702, C23H2oN6F3 requires 437.1702.
9-(4-fluorobenzylidene)-2,7-dinitro-9//-fluorene (84) To a suspension of 2,7-dinitro-9//- 
fluorene (1.01 g, 3.94 mmol) and KF:Al203 (0.65 g, 4.68 mmol) in anhyd. DMF (16 mL) was 
added p-fluorobenzaldehyde (0.45 mL, 4.29 mmol) and the mixture was stirred overnight at 
room temperature. The resulting suspension was filtered under reduced pressure, washed with an 
excess of DCM and reduced in vacuo furnishing 84 as a flocculent yellow solid (1.12 g, 79%). 
Mp >319°C (decomp); 'H NMR (CDC13, 400 MHz) 5 8.73 (s, 1H, ArH), 8.56 (s, 1H, ArH), 8.37 
(d, 1H, J  -  8.2 Hz, ArH), 8.31 (d, 1H, J =  8.2 Hz, ArH), 8.01 (s, 1H, CH), 7.97 (m, 4H, ArH), 
7.63 (m, 2H, ArH); 13C NMR (CDC13, 100 MHz) 8 164.1, 138.5, 133.4, 132.9, 131.8, 131.2,
F
V / ^ ~ no2
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123.4, 121.1, 119.2, 118.9, 116.5; vmax (Neat) / cm' 1 3106 (Ar-H), 2908 (C-H), 1600 (Ar), 1509 
(Ar), 1332 (N=0), anal; Found C 65.96, H 2.98, N, 7.70, C20H 11FN2O4 requires C 66.30, FI 3.06, 
N 7.73.
9-(4-fluorobenzylidene)-9//-fluorene-2,7-diamine (90) To a suspension of compound 84 (0.12 
g, 0.33 mmol) and zinc (0.71 g, 10.85 mmol) in EtOH (4 mL) was added calcium chloride (24 
mg, 0.21 mmol) in water (4 pL). The mixture was stirred for 2 hrs at reflux and filtered hot under 
reduced pressure, washed with excess hot EtOH and the filtrate reduced. Purification by column 
chromatography eluting with DCM:MeOH (8:2) afforded title compound 90 as a red solid (82 
mg, 82%). 'H NMR (CDCI3, 400 MHz) 5 7.60 (d, 2H, J  = 7.8 Hz, ArH), 7.55 (d, 2H, J =  7.8 Hz, 
ArH), 7.45 (s, 1H, CH), 7.34 (m, 2H, ArH), 6.63 (m, 4H, ArH), 3.59 (brs, 4H, NH2); l3C NMR 
(CDCI3, 100 MHz) 5 160.2, 147.5, 147.1, 144.6, 138.4, 134.8, 134.3, 131.1, 124.4, 123.5, 121.1,
119.2, 118.9, 114.5; vmax (Neat) / cm' 1 3482 (N-H), 3049 (Ar-H), 2919 (C-H), 1596 (Ar), 1504 
(Ar); anal. C 78.82, H 4.62, N, 8.98, C2oH,5N2F requires C 79.45, H 5.00, N 9.27.
tert-butyl(9-(4-fluorobenzylidene)-9//-fluorene-2,7-diyI)Z>i.s(azanediyl)Z>/.s((im-butoxy 
carbonylamino)methan-l-yl-l-ylidene)dicarbamate (96) Compound 90 (0.15 g, 0.49 mmol), 
triethylamine (0.41 mL, 2.94 mmol), l,3-6w(/ert-butoxycarbonyl)-2-methyl-thiopseudourea 
(0.30 g, 1.03 mmol), and mercury (II) chloride (0.31 g, 1.13 mmol) were suspended in anhyd.
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DMF (3.15 mL) and stirred overnight under a nitrogen atmosphere. The mixture was diluted with 
DCM (120 mL), washed with Na2SC>3 and filtered through a pad of celite. The filtrate was 
washed with water, brine, dried over Na2S04, filtered and reduced in vacuo. The solid was 
recrystallised from DCM/MeOH after which purification by column chromatography eluting 
with DCM afforded title compound 96 as a yellow solid (0.25 g, 65%). Mp >300°C; 'H NMR 
(CDC13, 400 MHz) 8 11.65 (s, 2H, NH), 10.45 (s, 1H, NH), 10.14 (s, 1H, NH), 8.07 (s, 1H, CH), 
7.79 (d, 1H, J =  1.7, ArH), 7.60 (m, 6H, ArH), 7.36 (dd, 1H, 1.9, 8.2 Hz, ArH), 7.18 (m, 2H,
ArH), 1.52 (m, 36H, CH3); 13C NMR (CDC13, 100 MHz) 5 161.7, 154.3, 153.8, 146.3, 140.9,
138.6, 137.3, 136.3, 136.2, 135.8, 132.6, 131.8, 131.7, 127.4, 123.9, 122.7, 120.3, 120.1, 120.0,
116.0, 115.8, 114.6, 80.0, 28.6, 28.5; anal. Found C 63.90, H 6.60, N 10.60, C42H5|N60 8F 
requires C 64.11,H 6.53, N 10.68.
l , l ’-(9-(4-fluorobenzylidene)-9//-fluorene-2,7-diyl)diguanidine (102) Compound 96 (0.19 g, 
0.25 mmol) was suspended in a mixture of dry DCM (2.0 mL) and EtOH (1.5 mL), cooled to 0 
°C and saturated with gaseous hydrogen chloride. The mixture was sealed and stirred at room 
temperature for 4 days after which the mixture was reduced in vacuo and the residue crystallised 
with EtOH/Et20 yielding title compound 102 as a yellow solid (89 mg, 72%). Mp >320°C; 'H 
NMR (CDCI3, 400 MHz) 5 8.01 (s, 1H, CH), 7.96 (d, 1H, J =  8.0 Hz, ArH), 7.95 (d, 1H, J =  8.0 
Hz, ArH), 7.86 (d, 1H, J=  1.7 Hz, ArH), 7.76 (d, 1H, J =  8.4 Hz, ArH), 7.74 (d, 1H, 8.3 Hz,
ArH), 7.55 (m, 8H, NH), 7.43 (d, 1H, J =  1.9 Hz, ArH), 7.37 (d, 1H, J  = 8.7 Hz, ArH), 7.35 (d, 
1H, J =  8.9 Hz, ArH), 7.27 (m, 2HS ArH); 13C NMR (CDC13, 100 MHz) 8 156.6, 156.3, 152.3,
140.8, 138.4, 137.4, 137.2, 136.4, 134.4, 132.0, 131.9, 129.9, 125.7, 125.3, 121.6, 121.3, 120.0,
118.0, 116.2, 116.0; m/z (ESP) 387 ([M+H]+), found 387.1733, C22H20N6F requires 387.1714.
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9-(4-chlorobenzylidene)-2,7-dinitro-9.//-fluorene (85) To a suspension of 2,7-dinitro-9//- 
fluorene (1.00 g, 3.90 mmol) and KF:Al2C>3 (0.65 g, 4.68 mmol) in anhydrous DMF (16 mL) was 
added /»-chlorobenzaldéhyde (0.60 g, 4.29 mmol), and the mixture was stirred overnight at room 
temperature. The resulting mixture was filtered under reduced pressure, washed with an excess 
of DCM and reduced in vacuo furnishing 85 as a flocculent yellow solid (1.23 g, 83%). Mp >252 
°C (decomp); !H NMR (CDC13, 400 MHz) S 8.73 (d, 1H, J =  2.1 Hz, ArH), 8.58 (d, 1H, J =  2.1 
Hz, ArH), 8.37 (dd, 1H, J =  1.9, 8.4 Hz, ArH), 8.32 (dd, 1H, J =  2.1, 8.4 Hz, ArH), 7.97 (m, 3H, 
ArH, CH), 7.55 (m, 4H, ArH); 13C NMR (CDC13, 100 MHz) Ô 148.9, 148.7, 142.3, 137.0, 134.4,
131.8, 131.0, 129.8, 126.6, 122.8, 121.9, 119.8, 118.6, 114.5; anal. Found C 63.45, H 3.01, N 
7.45, C20H 11N2O4CI requires C 63.42, H 2.93, N 7.40.
9-(4-chlorobenzylidene)-9//-fluorene-2,7-diamine (91) To a suspension of compound 85 (0.13 
g, 0.34 mmol) and zinc (0.73 g, 11.14 mmol) in EtOH (4 mL) was added calcium chloride (24 
mg, 0.22 mmol) in water (40 pL). The mixture was stirred for 2 hrs at reflux and filtered hot 
under reduced pressure, washed with excess hot EtOH and the fíltrate reduced. Purification by 
column chromatography eluting with DCM:MeOH (8:2) afforded compound 91 as a red solid 
(88 mg, 81%). 'H NMR (CDC13, 400 MHz) 5 7.60 (d, 2H, J =  8.0 Hz, ArH), 7.52 (d, 2H, J =  8.2 
Hz, ArH), 7.45 (s, 1H, CH), 7.30 (m, 4H, ArH), 6.61 (m, 2H, ArH), 3.60 (brs, 4H, NH2); 13C 
NMR(CDC13, 100 MHz) 5 148.3, 147.1, 144.1, 141.0, 134.9, 129.7, 120.1, 119.8, 114.6, 111.1.
Experimental Details 248
7Vrt-butyl(9-(4-chlorobenzylidene)-9//-fluorene-2,7-diyl)Z>i',s(azanediyl)Z>/.s((fó/7-butoxycarb- 
onyIamino)methan-l-yl-l-ylidene)dicarbamate (97) Compound 91 (0.13 g, 0.41 mmol), 
triethylamine (0.34 mL, 2.46 mmol), l,3-6ú(íer/-butoxycarbonyl)-2-methyl-thiopseudourea 
(0.25 g, 0.86 mmol), and mercury (II) chloride (0.26 g, 0.95 mmol) were suspended in anhyd. 
DMF (2.56 mL) and stirred overnight under a nitrogen atmosphere. The mixture was diluted with 
DCM, washed with Na2S0 3 and filtered through a pad of celite. The filtrate was washed with 
water, brine, dried over Na2SC>4, filtered and reduced in vacuo. The solid was recrystallised from 
DCM/MeOH after which purification by column chromatography eluting with DCM afforded 
compound 97 as a pale yellow solid (0.22 g, 67%). Mp >300°C; 'H NMR (CDCfi, 400 MHz) 5 
11.68 (s, 1H, NH), 11.64 (s, 1H, NH), 10.45 (s, 1H, NH), 10.15 (s, 1H, NH), 8.08 (s, 1H, CH), 
7.79 (d, 1H, J =  1.7 Hz, ArH), 7.58 (m, 6H, ArH), 7.47 (d, 2H, J =  8.6 Hz, ArH), 7.36 (dd, 1H, J  
= 1.9, 8.2 Hz, ArH), 1.52 (m, 36H, CH3); '3C NMR (CDC13, 100 MHz) 5 164.1, 154.4, 153.8,
140.9, 138.7, 137.2, 136.6, 136.3, 135.9, 135.1, 135.0, 134.4, 131.3, 129.9, 129.1, 127.1, 124.0,
122.8, 120.6, 120.1, 120.0, 114.6, 28.6, 28.5; vmax (Neat) / cm' 1 3305, (N-H), 2971 (Ar-H), 1718 
(C=0), 1631 (N-H), 1367 (C-H), 1149 (C-0-CH3), 740 (C-Cl); m/z (ESP) 803/805/807 
([M+H]+); anal. Found C 62.72, H 6.51, N 10.39, C42H5lClN60g requires C 62.79, H 6.40, N 
10.46.
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l , l ’-(9-(4-chlorobenzylidene)-9//-fluorene-2,7-diyl)diguanidine (103) Compound 97 (0.10 g, 
0.13 mmol) was suspended in a mixture of dry DCM (1.17 mL) and EtOH (0.78 mL), cooled to 
0°C and saturated with gaseous hydrogen chloride. The mixture was sealed and stirred at room 
temperature for 4 days after which the mixture was reduced in vacuo and the residue crystallised 
with EtOH/Et20 yielding compound 103 as a yellow solid (24 mg, 37%). Mp >300°C; 'H NMR 
(DMSO, 400 MHz) 8 7.99 (s, 1H, CH), 7.96 (d, 1H, J  = 7.8 Hz, ArH), 7.94 (d, 1H, J =  7.8 Hz, 
ArH), 7.86 (d, 1H, J  = 1.7 Hz, ArH), 7.72 (d, 2H, J  = 8.4 Hz, ArH), 7.53 (m, 10H, NH, ArH), 
7.29 -  7.25 (dd, 1H, J  = 1.9, 17.3 Hz, ArH), 7.27 (s, 1H, ArH); 13C NMR (DMSO, 100 MHz) 5
156.6, 140.8, 137.1, 136.4, 135.0, 134.8, 134.5, 131.5, 129.1, 125.9, 121.7, 121.3; m/z (ESP) 
403/405/407 ([M+H]+), found 403.1438, C22H2oN635C1 requires 403.1453.
9-(2,6-dichlorobenzylidene)-2,7-dinitro-9/7-fluorene (86) To a suspension of 2,7-dinitro-9H- 
fluorene (1.00 g, 3.90 mmol) and KF:A1203 (0.65 g, 4.68 mmol) in anhyd. DMF (16 mL) was 
added 2,6-dichlorobenzaldehyde (0.75 g, 4.29 mmol), after which the mixture was stirred 
overnight at room temperature. The resulting suspension was filtered under reduced pressure, 
washed with an excess of DCM and reduced in vacuo furnishing 86 as flocculent yellow solid 
(1.26 g, 78%). Mp 250°C (decomp); 'H NMR (CDC13, 400 MHz) 5 8.79 (d, 1H, J =  1.9 Hz, 
ArH), 8.39 (dd, 1H, .7=2.1, 8.4 Hz, ArH), 8.31 (dd, m , J  = 1.9, 8.4 Hz, ArH), 7.96 (d, 1H, J  =
8.5 Hz, ArH), 7.93 (d, 1H, J =  8.5 Hz, ArH), 7.73 (m, 2H, ArH), 7.56 (d, 1H, J  = 1.1 Hz, ArH),
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7.54 (s, 1H, CH), 7.46 (m, 1H, ArH); 13C NMR (CDC13, 100 MHz) 5 148.9, 148.7, 148.3, 144.3,
143.0, 140.8, 138.7, 136.9, 135.0, 132.8, 131.3, 129.1, 126.4, 125.2, 125.0, 121.8, 121.6, 120.1, 
117.1; anal. Found C 58.22, H 2.11, N 6.33, C20H 10N2O4CI2 requires C 58.13, H 2.44, N 6.78.
9-(2,6-dichlorobenzylidene)-9//-fluorene-2,7-diamine (92) To a suspension of compound 86 
(0.15 g, 0.36 mmol) and zinc (0.77 g, 11.79 mmol) in EtOH (5 mL) was added calcium chloride 
(26 mg, 0.23 mmol) in water (40 pL). The mixture was stirred for 2 hrs at reflux and filtered hot 
under reduced pressure, washed with excess hot EtOH and the filtrate reduced. Purification by 
column chromatography eluting with DCM:MeOH (8:2) afforded compound 92 as a red solid 
(96 mg, 75%). 'H NMR (CDC13, 400 MHz) 5 7.42 (d, 2H, J =  8.0 Hz, ArH), 7.30 (m, 3H, ArH), 
7.15 (s, 1H, CH), 7.10 (d, 1H, J =  2.1 Hz, ArH), 6.65 (dd, 1H, J =  2.1, 8.0 Hz, ArH), 6.58 (dd, 
1H, .7=2.1, 8.0 Hz, ArH), 6.06 (d, 1H, 7 = 2 .1  Hz, ArH); l3C NMR (CDC13, 100 MHz) 8 145.2,
135.6, 129.6, 128.5, 126.5, 119.7, 119.5, 119.2, 116.3, 116.2, 111.8, 108.2; anal. Found C 67.38, 
H 4.30, N 7.19, C20H 14CI2N2 requires C 68.00, H 3.99, N 7.93.
tert-butyl(9-(2,6-dichlorobenzylidene)-97r-fluorene-2,7-diyl)6«(azanediyl)6is((/crt-butoxy- 
carbonylamino)methan-l-yl-l-ylidene)dicarbamate (98) Compound 92 (0.24 g, 0.70 mmol), 
triethylamine (0.59 mL, 4.21 mmol), l,3-fe(te/7-butoxycarbonyl)-2-methylthiopseudourea (0.43 
g, 1.47 mmol), and mercury (II) chloride (0.44 g, 1.61 mmol) were suspended in anhyd. DMF
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(4.22 mL) and stirred overnight under a nitrogen atmosphere. The mixture was diluted with 
DCM (150 mL), washed with Na2SC>3 and filtered through a pad of celite. The filtrate was 
washed with water, brine, dried over Na2SC>4, filtered and reduced in vacuo. The solid was 
recrystallised from DCM/MeOH after which purification by column chromatography eluting 
with DCM afforded the compound 98 as a yellow solid (0.39 g, 67%). Mp >342°C; 'H NMR 
(CDC13, 400 MHz) 5 11.64 (s, 1H, NH), 11.53 (s, 1H, NH), 10.43 (s, 1H, NH), 10.02 (s, 1H, 
NH), 8.07 (s, 1H, ArH), 7.63 (dd, 1H, J =  1.7, 8.2 Hz, ArH), 7.56 (m, 3H, ArH), 7.45 (d, 2H, J  = 
8.2 Hz, ArH), 7.34 (s, 1H, CH), 7.28 (d, 1H, J =  8.3 Hz, ArH), 6.68 (s, 1H, ArH), 1.51 (m, 36H, 
CH3); l3C NMR (CDC13, 100 MHz) 5 164.0, 153.9, 139.7, 139.4, 138.3, 137.7, 136.6, 136.3,
135.5, 134.7, 129.7, 128.6, 124.4, 123.5, 121.1, 120.1, 120.0, 119.6, 115.4, 83.9, 79.9, 28.6, 
28.5; vmax (Neat) / cm*1 3305 (N-H), 3014 (Ar-H), 1720 (C=0), 1635 (C=N-H), 1369 (C-H), 
1151 (C-O-CH3); m/z (ESP) 837/839/841 ([M+H]+), found 839.3116, C42H5!N60 835Cl2 requires 
839.3125; anal. Found C 59.60, H 5.70, N 9.22, C42H50N6O8CI2 requires C 60.21, H 6.02, N 
10.03.
l , l ’-(9-(2,6-dichlorobenzylidene)-9iT-fluorene-2,7-diyl)diguanidine (104) Compound 98 
(0.21 g, 0.25 mmol) was suspended in a mixture of anhyd. DCM (2.36 mL) and anhyd. EtOH 
(1.60 mL), cooled to 0°C and saturated with gaseous hydrogen chloride. The mixture was sealed 
and stirred at room temperature for 4 days after which the mixture was reduced in vacuo and the 
residue crystallised with EtOH/Et20 yielding compound 104 as a yellow solid (98 mg, 70%). Mp 
>320°C; 'H NMR (CDC13, 400 MHz) 5 7.95 (d, 3H, J =  7.6 Hz, ArH), 7.80 (s, 1H, CH), 7.68 (d, 
2H, J  = 7.8 Hz, ArH), 7.58 (m, 5H, NH, ArH), 7.44 (brs, 4, NH), 7.33 (dd, 1H, J =  1.7, 8.2 Hz, 
ArH), 7.28 (dd, 1H, J =  1.9, 8.2 Hz, ArH), 6.50 (d, 1H, J =  1.9 Hz, ArH); l3C NMR (CDC13, 100 
MHz) 5 156.7, 156.4, 139.7, 138.5, 137.9, 137.5, 137.1, 135.1, 134.9, 134.0, 133.6, 131.4, 129.1,
126.7, 126.3, 123.6, 121.7, 121.5, 120.1, 118.8; vmax (Neat) / cm' 1 3635 (N-H), 1667 (C=N-H),
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111 (C-Cl); m/z (ESP) 437/439/441 ([M+H]+), found 437.1046, C22H,9N635Cl2 requires 
437.1048.
2,7-dichloro-9//-fluorene (110) 9/7-fluorene (3.00 g, 18.05 mmol) was added to N- 
chlorosuccinamide (2.29 g, 43.31 mmol) in MeCN (7.0 mL) and cone. HC1 (1.45 mL) was added 
dropwise with caution. The mixture was stirred at room temperature for 1 day after which the 
solid was filtered and dried under vacuum. Recrystallisation from MeOH gave the desired 
compound 110 as white crystals (3.40 g, 86%). 'H (CDCI3, 400 MHz) 5 7.59 (d, 2H, J  = 8.0 Hz, 
ArH), 7.63 (s, 2H, ArH), 7.48 (d, 2H, J  = 8.0 Hz, ArH), 3.82 (s, 2H, CH2), ,3C NMR (CDC13, 
100 MHz) 5 144.3, 143.9, 133.0, 128.4, 126, 36.5; vmax (Neat) / cm' 1 3298 (Ar-H), 2931 (C-H), 
1606 (Ar), 1501 (Ar), 727 (C-Cl).
4-((2,7-dichloro-9//-fluoren-9-ylidene)methyl)phenol (111) 4-hydroxybenzaldehyde (0.52 g, 
4.26 mmol) was added to a mixture of 2,7-dichlorofluorene (1.00 g, 4.26 mmol) and KF:A1203 
(0.37 g, 4.26 mmol) in anhyd. DMF (10 mL) and heated to 150 °C overnight. The mixture was 
poured into water and extracted with EtOAc (2 x 100 mL). The organic extract was washed with 
water (2 x 50 mL), brine (50 mL) and dried over MgSCL. Removal of solvent gave a yellow oil 
which was purified by column chromatography eluting with EtOAc: hexane (1:9) followed by 
recrystallisation from CHCI3: hexane (1:1) giving the compound 111 as yellow crystals (1.08 g, 
75%); Mp 106-108°C; ]H NMR (CDC13,400 MHz) 8 7.69 (d, 1 H ,J=  1.5 Hz, ArH), 7.67 (d, 1H, 
J  = 1.9 Hz, ArH), 7.62 (s, 1H, CH), 7.57 (d, 2H, J  = 8.0 Hz, ArH), 7.47 (d, 2H, J  = 8.0 Hz, 
ArH), 7.42 (ddd, 2H, J =  1.7, 8.2, 16.5 Hz, ArH), 6.94 (d, 2H, J  = 8.7 Hz, ArH); 13C NMR
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(CDC13, 100 MHz) 8 156.6, 141.6, 138.9, 138.3, 136.7, 133.9, 133.4, 132.9, 131.5, 130.2, 128.8,
128.5, 128.4, 124.6, 120.9, 116.1; vmax (Neat) / cm' 1 3270 (O-H), 3083 (Ar-H), 2940 (C-H), 1592 
(Ar), 1609 (Ar); m/z (ESP) 377/339/341 ([M-H]'), found 337.0187, C2oH n035Cl2 requires 
337.0180.
4-((2,7-dichloro-9//-fluoren-9-ylidene)methyl)-2-((diethylainino)methyl)phenol (112)
Formaldehyde (58 pL, 0.73 mmol) and diethylamine (264 pL, 2.56 mmol) were added to a 
solution of compound 111 (250 mg, 0.73 mmol) in CHCI3 (4 mL) and heated to reflux for 2 hr. 
On cooling the solvent was removed in vacuo and the residue taken up in EtOAc (50 mL). The 
organic extract was washed with water (50 mL), brine (50 mL) before drying over MgS04. 
Purification by column chromatography eluting with MeOH: DCM (1:99) giving compound 112 
as yellow crystals (127 mg, 41%). Mp 103°C; 'H NMR(CDC13,400 MHz) 5 7.76 (d, 1H, / =  1.7 
Hz, ArH), 7.70 (d, 1H, J =  1.7 Hz, ArH), 7.62 (s, 1H, CH), 7.58, (d, 2H, J =  8.0 Hz, ArH), 7.38 
(dd, 1H, J  = 1.9, 8.3 Hz, ArH), 7.29 (m, 3H, ArH), 6.91 (d, 1H, J =  8.2 Hz, ArH), 3.82 (s, 2H, 
CH2), 2.70 (q, 4H, J  = 7.2 Hz, CH2), 1.16 (t, 6H, J  = 12  Hz, CH3); 13C NMR (CDC13, 100 MHz) 
5 159.9, 141.7, 138.8, 138.5, 136.5, 133.4, 133.1, 132.8, 131.1, 130.5, 130.2, 128.5, 128.1, 126.4,
124.5, 122.8, 120.9, 120.8, 116.9, 57.2, 46.8, 11.6; vmax (Neat) / cm' 1 3554 (O-H), 3048 (Ar-H), 
2938 (C-H), 1592 (Ar), 1494 (Ar), 1253 (C-N); m/z (ESP) 424/426/428 ([M+H]+), found 
424.1238, C25H24N 0 35C12; requires 424.1235; anal. Found C 70.27, H 5.45, N 3.22, 
C25H23N0C12 requires C 70.70, H 5.46, N 3.30.
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4-((2,7-dichloro-9//-fluoren-9-ylidene)methyl)-2-(pyrrolidin-l-ylmethyl)phenol (113)
Formaldehyde (58 pL, 0.73 mmol) and pyrolidine (214 pL, 2.56 mmol) were added to a solution 
of compound 111 (0.25 g, 0.73 mmol) in CHC13 (4.0 mL) and heated to reflux overnight. On 
cooling the solvent was removed in vacuo and the residue taken up into CHCI3 (50 mL). The 
organic extract was washed with water (50 mL), brine (50 mL) and dried (Na2S04). Purification 
by column chromatography eluting with MeOH: DCM (1:99) gave the title compound 113 as 
yellow crystals (0.19 g, 62%). Mp 182-183°C; 'H NMR (CDC13,400 MHz) 5 7.77 (d, 1H, J =  1.9 
Hz, ArH), 7.70 (d, 1H, J  = 1.9 Hz, ArH), 7.62 (s, 1H, CH), 7.58 (d, 2H, J =  8.0 Hz, ArH), 7.39 
(dd, 1H, J =  1.9, 8.4 Hz, ArH), 7.29 (m, 3H, ArH), 6.93 (d, 1H, J =  8.1 Hz, ArH), 3.87 (s, 2H, 
CH2), 2.71 (bs, 4H, CH2), 1.89 (s, 4H, CH2); 13C NMR (CDC13, 100 MHz) 5 160.9, 143.1, 140.2,
139.8, 137.9, 134.7, 134.6, 134.1, 132.3, 132.0, 131.2, 129.9, 129.5, 127.8, 125.9, 124.4, 122.3,
122.2, 122.1, 118.3, 60.3, 55.3, 25.4; m/z (ESP) 422/424/426 ([M+H]+), found 422.1084, 
C25H22N35C120  requires 422.1078; anal. Found C 68.97, H 4.92, N 3.17, C25H22N0C12 requires 
C 71.09, H 5.01, N 3.32.
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4-((2,7-dichloro-9//-fiuoren-9-ylidene)methyl)-2-(piperidin-l-ylmethyl)phenol (114)
Formaldehyde (58 pL, 0.73 mmol) and piperidine (253 pL, 2.56 mmol) were added to a solution 
of compound 111 (0.25 g, 0.73 mmol) in CHCI3 (5.0 mL). The resulting suspension was heated 
to 65 °C for 6 hr before a second portion of formaldehyde (58 pL, 0.73 mmol) was added and the 
solution left stirring at 65 °C overnight. On cooling, the solvent was removed under reduced 
pressure and the residue taken up into CHCI3 (50 mL). The organic extract was washed with 
water (50 mL), brine (50 mL) and dried (Na2S 04). Removal of solvent gave a yellow solid which 
was purified by column chromatography eluting with MeOH: DCM (4:96) to give the title 
compound 114 as yellow crystals (212 mg, 67%). Mp 172°C; 'H NMR (0003,400  MHz) 5 7.75 
(d, 1H, J =  1.7 Hz, ArH), 7.70 (d, 1H, J  = 1.7 ArH), 7.62 (s, 1H, CH), 7.58 (d, 2H, J  = 8.2 Hz, 
ArH), 7.38 (dd, 1H, J =  1.9, 8.4 Hz, ArH), 7.29 (m, 3H, ArH), 6.92 (d, 1H, J =  8.4 Hz, ArH), 
3 71 (s, 2H, CH2), 2.57 (bs, 4H, CH2), 1.68 (t, 4H, J =  5.3 Hz, CH2) 1.53 (bs, 2H, CH2); l3C 
(CDCI3, 100MHz) 8 159.6, 141.7, 138.8, 138.4, 136.5, 133.3, 133.1, 132.7, 131.0, 130.5, 130.4,
128.5, 128.2, 126.5, 124.5, 122.3, 121.0, 120.9, 120.8, 116.8, 62.3, 54.3, 26.2, 24.3; m/z (ESP) 
436/438/440 ([M+H]+), found 436.1234, C26H24N 0 35C12 requires 436.1235; anal. Found C 
71.54, H 5.38, N 3.16, C26H23N0C12 requires C 71.60, H 5.31, N 3.21.
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4-( (2,7-dichloro-9.ff-fluoren-9-ylidene) methyI)-2-((4-methyIpiperazin-l-yl) methyl) phenol 
(115) Formaldehyde (115 pL, 1.46 mmol) and A-methyl-piperazine (284 pL, 2.56 mmol) were 
added to a solution of compound 111 (0.25 g, 0.73 mmol) in CHCI3 (5.0 mL) and heated to 65 °C 
overnight (16 hr).The reaction mixture was poured into water and the organic layer was washed 
with water (50 mL), brine (50 mL) and dried (Na2S04). Removal of solvent gave a yellow oil, 
which was crystallized from EtOH and filtered to give the title compound 115 as yellow crystals 
(0.21 g, 64%). Mp 129-130°C; 'H NMR (CDC13, 400 MHz) 8 7.70 (dd, 2H, J  = 1.7, 12.3 Hz, 
ArH), 7.59 (s, 1H, CH), 7.56 (d, 2H, J =  8.2 Hz, ArH), 7.37 (dd, 1H, J =  1.9, 8.2 Hz, ArH), 7.29 
(m, 3H, ArH), 6.93 (d, 1H, J=  8.4 Hz, ArH), 3.76 (s, 2H, CH2), 2.58 (brs, 8H, CH2), 2.32 (s, 3H, 
CH3); 13C NMR (CDC13, 100 MHz) 5 159.2, 141.6, 138.8, 138.4, 136.6, 133.4, 132.8, 130.8, 
130.7, 130.5, 128.6, 128.2, 126.8, 124.5, 121.8, 120.9, 120.8, 116.9, 61.5, 55.3, 53.0, 46.2; m/z 
(ESP) 451/453/455 ([M+H]+), found 451.1355, C26H25N20 35C12 requires 451.1344; anal. Found 
C 68.80, H 5.33, N 6.16, C26H24N2OCl2 requires C 69.20, H 5.36, N 6.20.
2-((teJ',f-butylamino)methyI)-4-((2,7-dichloro-9//-iluoren-9-ylidene)methyl)phenoIhydrochl- 
oride (116) Formaldehyde (87 pL, 1.10 mmol) and te/7-butylamine (269 pL, 2.56 mmol) were 
added to a solution of compound 111 (0.25 g, 0.73 mmol) in CHCI3 (5.0 mL) and heated to 
reflux overnight. On cooling, the solvent was removed under reduced pressure and the residue
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dissolved in DCM (50 mL). The organic extract was washed with water (50 mL), brine (50 mL), 
dried (Na2S04) and reduced./« vacuo yielding a yellow oil. Purification by crystallisation (EtOH) 
followed by addition of /so-propyl alcohol (20% HC1) gave the title compound 116 as a pale 
yellow solid (0.11 g, 33%). Mp 259-260°C, 'H NMR (DMSO, 400 MHz) 8 8.10 (d, 1H, J  = 1.7 
Hz, ArH), 8.01 (s, 1H, CH), 7.94 (d, 1H, J =  8.2 Hz, ArH), 7.92 (d, 1H, J =  8.3 Hz, ArH), 7.74 
(s, 1H, ArH), 7.67 (d, 1H, J=  1.9 Hz, ArH), 7.58 (dd, 1H, J =  1.7, 8.4 Hz, ArH), 7.45 (d, 2H, J  = 
8.2 Hz, ArH), 7.18 (d, 1H, J =  8.4 Hz, ArH), 4.08 (s, 2H, CH2), 1.39 (s, 9H, CH3); l3C NMR 
(DMSO, 100 MHz) 5 158.9, 143.0, 140.5, 139.6, 138.1, 135.5, 134.8, 134.3, 134.0, 133.9, 131.5,
130.1, 129.7, 129.2, 125.3, 122.6, 122.4, 122.1, 120.8, 117.1, 59.1, 42.7, 26.3; m/z (ESP) 
424/426/428 ([M+H]+), found 424.1233, C25H24N0 35Cl2 requires 424.1235; anal. Found C 
64.80, H 5.28, N 2.88, C25H24NOCl3 requires C 65.2, H 5.24, N 3.04.
4-(2,7-dichloro-fluoren-9-ylidenemethyl)-2-(4-ethyl-piperazin-l-ylmethyl)-phenol (117)
Formaldehyde (58 pL, 0.73 mmol) and 1-ethyl-piperazine (330 pL, 2.58 mmol) were added to a 
solution of compound 111 (250 mg, 0.73 mmol) in CHC13 (4 mL). The resulting suspension was 
heated to 65 °C overnight. On cooling, the solvent was removed under reduced pressure and the 
residue taken up into CHC13 (50 mL). The organic extract was washed with water (50 mL), brine 
(50 mL) and dried over Na2S 04. Removal of solvent gave a yellow solid which was purified by 
column chromatography eluting with MeOH: DCM (4:96) to give the title compound 117 as 
yellow crystals (198 mg, 58%). Mp 134°C; 'H NMR (CDC13, 400 MHz) 5 7.72 (d, 1H, J =  1.9 
Hz, ArH), 7.68 (d, 1H, / =  1.7 Hz, ArH), 7.60 (s, 1H, CH), 7.57 (d, 2H, J =  8.1 Hz, ArH), 7.39 
(dd, 1H, J =  1.9, 8.4 Hz, ArH), 7.29 (m, 3H, ArH), 6.93 (d, 1H, J =  8.4 Hz, ArH), 3.76 (s, 2H, 
CH2), 2.64 (brs, 7H, CH2), 2.46 (q, 3H, J  = 7.2 Hz, CH2), 1.10 (t, 3H, J  = 7.4 Hz, CH3); 13C 
NMR(CDC13, 100 MHz) 5 158.8, 141.3, 138.5, 138.4, 138.0, 136.2, 133.0, 132.4, 130.3, 130.1,
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128.2, 127.9, 127.5, 126.4, 125.4, 124.1, 121.5, 120.7, 120.6, 120.5, 120.4, 116.5, 61.6, 61.5,
53.0, 52.9, 52.5, 49.4, 12.3; vmax (Neat) / cm' 1 3562 (O-H), 3091 (Ar-H), 2942 (C-H), 1592 (Ar), 
1496 (Ar), (C-N) 1253; m/z (ESP) 463/465/467 ([M-H]'), found 463.1344, C27H26N20 35Cl2 
requires 463.1344; anal. Found C 69.29, H 5.69, N 5.92, requires C 69.68, H 5.63, N 6.02.
4-(2,7-dichIoro-fluoren-9-ylidenemethyl)-2-(4-isopropyl-piperazin-l-ylmethyl)-phenol (118)
Formaldehyde (30 pL, 0.37mmol) and 1-isopropyl-piperazine (190 pL, 1.32 mmol) were added 
to a solution of compound 111 (128 mg, 0.37 mmol) in CHCI3 (2.5 mL). The resulting 
suspension was heated to 65°C overnight. On cooling, the solvent was removed under reduced 
pressure and the residue taken up into CHCI3 (30 mL). The organic extract was washed with 
water (30 mL), brine (30 mL) and dried over Na2S04. Removal of solvent gave a yellow solid 
which was purified by column chromatography eluting with MeOH: DCM (4:96) to give the title 
compound 118 as yellow crystals (98 mg, 55%). Mp 135-138°C; ‘H NMR (CDCI3, 400 MHz) 8 
7.73 (d, lH ,y =  1.9 Hz, ArH), 7.70 (d, 1H, J =  1.7 Hz, ArH), 7.62 (s, 1H, CH), 7.59 (d, 2H, J  = 
8.2 Hz, ArH), 7.39 (dd, 1H, J =  1.9, 8.4 Hz, ArH), 7.29 (m, 3H, ArH), 6.93 (d, 1H, J =  8.4 Hz, 
ArH), 3.76 (s, 2H, CH2), 2.64 (brs, 8H, CH2), 1.06 (d, 6H, J  = 6.4 Hz, CH3); 13C NMR (CDC13, 
100 MHz) 8 158.9, 141.3, 138.4, 138.1, 136.3, 133.0, 132.6, 132.5, 130.4, 130.1, 128.3, 127.9,
127.6, 125.4, 124.2, 121.6, 120.7, 120.6, 120.5, 116.6, 63.7, 63.5, 53.9, 53.5, 48.8, 19.4, 17.2; 
m/z (ESP) 477/479/481 ([M-H]'), found 477.1500, C28H27N20 35C12 requires 477.1505; anal. 
Found C 69.68, H 5.82, N 5.48, C28H28N2OCl2 requires C 70.14, H 5.88, N 5.84
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4-(2,7-dichloro-fluoren-9-ylidenemethyl)-2-(4-phenethyl-piperazin-l-ylmethyl)-phenol(119)
Formaldehyde (58 pL, 0.73 mmol) and l-(2-phenylethyl) piperazine (0.4 mL, 2.06 mmol) were 
added to a solution of compound 111 (0.20 g, 0.58 mmol) in CHCI3 (3.0 mL). The resulting 
suspension was heated to 65°C overnight. On cooling, the solvent was removed in vacuo and the 
residue taken up into CHCI3 (30 mL). The organic extract was washed with water (30 mL), brine 
(30 mL) and dried (Na2S04). Removal of solvent gave a yellow solid which was purified by 
column chromatography eluting with MeOH: DCM (4:96) to give the title compound 119 as 
yellow crystals (0.17 g, 54%). Mp 185-186°C; 'H NMR (CDC13,400 MHz) 5 7.72 (d, 1H, .7=1.9 
Hz, ArH), 7.70 (d, 1H, J =  1.7 Hz, ArH), 7.62 (s, 1H, CH), 7.58 (d, 2H, J =  8 0 Hz, ArH), 7.56 
(d, 2H, J =  8.0 Hz, ArH), 7.38 (dd, 1H, J =  1.9, 8.3 Hz, ArH), 7.29 (m, 3H, ArH), 7.20 (m, 4H, 
ArH), 3.77 (s, 2H, CH2), 2.96 (d, 2H, J =  7.8 Hz, CH2), 2.81 (m, 6H, CH2), 2.64 (brt, 4H, J  = 7.0 
Hz, CH2); !3C NMR (CDC13, 100 MHz) 5 159.2, 138.9, 138.8, 138.4, 136.6, 133.4, 129.7, 129.5,
129.0, 128.8, 128.6, 128.2, 127.9, 125.7, 121.8, 121.4, 121.0, 116.9, 61.5, 60.5, 53.3, 52.9, 34.0; 
m/z (ESP) 539/541/543 ([M-H]'), found 539.1657, C33H29N20 35C12 requires 539.1672; anal. 
Found C 72.90, H 5.70, N 4.69, C33H3oN2OCl2 requires C 73.19, H 5.58, N 5.17
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4-(2,7-dichloro-fluoren-9-ylidenemethyl)-2-thiomorpholin-4-ylmethyl-phenol (120)
Formaldehyde (58 pL, 0.73 mmol) and thiomorpholine (250 pL, 2.56 mmol) were added to a 
solution of compound 111 (0.25 g, 0.73 mmol) in CHCI3 (5.0 mL). The resulting suspension was 
heated to 65°C overnight. On cooling, the solvent was removed under reduced pressure and the 
residue taken up into CHCI3 (50 mL). The organic extract was washed with water (50 mL), brine 
(50 mL) and dried (Na2S04). Removal of solvent gave a yellow solid which was purified by 
column chromatography eluting with MeOH: DCM (4:96) to give the title compound 120 as 
yellow crystals (0.18 g, 54%). Mp 147°C; 'H NMR (CDC13,400 MHz) 5 7.69 (d, 1H, J =  1.7 Hz, 
ArH), 7.68 (d, 1H, J  = 1.9 Hz, ArH), 7.61 (s, 1H, CH), 7.58 (dd, 2H, J =  1.0, 8.2 Hz, ArH), 7.39 
(dd, 1H, J  = 1.9, 8.2 Hz, ArH), 7.29 (m, 3H, ArH), 6.94 (d, 1H, ./ = 8.3 Hz, ArH), 3.76 (s, 2H, 
CH2), 2.91 (brs, 4H, CH2), 2.78 (brs, 4H, CH2); ,3C NMR (CDC13, 100 MHz) 5 159.0, 146.4,
141.6, 138.9, 138.4, 136.6, 133.6, 133.4, 132.7, 130.8, 130.7, 130.6, 128.6, 128.3, 127.0, 124.5,
121.5, 121.0, 120.9, 120.8, 117.0, 62.4, 54.9, 28.3; m/z (ESP) 454/456/458 ([M+H]+), found 
454.0799, C25H22NOS35Cl2 requires 454.0777; anal. Found C 66.89, H 4.51, N 2.58, 
C25H2,NOSCl2 requires C 66.08, H 4.66, N 3.08
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4-(2,7-dichloro-fluoren-9-ylidenemethyl)-2-(4-pyridin-2-yl-piperazin-l-ylmethyl)-phenol 
(121) Formaldehyde (60 pL, 0.73 mmol) and l-(2-pyridyl)piperazine (0.4 mL, 2.56 mmol) were 
added to a solution of compound 111 (0.25 g, 0.73 mmol) in CHCI3 (5.0 mL). The resulting 
suspension was heated to 65°C overnight (20 hr). On cooling, the solvent was removed under 
reduced pressure and the residue taken up into CHCI3 (50 mL). The organic extract was washed 
with water (50 mL), brine (50 mL) and dried (Na2S 04). Removal of solvent gave a yellow solid 
which was purified by column chromatography eluting with MeOH: DCM (4:96) to give the title 
compound 121 as yellow crystals (180mg, 48%). Mp 164°C; 'H NMR (CDCI3, 400 MHz) 5 8.20 
(dd, 1H, J =  1.7, 5.1 Hz, ArH), 7.71 (dd, 2H, J =  1.9, 5.9 Hz, ArH), 7.62 (s, 1H, CH), 7.59 (d, 
2H, J  = 8.2 Hz, ArH), 7.49 (m, 1H, ArH), 7.41 (dd, 1H, J =  1.9, 8.6 Hz, ArH), 7.30 (m, 3H, 
ArH), 6.97 (d, 1H, J =  8.2 Hz, ArH), 6.67 (m, 2H, ArH), 3.81 (s, 2H, CH2), 3.66 (brs, 4H, CH2), 
2.76 (brs, 4H, CH2); i3C NMR (CDC13, 100 MHz) 5 159.6, 159.0, 148.4, 141.6, 138.9, 138.4,
137.9, 136.6, 133.5, 133.5, 132.8, 130.8, 130.6, 128.6, 128.3, 127.0, 125.7, 124.5, 121.7, 121.0,
120.9, 120.8, 117.0, 114.2, 107.5, 61.7, 52.8, 45.5; m/z (ESP) 512/514/516 ([M+H]+), found 
512.1296, C3oH25N30 35C12 requires 512.1302; anal. Found C 69.29, H 4.96, N 7.50, 
C3oH24N3OC12 requires C 70.04, H 4.90, N 8.17
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F
2-(4-(liw-(4-fluoro-phenyl)-methyl)-piperazin-l-ylmethyl)-4-(2,7-dichloro-fluoren-9- 
ylidenemethyl)-phenol (122) Formaldehyde (23 pL, 0.29 mmol) and l-6«-(4-fluorophenyl)- 
methyl piperazine (0.29 g, 1.0 mmol) were added to a solution of compound 111 (100 mg, 0.29 
mmol) in CHCI3 (3.0 mL). The resulting suspension was heated to 65°C overnight. On cooling, 
the solvent was removed in vacuo and the residue taken up into CHCI3 (20 mL). The organic 
extract was washed with water (20 mL), brine (20 mL) and dried (Na2S04). Removal of solvent 
gave a yellow solid which was purified by column chromatography eluting with MeOH: DCM 
(4:96) to give the title compound 122 as yellow crystals (85mg, 46%). Mp 249°C; 'H NMR 
(CDCI3, 400 MHz) 6 7.69 (d, 1H, J =  1.7 Hz, ArH), 7.68 (d, 1H, J  = 1.9 Hz, ArH), 7.61 (s, 1H, 
CH), 7.59 (d, 2H, J  = 8.2 Hz, ArH), 7.32 (m, 8H, ArH), 6.98 (d, 2H, J  = 8.7 Hz, ArH), 6.96 (d, 
2H, J  = 8.7 Hz, ArH), 6.90 (d, 1H, J =  8.4 Hz, ArH), 4.28 (s, 1H, CH), 3.75 (s, 2H, CH2), 2.66 
(brs, 4H, CH2), 2.48 (brs, 4H, CH2); 13C NMR (CDC13, 100 MHz) 5 163.5, 159.1, 138.4, 138.1,
136.6, 133.4, 132.7, 130.7, 130.5, 129.6, 129.5, 128.6, 128.3, 126.8, 124.5, 121.8, 120.9, 120.8,
116.9, 115.9, 115.7, 74.5, 61.5, 53.2, 51.8; anal. Found C 70.92, H 4.74, N 4.45, C38H3oC12F2N2 
requires C 71.36, H 4.73, and N 4.38.
Experimental Details 263
2-{((2-chloro-benzyl)-methyl-amino)-methyl}-4-(2, 7-dichloro-fluoren-9-ylidenemethyl)- 
phenol (123) Formaldehyde (58 pL, 0.73 mmol) and 2-chloro-7V-methyl-benzylamine (360 pL, 
2.56 mmol) were added to a solution of compound 111 (250 mg, 0.73 mmol) in CHCI3 (5 mL). 
The resulting suspension was heated to 65°C overnight. On cooling, the solvent was removed 
under reduced pressure and the residue taken up into CHCI3 (50 mL). The organic extract was 
washed with water (50 mL), brine (50 mL) and dried over Na2S04. Removal of solvent gave a 
yellow solid which was purified by column chromatography eluting with MeOH: DCM (4:96) to 
give the title compound 123 as yellow crystals (196 mg, 53%). Mp 159°C; *H NMR (CDCl3,400 
MHz) 5 7.74 (d, 1H, J  = 1.9 Hz, ArH), 7.70 (d, 1H, J =  1.9 Hz, ArH), 7.62 (s, J.H, CH), 7.58 (d, 
2H, J=  8.1 Hz, ArH), 7.55 (d, 2H, J=  8.1 Hz, ArH), 7.41 (m, 4H, ArH), 7,29 (m, 3H, ArH), 6.94 
(d, 1H, J  = 8.4 Hz, ArH), 3.80 (s, 4H, CH2), 2.35 (s, 3H, CH3); 13C NMR (CDCI3, 100 MHz) 5
156.8, 148.7, 138.8, 133.0, 132.0, 130.8, 130.4, 130.3, 129.7, 128.6, 128.2, 127,3, 125.7, 124.5,
122.5, 121.0, 120.9, 120.8, 116.9, 61.1, 60.9, 41.7, 41.5; m/z (ESP) 512/514/516 ([M+H]+), 
found 506.0856, C29H23N035Cl3 requires 506.0845; anal. Found C 68.38, H 4.52, N 2.38, 
C29H22N0C13 requires C 68.72, H 4.37, N 2.76.
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3-((2,7-dichloro-9//-fluoren-9-ylidene)methyl)phenol (124) 3-hydroxybenzaldehyde (0.52 g, 
4.26 mmol) was added to a mixture of 2,7-dichlorofluorene 110 (1.00 g, 4.26 mmol) and 
KFiAbOs (0.37 g, 4.26 mmol) in anhyd. DMF (10 mL) and heated to 150°C overnight. The 
mixture was poured into water and extracted with EtOAc (2 x 100 mL). The organic extract was 
washed with water (2 x 50 mL), brine (50 mL) and dried (MgSCL). Removal of solvent gave a 
yellow oil which was purified by column chromatography eluting with EtOAc: hexane (1:9). 
Recrystallisation from CHCI3: hexane (1:1) gave the title compound 124 as yellow crystals (0.87 
g, 60%). 'H (CDCI3,400 MHz) 5 7.71 (d, 1H, J=  1.7 Hz, ArH), 7.63 (s, 1H, CH), 7.57 (dd, 2H, J  
= 3.4, 8.2 Hz, ArH), 7.53 (d, 1H, J =  1.7 Hz, ArH), 7.35 (m, 2H, ArH), 7.28 (dd, 1H, J =  1.9, 8.2 
Hz, ArH), 7.12 (d, 1H, J=  7 A Hz, ArH), 6.99 (bs, 1H, OH), 6.91 (dd, 1H, J =  2.3, 8.2 Hz, ArH), 
l3C NMR (CDCI3, 100 MHz) 6 156.2, 137.7, 133.5, 133.0, 130.5, 129.6, 129.1, 128.8, 125.1,
122.0, 121.1, 120.9, 116.2; vmax (Neat) / cm"1 3272 (O-H), 3083 (Ar-H), 2940 (C-H), 1509 (Ar), 
1619 (Ar); m/z (Cl) 338 ([M-H]').
5-((2,7-dichloro-9i/-fluoren-9-ylidene)methyl)-2-((diethylamino)methyl)phenol (125)
Formaldehyde (58 pL, 0.73 mmol) and diethylamine (264 pL, 2.56 mmol) were added to a 
solution o f compound 124 (0.25 g, 0.73 mmol) in CHCI3 (4.0 mL) and heated to reflux for 1 hr. 
On cooling the solvent was removed under reduced pressure and the residue taken up in EtOAc 
(50 mL). The organic extract was washed with water (50 mL), brine (50 mL) before drying
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(MgSO/i). Purification by column chromatography eluting with MeOH: DCM (1:99) gave the 
title compound 125 as yellow crystals (0.17 g, 57%). Mp 112°C; 'H NMR (CDC13i 400 MHz) 5 
7.71 (d, 1H, J  = 1.7 Hz, ArH), 7.64 (s, 1H, CH), 7.57 (m, 3H, ArH), 7.32 (dd, 1H, J =  1.7, 8.2 
Hz, ArH), 7.26 (dd, 1H, J =  1.7, 8.2, ArH), 7.06 (d, 1H, J =  8.2 Hz, ArH), 6.95 (d, 2H, J =  6.8 
Hz, ArH), 3.85 (s, 2H, CH2), 2.68 (q, 4H, J = 7.0, 14.2 Hz, CH2), 1.16 (t, 6H, J = 7.2, CH3); 13C 
NMR(CDC13, 100 MHz) 5 159.1, 141.4, 138.9, 136.9, 136.5, 135.0, 133.4, 132.9, 130.5, 128.9,
128.8, 128.5, 125.3, 123.4, 121.1, 120.9, 120.8, 119.9, 116.9, 57.3, 46.9, 11.6; m/z (ESP) 
422/424/426 ([M-H]'), found 422.1063, C25H22N 0 35C12 requires 422.1078; anal. Found C 70.49, 
H 5.44, N 3.33, C25H23N0C12 requires C 70.70, H 5.46, N 3.30.
5-((2,7-dichloro-9//-fluoren-9-ylidene)methyl)-2-(pyrrolidin-l-ylmethyl)phenol (126)
Formaldehyde (39 pL, 0.49 mmol) and pyrolidine (129 pL, 1.54 mmol) were added to a solution 
of compound 124 (0.15 mg, 0.44 mmol) in CHC13 (4.0 mL) and heated to reflux overnight. On 
cooling, the solvent was removed under reduced pressure and the residue dissolved in CHC13 (30 
mL). The organic layer was washed with water (50 mL), brine (50 mL) and dried (Na2S04). 
Purification by column chromatography MeOH: DCM (1:99) gave the title compound 126 as 
yellow needles (0.13 mg, 73%). Mp 149-150°C; 'H NMR (CDC13,400 MHz) 8 7.71 (d, 1H, J  =
1.9 Hz, ArH), 7.65 (s, 1H, CH), 7.57 (m, 3H, ArH), 7.33 (dd, 1H, J =  1.7, 8.2 Hz, ArH), 7.26 
(dd, 1H, J  = 1.9, 8.2, ArH), 7.07 (d, 1H, J =  8.2 Hz, ArH), 6.96 (d, 2H, J =  6.2 Hz, ArH), 3.91 
(s, 2H, CH2), 2.71 (s, 4H, CH2), 1.88 (s, 4H, CH2); l3C NMR (CDC13, 100 MHz) 5 158.9, 141.5,
138.9, 138.4, 136.9, 136.6, 134.9, 133.5, 133.0, 130.5, 128.9, 128.6, 125.3, 123.7, 121.1, 120.9,
120.8, 120.0, 116.8, 59.2, 53.9, 24.1; vmax (Neat) / cm '1 3585 (O-H), 3073 (Ar-H), 2938 (C-H), 
1587 (Ar), 1496 (Ar), 1270 (C-N); m/z (ESP) 422/424/426 ([M+H]+), found 422.1075, 
C25H22N 0 35C12 requires 422.1078; anal. Found C 70.84, H 5.02, N 3.28, C25H2iNOC12 requires C
71.0, H 5.01, N 3.32.
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5-((2,7-dichloro-9//-fluoren-9-ylidene)methyl)-2-(piperidin-l-ylmethyl) phenol (127)
Formaldehyde (39 pL, 0.49 mmol) and piperidine (152 pL, 1.54 mmol) were added to a solution 
of compound 124 (0.15 g, 0.44 mmol) in CHCI3 (4.0 mL) and heated to reflux overnight. On 
cooling, the solvent was removed under reduced pressure and the residue dissolved in CHC13 (30 
mL). The organic layer was washed with water (50 mL), brine (50 mL) and dried (Na2S04). 
Purification by column chromatography eluting with MeOH: DCM (1:99) followed by 
recrystallisation from CHCI3: EtOH (1:2) gave the title compound 127 as yellow crystals (0.14 g, 
72%). Mp 171-172°C; 'H NMR (CDC13i 400 MHz) 5 7.70 (d, 1H, J =  1.9 Hz, ArH), 7.64 (s, 1H, 
CH), 7.56 (m, 3H, ArH), 7.31 (dd, 1H, J =  1.7, 8.2 Hz, ArH), 7.26 (dd, 1H, J =  1.9, 8.2, ArH),
7.05 (d, 1H, J  = 8.0 Hz, ArH), 6.95 (m, 2H, ArH), 3.75 (s, 2H, CH2), 2.57 (bs, 4H, CH2), 1.67 (t, 
4H, J =  5.3 Hz, CH2), 1.52 (bs, 2H, CH2); 13C NMR (CDC13, 100 MHz) 5 158.9, 141.5, 138.9,
138.3, 136.9, 136.5, 134.8, 133.4, 132.9, 130.4, 129.1, 128.8, 128.6, 125.3, 122.8, 121.1, 120.9,
120.8, 120.0, 116.9, 62.4, 54.4, 26.3, 24.3; m/z (ESP) 436/438/440 ([M+H]+), found 436.1229, 
C26H24N 0 35C12 requires 436.1235; anal. Found C 71.44, H 5.31, N 3.17, C26H23N0C12 requires C 
71.60, H 5.31.N 3.21.
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2-((teri-butylamino)methyl)-5-((2,7-dichloro-9/y-fluoren-9-ylidene)inethyl)-phenolhydrochl- 
oride (128) Formaldehyde (23 pL, 0.29 mmol) and im-butylamine (106 pL, 1.0 mmol) were 
added to a solution of compound 124 (0.10 g, 0.29 mmol) in CHCI3 (2.0 mL) and heated to 
reflux overnight. On cooling, the solvent was removed under reduced pressure and the residue 
dissolved in DCM (50 mL). The organic extract was washed with water (50 mL), brine (50 mL) 
and dried (Na2S04). Removal of solvent gave a yellow oil which was purified by column 
chromatography MeOH: DCM (0.5:99.5) to give the title compound 128 as a yellow oil. The oil 
was treated with Ao-propyl alcohol (20% HC1), stirred and the solid filtered, washed (EtOH) and 
dried in vacuo to give the title compound 128 as a pale yellow solid (82 mg, 61%). Mp 259- 
260°C, 'HNM R(DM SO,400 MHz) S 8.78 (brs, 1H, N H ),8.14(d, 1 H ,J=  1.8 Hz, ArH), 8.07 (s, 
1H, CH), 7.94 (t, 2H, J =  8.3 Hz, ArH), 7.63 (d, 1H, J =  2.0 Hz, ArH), 7.61 (s, 1H, ArH), 7.48 
(m, 2H, ArH), 7.21 (s, 1H, ArH), 7.12 (d, 1H, J =  7.7 Hz, ArH), 4.11 (s, 2H, CH2), 1.39 (s, 9H, 
CH3); l3C NMR (DMSO, 100 MHz) 5 156.7, 141.1, 138.9, 137.9, 137.5, 136.3, 133.9, 132.8,
132.5, 131.9, 129.2, 128.7, 123.9, 122.4, 122 0, 121.6, 120.1, 119.9, 115.8, 57.2, 25.8, 25.5; m/z 
(ESP) 424/426/428 ([M+H]+), found 424.1229, C25H24N035Cl2 requires 424.1235; anal. Found C 
63.85, H 5.38, N 2.53, C25H25NOCI3 requires C 63.91, H 5.36, N 2.98.
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5.2.1 Preparation of P-hematin
Hemin (0.4176 g) was dissolved in NaOH (0.1M, 83.5 mL) and HC1 (1.0 M, 8.35 mL) 
introduced to give a red precipitate. The mixture was stirred for a few minutes and sodium 
acetate (pH 5.0) added. This was heated for 2hrs at 60°C, cooled on ice, filtered (8 pM Millipore 
nitrocellulose filter) under reduced pressure and washed with excess water until the filtrate ran 
clear. The brown crystals were dried over P2O5 for 3 days. vmax (Nujol / cm '1) 1660.3 (C=0), 
1209.6 (C-O).
5.2.2 Determination of Inhibition of Hemozoin Formation
Using an eppendorf preparation 10 pL ghosts, 780 pL NaOAc (0.5 M, pH 5.2), 10 pL HC1 (0.1 
M), 100 pL drug (in ammonium acetate), and 100 pL hemin (3 mM in 0.1 M NaOH) were 
incubated at 37°C for 72 hours, after which the samples were centrifuged for 20 minutes yielding 
a small green pellet. The supernatant was carefully extracted and the pellet washed with 1 mL 
NaHC03 solution (0.23 M, 3% SDS, pH 9.1), centrifuged for 20min and the supernatant 
removed with caution. The washing/extraction procedure was repeated twice more after which 
0.5ml NaOH (0.1 M) was introduced and the mixture left standing at room temperature for lhr. 
The green solution (0.5 mL) was transferred to a 48-well plate and the absorbance obtained. This 
procedure was repeated for all drugs in triplicate at 8 concentrations over a concentration 
gradient.
5.2.3 Determination of Inhibition of Parasite Growth
-I
In vitro antimalarial activity was measured using the [ H]-hypoxanthine incorporation assay 
with the appropriate strains of P. falciparum}52
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6.0 High-Throughput Assay
Due to the inconsistent values obtained across triplicate wells for the p-hematin inhibition assay, 
we further probed the system to ascertain the optimum conditions for P-hematin formation, as 
shown in Table 1. In addition to this, the concentration of both hemin and drug was varied in 
order to obtain the most favourable conditions for a sigmoidal IC5 0  curve. Furthermore, ghost 
erythrocytes were used in place of P-hematin to assess their viability in this test system.
Table 1. Inhibition of Hemozoin formation in vitro
Entry Drug Haemin (10 
mM) / nL
ß-Haematin / 
jiL in NHîOAc
Ghosts / pL
1 CQ + 
Amidine 
Series
1.25 2.5 0
2 CQ + 
Amidine 
Series
1.25 2.5 In DMSO 0
3 CQ 1.25 0 5
4 CQ 1.25 5 0
5 0 5.00 0-150 0
6 0 1.25 0-150 0
7 CQ 1.25 50 0
8 0 0 0-150 0
9 0 0-10 5 0
10 0 0 0 0-50
Parameters adjusted in order to obtain the optimal conditions for FP crystal growth and reproducibility of inhibition
data for the various drugs tested in triplicate.
Table 1 shows the parameters adjusted in order to improve the assay system. Firstly we 
addressed the disproportionate quantities of P-hematin present in each of the drug concentration 
wells by dissolving p-hematin in DMSO, thereby ensuring that the concentration of P-hematin
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present in each well was accurate and consistent. This assay was performed for amidines 6-18 
and CQ, all of which gave questionable results. Control wells absent of the test drugs were found 
to contain very little P-hematin. We attribute this property to the use of DMSO; presumably 
DMSO is able to solvate the iron-carboxylate bonds forming the P-hematin dimer. This then 
leads to the formation of the monomer thus the crystal seed for P-hematin formation is no longer 
present or is present but at an inadequate concentration (entry 2, Table 5).
Ghost membranes are commonly used in the inhibition of hemozoin formation assay. However 
as previously mentioned, due to the arduous method associated with the Ghost assay we were 
keen to avoid it. However, it was clear at this point that we would have to assess the use of 
ghosts and therefore we attempted to combine the two methods by using ghosts as a substitute 
for P-hematin, in a 48 well plate as oppose to eppendorfs (commonly used for Ghost method, 
Figure 4) as shown in Table 5, entry 3. However inconsistent results were obtained, shown in 
subsequent tests to be due to insufficient agitation of the plate (achieved more efficiently with 
eppendorfs) in order to obtain the hemozoin pellet (hemozoin pellet obtained in order to quantify 
the amount of hemozoin present thereby determining the potency of the drug versus hemozoin 
formation).
We then considered that the problem may be due to both a varied and/or insufficient 
concentration of P-hematin. The reaction was therefore repeated using an increased concentration 
of P-hematin as depicted in table 5, entry 4 however we did not obtain consistent and robust data. 
We then attempted to vary the concentration of P-hematin while maintaining a hemin 
concentration double that previously used (entry 5), in addition to varying the concentration P- 
hematin while maintaining a fixed concentration of hemin (entry 6). This was attempted in order 
to ascertain the optimum hemin and P-hematin concentrations respectively. These results led to 
the conclusion that maintaining a constant concentration of P-hematin 20 times that previously 
used (this concentration gave the most promising results of the previous tests) would give 
acceptable levels of p-hematin formation across the triplicate wells. However, when the drugs 
were introduced the results again were not consistent across the concentration range in order to 
obtain the required sigmoid curve for the inhibition plot (see Figure 6) and thus we embarked on 
the last three experiments as entries 8, 9 and 10 were we; observed the uninhibited growth of P-
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hematin (8), varied the concentration of hemin while keeping P-hematin concentration constant 
in order to ascertain if the concentration of hemin was the issue (9), and observed the uninhibited 
growth of ghosts to confirm that they are able to do so in this test method (10). The results of 
which led us believe that a high-throughput method with P-hematin would require further 
investigation which would be time consuming.
As one last attempt to improve this methodology we compared Eppendorf/Ghost and plate/Ghost 
methods in order to develop some form of high-throughput technique. We were keen to use 48- 
well plates as the quantification method since reading of the plate is much quicker than the 
alternative colorimetric techniques. As mentioned, ghosts are commonly used in Eppendorfs thus 
to assess the amenability of the 48-well plates we compared the two methods but found that due 
to inadequate agitation of the 48-well plate the more time consuming Eppendorf preparation 
gave the most consistent and robust results. We did however manage to increase the efficiency of 
the assay and avoid the use of colorimetric techniques by incubating the preparation in an 
Eppendorf after which centrifugation steps gave the hemozoin pellet, which was dissolved in 
NaOH and transferred to a 48-well plate for analysis.
Bibliography
CHAPTER VII
LSTM f U N I V E R S I T Y  O FLIVERPOOL
Bibliography 272
7.0 Bibliography
(1) Fauci, A. S.; Touchette, N. A.; Folkers, G. K. Emerging Infectious Diseases 2005, 7 7 ,  519-525.
(2) www.who.int/topics/malaria.
(3) Heilbron, I. Nature 1948,161, 956-960.
(4) Rosenthal, P. J. Antimalarial Chemotherapy, 1 ed.; Humana Press: Totowa, 2001, 15-24.
(5) Greenwood, B. M.; Fidock, D. A.; Kyle, D. E.; Kappe, S. H. I.; Alonso, P. L.; Collins, F. H.; Duffy, P.
E. Journal o f  Clinical Investigation 2008,118, 1266-1276.
(6) Guerin, P. J.; Olliaro, P.; Nosten, F.; Druilhe, P.; Laxminarayan, R.; Binka, F.; Kilama, W. L.; Ford, N.; 
White, N. J. Lancet Infectious Diseases 2002, 2, 564-573.
(7) Moorthy, V.; Hill, A. V. S. British Medical Bulletin 2002, 62, 59-72.
(8) Sachs, J.; Malaney, P. Nature 2002, 415, 680-685.
(9) Luzzatto, L. Blood 1979, 54, 961-976.
(10) Gelband, H.; Seiter, A. American Journal o f  Tropical Medicine and Hygiene 2007, 7 7 ,  219-221.
(11) Gissot, M.; Ting, L. M.; Daly, T. M.; Bergman, L. W.; Sinnis, P.; Kim, K. Journal o f  Biological 
Chemistry 2008, 283, 17030-17038.
(12) www.emro.who.int/..7MalariaLifeCycle-l.gif.
(13) Baird, J. K.; Rieckmann, K. H. Trends in Parasitology 2003,19, 115-120.
(14) www.cdc.gov/malaria/biology.
(15) Gardner, M. J.; Hall, N.; Fung, E.; White, O.; Berriman, M.; Hyman, R. W.; Carlton, J. M.; Pain, A.; 
Nelson, K. E.; Bowman, S.; Paulsen, I. T.; James, K.; Eisen, J. A.; Rutherford, K.; Salzberg, S. L.; 
Craig, A.; Kyes, S.; Chan, M. S.; Nene, V.; Shallom, S. J.; Suh, B.; Peterson, J.; Angiuoli, S.; Pertea, 
M.; Allen, J.; Selengut, J.; Haft, D.; Mather, M. W.; Vaidya, A. B.; Martin, D. M. A.; Fairlamb, A. H.; 
Fraunholz, M. J.; Roos, D. S.; Ralph, S. A.; McFadden, G. I.; Cummings, L. M.; Subramanian, G. M.; 
Mungall, C.; Venter, J. C.; Carucci, D. J.; Hoffman, S. L.; Newbold, C.; Davis, R. W.; Fraser, C. M.; 
Barrell, B. Nature 2002, 419, 498-511.
(16) Gardner, M. J.; Tettelin, H.; Carucci, D. J.; Cummings, L. M.; Aravind, L.; Koonin, E. V.; Shallom, S.; 
Mason, T.; Yu, K.; Fujii, C.; Pederson, J.; Shen, K.; Jing, J. P.; Aston, C.; Lai, Z. W.; Schwartz, D. C ; 
Pertea, M.; Salzberg, S.; Zhou, L. X.; Sutton, G. G.; Clayton, R.; White, O.; Smith, H. O.; Fraser, C. M.; 
Adams, M. D.; Venter, J. C.; Hoffman, S. L. Science 1998, 282, 1126-1132.
(17) Bowman, S.; Lawson, D.; Basham, D.; Brown, D.; Chillingworth, T.; Churcher, C. M.; Craig, A.; 
Davies, R. M.; Devlin, K.; Feltwell, T.; Gentles, S.; Gwilliam, R.; Hamlin, N.; Harris, D.; Holroyd, S.; 
Hornsby, T.; Horrocks, P.; Jagels, K.; Jassal, B.; Kyes, S.; McLean, J.; Moule, S.; Mungall, K.; Murphy,
L. ; Oliver, K.; Quail, M. A.; Rajandream, M. A.; Rutter, S.; Skelton, J.; Squares, R.; Squares, S.; 
Sulston, J. E.; Whitehead, S.; Woodward, J. R.; Newbold, C.; Barrell, B. G. Nature 1999, 400, 532-538.
(18) Hall, N.; Pain, A.; Berriman, M.; Churcher, C.; Harris, B.; Harris, D.; Mungall, K.; Bowman, S.; Atkin, 
R.; Baker, S.; Barron, A.; Brooks, K.; Buckee, C. O.; Burrows, C.; Cherevach, I.; Chillingworth, C.; 
Chillingworth, T.; Christodoulou, Z.; Clark, L.; Clark, R.; Corton, C.; Cronin, A.; Davies, R.; Davis, P.; 
Dear, P.; Dearden, F.; Doggett, J.; Feltwell, T.; Goble, A.; Goodhead, L; Gwilliam, R.; Hamlin, N.; 
Hance, Z.; Harper, D.; Hauser, H.; Hornsby, T.; Holroyd, S.; Horrocks, P.; Humphray, S.; Jagels, K.; 
James, K. D.; Johnson, D.; Kerhomou, A.; Knights, A.; Konfortov, B.; Kyes, S.; Larke, N.; Lawson, D.; 
Lennard, N.; Line, A.; Maddison, M.; McLean, J.; Mooney, P.; Moule, S.; Murphy, L.; Oliver, K.; 
Ormond, D.; Price, C.; Quail, M. A.; Rabbinowitsch, E.; Rajandream, M. A.; Rutter, S.; Rutherford, K.
M. ; Sanders, M.; Simmonds, M.; Seeger, K.; Sharp, S.; Smith, R.; Squares, R.; Squares, S.; Stevens, K.; 
Taylor, K.; Tivey, A.; Unwin, L.; Whitehead, S.; Woodward, J.; Sulston, J. E.; Craig, A.; Newbold, C.; 
Barrell, B. G. Nature 2002, 419, 527-531.
(19) Gardner, M. J.; Shallom, S. J.; Carlton, J. M.; Salzberg, S. L.; Nene, V.; Shoaibi, A.; Ciecko, A.; Lynn, 
J.; Rizzo, M.; Weaver, B.; Jarrahi, B.; Brenner, M.; Parvizi, B.; Talion, L.; Moazzez, A.; Granger, D.; 
Fujii, C.; Hansen, C.; Pederson, J.; Feldblyum, T.; Peterson, J.; Suh, B.; Angiuoli, S.; Pertea, M.; Allen, 
J.; Selengut, J.; White, O.; Cummings, L. M.; Smith, H. O.; Adams, M. D.; Venter, J. C.; Carucci, D. J.; 
Hoffman, S. L.; Fraser, C. M. Nature 2002, 419, 531-534.
(20) Hyman, R. W.; Fung, E.; Conway, A.; Kurdi, O.; Mao, J.; Miranda, M.; Nakao, B.; Rowley, D.; 
Tamaki, T.; Wang, F.; Davis, R. W. Nature 2002, 419, 534-537.
(21) Bishop, L. P. D.; Maggs, J. L.; O'Neill, P. M.; Park, B. K. Journal o f  Pharmacology and Experimental 
Therapeutics 1999, 289, 511-520.
(22) Wu, Y. L.; Li, Y. Medicinal Chemistry Research 1995, 5, 569-586.
(23) Brockman, A.; Price, R. N.; van Vugt, M.; Heppner, D. G.; Walsh, D.; Sookto, P.; Wimonwattrawatee, 
T.; Looareesuwan, S.; White, N. J.; Nosten, F. Transactions o f  the Royal Society o f  Tropical Medicine 
and Hygiene 2000, 94, 537-544.
Bibliography 273
(24) WHO/CDS/RBM/2001.33, R. N. World Health Organization, 2001, Geneva.
(25) Crespo, M. D.; Avery, T. D.; Hanssen, E.; Fox, E.; Robinson, T. V.; Valente, P.; Taylor, D. K.; Tilley, 
L. Antimicrobial Agents and Chemotherapy 2008, 52, 98-109.
(26) Tonmunphean, S.; Parasuk, V.; Kokpol, S. Bioorganic and Medicinal Chemistry 2006,14, 2082-2088.
(27) Taylor, D. K.; Avery, T. D.; Greatrex, B. W.; Tiekink, E. R. T.; Macreadie, I. G.; Macreadie, P. I.; 
Humphries, A. D.; Kalkanidis, M.; Fox, E. N.; Klonis, N.; Tilley, L. Journal o f  Medicinal Chemistry 
2004,47 ,  1833-1839.
(28) Drew, M. G. B.; Metcalfe, J.; Ismail, F. M. D. Journal o f  Molecular Structure-Theochem 2005, 756, 87- 
95.
(29) Drew, M. G. B.; Metcalfe, J.; Dascombe, M. J.; Ismail, F. M. D. Journal o f  Medicinal Chemistry 2006, 
49, 6065-6073.
(30) Meshnick, S. R. International Journal fo r  Parasitology 2002, 32, 1655-1660.
(31) Kannan, R.; Sahal, D.; Chauhan, V. S. Chemistry and Biology 2002, 9, 321-332.
(32) Robert, A.; Dechy-Cabaret, O.; Cazelles, J.; Meunier, B. Accounts o f  Chemical Research 2002, 35, 167- 
174.
(33) Taranto, A. G.; Cameiro, J. W. D.; de Oliveira, F. G.; de Araujo, M. T.; Correa, C. R. Journal o f  
Molecular Structure-Theochem 2002, 580, 207-215.
(34) Taranto, A. G.; Cameiro, J. W. D.; de Araujo, M. T. Bioorganic and Medicinal Chemistry 2006, 14, 
1546-1557.
(35) Arantes, C.; de Araujo, M. T.; Taranto, A. G.; Cameiro, J. W. D. International Journal o f Quantum 
Chemistry 2005, 103, 749-762.
(36) Peters, W.; Zelin, L.; Robinson, B. L.; Warhurst, D. C. Annals o f  Tropical Medicine and Parasitology 
1986, 80, 483-489.
(37) Wittner, M.; Lederman, J.; Tanowitz, H. B.; Rosenbaum, G. S.; Weiss, L. M. American Journal o f  
Tropical Medicine and Hygiene 1996, 55, 219-222.
(38) Paitayatat, S.; Tarnchompoo, B.; Thebtaranonth, Y.; Yuthavong, Y. Journal o f Medicinal Chemistry 
1997, 40, 633-638.
(39) Brossi, A.; Venugopalan, B.; Gerpe, L. D.; Yeh, H. J. C.; Flippenanderson, J. L.; Buchs, P.; Luo, X. D.; 
Milhous, W.; Peters, W. Journal o f  Medicinal Chemistry 1988, 31, 645-650.
(40) Cazelles, J.; Robert, A.; Meunier, B. Journal o f  Organic Chemistry 2002, 67, 609-619.
(41) Bhisutthibhan, J.; Pan, X. Q.; Hossler, P. A.; Walker, D. J.; Yowell, C. A.; Carlton, J.; Dame, J. B.; 
Meshnick, S. R. Journal o f  Biological Chemistry 1998, 273, 16192-16198.
(42) Eckstein-Ludwig, U.; Webb, R. J.; van Goethem, I. D. A.; East, J. M.; Lee, A. G. Nature 2003, 424, 
957-961.
(43) Bez, G.; Kalita, B.; Sarmah, P.; Barua, N. C.; Dutta, D. K. Current Organic Chemistry 2003, 7, 1231- 
1255.
(44) Vennerstrom, J. L.; Arbe-Bames, S.; Brun, R.; Charman, S. A.; Chiu, F. C. K.; Chollet, J.; Dong, Y. X.; 
Dom, A.; Hunziker, D.; Matile, H.; McIntosh, K.; Padmanilayam, M.; Tomas, J. S.; Scheurer, C.; 
Scomeaux, B.; Tang, Y. Q.; Urwyler, H.; Wittlin, S.; Charman, W. N. Nature 2004, 430, 900-904.
(45) Perry, C. S.; Charman, S. A.; Prankerd, R. J.; Chiu, F. C.; Dong, Y. X.; Vennerstrom, J. L.; Charman, 
W. N. Journal o f  Pharmaceutical Sciences 2006, 95, 737-747.
(46) Yang, Z.-s.; Li, Y. YaoXueXueBao  2005, 40, 1057-1063.
(47) Borstnik, K.; Paik, I.-H.; Posner, G. H. Mini Reviews in Medicinal Chemistry 2002, 2, 573-583.
(48) Amewu, R.; Stachulski, A. V.; Ward, S. A.; Berry, N. G.; Bray, P. G.; Davies, J.; Labat, G.; Vivas, L.;
O'Neill, P. M. Organic and Biomolecular Chemistry 2006, 4, 4431-4436.
(49) Amewu, R.; Stachulski, A. V.; Ward, S. A.; Berry, N. G.; Bray, P. G.; Davies, J.; Labat, G.; Vivas, L.; 
O'Neill, P. M. Organic and Biomolecular Chemistry 2007, 5, 708-708.
(50) Dechy-Cabaret, O.; Benoit-Vical, F.; Robert, A.; Meunier, B. ChemBioChem 2000,1, 281-283.
(51) Strebhardt, K.; Ullrich, A. Nature Reviews Cancer 2008, 8 ,473-480.
(52) Bray, P. G.; Mungthin, M.; Ridley, R. G.; Ward, S. A. Molecular Pharmacology 1998, 54, 170-179.
(53) Bray, P. G.; Hawley, S. R.; Mungthin, M.; Ward, S. A. Molecular Pharmacology 1996, 50, 1559-1566.
(54) Ciak, J.; Hahn, F. Science 1966,151, 347-349.
(55) Sullivan, D. J.; Matile, H.; Ridley, R. G.; Goldberg, D. E. Journal o f  Biological Chemistry 1998, 273, 
31103-31107.
(56) Mungthin, M.; Bray, P. G.; Ridley, R. G.; Ward, S. A. Antimicrobial Agents and Chemotherapy 1998, 
42, 2973-2977.
(57) Dom, A.; Vippagunta, S. R.; Matile, H.; Jaquet, C.; Vennerstrom, J. L.; Ridley, R. G. Biochemical 
Pharmacology 1998, 55, 727-736.
Klonis, N.; Tan, O.; Jackson, K.; Goldberg, D.; Klemba, M.; Tilley, L. Biochemical Journal 2007, 407, 
343-354.
(58)
Bibliography 274
(59) Bray, P. G.; Janneh, O.; Raynes, K. J.; Mungthin, M.; Ginsburg, H.; Ward, S. A. Journal o f  Cell 
Biology 1999,145, 363-376.
(60) Vippagunta, S. R.; Dorn, A.; Matile, H.; Bhattacharjee, A. K.; Karle, J. M.; Ellis, W. Y.; Ridley, R. G.; 
Vennerstrom, J. L. Journal o f  Medicinal Chemistry 1999, 42, 4630-4639.
(61) Bray, P. G.; Hawley, S. R.; Ward, S. A. Molecular Pharmacology 1996, 50, 1551-1558.
(62) Churchill, F. C.; Patchen, L. C.; Campbell, C. C.; Schwartz, I. K.; Phuc, N. D.; Dickinson, C. M. Life 
Sciences 1985, 36, 53-62.
(63) O'Neill, P. M.; Mukhtar, A.; Stocks, P. A.; Randle, L. E.; Hindley, S.; Ward, S. A.; Storr, R. C ; 
Bickley, J. F.; O'Neil, I. A.; Maggs, J. L.; Hughes, R. H.; Winstanley, P. A.; Bray, P. G.; Park, B. K. 
Journal o f  Medicinal Chemistry 2003, 46, 4933-4945.
(64) White, N. J. British Medical Journal 1994, 308, 286-287.
(65) Fitch, C. D.; Chan, R. L.; Chevli, R. Antimicrobial Agents and Chemotherapy 1979,15, 258-262.
(66) Katsenos, S.; Psathakis, K.; Nikolopoulou, M. L; Constantopoulos, S. H. Pharmacotherapy 2007, 27, 
1767-1771.
(67) Alkadi, H. O. Chemotherapy 2007, 53, 385-391.
(68) Greenwood, D. Journal o f Antimicrobial Chemotherapy 1995, 36, 857-872.
(69) Bryson, H. M.; Goa, K. L. Drugs 1992, 43, 236-258.
(70) Baudon, D.; Bernard, J.; Mouliatpelat, J. P.; Martet, G.; Sarrouy, J.; Touze, J. E.; Spiegel, A.; Lantrade, 
P.; Picq, J. J. Annales De La Société Belge De Medecine Tropicale 1992, 72, 263-270.
(71) Bernard, J.; Sarrouy, J.; Dupasquier, I.; Lesbordes, J. L.; Gimenez, M.; Geffray, L.; Becker, J. M.; 
Molinas, J. M.; Jourdan, G. Médecine tropicale (Mars) 1990, 50, 167-171.
(72) White, N. J. Lancet Infectious Diseases 2007, 7, 549-558.
(73) Bindschedler, M.; Lefevre, G.; Degan, P.; Sioufi, A. American Journal o f  Tropical Medicine and 
Hygiene 2002, 66, 293-298.
(74) Reed, M. B.; Saliba, K. J.; Caruana, S. R.; Kirk, K.; Cowman, A. F. Nature 2000, 403, 906-909.
(75) Skelton-Stroud, P.; Mull, R. Médecine tropicale (Mars) 1998, 58, 77-81.
(76) Ashley, E. A.; Stepniewska, K.; Lindegardh, N.; Annerberg, A.; Kham, A.; Brockman, A.; 
Singhasivanon, P.; White, N. J.; Nosten, F. Tropical Medicine and International Health 2007, 12, 195- 
200.
(77) Ezzet, F.; van Vugt, M.; Nosten, F.; Looareesuwan, S.; White, N. J. Antimicrobial Agents and 
Chemotherapy 2000, 44, 697-704.
(78) Fanello, C. I.; Karema, C.; van Doren, W.; van Overmeir, C.; Ngamije, D.; D'Alessandro, U. 
Transactions o f  the Royal Society o f  Tropical Medicine and Hygiene 2007, ¡01, 344-350.
(79) Mulenga, M.; Van Geertruyden, J. P.; Mwananyanda, L.; Chalwe, V.; Moerman, F.; Chilengi, R.; Van 
Overmeir, C.; Dujardin, J. C.; D'Alessandro, U. Malaria Journal 2006, 5.
(80) Misson, J.; Clark, W.; Kendall, M. J. Journal o f Clinical Pharmacy and Therapeutics 1997, 22, 109- 
117.
(81) van Heeswijk, R. P. G.; Veldkamp, A.; Mulder, J. W.; Meenhorst, P. L.; Lange, J. M. A.; Beijnen, J. H.; 
Hoetelmans, R. M. W. Antiviral Therapy 2001, 6, 201-229.
(82) Redmond, A. M.; Skinner-Adams, T.; Andrews, K. T.; Gardiner, D. L.; Ray, J.; Kelly, M.; McCarthy, J. 
S. Aids 2007, 21, 763-765.
(83) Goldberg, D. E.; Slater, A. F. G. Parasitology Today 1992, 8, 280-283.
(84) Gluzman, I. Y.; Francis, S. E.; Oksman, A.; Smith, C. E.; Duffin, K. L.; Goldberg, D. E. Journal o f  
Clinical Investigation 1994, 93, 1602-1608.
(85) Coombs, G. H.; Goldberg, D. E.; Klemba, M.; Berry, C ; Kay, J.; Mottram, J. C. Trends in Parasitology 
2001, 17, 532-537.
(86) Goldberg, D. E.; Slater, A. F. G.; Beavis, R.; Chait, B.; Cerami, A.; Henderson, G. B. Journal o f  
Experimental Medicine 1991,173, 961-969.
(87) Shenai, B. R.; Sijwali, P. S.; Singh, A.; Rosenthal, P. J. Journal o f Biological Chemistry 2000, 275, 
29000-29010.
(88) Sijwali, P. S.; Shenai, B. R.; Gut, J.; Singh, A.; Rosenthal, P. J. Biochemical Journal 2001, 360, 481 - 
489.
(89) Siiwali, P. S.; Rosenthal, P. J. Proceedings o f the National Academy o f  Sciences o f  the United States o f  
America 2004,101, 4384-4389.
(90) Liu, M.; Wilairat, P.; Go, M. L. Journal o f  Medicinal Chemistry 2001, 44, 4443-4452.
(91) Dominguez, J. N.; Lopez, S.; Charris, J.; Iarruso, L.; Lobo, G.; Semenov, A.; Olson, J. E.; Rosenthal, P. 
J. Journal o f  Medicinal Chemistry 1997, 40, 2726-2732.
(92) Nzila, A. Journal o f  Antimicrobial Chemotherapy 2006, 57, 1043-1054.
(93) Ridley, R. G. Nature 2002, 415, 686-693.
Bibliography 275
(94) A-Elbasit, I. E.; Elbashir, M. I.; Khalil, I. F.; Alifrangis, M.; Giha, H. A. Tropical Medicine and 
International Health 2006, 11, 604-612.
(95) Dahl, E. L.; Rosenthal, P. J. Trends in Parasitology 2008, 24, 279-284.
(96) Dahl, E. L.; Shock, J. L.; Shenai, B. R.; Gut, J.; DeRisi, J. L.; Rosenthal, P. J. Antimicrobial Agents and 
Chemotherapy 2006, 50, 3124-3131.
(97) Wiesner, J.; Reichenberg, A.; Heinrich, S.; Schlitzer, M.; Jomaa, H. Current Pharmaceutical Design 
2008 ,14, 855-871.
(98) Lalloo, D. G.; Hill, D. R. British Medical Journal 2008, 336, 1362-1366.
(99) Senn, N.; D'Acremont, V.; Landry, P.; Genton, B. American Journal o f  Tropical Medicine and Hygiene
2007, 77, 1010-1014.
(100) Gutteridge, W. E. Journal o f  Protozoology 1991, 38, S141 -S143.
(101) Haile, L. G.; Flaherty, J. F. Annals o f  Pharmacotherapy 1993, 27, 1488-1494.
(102) Hudson, A. T.; Dickins, M.; Ginger, C. D.; Gutteridge, W. E.; Holdich, T.; Hutchinson, D. B. A.; 
Pudney, M.; Randall, A. W.; Latter, V. S. Drugs Under Experimental and Clinical Research 1991, 17, 
427-435.
(103) Cushion, M. T.; Collins, M.; Hazra, B.; Kaneshiro, E. S. Antimicrobial Agents and Chemotherapy 2000, 
44, 713-719.
(104) Looareesuwan, S.; Chulay, J. D.; Canfield, C. J.; Hutchinson, D. B. A. American Journal o f Tropical 
Medicine and Hygiene 1999, 60, 533-541.
(105) van Genderen, P. J. J.; Koene, H. R. A.; Spong, K.; Overbosch, D. Journal o f  Travel Medicine 2007,14, 
92-95.
(106) Kumar, G.; Parasuraman, P.; Sharma, S. K.; Banerjee, T.; Karmodiya, K.; Surolia, N.; Surolia, A. 
Journal o f  Medicinal Chemistry 2007, 50, 2665-2675.
(107) Lu, J. Z. Q.; Lee, P. J.; Waters, N. C.; Prigge, S. T. Combinatorial Chemistry and High Throughput 
Screening 2005, 8, 15-26.
(108) Surolia, A.; Ramya, T. N. C.; Ramya, V.; Surolia, N. Biochemical Journal 2004, 383, 401-412.
(109) Goodman, C. D.; Su, V.; McFadden, G. I. Molecular and Biochemical Parasitology 2007, 152, 181- 
191.
(110) Patel, A. P.; Staines, H. M.; Krishna, S. Travel Medicine and Infectious Disease 2008, 6, 58-66.
(111) Ramya, T. N. C.; Surolia, N.; Surolia, A. Current Science 2002, 83, 818-825.
(112) Kirk, K.; Saliba, K. J. Current Drug Targets 2007, 8, 75-88.
(113) Meza-Avina, M. E.; Wei, L.; Buhendwa, M. G.; Poduch, E.; Bello, A. M.; Pai, E. F.; Kotra, L. P. Mini- 
Reviews in Medicinal Chemistry 2008, 8, 239-247.
(114) Woynarowski, J. M.; Trevino, A. V.; Rodriguez, K. A.; Hardies, S. C.; Benham, C. J. Journal o f  
Biological Chemistry 2001, 276, 40555-40566.
(115) Woynarowski, J. M.; Krugliak, M.; Ginsburg, H. Molecular and Biochemical Parasitology 2007, 154, 
70-81.
(116) Lau, H.; Ferian, J. T.; Brophy, V. H.; Rosowsky, A.; Sibley, C. H. Antimicrobial Agents and 
Chemotherapy 2001, 45, 187-195.
(117) Nzila, A. Drug Discovery Today 2006, I I ,  939-944.
(118) Massimine, K. M.; McIntosh, M. T.; Doan, L. T.; Atreya, C. E.; Gromer, S.; Sirawarapom, W.; Elliott, 
D. A.; Joiner, K. A.; Schirmer, R. H.; Anderson, K. S. Antimicrobial Agents and Chemotherapy 2006, 
50, 3132-3141.
(119) Guan, J.; Zhang, Q.; O'Neil, M.; Obaldia, N.; Ager, A.; Gerena, L.; Lin, A. J. Antimicrobial Agents and 
Chemotherapy 2005, 49, 4928-4933.
(120) Chemaly, S. M.; Chen, C. T.; van Zyl, R. L. Journal o f  Inorganic Biochemistry 2007,101, 764-773.
(121) Prudhomme, J.; McDaniel, E.; Ponts, N.; Bertani, S.; Fenical, W.; Jensen, P.; Le Roch, K. PLoS ONE
2008, 3, e2335.
(122) Benoit-Vical, F.; Salery, M.; Soh, P. N.; Ahond, A.; Poupat, C. Planta Medica 2008, 74, 438-444.
(123) Frederich, M.; Tits, M.; Angenot, L. Transactions o f  the Royal Society o f  Tropical Medicine and 
Hygiene 2008,102, 11-19.
(124) Isaka, M.; Boonkhao, B.; Rachtawee, P.; Auncharoen, P. Journal o f  Natural Products 2007, 70, 656- 
658.
(125) Udeinya, I. J.; Mbah, A. U.; Chijioke, C. P.; Shu, E. N. Transactions o f  the Royal Society o f Tropical 
Medicine and Hygiene 2004, 98, 435-437.
(126) Gelhaus, C.; Jacobs, T.; Andra, J.; Leippe, M. Antimicrobial Agents and Chemotherapy 2008, 52, 1713- 
1720.
(127) Barthel, D.; Schlitzer, M.; Pradel, G. Antimicrobial Agents and Chemotherapy 2008, 52, 774-777.
(128) Dahl, E. L.; Rosenthal, P. J. Antimicrobial Agents and Chemotherapy 2007, 51, 3485-3490.
Bibliography 276
(129) Parikh, S.; Gut, J.; Istvan, E.; Goldberg, D. E.; Havlir, D. V.; Rosenthal, P. J. Antimicrobial Agents and 
Chemotherapy 2005, 49, 2983-2985.
(130) Skinner-Adams, T. S.; McCarthy, J. S.; Gardiner, D. L.; Hilton, P. M.; Andrews, K. T. Journal o f  
Infectious Diseases 2004,190, 1998-2000.
(131) Hershko, C.; Peto, T. E. A. Journal o f  Experimental Medicine 1988,168, 375-387.
(132) Raventossuarez, C.; Pollack, S.; Nagel, R. L. American Journal o f Tropical Medicine and Hygiene 
1982, 31, 919-922.
(133) Yinnon, A. M.; Theanacho, E. N.; Grady, R. W.; Spira, D. T.; Hershko, C. Blood 1989, 74, 2166-2171.
(134) Dehkordi, L. S.; Liu, Z. D.; Hider, R. C. European Journal o f  Medicinal Chemistry 2008, 43, 1035- 
1047.
(135) Nathoo, S.; Serghides, L.; Kain, K. C. Lancet 2003, 362, 1039-1041.
(136) Corbett, E. L.; Steketee, R. W.; ter Kuile, F. O.; Latif, A. S.; Kamali, A.; Hayes, R. J. Lancet 2002, 359, 
2177-2187.
(137) He, Z.; Qin, L.; Chen, L.; Peng, N.; You, J.; Chen, X. Antimicrobial Agents and Chemotherapy 2008, 
52, 2653-2656.
(138) Skinner-Adams, T. S.; Andrews, K. T.; Melville, L.; McCarthy, J.; Gardiner, D. L. Antimicrobial 
Agents and Chemotherapy 2007, 51, 759-762.
(139) Andrews, K. T.; Fairlie, D. P.; Madala, P. K.; Ray, J.; Wyatt, D. M.; Hilton, P. M.; Melville, L. A.; 
Beattie, L.; Gardiner, D. L.; Reid, R. C.; Stoermer, M. J.; Skinner-Adams, T.; Berry, C.; McCarthy, J. 
S.Antimicrobial Agents and Chemotherapy 2006, 50, 639-648.
(140) Savarino, A.; Cauda, R.; Cassone, A. Journal o f  Infectious Diseases 2005,191, 1381-1382.
(141) Sritangratanakul, S.; Nuchprayoon, S.; Nuchprayoon, I. Journal o f  the Medical Association o f Thailand 
2004,8 7  Suppl 2, S309-317.
(142) Sherman, I. W. Microbiological Reviews 1979, 43, 453-495.
(143) Ancelin, M. L.; Vial, H. J. Biochimica Et Biophysica Acta 1989,1001, 82-89.
(144) Choubey, V.; Maity, P.; Guha, M.; Kumar, S.; Srivastava, K.; Puri, S. K.; Bandyopadhyay, U. 
Antimicrobial Agents and Chemotherapy 2007, 51, 696-706.
(145) Vial, H. J.; Thuet, M. J.; Broussal, J. L.; Philippot, J. R. Journal o f  Parasitology 1982, 68, 379-391.
(146) Pessi, G.; Choi, J. Y.; Reynolds, J. M.; Voelker, D. R.; Ben Mamoun, C. Journal o f  Biological 
Chemistry 2005, 280, 12461-12466.
(147) Bahamontes-Rosa, N.; Robin, A.; Ambrosio, A. R.; Messias-Reason, I.; Beitz, E.; Flitsch, S. L.; Kun, J.
F. J. Parasitology International 2008, 57, 132-137.
(148) Ancelin, M. L.; Vial, H. J. Antimicrobial Agents and Chemotherapy 1986, 29, 814-820.
(149) Ancelin, M. L.; Vial, H. J.; Philippot, J. R. Biochemical Pharmacology 1985, 34, 4068-4071.
(150) Calas, M.; Cordina, G.; Bompart, J.; BenBari, M.; Jei, T.; Ancelin, M. L.; Vial, H. Journal o f Medicinal 
Chemistry 1997, 40, 3557-3566.
(151) Calas, M.; Ancelin, M. L.; Cordina, G.; Portefaix, P.; Piquet, G.; Vidal-Sailhan, V.; Vial, H. Journal o f  
Medicinal Chemistry 2000, 43, 505-516.
(152) Calas, M.; Ouattara, M.; Piquet, G.; Ziora, Z.; Bordat, Y.; Ancelin, M. L.; Escale, R.; Vial, H. Journal 
o f  Medicinal Chemistry 2007, 50, 6307-6315.
(153) Wengelnik, K.; Vidal, V.; Ancelin, M. L.; Cathiard, A. M.; Morgat, J. L.; Kocken, C. H.; Calas, M.; 
Herrera, S.; Thomas, A. W.; Vial, H. J. Science 2002, 295, 1311-1314.
(154) Gelb, M. H. Current Opinion in Chemical Biology 2007,11, 440-445.
(155) Roggero, R.; Zufferey, R.; Minca, M.; Richier, E.; Calas, M.; Vial, H.; Ben Mamoun, C. Antimicrobial 
Agents and Chemotherapy 2004, 48, 2816-2824.
(156) Biagini, G. A.; Ward, S. A.; Bray, P. G. Trends in Parasitology 2005, 21, 299-301.
(157) Biagini, G. A.; Richier, E.; Bray, P. G.; Calas, M.; Vial, H.; Ward, S. A. Antimicrobial Agents and 
Chemotherapy 2003, 47, 2584-2589.
(158) Nicolas, O.; Margout, D.; Taudon, N.; Wein, S.; Calas, M.; Vial, H.; Bressolle, F. Antimicrobial Agents 
and Chemotherapy 2005, 49, 3631-3639.
(159) Motoshima, K.; Hiwasa, Y.; Yoshikawa, M.; Fujimoto, K.; Tai, A.; Kakuta, H.; Sasaki, K. 
Chemmedchem 2007, 2, 1527-1532.
(160) Kelly, J. X.; Winter, R.; Riscoe, M.; Peyton, D. H. Journal o f  Inorganic Biochemistry 2001, 86, 617- 
625.
(161) Kelly, J. X.; Winter, R.; Peyton, D. H.; Hinrichs, D. J.; Riscoe, M. Antimicrobial Agents and 
Chemotherapy 2002, 46, 144-150.
(162) Kelly, J. X.; Winter, R. W.; Cornea, A.; Peyton, D. H.; Hinrichs, D. J.; Riscoe, M. Molecular and 
Biochemical Parasitology 2002,123, 47-54.
(163) Salom-Roig, X. J.; Hamze, A.; Calas, M.; Vial, H. J. Combinatorial Chemistry and High Throughput 
Screening 2005, 8, 49-62.
Bibliography 277
(164) Biagini, G. A.; Pasini, E. M.; Hughes, R.; De Koning, H. P.; Vial, H. J.; O'Neill, P. M.; Ward, S. A.; 
Bray, P. G. Blood 2004,104, 3372-3377.
(165) Schlitzer, M. ChemMedChem 2007, 2, 944-986.
(166) Clayden, J.; Greeves, N.; Warren, S.; Wothers, P. Organic Chemistry, Oxford University Press, 2001.
(167) Cunningham, I. D.; Llor, J.; Munoz, L. Journal o f  the Chemical Society-Perkin Transactions 2 1991, 
1751-1753.
(168) Shieh, W. C.; Lozanov, M.; Loo, M.; Repic, J.; Blacklock, T. J. Tetrahedron Letters 2003, 44, 4563- 
4565.
(169) Helinski, J.; Dabkowski, W.; Michalski, J. Tetrahedron Letters 1993, 34, 6451-6454.
(170) Sakurai, H.; Sasaki, K.; Hosomi, A. Tetrahedron Letters 1980, 21, 2329-2332.
(171) Shieh, W. C.; Dell, S.; Repic, O. Organic Letters 2001, 3, 4279-4281.
(172) Baidya, M.; Mayr, H. Chemical Communications 2008, 1792-1794.
(173) Birman, V. B.; Li, X. M.; Han, Z. F. Organic Letters 2007, 9, 37-40.
(174) Kers, A.; Kers, I.; Stawinski, J. Journal o f  the Chemical Society-Perkin Transactions 2 1999, 2071- 
2075.
(175) Baiget, L.; Batsanov, A. S.; Dyer, P. W.; Fox, M. A.; Hanton, M. J.; Howard, J. A. K.; Lane, P. K.; 
Solomon, S. A. Dalton Transactions 2008, 1043-1054.
(176) Coles, M. P. Dalton Transactions 2006, 985-1001.
(177) Boere, R. T.; Klassen, V.; Wolmershauser, G. Journal o f  the Chemical Society-Dalton Transactions 
1998,4147-4154.
(178) Tidwell, R. R.; Webster, W. P.; Shaver, S. R.; Geratz, J. D. Thrombosis Research 1980,19, 339-349.
(179) Sturzebecher, J.; Markwardt, F.; Walsmann, P. Thrombosis Research 1980,17, 545-548.
(180) Geratz, J. D.; Cheng, M. C. F.; Tidwell, R. R. Journal o f  Medicinal Chemistry 1975,18, 477-481.
(181) Geratz, J. D.; Cheng, M. C. F.; Tidwell, R. R. Journal o f  Medicinal Chemistry 1976,19, 634-639.
(182) Dubovi, E. J.; Geratz, J. D.; Shaver, S. R.; Tidwell, R. R. Antimicrobial Agents and Chemotherapy 
1981,19, 649-656.
(183) Vonderfecht, S. L.; Miskuff, R. L.; Wee, S. B.; Sato, S.; Tidwell, R. R.; Geratz, J. D.; Yolken, R. H. 
Journal o f  Clinical Investigations 1988, 82, 2011-2016.
(184) Elson, W. O. Journal o f  Infectious Diseases 1945, 76, 193-197.
(185) Bichowskyslomnitzki, L. Journal o f  Bacteriology 1948, 55, 27-31.
(186) Kopac, M. J. Cancer Research 1947, 7, 44-46.
(187) Farrell, N. P.; Williamson, J.; McLaren, D. J. M. Biochemical Pharmacology 1984, 33, 961-971.
(188) S.J. Angyal, W. K. W. Journal o f  the Chemical Society 1951, 2492-2494.
(189) Williams, M. L.; Gready, J. E. Journal o f Computational Chemistry 1989,10, 35-54.
(190) Lasri, J.; Gonzalez-Rosende, M. E.; Sepulveda-Arques, J. Organic Letters 2003, 5, 3851-3853.
(191) Tsuchiya, Y.; Kumamoto, T.; Ishikawa, T. Journal o f Organic Chemistry 2004, 69, 8504-8505.
(192) Kita, T.; Georgieva, A.; Hashimoto, Y.; Nakata, T.; Nagasawa, K. Angewandte Chemie-International 
Edition 2002, 41, 2832-2834.
(193) Xie, H. B.; Zhang, S. B.; Duan, H. F. Tetrahedron Letters 2004, 45, 2013-2015.
(194) Jiang, T.; Gao, H. X.; Han, B. X.; Zhao, G. Y.; Chang, Y. H.; Wu, W. Z.; Gao, L.; Yang, G. Y.
Tetrahedron Letters 2004, 45, 2699-2701.
(195) Ma, D. W.; Pan, Q. B.; Han, F. S. Tetrahedron Letters 2002, 43, 9401-9403.
(196) Ishikawa, T.; Isobe, T. Chemistry-a European Journal 2002, 8, 553-557.
(197) Piatek, A. M.; Gray, M.; Anslyn, E. V. Journal o f  the American Chemical Society 2004, 126, 9878- 
9879.
(198) Chinchilla, R.; Najera, C.; Sanchezagullo, P. Tetrahedron-Asymmetry 1994, 5, 1393-1402.
(199) Iyer, M. S.; Gigstad, K. M.; Namdev, N. D.; Lipton, M. Journal o f  the American Chemical Society 
1996,118, 4910-4911.
(200) Li, J.; Jiang, W. Y.; Han, K. L.; He, G. Z.; Li, C. Journal o f  Organic Chemistry 2003, 68, 8786-8789.
(201) Alcazar, V.; Moran, J. R.; Demendoza, J. Tetrahedron Letters 1995, 36, 3941-3944.
(202) Howard-Jones, A.; Murphy, P. J.; Thomas, D. A.; Caulkett, P. W. R. Journal o f  Organic Chemistry 
1999, 64, 1039-1041.
(203) Juyal, P.; Anand, O. N. Fuel 2003, 82, 97-103.
(204) Matsunaga, S.; Fusetani, N.; Kato, Y.; Hirota, H. Journal o f  the American Chemical Society 1991, 113, 
9690-9692.
(205) Berlinck, R. G. S.; Kossuga, M. H. Natural Product Reports 2005, 22, 516-550.
(206) Banker, R.; Carmeli, S. Tetrahedron 1999, 55, 10835-10844.
(207) Carroll, A. R.; Buchanan, M. S.; Edser, A.; Hyde, E.; Simpson, M.; Quinn, R. J. Journal o f  Natural 
Products 2004, 67, 1291-1294.
(208) Nicholas, G. M.; Newton, G. L.; Fahey, R. C.; Bewley, C. A. Organic Letters 2001, 3, 1543-1545.
Bibliography 278
(209) Suzuki, H.; Morita, H.; Iwasaki, S.; Kobayashi, J. Tetrahedron 2003, 59, 5307-5315.
(210) Patil, A. D.; Freyer, A. J.; Offen, P.; Bean, M. F.; Johnson, R. K. Journal o f  Natural Products 1997, 60, 
704-707.
(211) Heys, L.; Moore, C. G.; Murphy, P. J. Chemical Society Reviews 2000, 29, 57-67.
(212) Hua, H. M.; Peng, J. N.; Fronczek, F. R.; Kelly, M.; Hamann, M. T. Bioorganic and Medicinal 
Chemistry 2004, 12, 6461-6464.
(213) Harbour, G. C.; Tymiak, A. A.; Rinehart, K. L.; Shaw, P. D.; Hughes, R. G.; Mizsak, S. A.; Coats, J. H.; 
Zurenko, G. E.; Li, L. H.; Kuentzel, S. L. Journal o f  the American Chemical Society 1981, 103, 5604- 
5606.
(214) Tavares, R.; Daloze, D.; Braekman, J. C.; Hajdu, E.; Vansoest, R. W. M. Journal o f  Natural Products- 
Lloydia 1995, 58, 1139-1142.
(215) Waring, M. J. Journal o f Molecular Biology 1965,13, 269-282.
(216) Sobell, H. M.; Tsai, C.; Jain, S. C.; Gilbert, S. G. Journal o f  Molecular Biology 1977,114, 333-365.
(217) Bailly, C.; Arafa, R. K.; Tanious, F. A.; Laine, W.; Tardy, C.; Lansiaux, A.; Colson, P.; Boykin, D. W.; 
Wilson, W. D. Biochemistry 2005, 44, 1941-1952.
(218) Jana, G. H.; Jain, S.; Arora, S. K.; Sinha, N. Bioorganic and Medicinal Chemistry Letters 2005, 15, 
3592-3595.
(219) Stephens, C. E.; Tanious, F.; Kim, S.; Wilson, W. D.; Schell, W. A.; Perfect, J. R.; Franzblau, S. G.; 
Boykin, D. W. Journal o f Medicinal Chemistry 2001, 44, 1741-1748.
(220) Gonzalez, J. L.; Stephens, C. E.; Wenzler, T.; Brun, R.; Tanious, F. A.; Wilson, W. D.; Barszcz, T.; 
Werbovetz, K. A.; Boykin, D. W. European Journal o f  Medicinal Chemistry 2007, 42, 552-557.
(221) Dardonville, C.; Brun, R. Journal o f  Medicinal Chemistry 2004, 47, 2296-2307.
(222) Stephens, C. E.; Brun, R.; Salem, M. M.; Werbovetz, K. A.; Tanious, F.; Wilson, W. D.; Boykin, D. W. 
Bioorganic and Medicinal Chemistry Letters 2003, 13, 2065-2069.
(223) Dardonville, C.; Barrett, M. P.; Brun, R.; Kaiser, M.; Tanious, F.; Wilson, W. D. Journal o f Medicinal 
Chemistry 2006, 49, 3748-3752.
(224) Arafa, R. K.; Brun, R.; Wenzler, T.; Tanious, F. A.; Wilson, W. D.; Stephens, C. E.; Boykin, D. W. 
Journal o f  Medicinal Chemistry 2005, 48, 5480-5488.
(225) Sheng, X.; Lu, X. M.; Chen, Y. T.; Lu, G. Y.; Zhang, J. J.; Shao, Y.; Liu, F.; Xu, Q. Chemistry-a 
European Journal 2007,13, 9703-9712.
(226) Kashman, Y.; Hirsh, S.; McConnell, O. J.; Ohtani, I.; Kusumi, T.; Kakisawa, H. Journal o f  the 
American Chemical Society 1989, 111, 8925-8926.
(227) Jareserijman, E. A.; Sakai, R.; Rinehart, K. L. Journal o f  Organic Chemistry 1991, 56, 5712-5715.
(228) Jareserijman, E. A.; Ingrum, A. L.; Carney, J. R.; Rinehart, K. L.; Sakai, R. Journal o f Organic 
Chemistry 1993, 58, 4805-4808.
(229) Patil, A. D.; Kumar, N. V.; Kokke, W. C.; Bean, M. F.; Freyer, A. J.; Debrosse, C.; Mai, S.; Truneh, A.; 
Faulkner, D. J.; Carte, B.; Breen, A. L.; Hertzberg, R. P.; Johnson, R. K.; Westley, J. W.; Potts, B. C. 
M. Journal o f  Organic Chemistry 1995, 60, 1182-1188.
(230) Chang, L. C.; Whittaker, N. F.; Bewley, C. A. Journal o f  Natural Products 2003, <56, 1490-1494.
(231) Tagmose, T. M.; Schou, S. C.; Mogensen, J. P.; Nielsen, F. E.; Arkhammar, P. O. G.; Wahl, P.; Hansen,
B. S.; Worsaae, A.; Boonen, H. C. M.; Antoine, M. H.; Lebrun, P.; Hansen, J. B. Journal o f  Medicinal 
Chemistry 2004, 47, 3202-3211.
(232) Vagner, J.; Handl, H. L.; Gillies, R. J.; Hruby, V. J. Bioorganic and Medicinal Chemistry Letters 2004, 
14, 211-215.
(233) Kokko, K. P.; Hooper, H. B.; Dix, T. A. Tetrahedron Letters 2004, 45, 2151-2153.
(234) Tamamura, H.; Hiramatsu, K.; Ueda, S.; Wang, Z. X.; Kusano, S.; Terakubo, S.; Trent, J. O.; Peiper, S.
C. ; Yamamoto, N.; Nakashima, H.; Otaka, A.; Fujii, N. Journal o f  Medicinal Chemistry 2005, 48, 380- 
391.
(235) Garcia, O.; Nicolas, E.; Albericio, F. Tetrahedron Letters 2003, 44, 5319-5321.
(236) Kim, J.; Jung, Y. S.; Han, W. S.; Kim, M. Y.; Namkung, W.; Lee, B. H.; Yi, K. Y.; Yoo, S. E.; Lee, M.
G.; Kim, K. H. European Journal o f  Pharmacology 2007, 567, 131-138.
(237) Ravens, U.; Himmel, H. M. Pharmacological Research 1999, 39, 167-174.
(238) Berlinck, R. G. S.; Braekman, J. C.; Daloze, D.; Bruno, I.; Riccio, R.; Ferri, S.; Spampinato, S.; 
Speroni, E. Journal o f  Natural Products 1993, 56, 1007-1015.
(239) Lochner, A.; Genade, S.; Tromp, B.; Theron, S.; Trollip, G. Cardiovascular Drugs and Therapy 1998, 
12, 267-277.
(240) Reddy, N. L.; Connaughton, S.; Daly, D.; Fischer, J. B. Bioorganic and Medicinal Chemistry Letters 
1995, 5, 2259-2262.
(241) Wender, P. A.; Galliher, W. C.; Goun, E. A.; Jones, L. R.; Pillow, T. H. Advanced Drug Delivery 
Reviews 2008, 60, 452-472.
Bibliography 279
(242) Bray, P. G.; Barrett, M. P.; Ward, S. A.; de Koning, H. P. Trends in Parasitology 2003,19, 232-239.
(243) Stewart, M. L.; Boussard, C.; Brun, R.; Gilbert, I. H.; Barrett, M. P. Antimicrobial Agents and 
Chemotherapy 2005, 49, 5169-5171.
(244) Rodriguez, F.; Rozas, I.; Kaiser, M.; Brun, R.; Nguyen, B.; Wilson, W. D.; Garcia, R. N.; Dardonville,
C. Journal o f  Medicinal Chemistry 2008, 51, 909-923.
(245) Bailly, C.; Dassonneville, L.; Carrasco, C.; Lucas, D.; Kumar, A.; Boykin, D. W.; Wilson, W. D. Anti- 
Cancer Drug Design 1999,14, 47-60.
(246) Fitzgerald, D. J.; Anderson, J. N. Journal o f  Biological Chemistry 1999, 274, 27128-27138.
(247) Silva, C. F.; Batista, M. M.; Mota, R. A.; de Souza, E. M.; Stephens, C. E.; Som, P.; Boykin, D. W.; 
Soeiro, M. D. C. Biochemical Pharmacology 2007, 73, 1939-1946.
(248) Rosypal, A. C.; Hall, J. E.; Bakunova, S.; Patrick, D. A.; Bakunov, S.; Stephens, C. E.; Kumar, A.; 
Boykin, D. W.; Tidwell, R. R. Veterinary Parasitology 2007,145, 207-216.
(249) Silva, C. F.; Meuser, M. B.; De Souza, E. M.; Meirelles, M. N. L.; Stephens, C. E.; Som, P.; Boykin, D. 
W.; Soeiro, M. N. C. Antimicrobial Agents and Chemotherapy 2007, 51, 3803-3809.
(250) Gysin, J. Research in Immunology 1991,142, 649-654.
(251) Riethmiller, S. Chemotherapy 2005, 51, 234-242.
(252) Lloyd, N. C.; Morgan, H. W.; Nicholson, B. K.; Ronimus, R. S. Angewandte Chemie-International 
Edition 2005, 44, 941-944.
(253) Lourie, E.; Yorke, W. Annals o f  Tropical Medicine and Parasitology 1937, 31, 435.
(254) King, H.; Lourie, E. M.; Yorke, W. Lancet 1937, 233, 136.
(255) Ashley, J. N.; Barber, H. J.; Ewins, A. J.; Newbery, G.; Self, A. D. H. Journal o f  the Chemical Society 
1942, 103 - 116.
(256) Bella, J. L.; Gosalvez, J. Biotechnic and Histochemistry 1991,1, 44-52.
(257) Bella, J. L.; Gosalvez, J. Biotechnic and Histochemistry 1994, 69, 243-248.
(258) Stockert, J. C.; Trigoso, C. I.; Cuellar, T.; Bella, J. L.; Lisanti, J. A. Journal o f Histochemistry and 
Cytochemistry 1997, 45, 97-105.
(259) Lindsay, D. S.; Blagbum, B. L.; Hall, J. E.; Tidwell, R. R. Antimicrobial Agents and Chemotherapy 
1991,35,1914-1916.
(260) Lombardi, P.; Crisanti, A. Pharmacology and Therapeutics 1997, 76, 125-133.
(261) Montanari, C. A.; Tute, M. S.; Beezer, A. E.; Mitchell, J. C. Journal o f  Computer-Aided Molecular 
Design 1996, 10, 67-73.
(262) Johnson, V. A.; Smith, R. L. Archives o f  Biochemistry and Biophysics 1976,175, 190-195.
(263) Maduskuie, T. P.; McNamara, K. J.; Ru, Y.; Knabb, R. M.; Stouten, P. F. W. Journal o f  Medicinal 
Chemistry 1998, 41, 53-62.
(264) Wright, P.; Warhurst, D.; Jones, B. R. British Journal o f  Ophthalmology 1985, 69, 778-782.
(265) Perrine, D.; Chenu, J. P.; Georges, P.; Lancelot, J. C.; Satumino, C.; Robba, M. Antimicrobial Agents
and Chemotherapy 1995, 39, 339-342.
(266) Herz, N. L.; Matoba, A. Y.; Wilhelmus, K. R. Ophthalmology 2008,115, 866-869.
(267) Brasseur, G.; Favennec, L.; Perrine, D.; Chenu, J. P.; Brasseur, P. Cornea 1994, 13, 459-462.
(268) Casida, J. E.; Tomizawa, M. Journal o f Pesticide Science 2008, 33, 4-8.
(269) Besan, J.; Kulcsar, L.; Kovacs, M. Synthesis-Stuttgart 1980, 883-884.
(270) Wu, J. Z.; Yeh, L.-T.; Lin, C.-C.; Hong, Z. Antiviral Chemistry and Chemotherapy 2006,17, 33-39.
(271) Sidwell, R. W.; Bailey, K. W.; Wong, M. H.; Barnard, D. L.; Smee, D. F. Antiviral Research 2005, 68, 
10-17.
(272) Minagawa, K.; Kouzuki, S.; Tani, H.; Ishii, K.; Tanimoto, T.; Terui, Y.; Kamigauchi, T. Journal o f  
Antibiotics 2002, 55, 239-248.
(273) Blériot, Y.; Dintinger, T.; Guillo, N.; Tellier, C. Tetrahedron Letters 1995, 36, 5175-5178.
(274) Gabrielsen, B.; Phelan, M. J.; Barthelrosa, L.; See, C.; Huggins, J. W.; Kefauver, D. F.; Monath, T. P.; 
Ussery, M. A.; Chmurny, G. N.; Schubert, E. M.; Upadhya, K.; Kwong, C.; Carter, D. A.; Secrist, J. A.; 
Kirsi, J. J.; Shannon, W. M.; Sidwell, R. W.; Kini, G. D.; Robins, R. K. Journal o f  Medicinal Chemistry 
1992, 35, 3231-3238.
(275) Liebeschuetz, J. W.; Katz, R. B.; Duriatti, A. D.; Arnold, M. L. Pesticide Science 1997, 50, 258-274.
(276) Anthony, N. G.; Breed, D.; Clarke, J.; Donoghue, G.; Drummond, A. J.; Ellis, E. M.; Gemmell, C. G.; 
Helesbeux, J. J.; Hunter, I. S.; Khalaft, A. I.; Mackay, S. P.; Parkinson, J. A.; Suckling, C. J.; Waiah, R.
D. Journal o f  Medicinal Chemistry 2007, 50, 6116-6125.
(277) Del Poeta, M.; Schell, W. A.; Dykstra, C. C.; Jones, S. K.; Tidwell, R. R.; Kumar, A.; Boykin, D. W.; 
Perfect, J. R. Antimicrobial Agents and Chemotherapy 1998, 42, 2503-2510.
(278) Tanious, F. A.; Wilson, W. D.; Patrick, D. A.; Tidwell, R. R.; Colson, P.; Houssier, C.; Tardy, C.; 
Bailly, C. European Journal o f  Biochemistry 2001, 268, 3455-3464.
Bibliography 280
(279) Koga, T.; Abe, T.; Inoue, H.; Takenouchi, T.; Kitayama, A.; Yoshida, T.; Masuda, N.; Sugihara, C.; 
Kakuta, M.; Nakagawa, M.; Shibayama, T.; Matsushita, Y.; Hirota, T.; Ohya, S.; Utsui, Y.; Fukuoka, 
T.; Kuwahara, S. Antimicrobial Agents and Chemotherapy 2005, 49, 3239-3250.
(280) Ozden, S.; Atabey, D.; Yildiz, S.; Goker, H. Bioorganic and Medicinal Chemistry 2005,13, 1587-1597.
(281) Ramstrom, H.; Bourotte, M.; Philippe, C.; Schmitt, M.; Haiech, J.; Bourguignon, J. J. Journal o f  
Medicinal Chemistry 2004, 47, 2264-2275.
(282) Jen, T.; Vanhoeven, H.; Groves, W.; McLean, R. A.; Loev, B. Journal o f  Medicinal Chemistry 1975, 
18,90-99. '
(283) Marzano, C.; Sbovata, S. M.; Bettio, F.; Michelin, R. A.; Seraglia, R.; Kiss, T.; Venzo, A.; Bertani, R. 
Journal o f  Biological Inorganic Chemistry 2007,12, 477-493.
(284) Bielawska, A.; Bielawski, K.; Anchim, T. Archiv Der Pharmazie 2007, 340, 251-257.
(285) Czyz, M.; Szulawska, A.; Bednarek, A. K.; Duchler, M. Biochemical Pharmacology 2005, 70, 1431- 
1442.
(286) Bielawska, A.; Bielawski, K.; Wolczynski, S.; Anchim, T. Archiv Der Pharmazie 2003, 336, 293-299.
(287) Lansiaux, A.; Tanious, F.; Mishal, Z.; Dassonneville, L.; Kumar, A.; Stephens, C. E.; Hu, Q. Y.; 
Wilson, W. D.; Boykin, D. W.; Bailly, C. Cancer Research 2002, 62, 7219-7229.
(288) Nastruzzi, C.; Pastesini, C.; Cortesi, R.; Esposito, E.; Gambari, R.; Menegatti, E. Journal o f  
Microencapsulation 1994,11, 249-260.
(289) Lonez, C.; Legat, A.; Vandenbranden, M.; Ruysschaert, J. M. Cellular and Molecular Life Sciences 
2008, 65, 620-630.
(290) Sondhi, S. M.; Dinodia, M.; Kumar, A. Bioorganic and Medicinal Chemistry 2006, 14, 4657-4663.
(291) Meyers, A. I.; Hutchings, R. Heterocycles 1996, 42, 475-478.
(292) Delarue, S.; Sergheraert, C. Tetrahedron Letters 1999, 40, 5487-5490.
(293) Whitener, G. D.; Hagadom, J. R.; Arnold, J. Journal o f  the Chemical Society-Dalton Transactions 
1999, 1249-1255.
(294) Haverkos, H. W. American Journal o f Medicine 1984, 76, 501-508.
(295) Bomstein, R. S.; Yarbro, J. W. Journal o f Surgical Oncology 1970, 2, 393-398.
(296) Puckowska, A.; Bielawski, K.; Bielawski, A.; Midura-Nowaczek, K. European Journal o f  Medicinal 
Chemistry 2004, 39, 99-105.
(297) Vanden Eynde, J. J.; Mayence, A.; Johnson, M. T.; Huang, T. L.; Collins, M. S.; Walzer, P. D.; 
Cushion, M. T.; Donkor, I. O. Medicinal Chemistry Research 2005, 14, 143-157.
(298) Bielawski, K.; Wolczynski, S.; Bielawska, A. Biological and Pharmaceutical Bulletin 2001, 24, 704- 
706.
(299) Bielawski, K.; Wolczynski, S.; Bielawska, A. Polish Journal o f  Pharmacology 2001, 53, 143-147.
(300) Goker, H.; Ozden, S.; Yildiz, S.; Boykin, D. W. European Journal o f  Medicinal Chemistry 2005, 40, 
1062-1069.
(301) Bouteille, B.; Oukem, O.; Bisser, S.; Dumas, M. Fundamental and Clinical Pharmacology 2003, 17, 
171-181.
(302) Bronner, U.; Doua, F.; Ericsson, O.; Gustafsson, L. L.; Miezan, T. W.; Rais, M.; Rombo, L. 
Transactions o f  the Royal Society o f  Tropical Medicine and Hygiene 1991, 85, 608-611.
(303) Donkor, I. O.; Huang, T. L.; Tao, B.; Rattendi, D.; Lane, S.; Vargas, M.; Goldberg, B.; Bacchi, C. 
Journal o f  Medicinal Chemistry 2003, 46, 1041-1048.
(304) Huang, T. L.; Eynde, J. J. V.; Mayence, A.; Donkor, I. O.; Khan, S. I.; Tekwani, B. L. Journal o f  
Pharmacy and Pharmacology 2006, 58, 1033-1042.
(305) Mayence, A.; Vanden Eynde, J. J.; Krogstad, F. M.; Krogstad, D. J.; Cushion, M. T.; Huang, T. L. 
Journal o f  Medicinal Chemistry 2004, 47, 2700-2705.
(306) Bell, C. A.; Hall, J. E.; Kyle, D. E.; Grogl, M.; Ohemeng, K. A.; Allen, M. A.; Tidwell, R. R. 
Antimicrobial Agents and Chemotherapy 1990, 34, 1381-1386.
(307) Sands, M.; Kron, M. A.; Brown, R. B. Reviews o f  Infectious Diseases 1985, 7, 625-634.
(308) Becker, I.; Volkow, P.; Velasco-Castrejon, O.; Salaiza-Suazo, N.; Berzunza-Cruz, M.; Dominguez, J. S. 
D.; Morales-Vargas, A.; Ruiz-Remigio, A.; Perez-Montfort, R. Parasitology Research 1999, 85, 165- 
170.
(309) Mayence, A.; Vanden Eynde, J. J.; LeCour, L.; Walker, L. A.; Tekwani, B. L.; Huang, T. L. European 
Journal o f  Medicinal Chemistry 2004, 39, 547-553.
(310) Mehta, A.; Shaha, C. Journal o f  Biological Chemistry 2004, 279, 11798-11813.
(311) Damper, D.; Patton, C. L. Biochemical Pharmacology 1976, 25, 271-276.
(312) Gale, E. F.; Folkes, J. P. Biochimica et Biophysica Acta 1967, 144, 467-470.
(313) Barchiesi, F.; Delpoeta, M.; Morbiducci, V.; Ancarani, F.; Scalise, G. Journal o f  Antimicrobial 
Chemotherapy 1994, 33, 1229-1232.
(314) St-Germain, G. Antimicrobial Agents and Chemotherapy 1990, 34, 2304-2306.
Bibliography 281
(315) Miletti, K. E.; Leibowitz, M. J. Antimicrobial Agents and Chemotherapy 2000, 44, 958-966.
(316) Zhang, Y.; Li, Z. J.; Pilch, D. S.; Leibowitz, M. J. Nucleic Acids Research 2002, 30, 2961-2971.
(317) Goker, H.; Boykin, D. W.; Yildiz, S. Bioorganic and Medicinal Chemistry 2005, 13, 1707-1714.
(318) Amos, H.; Vollmayer, E. Journal o f  Bacteriology 1957, 73, 172-177.
(319) Goldberg, B.; Lambros, C.; Bacchi, C. J.; Hutner, S. H. Journal o f  Protozoology 1974, 21, 322-326.
(320) Lionakis, M. S.; Lewis, R. E.; Samonis, G.; Kontoyiannis, D. P. Antimicrobial Agents and 
Chemotherapy 2003, 47, 3252-3259.
(321) Ruebush, T. K.; Contacos, P. G.; Steck, E. A. Antimicrobial Agents and Chemotherapy 1980, 18, 289- 
291.
(322) Afeltra, J.; Meis, J.; Vitale, R. G.; Mouton, J. W.; Verweij, P. E.; Eurofung, N. Antimicrobial Agents 
and Chemotherapy 2002, 46, 2029-2031.
(323) Crowell, A. L.; Stephens, C. E.; Kumar, A.; Boykin, D. W.; Secor, W. E. Antimicrobial Agents and 
Chemotherapy 2004, 48, 3602-3605.
(324) Afeltra, J.; Dannaoui, E.; Meis, J.; Rodriguez-Tudela, J. L.; Verweij, P. E.; Eurofung, N. Antimicrobial 
Agents and Chemotherapy 2002, 46, 3323-3326.
(325) Peters, B. S.; Carlin, E.; Weston, R. J.; Loveless, S. J.; Sweeney, J.; Weber, J.; Main, J. Drug Safety 
1994,10, 439-454.
(326) Tao, B.; Huang, T. L.; Zhang, Q.; Jackson, L.; Queener, S. F.; Donkor, I. O. European Journal o f  
Medicinal Chemistry 1999, 34, 531-538.
(327) Huang, T. L.; Tao, B.; Quarshie, Y.; Queener, S. F.; Donkor, I. O. Bioorganic and Medicinal Chemistry 
Letters 2001,11, 2679-2681.
(328) Cushion, M. T.; Walzer, P. D.; Collins, M. S.; Rebholz, S.; Eynde, J. J. V.; Mayence, A.; Huang, T. L. 
Antimicrobial Agents and Chemotherapy 2004, 48, 4209-4216.
(329) Reynolds, I. J.; Aizenman, E. Journal o f  Neuroscience 1992,12, 970-975.
(330) Donkor, I. O.; Berger, M. L. Bioorganic and Medicinal Chemistry Letters 1997, 7, 1455-1460.
(331) Boykin, D. W. Journal o f the Brazilian Chemical Society 2002, 13, 763-771.
(332) Miao, Y.; Lee, M. P. H.; Parkinson, G. N.; Batista-Parra, A.; Ismail, M. A.; Neidle, S.; Boykin, D. W.; 
Wilson, W. D. Biochemistry 2005, 44, 14701-14708.
(333) Bailly, C.; Donkor, I. O.; Gentle, D.; Thomalley, M.; Waring, M. J. Molecular Pharmacology 1994, 46, 
313-322.
(334) Bailly, C.; Perrine, D.; Lancelot, J. C.; Satumino, C.; Robba, M.; Waring, M. J. Biochemical Journal 
1997, 323, 23-31.
(335) Bell, C. A.; Cory, M.; Fairley, T. A.; Hall, J. E.; Tidwell, R. R. Antimicrobial Agents and Chemotherapy 
1991, 35, 1099-1107.
(336) Edwards, K. J.; Jenkins, T. C.; Neidle, S. Biochemistry 1992, 31, 7104-7109.
(337) Ismail, M. A.; Arafa, R. K.; Brun, R.; Wenzler, T.; Miao, Y.; Wilson, W. D.; Generaux, C.; Bridges, A.; 
Hall, J. E.; Boykin, D. W. Journal o f  Medicinal Chemistry 2006, 49, 5324-5332.
(338) Nguewa, P. A.; Fuertes, M. A.; Cepeda, V.; Iborra, S.; Carrion, J.; Valladares, B.; Alonso, C.; Perez, J. 
M. Chemistry and Biodiversity 2005, 2, 1387-1400.
(339) Miezan, T. W.; Bronner, U.; Doua, F.; Cattand, P.; Rombo, L. Transactions o f  the Royal Society o f 
Tropical Medicine and Hygiene 1994, 88, 332-333.
(340) Doua, F.; Miezan, T. W.; Singaro, J. R. S.; Yapo, F. B.; Baltz, T. American Journal o f  Tropical 
Medicine and Hygiene 1996, 55, 586-588.
(341) Jones, S. K.; Hall, J. E.; Allen, M. A.; Morrison, S. D.; Ohemeng, K. A.; Reddy, V. V.; Geratz, J. D.; 
Tidwell, R. R. Antimicrobial Agents and Chemotherapy 1990, 34, 1026-1030.
(342) Sauleda, J.; Gea, J. G.; Aguar, C.; Aran, X.; Pasto, M.; Broquetas, J. M. Annals o f  Pharmacotherapy 
1994, 28, 52-53.
(343) Berger, B. J.; Naiman, N. A.; Hall, J. E.; Peggins, J.; Brewer, T. G.; Tidwell, R. R. Antimicrobial Agents 
and Chemotherapy 1992, 36, 1825-1831.
(344) Chen, D.; Marsh, R.; Aberg, J. A. Expert Review o f Anti-Infective Therapy 2007, 5, 921-928.
(345) Angulo-Barturen, I.; Jimenez-Diaz, M. B.; Mulet, T.; Rullas, J.; Herreros, E.; Ferrer, S.; Jimenez, E.; 
Mendoza, A.; Regadera, J.; Rosenthal, P. J.; Bathurst, I.; Pompliano, D. L.; Gomez de las Heras, F.; 
Gargallo-Viola, D.PLoS ONE 2008, 3, e2252.
(346) Heischkeil, R. Zeitschriftfuer Tropenmedizin und Parasitologie 1971, 22, 243-249.
(347) Hall, J. E.; Kerrigan, J. E.; Ramachandran, K.; Bender, B. C.; Stanko, J. P.; Jones, S. K.; Patrick, D. A.; 
Tidwell, R. R. Antimicrobial Agents and Chemotherapy 1998, 42, 666-674.
(348) Apted, F. I. C. Pharmacology and Therapeutics 1980,11, 391-413.
(349) Waalkes, T. P.; Makulu, D. R. Journal of the National Cancer Institute Monograph 1976, 43, 171-177.
(350) Helmick, C. G.; Green, J. K. Annals o f  Internal Medicine 1985,103, 480-480.
(351) Leen, C. L. S.; Mandal, B. K. Lancet 1988, 2, 1250-1251.
Bibliography 282
(352) Antoniou, T.; Gough, K. A. Pharmacotherapy 2005, 25, 899-903.
(353) Chua, A.; Busse, J.; Papendick, R.; Alpert, H.; Vaamonde, C. A. Kidney International 1990, 37, 478- 
478.
(354) Feddersen, A.; Sack, K. Journal o f  Antimicrobial Chemotherapy 1991, 28, 437-446.
(355) Lachaal, M.; Venuto, R. Kidney International 1988, 33, 198-198.
(356) Lachaal, M.; Venuto, R. C. American Journal o f  Medicine 1989, 87, 260-263.
(357) Poola, N. R.; Kalis, M.; Plakogiannis, F. M.; Taft, D. R. Journal o f  Antimicrobial Chemotherapy 2003, 
52, 397-404.
(358) Liegl, U.; Bogner, J. R.; Goebel, F. D. Clinical Investigator 1994, 72, 1027-1029.
(359) Bouchard, P.; Sai, P.; Reach, G.; Caubarrere, I.; Ganeval, D.; Assan, R. Diabetes 1982, 31, 40-45.
(360) Ubukata, E.; Mokuda, O.; Nagata, M.; Ogino, Y.; Sakamoto, Y.; Tanaka, K.; Shimizu, N. Journal o f 
Diabetes and Its Complications 1997,11, 256-258.
(361) Assan, R.; Mayaud, C.; Perronne, C.; Matheron, S.; Assan, D.; Zucman, D.; Chotard, L. Diabetes Care 
1995,18, 47-55.
(362) Sundar, S. Medical Microbiology and Immunology 2001,190, 89-92.
(363) Sai, P.; Boillot, D.; Boitard, C.; Debraysachs, M.; Reach, G.; Assan, R. Diabetologia 1983, 25, 418- 
423.
(364) Zhang, X. N.; Berger, B. J.; Ulrich, P. Bioorganic and Medicinal Chemistry Letters 1996, 6, 1035-1036.
(365) Obaji, J.; Lee-Pack, L. R.; Gutierrez, C.; Chan, C. K. N. Chest 2003, 123, 1983-1987.
(366) Moreno, S. N. J. Archives o f  Biochemistry and Biophysics 1996, 326, 15-20.
(367) Stead, A. M. W.; Bray, P. G.; Edwards, I. G.; DeKoning, H. P.; Elford, B. C.; Stocks, P. A.; Ward, S. A. 
Molecular Pharmacology 2001, 59, 1298-1306.
(368) Carter, N. S.; Berger, B. J.; Fairlamb, A. H. Journal o f  Biological Chemistry 1995, 270, 28153-28157.
(369) Matovu, E.; Stewart, M. L.; Geiser, F.; Brun, R.; Maser, P.; Wallace, L. J. M.; Burchmore, R. J.; 
Enyaru, J. C. K.; Barrett, M. P.; Kaminsky, R.; Seebeck, T.; de Koning, FI. P. Eukaryotic Cell 2003, 2, 
1003-1008.
(370) Basselin, M.; Lawrence, F.; RobertGero, M. Biochemical Journal 1996, 315, 631-634.
(371) De Koning, H. P. Molecular Pharmacology 2001, 59, 586-592.
(372) Terada, H.; Nagamune, H.; Morikawa, N.; Ikuno, M. Biochimica et Biophysica Acta 1985, 807, 168- 
176.
(373) Macadam, R. F.; Williamson, J. Transactions o f  the Royal Society o f  Tropical Medicine and Hygiene 
1964, 58, 13-16.
(374) Macadam, R. F.; Williams. J Transactions o f the Royal Society o f  Tropical Medicine and Hygiene 1972, 
66, 897-904.
(375) De Koning, H. P.; Jarvis, S. M. Molecular Pharmacology 1999, 56, 1162-1170.
(376) Geiser, F.; Luscher, A.; de Koning, FI. P.; Seebeck, T.; Maser, P. Molecular Pharmacology 2005, 68, 
589-595.
(377) Carter, N. S.; Fairlamb, A. FI. Nature 1993, 361, 173-176.
(378) De Koning, H. P.; Jarvis, S. M. Acta Tropica 2001, 80, 245-250.
(379) Kirk, K. Physiological Reviews 2001, 81, 495-537.
(380) McKerrow, J. H.; Caffrey, C.; Kelly, B.; Loke, P.; Sajid, M. Annual Review o f  Pathology-Mechanisms 
o f  Disease 2006,1, 497-536.
(381) Krugliak, M.; Zhang, J. M.; Ginsburg, H. Molecular and Biochemical Parasitology 2002,119, 249-256.
(382) Downie, M. J.; Kirk, K.; Mamoun, C. B. Eukaryotic Cell 2008, 7, 1231-1237.
(383) Oelshlegel, F. J.; Sander, B. J.; Brewer, G. J. Nature 1975, 255, 345-347.
(384) Roth, E. F.; Calvin, M. C.; Maxaudit, I.; Rosa, J.; Rosa, R. Blood 1988, 72, 1922-1925.
(385) Ginsburg, H. Biochemical Pharmacology 1994, 48, 1847-1856.
(386) Geary, T. G.; Divo, A. A.; Bonanni, L. C.; Jensen, J. B. Journal o f  Protozoology 1985, 32, 608-613.
(387) Divo, A. A.; Geary, T. G.; Davis, N. L.; Jensen, J. B. Journal o f  Protozoology 1985, 32, 59-64.
(388) Pfaller, M. A.; Krogstad, D. J.; Parquette, A. R. Experimental Parasitology 1982, 54, 391-396.
(389) Vanderjagt, D. L.; Hunsaker, L. A.; Campos, N. M.; Baack, B. R. Molecular and Biochemical 
Parasitology 1990, 42, 277-284.
(390) Spiller, D. G.; Bray, P. G.; Hughes, R. H.; Ward, S. A.; White, M. R. H. Trends in Parasitology 2002, 
18, 441-444.
(391) Staines, H. M.; Rae, C.; Kirk, K. Biochimica et Biophysica Acta-Biomembranes 2000,1463, 88-98.
(392) Kirk, K.; Homer, H. A.; Spillett, D. J.; Elford, B. C. Febs Letters 1993, 323, 123-128.
(393) Kirk, K.; Homer, H. A.; Elford, B. C.; Ellory, J. C.; Newbold, C. I. Journal o f  Biological Chemistry 
1994, 269, 3339-3347.
(394) Kirk, K.; Homer, H. A. Journal o f  Biological Chemistry 1995, 270, 24270-24275.
Bibliography 283
(395) Ancelin, M. L.; Parant, M.; Thuet, M. J.; Philippot, J. R.; Vial, H. J. Biochemical Journal 1991, 273, 
701-709.
(396) Bakunova, S. M.; Bakunov, S. A.; Wenzler, T.; Barszcz, T.; Werbovetz, K. A.; Brun, R.; Hall, J. E.; 
Tidwell, R. R. Journal o f Medicinal Chemistry 2007, 50, 5807-5823.
(397) Vohringer, H. F.; Arasteh, K. Clinical Pharmacokinetics 1993, 24, 388-412.
(398) Berger, B. J.; Reddy, V. V.; Le, S. T.; Lombardy, R. J.; Hall, J. E.; Tidwell, R. R. Journal o f  
Pharmacology and Experimental Therapeutics 1991, 256, 883-889.
(399) Berger, B. J., R. J. Lombardy, G. D. Marbury, C. A. Bell, C. C.; Dykstra, J. E. H., and R. R. Tidwell. 
Antimicrobial Agents and Chemotherapy 1990, 34, 1678-1684.
(400) Berger, B. J.; Carter, N. S.; Fairlamb, A. H. Acta Tropica 1993, 54, 215-224.
(401) Del Poeta, M.; Schell, W. A.; Dykstra, C. C.; Jones, S.; Tidwell, R. R.; Czamy, A.; Bajic, M.; Kumar, 
A.; Boykin, D.; Perfect, J. R.Antimicrobial Agents and Chemotherapy 1998, 42, 2495-2502.
(402) Barrett, M. P.; Fairlamb, A. H. Parasitology Today 1999,15, 136-140.
(403) Basselin, M.; Denise, H.; Coombs, G. H.; Barrett, M. P. Antimicrobial Agents and Chemotherapy 2002, 
46, 3731-3738.
(404) Lanteri, C. A.; Stewart, M. L.; Brock, J. M.; Alibu, V. P.; Meshnick, S. R.; Tidwell, R. R.; Barrett, M. 
P. Molecular Pharmacology 2006, 70, 1585-1592.
(405) Fairlamb, A. H.; Carter, N. S.; Cunningham, M.; Smith, K. Molecular and Biochemical Parasitology 
1992,55,213-222.
(406) Denise, H.; Barrett, M. P. Biochemical Pharmacology 2001, 61, 1-5.
(407) Likeufack, A. C. L.; Brun, R.; Fomena, A.; True, P. Acta Tropica 2006, 100, 11-16.
(408) Davison, A. Archives o f  Biochemistry and Biophysics 1958, 77, 368-371.
(409) Lanteri, C. A.; Trumpower, B. L.; Tidwell, R. R.; Meshnick, S. R. Antimicrobial Agents and 
Chemotherapy 2004, 48, 3968-3974.
(410) Killick, R. Annals o f Tropical Medicine and Parasitology 1964, 58, 481 -490.
(411) Morty, R. E.; Troeberg, L.; Pike, R. N.; Jones, R.; Nickel, P.; Lonsdale-Eccles, J. D.; Coetzer, T. H. T. 
Febs Letters 1998, 433, 251-256.
(412) Antony, S.; Marchand, C.; Stephen, A. G.; Thibaut, L.; Agama, K. K.; Fisher, R. J.; Pommier, Y. 
Nucleic Acids Research 2007, 35, 4474-4484.
(413) Fox, K. R.; Sansom, C. E.; Stevens, M. F. G. Febs Letters 1990, 266, 150-154.
(414) Chackal-Catoen, S.; Miao, Y.; Wilson, W. D.; Wenzler, T.; Brun, R.; Boykin, D. W. Bioorganic and 
Medicinal Chemistry 2006, 14, 7434-7445.
(415) Ismail, M. A.; Batista-Parra, A.; Miao, Y.; Wilson, W. D.; Wenzler, T.; Brun, R.; Boykin, D. W. 
Bioorganic and Medicinal Chemistry 2005, 13, 6718-6726.
(416) Menezes, F. A. S.; Montanari, C. A.; Bruns, R. E. Journal o f  the Brazilian Chemical Society 2000, 11, 
393-397.
(417) Nguyen, B.; Tardy, C.; Bailly, C.; Colson, P.; Houssier, C.; Kumar, A.; Boykin, D. W.; Wilson, W. D. 
Biopolymers 2002, 63, 281-297.
(418) Yanow, S. K.; Purcell, L. A.; Lee, M.; Spithill, T. W. Pharmacogenomics 2007, 8, 1267-1272.
(419) Luck, G.; Zimmer, C.; Schweizer, D. Studia Biophysica 19 88 ,125, 107-119.
(420) Van Dross, R. T.; Sanders, M. M. Antimicrobial Agents and Chemotherapy 2002, 46, 2145-2154.
(421) Shapiro, T. A.; Englund, P. T. Proceedings o f  the National Academy o f  Sciences o f  the United States o f  
America 1990, 87, 950-954.
(422) Sun, T.; Zhang, Y. Nucleic Acids Research 2008, 36, 1654-1664.
(423) Nunn, C. M.; Jenkins, T. C.; Neidle, S. Biochemistry 1993, 32, 13838-13843.
(424) Neidle, S. Febs Letters 1992, 298, 97-99.
(425) Bacchi, C. J. Journal o f Protozoology 1981, 28, 20-27.
(426) Basselin, M.; BadetDenisot, M. A.; Lawrence, F.; RobertGero, M. Experimental Parasitology 1997, 85, 
274-282.
(427) Brown, D. G.; Sanderson, M. R.; Garman, E.; Neidle, S. Journal o f  Molecular Biology 1992, 226, 481- 
490.
(428) Bielawski, K.; Galicka, A.; Bielawska, A.; Sredzinska, K. Acta Biochimica Polonica 2000, 47, 113-120.
(429) Woynarowski, J. M.; McHugh, M.; Sigmund, R. D.; Beerman, T. A. Molecular Pharmacology 1989, 
35, 177-182.
(430) Barcellona, M. L.; Favilla, R.; Vonberger, J.; Avitabile, M.; Ragusa, N.; Masotti, L. Archives o f 
Biochemistry and Biophysics 1986, 250, 48-53.
(431) Wilson, W. D.; Tanious, F. A.; Barton, H. J.; Strekowski, L.; Boykin, D. W.; Jones, R. L. Journal o f  the 
American Chemical Society 1989, 111, 5008-5010.
Bibliography 284
(432) Boykin, D. W.; Kumar, A.; Spychala, J.; Zhou, M.; Lombardy, R. J.; Wilson, W. D.; Dykstra, C. C.; 
Jones, S. K.; Hall, J. E.; Tidwell, R. R.; Laughton, C.; Nunn, C. M.; Neidle, S Journal o f  Medicinal 
Chemistry 1995, 38, 912-916.
(433) Wilson, W. D.; Ratmeyer, L.; Zhao, M.; Strekowski, L.; Boykin, D. Biochemistry 1993, 32, 4098-4104.
(434) Laughton, C. A.; Tanious, F.; Nunn, C. M.; Boykin, D. W.; Wilson, W. D.; Neidle, S. Biochemistry 
1996, 35, 5655-5661.
(435) Lavery, R.; Pullman, A.; Pullman, B. Biophysical Chemistry 1983, 17, 75-86.
(436) Christophers, S. R.; Fulton, J. D. Annals o f  Tropical Medicine and Parasitology 1938, 32, 257-278.
(437) Mayence, A.; Jacques, J.; Eynde, V.; Huang, T. L. Bioorganic and Medicinal Chemistry Letters 2004, 
14, 1625-1628.
(438) Winter, R. W.; Kelly, J. X.; Smilkstein, M. J.; Dodean, R.; Hinrichs, D.; Riscoe, M. K. Experimental 
Parasitology 2 0 0 8 ,118, 487-497.
(439) Kessl, J. J.; Meshnick, S. R.; Trumpower, B. L. Trends in Parasitology 2007, 23, 494-501.
(440) Xiang, H.; McSurdy-Freed, J.; Moorthy, G. S.; Hugger, E.; Bambal, R.; Han, C.; Ferrer, S.; Gargallo, 
D.; Davis, C. B. Journal o f Pharmaceutical Sciences 2006, 95, 2657-2672.
(441) Ersmark, K.; Samuelsson, B.; Hallberg, A. Medicinal Research Reviews 2006, 26, 626-666.
(442) Jiang, S. P.; Prigge, S. T.; Wei, L.; Gao, Y. E.; Hudson, T. H.; Gerena, L.; Dame, J. B.; Kyle, D. E.
Antimicrobial Agents and Chemotherapy 2001, 45, 2577-2584.
(443) Bhattacharya, G.; Gerena, L.; Jiang, S. P.; Werbovetz, K. A. Letters in Drug Design and Discovery 
2005, 2, 162-164.
(444) Arcamone, F.; Nicolell.V; Penco, S.; Orezzi, P.; Pirelli, A. Nature 1964, 203, 1064-1065.
(445) Broyles, S. S.; Kremer, M.; Knutson, B. A. Journal o f  Virology 2004, 78, 2137-2141.
(446) Chen, X.; Ramakrishnan, B.; Sundaralingam, M. Journal o f  Molecular Biology 1997, 267, 1157-1170.
(447) Hiraku, Y.; Oikawa, S.; Kawanishi, S. Nucleic Acids Research Supplement 2002, 95-96.
(448) Pelton, J.; Wemmer, D. Journal o f  the American Chemical Society 1990,112, 1393-1399
(449) Marchini, S.; Broggini, M.; Sessa, C.; D'Incalci, M. Expert Opinion on Investigational Drugs 2001, 10
1703-1714
(450) Ismail, M. A.; Brun, R.; Easterbrook, J. D.; Tanious, F. A.; Wilson, W. D.; Boykin, D. W. Journal o f  
Medicinal Chemistry 2003, 46, 4761-4769.
(451) Ismail, M. A.; Brun, R.; Wenzler, T.; Tanious, F. A.; Wilson, W. D.; Boykin, D. W. Journal o f  
Medicinal Chemistry 2004, 47, 3658-3664.
(452) Das, B. P.; Boykin, D. W. Journal o f Medicinal Chemistry 1977, 20, 531-536.
(453) Das, B. P.; Boykin, D. W. Journal o f Medicinal Chemistry 1977, 20, 1219-1221.
(454) Das, B. P.; Wallace, R. A.; Boykin, D. W. Journal o f  Medicinal Chemistry 1980, 23, 578-581.
(455) Boykin, D. W.; Kumar, A.; Xiao, G.; Wilson, W. D.; Bender, B. C.; McCurdy, D. R.; Hall, J. E.; 
Tidwell, R. R. Journal o f Medicinal Chemistry 1998, 41, 124-129.
(456) Hopkins, K. T.; Wilson, W. D.; Bender, B. C.; McCurdy, D. R.; Hall, J. E.; Tidwell, R. R.; Kumar, A.; 
Bajic, M.; Boykin, D. W. Journal o f  Medicinal Chemistry 1998, 41, 3872-3878.
(457) Eynde, J. J. V.; Mayence, A.; Huang, T. L.; Collins, M. S.; Rebholz, S.; Walzer, P. D.; Cushion, M. T. 
Bioorganic and Medicinal Chemistry Letters 2004, 14, 4545-4548.
(458) Trent, J. O.; Clark, G. R.; Kumar, A.; Wilson, W. D.; Boykin, D. W.; Hall, J. E.; Tidwell, R. R.; 
Blagbum, B. L.; Neidle, S. Journal o f Medicinal Chemistry 1996, 39, 4554-4562.
(459) Calonge, M. M.; Bayoumi, A. E.; Cubria, J. C.; BalanaFouce, R.; Ordonez, D. Life Sciences 1996, 59, 
191-197.
(460) Kinnamon, K. E.; Steck, E. A.; Rane, D. S. Antimicrobial Agents and Chemotherapy 1 9 7 9 ,15, 157-160.
(461) Mbongo, N.; Loiseau, P. M.; Lawrence, F.; Bories, C.; Craciunescu, D. G.; RobertGero, M. 
Parasitology Research 1997, 83, 515-517.
(462) Dreyfuss, G.; Penicaut, B.; Nicolas, J. A.; Craciunescu, D.; Loiseau, P. Tropical Medicine and 
Parasitology 1993, 44, 95-98.
(463) Delia, T. J.; Nagarajan, A.; Queener, S. F.; Bartlett, M. S. Bioorganic and Medicinal Chemistry Letters 
1996, 6, 2367-2370.
(464) Wang, L.; Bailly, C.; Kumar, A.; Ding, D.; Bajic, M.; Boykin, D. W.; Wilson, W. D. Proceedings o f the 
National Academy o f Sciences o f the United States o f America 2000, 97, 12-16.
(465) Wang, L.; Carrasco, C.; Kumar, A.; Stephens, C. E.; Bailly, C.; Boykin, D. W.; Wilson, W. D. 
Biochemistry 2001, 40, 2511-2521.
(466) Donkor, I. O.; Assefa, H.; Rattendi, D.; Lane, S.; Vargas, M.; Goldberg, B.; Bacchi, C. European 
Journal o f  Medicinal Chemistry 2001, 36, 531-538.
(467) Nguyen, B.; Lee, M. P. H.; Hamelberg, D.; Joubert, A.; Bailly, C.; Brun, R.; Neidle, S.; Wilson, W. D. 
Journal o f  the American Chemical Society 2 0 0 2 ,124, 13680-13681.
Bibliography 285
(468) Brun, R.; Buhler, Y.; Sandmeier, U.; Kaminsky, R.; Bacchi, C. J.; Rattendi, D.; Lane, S.; Croft, S. L.; 
Snowdon, D.; Yardley, V.; Caravatti, G.; Frei, J.; Stanek, J.; Mett, H. Antimicrobial Agents and 
Chemotherapy 1996, 40, 1442-1447.
(469) Rowland, E. C.; Moore-Lai, D.; Seed, J. R.; Stephens, C. E.; Boykin, D. W. Journal o f  Parasitology 
2003, 89, 1078-1080.
(470) Schrodinger, L. QikProp Rapid ADME predictions o f  drug candidates, 2006
(471) Rang, H.; Dale, M.; Ritter, J. Pharmacology, 4th ed., 1999.
(472) Szakacs, G.; Varadi, A.; Ozvegy-Laczka, C.; Sarkadi, B. Drug Discovery Today 2 0 0 8 ,13, 379-393.
(473) Albert, A. Nature 1958,182, 421-423.
(474) Fleisher, D.; Bong, R.; Stewart, B. H. Advanced Drug Delivery Reviews 1 9 9 6 ,19, 115-130.
(475) Johansen, M.; Bundgaard, H. International Journal o f  Pharmaceutics 1980, 7, 119-127.
(476) Banerjee, G.; Nandi, G.; Mahato, S. B.; Pakrashi, A.; Basu, M. K. Journal o f  Antimicrobial 
Chemotherapy 1996, 38, 145-150.
(477) Bundgaard, H.; Johansen, M. Journal o f Pharmaceutical Sciences 1980, 69, 44-46.
(478) Riggs, J. R.; Kolesnikov, A.; Hendrix, J.; Young, W. B.; Shrader, W. D. Bioorganic and Medicinal 
Chemistry Letters 2006, 16, 2224-2228.
(479) Eldred, C. D.; Evans, B.; Hindley, S.; Judkins, B. D.; Kelly, H. A. Journal o f  Medicinal Chemistry 
1994, 37, 3882-3885.
(480) Boykin, D. W.; Kumar, A.; Hall, J. E.; Bender, B. C.; Tidwell, R. R. Bioorganic and Medicinal 
Chemistry Letters 1996, 6, 3017-3020.
(481) Maryanoff, B. E.; McComsey, D. F.; Costanzo, M. J.; Yabut, S. C.; Lu, T. B.; Player, M. R.; Giardino, 
E. C.; Damiano, B. P. Chemical Biology and Drug Design 2006, 68, 29-36.
(482) Wang, S. H.; Hall, J. E.; Tanious, F. A.; Wilson, W. D.; Patrick, D. A.; McCurdy, D. R.; Bender, B. C.; 
Tidwell, R. R. European Journal o f  Medicinal Chemistry 1999, 34, 2 15-224.
(483) Ansede, J. H.; Voyksner, R. D.; Ismail, M. A.; Boykin, D. W.; Tidwell, R. R.; Hall, J. E. Xenobiotica 
2005, 35, 211-226.
(484) Clement, B.; Burenheide, A.; Rieckert, W.; Schwarz, J. ChemMedChem 2 0 0 6 ,1, 1260-1267.
(485) Zhou, L.; Lee, K.; Thakker, D. R.; Boykin, D. W.; Tidwell, R. R.; Hall, J. E. Pharmaceutical Research 
2 0 0 2 ,19, 1689-1695.
(486) Saulter, J. Y.; Kurian, J. R.; Trepanier, L. A.; Tidwell, R. R.; Bridges, A. S.; Boykin, D. W.; Stephens, 
C. E.; Anbazhagan, M.; Hall, J. E. Drug Metabolism and Disposition 2005, 33, 1886-1893.
(487) Zhou, L.; Voyksner, R. D.; Thakker, D. R.; Stephens, C. E.; Anbazhagan, M.; Boykin, D. W.; Hall, J. 
E.; Tidwell, R. R. Rapid Communications in Mass Spectrometry 2002, 16, 1078-1085.
(488) Wang, M. Z.; Wu, J. Q.; Bridges, A. S.; Zeldin, D. C.; Kombluth, S.; Tidwell, R. R.; Hall, J. E.; Paine, 
M. F. Drug Metabolism and Disposition 2007, 35, 2067-2075.
(489) Gan, L. S. L.; Thakker, D. R. Advanced Drug Delivery Reviews 1997, 23, 77-98.
(490) Sturk, L. M.; Brock, J. L.; Bagnell, C. R.; Hall, J. E.; Tidwell, R. R. Acta Tropica 2004, 91, 131-143.
(491) Kocken, C. H. M.; van der Wei, A.; Arbe-Bames, S.; Brun, R.; Matile, H.; Scheurer, C.; Wittlin, S.; 
Thomas, A. W. Experimental Parasitology 2 0 0 6 ,113, 197-200.
(492) Yeramian, P.; Meshnick, S. R.; Krudsood, S.; Chalermrut, K.; Silachamroon, U.; Tangpukdee, N.; 
Allen, J.; Brun, R.; Kwiek, J. J.; Tidwell, R.; Looareesuwan, S Journal o f  Infectious Diseases 2005, 
192, 319-322.
(493) Reynaud, P.; Nguyentrixuong, E.; Davrinche, C.; Tran, G.; Rinjard, P.; Pieri, F.; Amouldguerin, M. L. 
European Journal o f Medicinal Chemistry 1992, 27, 245-250.
(494) Saulnier, M. G.; Frennesson, D. B.; Deshpande, M. S.; Hansel, S. B.; Vyas, D. M. Bioorganic and 
Medicinal Chemistry Letters 1994, 4, 1985-1990.
(495) Guan, J.; Zhang, Q.; Montip, G.; Karle, J. M.; Ditusa, C. A.; Milhous, W. K.; Skillman, D. R.; Lin, A. J. 
Bioorganic and Medicinal Chemistry 2 0 0 5 ,13, 699-704.
(496) Rahmathullah, S. M.; Hall, J. E.; Bender, B. C.; McCurdy, D. R.; Tidwell, R. R.; Boykin, D. W. Journal 
o f  Medicinal Chemistry 1999, 42, 3994-4000.
(497) Humphreys, W. G.; Obermeier, M. T.; Chong, S.; Kimball, S. D.; Das, J.; Chen, P.; Moquin, R.; Han, 
W. C.; Gedamke, R.; White, R. E.; Morrison, R. A. Xenobiotica 2003, 33, 93-106.
(498) Corcoran, K. D.; Hansukjariya, P.; Sattabongkot, J.; Ngampochjana, M.; Edstein, M. D.; Smith, C. D.; 
Shanks, G. D.; Milhous, W. K. American Journal o f Tropical Medicine and Hygiene 1993, 49, 473-477.
(499) Platt, K. L.; Aderhold, S.; Kulpe, K.; Fickler, M. Mutation Research/Genetic Toxicology and 
Environmental Mutagenesis 2008, 650, 96-103.
(500) Papa, E.; Pilutti, P.; Gramatica, P. Sar and Qsar in Environmental Research 2 0 0 8 ,19, 115-127.
(501) Spink, D. C.; Wu, S. J.; Spink, B. C.; Hussain, M. M.; Vakhania, D. D.; Pentecost, B. T.; Kaminsky, L. 
S. Toxicology and Applied Pharmacology 2008, 226, 213-224.
(502) Miller, E. C.; Miller, J. A. Advances in Experimental Medicine and Biology 1982, 136, 1-21.
Bibliography 286
(503) Namkung, M. J.; Fletcher, T. L.; Wetzel, W. H. Journal o f  Medicinal Chemistry 1965, 8, 551 - 554.
(504) Nelson, S. D. Journal o f Medicinal Chemistry 1982, 25, 753-765.
(505) Koganti, A.; Singh, R.; Rozett, K.; Modi, N.; Goldstein, L. S.; Roy, T. A.; Zhang, F. J.; Harvey, R. G.; 
Weyand, E. H. Carcinogenesis 2000, 21, 1601-1609.
(506) Heeney, M.; Bailey, C.; Giles, M.; Shkunov, M.; Sparrowe, D.; Tierney, S.; Zhang, W. M.; McCulloch, 
I. Macromolecules 2004, 37, 5250-5256.
(507) Skabara, P. J.; Berridge, R.; Serebryakov, I. M.; Kanibolotsky, A. L.; Kanibolotskaya, L.; Gordeyev, S.; 
Perepichka, I. F.; Sariciftci, N. S.; Winder, C. Journal o f  Materials Chemistry 2007, 1'7, 1055-1062.
(508) Fang, Q.; Xu, B.; Jiang, B.; Fu, H. T.; Zhu, W. Q.; Jiang, X. Y.; Zhang, Z. L. Synthetic Metals 2005, 
155, 206-210.
(509) Schafer-Hales, K. J.; Belfield, K. D.; Yao, S.; Frederiksen, P. K.; Hales, J. M.; Kolattukudy, P. E. 
Journal o f  Biomedical Optics 2 0 0 5 ,10, 1-8.
(510) Menard, E.; Meitl, M. A.; Sun, Y. G.; Park, J. U.; Shir, D. J. L.; Nam, Y. S.; Jeon, S.; Rogers, J. A. 
Chemical Reviews 2 0 0 7 ,107, 1117-1160.
(511) Zheng, Q. D.; He, G. S.; Lu, C. G.; Prasad, P. N. Journal o f  Materials Chemistry 2005,15, 3488-3493.
(512) Zhang, M.; Yang, C. D.; Mishra, A. K.; Pisula, W.; Zhou, G.; Schmaltz, B.; Baumgarten, M.; Mullen, 
K. Chemical Communications 2007, 1704-1706.
(513) Liu, C. P.; Hung, Y. T. Thin Solid Films 2005, 492, 269-274.
(514) Cho, N. S.; Park, J.-H.; Shim, H.-K. Current Applied Physics 2006, 6, 686-690.
(515) Spychala, J. Monatshefte fu r  Chemie /  Chemical Monthly 2006,137, 1203-1210.
(516) Torrens, A.; Mas, J.; Port, A.; Castrillo, J. A.; Sanfeliu, O.; Guitart, X.; Dordal, A.; Romero, G.; Fisas, 
M. A.; Sanchez, E.; Hernandez, E.; Perez, P.; Perez, R.; Buschmann, H. Journal o f  Medicinal Chemistry 
2005, 48, 2080-2092.
(517) Grundt, P.; Carlson, E. E.; Cao, J. J.; Bennett, C. J.; McElveen, E.; Taylor, M.; Luedtke, R. R.; 
Newman, A. H. Journal o f  Medicinal Chemistry 2005, 48, 839-848.
(518) Leonetti, F.; Favia, A.; Rao, A.; Aliano, R.; Paluszcak, A.; Hartmann, R. W.; Carotti, A. Journal o f  
Medicinal Chemistry 2004, 47, 6792-6803.
(519) Yu, M.; Danishefsky, S. J. Journal o f the American Chemical Society 2008, 130, 2783-2785.
(520) Rabanal, F.; Giralt, E.; Albericio, F. Tetrahedron 1995, 51, 1449-1458.
(521) Stigers, K. D.; Koutroulis, M. R.; Chung, D. M.; Nowick, J. S. Journal o f  Organic Chemistry 2000, 65, 
3858-3860.
(522) Wojciechowski, F.; Hudson, R. H. E. Journal o f  Organic Chemistry 2008, 73, 3807-3816.
(523) Overby, J. S.; Woofter, R. T.; Rheingold, A. L.; Incarvito, C. D.; Sommer, R. D. Journal o f  Chemical 
Crystallography 2003, 33, 357-364.
(524) Edelmann, F. T.; Freckmann, D. M. M.; Schumann, H. Chemical Reviews 2002,102, 1851-1896.
(525) Chang, S. W.; Hong, J. M.; Hong, J. W.; Cho, H. N. Polymer Bulletin 2001, 47, 231-238.
(526) Domercq, B.; Grasso, C.; Maldonado, J. L.; Halik, M.; Barlow, S.; Marder, S. R.; Kippelen, B. Journal
o f  Physical Chemistry B 2 0 0 4 ,108, 8647-8651.
(527) Li, W.; Qiao, J.; Duan, L.; Wang, L.; Qiu, Y. Tetrahedron 2007, 63, 10161-10168.
(528) Gambino, S.; Samuel, I. D. W.; Barcena, H.; Bum, P. L. Organic Electronics 2008, 9, 220-226.
(529) Bera, R. N.; Cumpstey, N.; Bum, P. L.; Samuel, I. D. W. Advanced Functional Materials 2007, 17,
1149-1152.
(530) Barsu, C.; Andraud, C.; Amari, N.; Spagnoli, S.; Baldeck, P. L. Journal o f  Nonlinear Optical Physics 
and Materials 2 0 0 5 ,14, 311-318.
(531) Setayesh, S.; Grimsdale, A. C.; Weil, T.; Enkelmann, V.; Mullen, K.; Meghdadi, F.; List, E. J. W.; 
Leising, G. Journal o f  the American Chemical Society 20 01 ,123, 946-953.
(532) Thomas Baumgartner, R. R. Chemical Reviews 2006,106, 4681-4727.
(533) Kelley, C. J.; Ghiorghis, A.; Qin, Y. X.; Kauffman, J. M.; Novinski, J. A.; Boyko, W. J. Journal o f 
Chemical Research 1999, 80-81.
(534) Promarak, V.; Punkvuang, A.; Sudyoadsuk, T.; Jungsuttiwong, S.; Saengsuwan, S.; Keawin, T.; 
Sirithip, K. Tetrahedron 2007, 63, 8881-8890.
(535) Destri, S.; Pasini, M.; Botta, C ; Porzio, W.; Bertini, F.; Marchio, L. Journal o f Materials Chemistry 
2 0 0 2 ,12, 924-933.
(536) Karim, M. A.; Cho, Y. R.; Park, J. S.; Kim, S. C.; Kim, H. J.; Lee, J. W.; Gal, Y. S.; Jin, S. H. Chemical 
Communications 2008, 1929-1931.
(537) Louis A. Pinck, G. E. H. Journal o f  the American Chemical Society 1937, 59, 8 - 13.
(538) Lothrop, W. C. Journal o f the American Chemical Society 1939, 61, 2115-2119.
(539) KUHN, R., JACOB, P. Ber. dtsch, chem. Ges. 1925, 58, 1432-1440.
(540) Hengstenberg J, M. H. Zeitschrift fü r  Kristallographie 1929, 70, 283.
(541) Cook, J. W., Iball, J. Journal o f  the Chemical Society. 1936, 25, 467-468.
Bibliography 287
(542) Brown, G. M.; Bortner, M. H. Acta Crystallographica 1954, 7, 139-139.
(543) Bums, D. M.; Iball, J. Nature 1954,173, 635-635.
(544) Weisburger, J. H.; Weisburger, E. K.; Ray, F. E. Journal o f  the American Chemical Society 1950, 72, 
4250-4253.
(545) Francis Earl Ray , E. K. Journal o f  the American Chemical Society, 69, 3068 - 3070.
(546) Sussmann, R.; Zitt, U.; Neusser, H. J. Journal o f  Chemical Physics 1994,101, 9257-9261.
(547) Stock, L. M.; Brown, H. C. Journal o f  the American Chemical Society 1962, 84, 1242 - 1248.
(548) Brown, H. C.; Dubeck, M.; Goldman, G. Journal o f  the American Chemical Society 1962, 84, 1229- 
1232.
(549) Griffith.A; Hine, R. Acta Crystallographica Section B-Structural Crystallography and Crystal
Chemistry 1970, B 26, 29-33.
(550) Griffith.A; Hine, R. Acta Crystallographica Section B-Structural Crystallography and Crystal
Chemistry 1970, B 26, 34-38.
(551) Browne, S. E.; Asher, S. E.; Cornwall, E. H.; Frisoli, J. K.; Harris, L. J.; Salot, E. A.; Sauter, E. A.; 
Trecoske, M. A.; Veale, P. S. Journal o f  the American Chemical Society 1984,106, 1432-1440.
(552) Zerger, R.; Rhine, W.; Stucky, G. D. Journal o f the American Chemical Society 1974, 96, 5441-5448.
(553) Gerkin, R. E.; Lundstedt, A. P.; Reppart, W. J. Acta Crystallographica Section C-Crystal Structure 
Communications 1984, 40, 1892-1894.
(554) Belsky, V. K.; Zavodnik, V. E.; Vozzhennikov, V. M. Acta Crystallographica Section C-Crystal 
Structure Communications 1984, 40, 1210-1211.
(555) V. A. Godik, S. N. D., G. G. Konoplev, A. N. Rodionov and D. N. Shigorin Theoretical and 
Experimental Chemistry 1983,18, 285-289.
(556) Badger, G. M.; Spotswood, T. M. Journal o f  the Chemical Society 1959, 1635-1641.
(557) Bermejo, J.; Fernandez, A. L.; Prada, V.; Granda, M.; Menendez, R. Journal o f  Chromatography A 
1999,849, 507-519.
(558) David E. Adelson, M. T. B. Chemical Reviews 1939, 24, 135-176.
(559) Stokker, G. E.; Alberts, A. W.; Gilfillan, J. L.; Huff, J. W.; Smith, R. L. Journal o f  Medicinal Chemistry 
1986, 29, 852-855.
(560) Ladd, D. L.; Weinstock, J.; Wise, M.; Gessner, G. W.; Sawyer, J. L.; Flaim, K. E. Journal o f  Medicinal 
Chemistry 1986, 29, 1904-1912.
(561) Cohen, S. Journal o f the American Chemical Society 1957, 79, 1499-1502.
(562) Kaluszyner, A.; Cohen, S. Tetrahedron 1960,11, 252-255.
(563) Creary, X. Chemical Reviews 1991, 91, 1625-1678.
(564) Fernandez, J. J.; Figueiras, A.; Granda, M.; Bermejo, J.; Menendez, R. Carbon 1995, 33, 295-307.
(565) Neuman, R. C. Journal o f  the American Chemical Society 1962, 84, 3025 - 3026.
(566) Sprinzak, Y. Journal o f  the American Chemical Society 1958, 80, 5449-5455.
(567) Henry E. Fritz, D. W. P., and Kenneth E. Atkins Journal o f  Organic Chemistry 1968, 33, 2575 - 2511.
(568) Wan, P.; Krogh, E.; Chak, B. Journal o f the American Chemical Society 1988,110, 4073-4074.
(569) Vanderdo.E; Nasielsk.J; Thiry, P. Journal o f  the Chemical Society D-Chemical Communications 1969, 
1249-1250.
(570) Perumattam, J.; Shao, C.; Confer, W. L. Synthesis-Stuttgart 1994, 1181-1184.
(571) Wan, P.; Shukla, D. Chemical Reviews 1993, 93, 571-584.
(572) Rathnayake, H. P.; Cirpan, A.; Karasz, F. E.; Odoi, M. Y.; Hammer, N. I.; Barnes, M. D.; Lahti, P. M. 
Chemistry o f  Materials 2007, 19, 3265-3270.
(573) Pan, H. L.; Fletcher, T. L. Journal o f  Medicinal Chemistry 1964, 7, 31 - 38.
(574) Fletcher, T. L.; Namkung, M. J.; Pan, H. L. Journal o f Medicinal Chemistry 1967, 10, 936 - 941.
(575) Albrecht, W. L.; Fleming, R. W.; Horgan, S. W.; Kihm, J. C.; Mayer, G. D. Journal o f  Medicinal 
Chemistry 1974, 17, 886-889.
(576) Minabe, M.; Yoshida, M.; Suzuki, K. Bulletin o f  the Chemical Society o f  Japan 1978, 51, 3373-3376.
(577) Pan, H. L.; Namkung, M. J.; Fletcher, T. L. Journal o f  Medicinal Chemistry 1968,11, 1236-1237.
(578) Balachan.Ks; Bhatnaga.I; George, M. V. Journal o f  Organic Chemistry 1968, 33, 3891-3895.
(579) Andrews, E. R.; Fleming, R. W.; Grisar, J. M.; Kihm, J. C.; Wenstrup, D. L.; Mayer, G. D. Journal o f  
Medicinal Chemistry 1974,17, 882-886.
(580) Agrawal, K. C. Journal o f  Medicinal Chemistry 1967,10, 99-101.
(581) Sill, A. D.; Albrecht, W. L.; Andrews, E. R.; Fleming, R. W.; Horgan, S. W.; Roberts, E. M.; Sweet, F. 
W. Journal o f  Medicinal Chemistry 1973, 16, 240-245.
(582) Pan, H. L.; Fletcher, T. L. Journal o f  Medicinal Chemistry 1965, 8, 491 - 497.
(583) Perry, P. J.; Read, M. A.; Davies, R. T.; Gowan, S. M.; Reszka, A. P.; Wood, A. A.; Kelland, L. R.;
Neidle, S. Journal o f Medicinal Chemistry 1999, 42, 2679-2684.
Bibliography 288
(584) Zhang, K.; Chen, Z.; Yang, C. L.; Tao, Y. T.; Zou, Y.; Qin, J. G.; Cao, Y. Journal o f  Materials 
Chemistry 2008, 18, 291-298.
(585) Metwallly, N. H. Phosphorus Sulfur and Silicon and the Related Elements 2008,183, 34-43.
(586) Grisorio, R.; Mastrorilli, P.; Ciccarella, G.; Suranna, G. P.; Nobile, C. F. Tetrahedron Letters 2008, 49, 
2078-2082.
(587) Hiroki, K.; Morii, N.; Yamashita, H.; Sugiyama, J. I. Synthetic Communications 2007, 37, 4407-4413.
(588) Arcus, C. L.; Coombs, M. M. Journal o f the Chemical Society 1954, 3977-3980.
(589) Fletcher, T. L.; Pan, H. L. Journal o f  the American Chemical Society 1956, 78, 4812-4812.
(590) Linares, M.; Scifo, L.; Demadrille, R.; Brocorens, P.; Beljonne, D.; Lazzaroni, R.; Grevin, B. Journal o f  
Physical Chemistry C 20 08 ,112, 6850-6859.
(591) Bergmann, E. D. Chemical Reviews 1968, 68, 41-84.
(592) Parry, J. A.; Warren, K. D. Journal o f  the Chemical Society 1965, 4049 - 4054.
(593) Arcus, C. L.; Coombs, M. M. Journal o f  the Chemical Society 1954, 4319-4329.
(594) Edward R. Atkinson, H. J. L., J. C. Heath, E. H. Kimball, and E. R. Read Journal o f  the American 
Chemical Society 1941, 63, 730-733.
(595) Lawler, E. R. A. a. H. J. Organic. Syntheses, Collections. 1941,1, 222.
(596) E. H. Huntress, E. B. H., and I. S. Cliff Journal o f the American Chemical Society 1931, 53, 2720 - 
2724.
(597) Tucker, S. H.; Whalley, M. Chemical Reviews 1952, 50, 483-538.
(598) Casson, D.; Tabner, B. J. Journal o f the Chemical Society B-Physical Organic 1969, 887-892.
(599) Greenhow, E. J.; White, E. N.; McNeil, D. Journal o f the Chemical Society 1951, 2848-2851.
(600) Hogenesc.Te; Smid, J. Journal o f the American Chemical Society 1966, 88, 318 - 324.
(601) Casson, D.; Tabner, B. J. Journal o f  the Chemical Society B-Physical Organic 1970, 1560-1564.
(602) Bruson, H. A. Journal o f the American Chemical Society 1942, 64, 2457-2461.
(603) Tucker, S. H. Journal o f the Chemical Society 1949, 2182-2186.
(604) Carpino, L. A. Journal o f Organic Chemistry 1980, 45, 4250-4252.
(605) Weldon G. Brown , B. A. B. Journal o f the American Chemical Society 1943, 65, 1082 - 1084.
(606) Burr, J. G. Journal o f  the American Chemical Society 1951, 73, 823 - 823.
(607) Carpino, L. A.; Han, G. Y. Journal o f  the American Chemical Society 1970, 92, 5748-5749.
(608) Carpino, L. A.; Han, G. Y. Journal o f  Organic Chemistry 1972, 37, 3404-3409.
(609) Chong, J. M.; Lajoie, G.; Tjepkema, M. W. Synthesis-Stuttgart 1992, 819-820.
(610) Melerò, C.; Herrera, R. P.; Guijarro, A.; Yus, M. Chemistry-a European Journal 2007, 13, 10096- 
10107.
(611) E. P. Kaplan, Z. I. K., E. D. Lubuzh and A. D. Petrov Russian Chemical Bulletin 1966, 15, 1384-1386.
(612) Konemann, M.; Erker, G.; Fröhlich, R.; Wurthwein, E. U. Journal o f  the American Chemical Society 
1997, 119, 11155-11164.
(613) Maeda, H.; Fujiwara, S.; Shinlke, T.; Kambe, N.; Sonoda, N. Journal o f  the American Chemical Society 
1996,118, 8160-8161.
(614) de Meijere, A. K., S. I. Chemical Reviews 2 0 0 0 ,100, 93-142.
(615) Harry F. Miller, G. B. B. Journal o f  the American Chemical Society 1935, 57, 766-771.
(616) M. S. Kharasch, W. G., Frank R. Mayo Journal o f  the American Chemical Society 1938, 60, 2004-2004.
(617) Brocklehurst, B.; Young, R. N. Physical Chemistry Chemical Physics 2001, 3, 3018-3026.
(618) Janzen, E. G.; Gerlock, J. L. Journal o f Organometallic Chemistry 1967, 8, 354-358.
(619) Cox, R. H.; Janzen, E. G.; Gerlock, J. L. Journal o f  the American Chemical Society 1968, 90, 5906- 
5909.
(620) Tabner, B. J.; Walker, T. Journal o f  the Chemical Society-Perkin Transactions 2 1972, 445-449.
(621) Casson, D.; Tabner, B. J. Journal o f  the Chemical Society B-Physical Organic 1970, 1565-1567.
(622) Waack, R.; Doran, M. A.; West, P. Journal o f the American Chemical Society 1965, 87, 5508-5510.
(623) Eisch, J. J.; Kaska, W. C. Journal o f Organic Chemistry 1962, 27, 3745-3752.
(624) Ulmschneider, S.; Muller-Vieira, U.; Klein, C. D.; Antes, I.; Lengauer, T.; Hartmann, R. W. Journal o f  
Medicinal Chemistry 2005, 48, 1563-1575.
(625) Johnson, A. W.; Lacount, R. B. Tetrahedron 1960, 9, 130-138.
(626) Johnson, A. W.; Lacount, R. B. Journal o f  the American Chemical Society 1961, 83, 417-423.
(627) Fletcher, T. L.; Namkung, M. J.; Dice, J. R.; Schaefer, S. K. Journal o f Medicinal Chemistry 1965, 8,
347 - 350.
(628) S. V. Anantakrishnan, E. D. H. Journal o f  the Chemical Society 1935, 1607-1609.
(629) M. J. S. DEWAR, D. S. U. Journal o f  the Chemical Society 1958, 3079-3084.
(630) Burdinski, D.; Cheng, K.; Lippard, S. J. Tetrahedron 2005, 61, 1587-1594.
(631) Bell, F.; Mulholland, D. B. Journal o f  the Chemical Society 1949, 2020-2022.
(632) Ranger, M.; Rondeau, D.; Leclerc, M. Macromolecules 1997, 30, 7686-7691.
Bibliography 289
(633) Dewhurst, F.; Shah, P. K. J. Journal o f  the Chemical Society C-Organic 1969, 1503-1504.
(634) Birch, A. J. Journal o f  the Chemical Society 1945, 809 - 813.
(635) Birch, A. J. Journal o f  the Chemical Society 1944, 430 - 436.
(636) Donohoe, T. J.; House, D. Journal o f  Organic Chemistry 2002, 67, 5015-5018.
(637) Smith, W. K.; Hardin, J. N.; Rabideau, P. W. Journal o f  Organic Chemistry 1990, 55, 5301-5302.
(638) Rabideau, P. W.; Karrick, G. L. Tetrahedron Letters 1987, 28, 2481-2484.
(639) W. E. Bachmann, J. C. S. Journal o f  the American Chemical Society 1940, 62, 2687 - 2690.
(640) Francis Earl Ray, G. R., Jr. Journal o f  the American Chemical Society 1943, 65, 836-839.
(641) Jones, W. D.; Albrecht, W. L.; Palopoli, F. P. Journal o f  Organic Chemistry 1977, 42, 4144-4146.
(642) Spencer, J. T.; Grimes, R. N. Organometallics 1987, 6, 323-328.
(643) Grimes, R. N. Chemical Reviews 1992, 92, 251-268.
(644) Bitterwolf, T.; Venzio, A.; Manoli, F. Journal o f  Organometallic Chemistry 1999, 583, 1-2.
(645) Carpino, L. A.; Sadataalaee, D.; Beyermann, M. Journal o f  Organic Chemistry 1990, 55, 1673-1675.
(646) Beyermann, M.; Bienert, M.; Niedrich, H.; Carpino, L. A.; Sadataalaee, D. Journal o f Organic 
Chemistry 1990, 55, 721-728.
(647) Shinya, K.; Furihata, K.; Teshima, Y.; Hayakawa, Y.; Seto, H. Tetrahedron Letters 1992, 33, 7025- 
7028.
(648) Gould, S. J. Chemical Reviews 1997, 97, 2499-2509.
(649) Cragoe, E. J.; Woltersdorf, O. W.; Gould, N. P.; Pietruszkiewicz, A. M.; Ziegler, C.; Sakurai, Y.; 
Stokker, G. E.; Anderson, P. S.; Bourke, R. S.; Kimelberg, H. K.; Nelson, L. R.; Barron, K. D.; Rose, J.
R.; Szarowski, D.; Popp, A. J.; Waldman, J. B. Journal o f  Medicinal Chemistry 1986, 29, 825-841.
(650) German, P. I.; Aweeka, F. T. Clinical Pharmacokinetics 2008, 47, 91-102.
(651 ) Kokwaro, G.; Mwai, L.; Nzila, A. Expert Opinion on Pharmacotherapy 2007, 8, 75-94.
(652) Wemsdorfer, W. H. Expert Review o f Anti-Infective Therapy 2004, 2, 181-196.
(653) Macgregor, I. R.; Neblett, R. F.; Cook, C. H. Journal o f  Organic Chemistry 1954, 19, 626-630.
(654) Baldwin, J. J.; McClure, D. E.; Gross, D. M.; Williams, M. Journal o f  Medicinal Chemistry 1982, 25, 
931-936.
(655) Imbs, J. L.; Miesch, F.; Schwartz, J.; Velly, J.; Ledere, G.; Mann, A.; Wermuth, C. G. British Journal 
o f  Pharmacology 1977, 60, 357-362.
(656) Bahner, C. T.; Kinder, H.; Brothert.D; Spiggle, J.; Gutman, L. Journal o f  Medicinal Chemistry 1965, 8, 
390-392.
(657) Fletcher, T. L.; Wetzel, W. H.; Namkung, M. J. Journal o f Medicinal Chemistry 1966, 9, 593 - 598.
(658) Bahner, C. T.; Brothert.D Journal o f  Medicinal Chemistry 1969, 12, 722-723.
(659) Claxton, G. P.; Roberts, E. M.; Fleming, R. W.; Grisar, J. M. Journal o f  Medicinal Chemistry 1972, 15, 
500-503.
(660) Kuo, W.-H.; Yang, S.-F.; Chu, S.-C.; Lu, S.-O.; Chou, F.-P.; Hsieh, Y.-S. Cancer Letters 2003, 189, 
103-112.
(661) Pan, H. L.; Fletcher, T. L. Journal o f  Medicinal Chemistry 1969,12, 822-825.
(662) Sprague, P. W.; Heikes, J. E. Journal o f  Medicinal Chemistry 1977, 20, 726-728.
(663) Prashad, M.; Seth, M.; Bhaduri, A. P.; Srimai, R. C. Indian Journal o f  Chemistry Section B-Organic 
Chemistry Including Medicinal Chemistry 1979, 17, 496-498.
(664) Gund, P.; Shen, T. Y. Journal o f  Medicinal Chemistry 1977, 20, 1146-1152.
(665) Langlois, M.; Rapin, M.; Meingan, J. P.; Van, T. V.; Maillard, J. European Journal o f Medicinal 
Chemistry 1976, 11, 493-499.
(666) Millonig, R. C.; Goldlust, M. B.; Rubin, B.; Turkheim.Ar; Schreibe.Wf; Bell, C. Abstracts o f  Papers o f 
the American Chemical Society 1972, 164, 38.
(667) Hamilton, G. S.; Mewshaw, R. E.; Bryant, C. M.; Feng, Y.; Endemann, G.; Madden, K. S.; Janczak, J. 
E.; Perumattam, J.; Stanton, L. W.; Yang, X. J.; Yin, Z. W.; Venkataramen, B.; Liu, D. Y .Journal o f  
Medicinal Chemistry 1995, 38, 1650-1656.
(668) Gualtieri, F.; Teodori, E.; Bellucci, C.; Pesce, E.; Piacenza, G. Journal o f  Medicinal Chemistry 1985, 
28, 1621-1628.
(669) Lotlikar, P. D.; Scribner, J. D.; Miller, J. A.; Miller, E. C. Life Sciences 1966, 5, 1263-1269.
(670) Weeks, C. E.; Allaben, W. T.; Louie, S. C.; Lazear, E. J.; King, C. M. Cancer Research 1978, 38, 613- 
618.
(671) Reigh, D. L.; Stuart, M.; Floyd, R. A. Cellular and Molecular Life Sciences 1978, 34, 107-108.
(672) Miller, J. A. Cancer Research 1970, 30, 559-576.
(673) Kitamura, S.; Takekawa, K.; Sugihara, K.; Tatsumi, K.; Ohta, S. Carcinogenesis 1999, 20, 347-350.
(674) Lin, J. K. Journal o f  the Chinese Chemical Society 1992, 39, 693-702.
(675) Elfarra, A. A.; Hanna, P. E. Journal o f Medicinal Chemistry 1985, 28, 1453-1460.
(676) Quinto, I.; De Marinis, E. Mutation Research/Genetic Toxicology 1983,124, 235-240.
Bibliography 290
(677) Vincent, S. H. Seminars in Hematology 1989, 26, 105-113.
(678) Chou, A. C.; Fitch, C. D. Journal o f  Clinical Investigation 1981, 68, 672-677.
(679) Egan, T. J. Journal o f  Inorganic Biochemistry 2008,102, 1288-1299.
(680) Sugioka, Y.; Suzuki, M. Biochimica et Biophysica Acta 1991,1074, 19-24.
(681) Chong, C. R.; Sullivan, D. J. Biochemical Pharmacology 2003, 66, 2201-2212.
(682) Tidwell, R. R.; Jones, S. K.; Geratz, J. D.; Ohemeng, K. A.; Cory, M.; Hall, J. E. Journal o f Medicinal 
Chemistry 1990, 33, 1252-1257.
(683) Wang, Y.; Zeng, F. W.; Zimmerman, S. C. Tetrahedron Letters 1997, 38, 5459-5462.
(684) Shriner, R.; Neumann, F. Chemical Reviews 1944, 35, 351-425.
(685) Pagola, S.; Stephens, P. W.; Bohle, D. S.; Kosar, A. D.; Madsen, S. K. Nature 2000, 404, 307-310.
(686) Slater, A. F. G.; Swiggard, W. J.; Orton, B. R.; Flitter, W. D.; Goldberg, D. E.; Cerami, A.; Henderson, 
G. B. Proceedings o f  the National Academy o f  Sciences o f  the United States o f  America 1991, 88, 325- 
329.
(687) Bohle, D. S.; Dinnebier, R. E.; Madsen, S. K.; Stephens, P. W. Journal o f  Biological Chemistry 1997, 
272, 713-716.
(688) Dorn, A.; Stoffel, R.; Matile, H.; Bubendorf, A.; Ridley, R. G. Nature 1995, 374, 269-271.
(689) Egan, T. J.; Ross, D. C.; Adams, P. A. Febs Letters 1994, 352, 54-57.
(690) Egan, T. J.; Mavuso, W. W.; Ncokazi, K. K. Biochemistry 2001, 40, 204-213.
(691) Egan, T. J.; Hempelmann, E.; Mavuso, W. W. Journal o f  Inorganic Biochemistry 1999, 73, 101-107.
(692) Parapini, S.; Basilico, N.; Pasini, E.; Egan, T. J.; Olliaro, P.; Taramelli, D.; Monti, D. Experimental 
Parasitology 2000, 96, 249-256.
(693) Donkor, I. O.; Jones, S. K.; Tidwell, R. R. Bioorganic and Medicinal Chemistry Letters 1993, 3, 1137- 
1140.
(694) Donkor, I. O.; Tidwell, R. R.; Jones, S. K. Journal o f  Medicinal Chemistry 1994, 37, 4554-4557.
(695) Patrick, D. A.; Bakunov, S. A.; Bakunova, S. M.; Kumar, E.; Lombardy, R. J.; Jones, S. K.; Bridges, A.
S.; Zhirnov, O.; Hall, J. E.; Wenzler, T.; Brun, R.; Tidwell, R. R .Journal o f  Medicinal Chemistry 2007, 
50, 2468-2485.
(696) Fuqua, S. A.; Silverstein, R. M. Journal o f  Organic Chemistry 1964, 29, 395-398.
(697) Lautens, M.; Roy, A. Organic Letters 2000, 2, 555-557.
(698) Muller, E. Justus Liebigs Annalen Der Chemie 1975,160-194.
(699) Sakamoto, T.; Kondo, Y.; Suginome, T.; Ohba, S.; Yamanaka, H. Synthesis-Stuttgart 1992, 552-554.
(700) Ikemoto, N.; Liu, J. C.; Brands, K. M. J.; McNamara, J. M.; Reider, P. J. Tetrahedron 2003, 59, 1317- 
1325.
(701) Weissman, S. A.; Zewge, D.; Chen, C. Journal o f  Organic Chemistry 2005, 70, 1508-1510.
(702) Garigipati, R. S. Tetrahedron Letters 1990, 31, 1969-1972.
(703) Moss, R. A.; Ma, W.; Merrer, D. C.; Xue, S. Tetrahedron Letters 1995, 36, 8761-8764.
(704) Levin, J. I.; Turos, E.; Weinreb, S. M. Synthetic Communications 1982,12, 989-993.
(705) Anbazhagan, M.; Boykin, D. W.; Stephens, C. E. Synthesis-Stuttgart 2003, 2467-2469.
(706) Phillips, G.; Davey, D. D.; Eagen, K. A.; Koovakkat, S. E.; Liang, A.; Ng, H. P.; Pinkerton, M.; Trinh, 
L.; Whitlow, M.; Beatty, A. M.; Morrissey, M. M. Journal o f  Medicinal Chemistry 1999, 42, 1749- 
1756.
(707) Serajuddin, A. T. M. Advanced Drug Delivery Reviews 2007, 59, 603-616.
(708) Martin, P.; Riley, R.; Back, D. J.; Owen, A. British Journal o f  Pharmacology 2008,153, 805-819.
(709) Chandler, B.; Almond, L.; Ford, J.; Owen, A.; Hoggard, P.; Khoo, S.; Back, D. Journal o f  Acquired 
Immune Deficiency Syndromes 2003, 33, 551 -556.
(710) Piskunova, I. P.; Eremeev, A. V.; Mishnev, A. F.; Vosekalna, I. A. Tetrahedron 1993, 49, 4671-4676.
(711) Ellis, G. L.; Amewu, R.; Sabbani, S.; Stocks, P. A.; Shone, A.; Stanford, D.; Gibbons, P.; Davies, J.;
Vivas, L.; Charnaud, S.; Bongard, E.; Hall, C.; Rimmer, K.; Lozanom, S.; Jesus, M.; Gargallo, D.; 
Ward, S. A.; O'Neill, P. M .Journal o f  Medicinal Chemistry 2008, 51, 2170-2177.
(712) Elmore, S. W.; Bruncko, M.; Park, C. United States Patent 20050272744 2005.
(713) Mathis, A. M.; Holman, J. L.; Sturk, L. M.; Ismail, M. A.; Boykin, D. W.; Tidwell, R. R.; Hall, J. E.
Antimicrobial Agents and Chemotherapy 2006, 50, 2185-2191.
(714) Borges, M.; Messeder, J. C.; Figueroa-Villar, J. D. European Journal o f  Medicinal Chemistry 2004, 39, 
925-929.
(715) Ulrich, P.; Cerami, A. Journal o f  Medicinal Chemistry 1984, 27, 35-40.
(716) Annunziata, R.; Molteni, V.; Raimondi, L. Magnetic Resonance in Chemistry 1998, 36, 520-528.
(717) Kolyadina, N. M.; Soldatenkov, A. T.; Gridunova, G. V.; Prostakov, N. S. Chemistry o f  Heterocyclic 
Compounds 1998, 34, 962-966.
(718) Shao, H. X.; Chen, X. P.; Wang, Z. X.; Lu, P. Journal o f  Luminescence 2007, 127, 349-354.
(719) Lund, H.; Svith, H.; Pedersen, S. U.; Daasbjerg, K. Electrochimica Acta 2005, 51, 655-664.
Bibliography 291
(720) Lu, W. X.; Yan, C. G.; Yao, R. Synthetic Communications 1996, 26, 3719-3723.
(721) Hellwinkel, D.; Goke, K.; Karle, R. Synthesis-Stuttgart 1994, 973-978.
(722) Mysyk, D. D.; Perepichka, I. F.; Perepichka, D. F.; Bryce, M. R.; Popov, A. F.; Goldenberg, L. M.; 
Moore, A. J. Journal o f  Organic Chemistry 1999, 64, 6937-6950.
(723) Plater, M. J.; Kemp, S.; Lattmann, E. Journal o f  the Chemical Society-Perkin Transactions 1 2000, 971 - 
979.
(724) Kuhn, W. Organic Syntheses Collections 1943, 2, 447-448.
(725) Clarke, H. T.; Hartman, W. W. Organic Syntheses Collection 1941,1, 455-456.
(726) Gowda, D. C.; Mahesh, B.; Gowda, S. Indian Journal o f  Chemistry Section B-Organic Chemistry 
Including Medicinal Chemistry 2001, 40,15-11.
(727) Stephens, C. E.; Tanious, F.; Kim, S.; Wilson, W. D.; Schell, W. A.; Perfect, J. R.; Franzblau, S. G.; 
Boykin, D. W. Journal o f Medicinal Chemistry 2001, 44, 1741-1748.
(728) Raffel, D. M.; Jung, Y. W.; Gildersleeve, D. L.; Sherman, P. S.; Moskwa, J. J.; Tluczek, L. J.; Chen, W. 
Journal o f  Medicinal Chemistry 2007, 50, 2078-2088.
(729) Makanga, M.; Premjl, Z.; Falade, C.; Karbwang, J.; Mueller, E. A.; Andriano, K.; Hunt, P.; Ibarra de 
Palacios, P. American Journal o f  Tropical Medicine and Hygiene 2006, 74, 991-998.
(730) Sowunmi, A.; Gbotosho, G. O.; Happi, C. T.; Adedeji, A. A.; Fehintola, F. A.; Folarin, O. A.; Tambo, 
E.; Fateye, B. A. American Journal o f  Tropical Medicine and Hygiene 2007, 77, 235-241.
(731) Tilley, L.; Davis, T. M. E.; Bray, P. G. Future Microbiology 2006, 1, 127-141.
(732) de Villiers, K. A.; Marques, H. M.; Egan, T. J. J  Inorganic Biochemistry 2008,102, 1660-1667.
(733) Beutler, U.; Fuenfschilling, P. C.; Steinkemper, A. Organic Process Research and Development 2007, 
77,341-345.
(734) White, N. J.; van Vugt, M.; Ezzet, F. Clinical Pharmacokinetics 1999, 37, 105-125.
(735) Denis, M. B.; Tsuyuoka, R.; Lim, P.; Lindegardh, N.; Yi, P. Tropical Medicine and International 
Health 2006, 77, 1800-1807.
(736) Lefevre, G.; Thomsen, M. S. Clinical Drug Investigation 19 99 ,18, 467-480.
(737) Bunnag, D.; Viravan, C.; Looareesuwan, S.; Karbwang, J.; Harinasuta, T. Southeast Asian Journal o f  
Tropical Medicine and Public Health 1991, 22, 380-385.
(738) Karbwang, J.; Na-Bangchang, K.; Wattankoon, Y.; Thanavibul, A.; Harinasuta, T. Southeast Asian 
Journal o f  Tropical Medicine and Public Health 1994, 25, 702-706.
(739) Looareesuwan, S. Transactions o f  the Royal Society o f  Tropical Medicine and Hygiene 1 9 9 4 ,  88, 9-11.
(740) van Agtmael, M. A.; Shan, C. Q.; Jiao, X. Q.; Mull, R.; van Boxtel, C. J. International Journal o f  
Antimicrobial Agents 1999,12, 151-158.
(741) Alin, M. H.; Bjorkman, A.; Wemsdorfer, W. H. American Journal o f  Tropical Medicine and Hygiene 
1999, 61, 439-445.
(742) Toovey, S.; Jamieson, A.; Nettleton, G. Travel Medicine and Infectious Disease 2003, 7, 177-179.
(743) Organisation, W. H.; WHO Press, Organization, W. H., Eds.; WHO Library Cataloguing-in-Publication 
Data: Geneva, Switzerland, 2006.
(744) Wasunna, B.; Zurovac, D.; Goodman, C. A.; Snow, R. W. Malaria Journal 2008, 7, 1-9.
(745) Mandi, G.; Mockenhaupt, F. P.; Coulibaly, B.; Meissner, P.; Muller, O. Malaria Journal 2008, 7, 1-7.
(746) Haque, R.; Thriemer, K.; Wang, Z. X.; Sato, K.; Wagatsuma, Y. American Journal o f  Tropical
Medicine and Hygiene 2007, 76, 39-41.
(747) Nsobya, S. L.; Dokomajilar, C.; Joloba, M.; Dorsey, G.; Rosenthal, P. J. Antimicrobial Agents and 
Chemotherapy 2007, 51, 3023-3025.
(748) Thapa, S.; Hollander, J.; Linehan, M.; Cox-Singh, J.; Bista, M. B.; Thakur, G. D.; Davis, W. A.; Davis,
T. M. E. American Journal o f  Tropical Medicine and Hygiene 2007, 77, 423-430.
(749) Nosten, F.; White, N. J. American Journal o f  Tropical Medicine and Hygiene 2007, 77, 181-192.
(750) van Vugt, M.; Ezzet, F.; Nosten, F.; Gathmann, I.; Wilairatana, P.; Looareesuwan, S.; White, N. J. 
American Journal o f  Tropical Medicine and Hygiene 1999, 61, 964-967.
(751) Kaufman, T. S.; Ruveda, E. A. Angewandte Chemie-International Edition 2005, 44, 854-885.
(752) R. B. Woodward, W. E. D. Journal o f the American Chemical Society 1944, 66 849-849.
(753) Ridley, R. G.; Dorn, A.; Vippagunta, S. R.; Vennerstrom, J. L. Annals o f  Tropical Medicine and 
Parasitology 1997, 91, 559-566.
(754) Loria, P.; Miller, S.; Foley, M.; Tilley, L. Biochemical Journal 1999, 339, 363-370.
(755) Kumar, S.; Guha, M.; Choubey, V.; Maity, P.; Bandyopadhyay, U. Life Sciences 2007, 80, 813-828.
(756) Foley, M.; Tilley, L. International Journal for Parasitology 1997, 27, 231-240.
(757) Warhurst, D. C. Annals o f Tropical Medicine and Parasitology 1987, 81, 65-67.
(758) Elandaloussi, L. M.; Smith, P. J. Chemotherapy 2006, 52, 50-52.
(759) Savarino, A.; Boelaert, J. R.; Cassone, A.; Majori, G.; Cauda, R. Lancet Infectious Diseases 2003, 3, 
722-727.
Bibliography 292
(760) Fowler, P. D.; Shadforth, M. F.; Crook, P. R.; Lawton, A. Annals o f  the Rheumatic Diseases 1984, 43, 
200-204.
(761) Romanelli, F.; Smith, K. M.; Hoven, A. D. Current Pharmaceutical Design 2004, 10, 2643-2648.
(762) Ciak, J.; Hahn, F. E. Science 1966,151, 347-349.
(763) Ginsburg, H.; Krugliak, M. Drug Resistance Updates 1999, 2, 180-187.
(764) Ginsburg, H.; Krugliak, M. Biochemical Pharmacology 1992, 43, 63-70.
(765) Menting, J. G. T.; Tilley, L.; Deady, L. W.; Ng, K.; Richard, J. S.; Cowman, A. F.; Foley, M. Molecular 
and Biochemical Parasitology 1997, 88, 215-224.
(766) Rosenthal, P. J. Antimalarial Chemotherapy, 1 ed.; Humana Press: Totowa, 2001, 87-108.
(767) Suginome, M.; Uehlin, L.; Murakami, M. Journal o f the American Chemical Society 2004, 126, 13196- 
13197.
(768) Arend, M.; Westermann, B.; Risch, N. Angewandte Chemie-International Edition 1998, 37, 1044-1070.
(769) Hayashi, Y.; Tsuboi, W.; Ashimine, I.; Urushima, T.; Shoji, M.; Sakai, K. Angewandte Chemie- 
International Edition 2003, 42, 3677-3680.
(770) Josephsohn, N. S.; Snapper, M. L.; Hoveyda, A. H. Journal o f  the American Chemical Society 2004, 
72(5,3734-3735.
(771) Liu, T. Y.; Cui, H. L.; Long, J.; Li, B. J.; Wu, Y.; Ding, L. S.; Chen, Y. C. Journal o f  the American 
Chemical Society 2007,129, 1878-1879.
(772) Song, J.; Shih, H. W.; Deng, L. Organic Letters 2007, 9, 603-606.
(773) Eftekhari-Sis, B.; Abdollahifar, A.; Hashemi, M. M.; Zirak, M. European Journal o f  Organic Chemistry 
2006, 5152-5157.
(774) Matsuo, J. I.; Tanaki, Y.; Ishibashi, H. Organic Letters 2006, 8, 4371-4374.
(775) Ollevier, T.; Nadeau, E.; Guay-Begin, A. A. Tetrahedron Letters 2006, 47, 8351-8354.
(776) Salter, M. M.; Kobayashi, J.; Shimizu, Y.; Kobayashi, S. Organic Letters 2006, 8, 3533-3536.
(777) Naisbitt, D. J.; Ruscoe, J. E.; Williams, D.; Oneill, P. M.; Pirmohamed, M.; Park, B. K. Journal o f  
Pharmacology and Experimental Therapeutics 1997, 280, 884-893.
(778) Lawrence, R. M.; Dennis, K. C.; O'Neill, P. M.; Hahn, D. U.; Roeder, M.; Struppe, C. Organic Process 
Research and Development 2008, 12, 294-297.
(779) Shone, A. E.; Park, B. K.; O'Neill, P. M.; Ward, S. A. Drug Metabolism Reviews
2006, 38, 132-133.
